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Abstract 
Surfactant proteins SP-A and SP-D are important key molecules responsible for 
pulmonary homeostasis and innate immunity against infectious pathogens. SP-A and 
SP-D are also found in various parts of the placenta as well as amniotic fluid. The levels 
of these proteins in the amniotic fluid are good biomarkers of fetal lung maturation. The 
development of the lungs in fetal growth is important for fetal survival in extrauterine 
life. In pregnant mice models, a huge increase in SP-A and SP-D levels in the amniotic 
sac has been reported close to parturition suggesting an important role of these 
proteins in the hormonal pathway to labour. In this thesis, full length natural and 
recombinant proteins of human SP-A and SP-D were generated and examined on the 
maternal-fetal tissues of the placenta (explants of amnion, chorion and decidua) under 
inflammatory conditions. A range of innate and adaptive immune markers and 
prostaglandin targets were examined to show that SP-A and SP-D modulate the 
prostaglandin pathway. Thus, an imbalance in this could potentially lead to disorders 
such as intrauterine growth retardation and preeclampsia. The cellular basis of immune 
regulation and prostaglandin pathway was also examined via fractionation of decidual 
macrophages. Curiously, SP-A and SP-D appears to suppress pro-inflammatory 
response of decidual macrophages after challenging with LPS. This thesis thus divulges 
specific and mutually inclusive functions of SP-A and SP-D in the maintenance of 
pregnancy, protection against intrauterine infection, dampening of inflammation, and 
premature activation of parturition. 
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1. General Introduction 
1.1 Pregnancy and Preterm birth  
According to the Office of National Statistics (ONS), in 2005, England and Wales alone 
had 1 in 13 cases of preterm births, ~8% of all births (Oakley et al., 2009). Preterm 
complications contribute to ~35% of world-wide (3.1 million) annual neonatal deaths 
and is the second major cause of death after pneumonia in infants (Liu et al., 2012).  
As per the World Health Organization (WHO), the duration of a normal term pregnancy 
is 37 to 42 weeks of gestation and birth preceding 37 weeks is classified as preterm. The 
extent of prematurity depends on how soon the infant is born prior to term. Human 
pregnancy is divided into three trimesters. The first trimester (first 12 weeks of 
pregnancy) initiates at the time of fertilisation and implantation of the embryo on the 
endometrial lining from the last normal menstrual period (LNMP). The highest rate of 
miscarriages occurs within the first trimester. The second trimester starts from 13 
weeks to 27 weeks gestation, transitioning to the final, third trimester spanning 
between 28 to 40 weeks (Figure.1.1).   
Preterm births, defined as parturition of the new born before 37 weeks gestation, are 
the leading cause of prenatal mortality and morbidity. Morbidity includes cerebral 
palsy, intrauterine growth retardation (IUGR), preeclampsia, hypoxia, impaired 
learning, visual disorders and lung malfunctions. Lung malfunctions are a result of 
improper lung maturation with an increased susceptibility to lung infections and risk of 
chronic diseases during adulthood (Mwaniki et al., 2012).  
Preterm birth can be sub-divided according to the timing of birth at different gestational 
stages. For example, extreme preterm birth (EPTB) is defined as birth between 24 and 
28 weeks of gestation. A very preterm birth (VPTB) is between 28 and 32 weeks of 
gestation, whereas moderate or late preterm birth (LPTB) is between 32 and 37 weeks 
of gestation. In extreme preterm cases, as recorded  in UK and Ireland in 1995 (Costeloe 
et al., 2000), babies born at 24 weeks have a 50% chance of survival, whereas babies 
born after 28 weeks have an 81% chance of survival. There is a high correlation 
between preterm birth and low birth weight, which is associated with increased 
mortality (within 28 days) and morbidity, ~94% of preterm born babies are of low 
birth weight (LBW), which is defined as weight less than 5.5 lbs and in extreme cases,  
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Figure 1.1 – Three trimesters of gestation – time range of preterm and term birth (this 
image was created by me for the purpose of this thesis).  
 
 
Figure 1.2 – Factors leading up to preterm births. This image was created by me for the 
purpose of this thesis adapted from (Haas, 2008). 
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less than 2.2 lbs. Women who have given preterm birth earlier have a 2/3rd higher 
chance of giving preterm births in subsequent pregnancies (Mercer et al., 1999).   
Globally, >1 in 10 babies are born premature, which has a huge financial burden on 
families and the government. A study carried out in 2006 shows, England and Wales 
alone incur a total cost of ~£3 billion since ~50% of spontaneous preterm births are 
invariably associated with infection (Lockwood, 2002).  
The cause of preterm birth is not fully understood, some cases are spontaneous. 
However, many cases of preterm births are associated with multiple births, infections 
or trauma/medical disorders (e.g. high blood pressure and diabetes) during pregnancy. 
Approximately 30% of spontaneous preterm births are unexplained, and an equal 
percentage of preterm cases are due to multiple births. Genital tract infections, 
premature rupture of membrane (PROM), cervical incompetence and uterine 
abnormalities contribute to 20 to 25% of cases (Figure 1.2). Finally, 15 to 20% of 
preterm births are due to other stresses including high blood pressure, foetal growth 
restriction, trauma and other medical disorders (Figure 1.2) (Haas, 2008). 
1.2 Placental development  
The placenta is a complex organ which houses the foetus/allograft, for 9 months, 
allowing foetal development to take place. The placenta is a ~500 grams (1lb) organ 
connecting to the foetus by the umbilical cord (55-60cm). The umbilical cord contains 2 
umbilical arteries and 1 umbilical vein (Figure 1.3). The placenta develops on the 
maternal endometrium from the same blastocyte that forms the embryo, foetus and the 
maternal placenta. The foetal tissues of the placenta make up the amniotic layer. The 
amniotic tissues constitute of two types of cells: the epiblast and extraembyonic 
mesoderm forming around the foetus, otherwise known as the amniotic sac. This sac is 
filled with amniotic fluid, which bathes the foetus and foetal lungs and increases in 
volume with foetal growth. This fluid is released at the timing of birth when the amnion 
membrane ruptures, also referred to as a woman’s ‘water break’. At 34 weeks of 
gestation the amniotic fluid is at its greatest, with an approximate volume of 800 ml, 
however, this decrease closer to term at 40 weeks gestation to 600 ml. The amniotic 
fluid circulates through the foetal lungs and within the amniotic sac and surrounds the 
baby carrying the surfactant proteins from the foetal lungs to enter the fluid.  
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Figure 1.3 – Different sections of the foetal and maternal membranes including; amnion, 
chorion and decidua. The umbilical cord joining from the maternal tissue providing nutrients 
and removing waste can be seen connecting to the foetus. The foetal head is facing the cervix and 
mechanical stretch triggering the hormonal pathway to initiate contractions occurs here  (Sood et 
al., 2006). 
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The maternal tissues of the placenta are constituted of chorionic and decidual tissues 
(Figure.1.3). The chorion connects the fetal and maternal tissues via chorionic villi. The 
chorion is adjacent to the amniotic layer and is made up of three main cell types; 
cytotrophoblasts, syncytiotrophoblasts and extraembryonic somatic mesoderm. The 
extraembryonic membrane is composed of trophoblasts lined with mesoderm. The 
chorion separates the amnion from cytotrophoblasts and the chorionic villi penetrates 
the fetal and maternal tissue to allow vascularisation for the transfer of nutrients from 
maternal to fetal blood. The outermost layer comprising of maternal tissue is the 
decidua, surrounding the chorionic layers.  This is composed of three main layers; 
decidua basalis, decidua capsularis and decidua periatelis. The placenta is the organ 
which separates the mother from the foetus and is the connection between foetal and 
maternal tissues to allow gaseous and nutrient exchange and the removal of waste via 
the mother’s blood supply. The maternal blood network to the placenta is fully formed 
within the first trimester and extends as far as the foetal chorionic tissues. The high 
pressure of the blood allows gaseous exchange to take place. The placenta also forms a 
barrier against the transmission of microbes to prevent infection. It is important for 
maternal antibodies to be transported to foetal blood circulation. Hence, 
syncytiotrophoblast express specific Fc receptors (FcR) and turn away cytotoxic 
antibodies by expressing complement regulatory proteins (Phillips et al., 2003). In this 
way, the mother’s antibodies penetrate the placenta to provide a memory of the 
mother’s humoral immunity to the foetus.  
Besides from serving as an interface for oxygen and nutrient exchange, the placenta is 
also viewed as an endocrine organ, which secretes hormones such as oestrogen, 
progesterone, human chorionic gonadotrophin (hCG) and human placental lactogen 
(hPL). Oestrogen is responsible for mammary gland development for lactation and 
uterine growth to accommodate the growing foetus. Similarly, progesterone functions 
in the development of maternal tissues, specifically the endometrium, in order to 
maintain the lining during pregnancy and prevent myometrial contractility – important 
for prevention of preterm birth. The hCG synergistically cooperates to maintain 
oestrogen and progesterone levels secreted by the corpus luteum, thus is important for 
the maintenance of endometrial lining, preventing it from shedding off. hPL stimulates 
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mammary gland growth to prepare for lactation and regulates glucose, protein and fat 
levels to provide the foetus.  
1.3 Innate immune functions in pregnancy and labour 
Maternal tolerance of the foetus is a major challenge which occurs during all the 
changes of the uterine environment and is driven by products of the foetal placenta and 
its associated membranes. Trophoblast cells are involved in protecting the foetus by 
controlling the expression of HLA molecules preventing an immune response against 
paternal alloantigens. Restricted expression of HLA molecules also contribute to the 
tolerance of the foetus. The allograft foetus is protected by foetal trophoblast cells in the 
placenta and membranes due to its restricted expression of surface antigens that 
normally stimulate graft rejection, like class Ia antigens on HLA-A and HLA-B and HLA-
class II antigens on HLA-D (Hunt and Langat, 2009). Antigen presentation via HLA-G5 or 
–G6 to encountering uterine (decidual) macrophages stimulates the release of 
immunosuppressive TGF-β, which is a critical dampener of graft rejection (Figure.1.4).  
The pregnant uterus is characterised by innate immune cells which are programmed for 
an anti-inflammatory response, consistent with tolerating the foetal antigens (Hunt, 
1992, Hunt and Robertson, 1996). A high number of natural killer (NK) cells and 
macrophages and low number of dendritic cells and regulatory T cells (Treg) are present 
in the pregnant uterus (Hunt, 1992) (Figure.1.5). During the first two trimesters of   
pregnancy, uterine NK cells are most abundant in the decidua (20-40% of decidual 
stromal cells), which rapidly decline in the third trimester (Moffett-King, 2002, 
Trundley and Moffett, 2004, Starkey et al., 1988). Uterine NK cells recognise infected 
and aberrant cells for destruction, however, this does not occur in the human decidua as 
selective expression of HLA molecules on cytotrophoblast cells suppresses the uterine 
NK cells (King et al., 2000) (Figure.1.6).  
Macrophages are also abundant in the human decidual stromal cells, averaging around 
15-20% throughout pregnancy (Bulmer et al., 1988, Hunt, 1990, Vince et al., 1990). 
Decidual macrophages (DMs) appear to be programmed into a suppressive mode, 
producing inhibitory cytokines such as IL-10 and TGF-β (McIntire et al., 2004, 
Heikkinen et al., 2003) and expressing immunosuppressive markers such as Human B7 
homolog 1 (B7-H1), Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing 
8 
 
Non-integrin (DC-SIGN), ILT3, and factor 13 (Hunt, 1992). Along with IL-10 release 
from uterine NK cells and macrophages (Heikkinen et al., 2003), TGF-β prevents cellular  
 
 
 
 
 
 
 
Figure 1.4 – Foetal tolerance by mother and foetal HLA expression. Human leukocyte antigen 
expression during pregnancy and expression of HLA-class 1b molecules, especially HLA-G, 
interacting with NK cell receptors and cytokine expression at the feto-maternal interface. The 
foetus is semi-allogenic to the mother as it inherits one haplotype of HLA from the mother and one 
haplotype from the father. Soluble HLA-G and HLA-G expressed on cytotrophoblast escape NK cell 
mediated lysis by modulating cytokine secretion (Hviid, 2006). 
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Figure 1.5 – Hormones and cytokines involved in maintaining pregnancy and inducing 
parturition. There is a hierarchically defined role for each component at the interface of the 
foetus-maternal interaction. However, cells and soluble factors in the local vicinity can also affect 
inflammatory process considerably under conditions of infection and stress (Hviid, 2006). 
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Figure 1.6 – An anchoring trophoblast connecting from the myometrium to foetal tissues. 
The anchoring trophoblast extends from the decidua and further differentiates into 
syncytiotrophoblasts, cytotrophoblast and extra-villous trophoblasts (EVTs) to allow maternal and 
foetal nutrient and gaseous exchange into the foetal site of the placenta. Chemokines and 
chemokine receptors surround the EVTs and maternal leukocytes invading the decidua. The EVTs 
therefore are in direct contact with leukocytes and dendritic stem cells (DSCs). DSCs and/or 
dendritic NK cells (dNK) produce TGF-β1 to inhibit decidua dendritic cells (dDCs) to provide a 
tolerogenic state (Arck and Hecher, 2013) 
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infiltration. This is aided by prostaglandin E2 and progesterone. Prostaglandins and 
other hormones are involved in maintaining the status of the non-pregnant uterus due 
to NK cells, macrophages and Treg cells and their secretory molecules – cytokines and 
chemokines. During placental development, hormones and prostaglandins are also 
important for implantation and parturition. During these stages, the placenta is 
regulated by HLA expression, complement regulatory proteins, B7 family and TNF 
superfamily. Parturition is designed as an inflammatory process involving chemokines 
and cytokines (Figure 1.5) (Miyazaki et al., 2003).  
DCs are potent antigen presenting cells which only make up 1% of decidual stromal 
cells (DSC) (Kammerer et al., 2000) and are programmed to exhibit an 
immunosuppressive phenotype. Mature CD83+ decidual DC secrete less IL-12, a 
promoter of T-cell activation (Th1), compared to monocyte derived DCs. T lymphocytes 
are present in the decidua, constituting ~10% of decidual leukocytes (Hunt, 1992) and 
Treg cells make up 14% of the CD3+CD4+ T cells in early pregnancy (Heikkinen et al., 
2003) whose proliferation is regulated by oestrogen (Polanczyk et al., 2004). Treg cells 
are responsible for the maintenance of peripheral tolerance via production of the two 
major immunosuppressive cytokines, IL-10 and TGF-β at the maternal-foetal interface 
(Itoh et al., 1999, Sakaguchi, 2000, Read and Powrie, 2001) (Figure.1.7). 
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Figure 1.7 – Functions of Treg cells in maintaining foetal tolerance. Treg cells stimulated in 
thymus by naïve CD4+CD44low cells are stimulated by semi-allogeneic foetal antigens. Treg cells 
released from thymus mediate tolerance to self-antigens (Ag) to protect against autoimmune 
responses. Treg cells express, CD4, CD25 and FoxP3 and functionally maintain foetal immune 
tolerance by suppressing decidual inflammation (Arck and Hecher, 2013). 
 
 
 
 
1.4 Physiological processes of labour 
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Physiologically, labour can be divided into three main stages including 
effacement/dilation, expulsion of the foetus and placental stage (Figure.1.8). The first 
stage, effacement, is the thinning and dilation of the cervix by 3-10 cm in width to allow 
full passage of the baby. This can last on average 8 hours.  The second stage, expulsion, 
is between the time the cervix has fully dilated and the passage of the baby to 
extrauterine life. This stage can take minutes to a couple of hours. The third stage is the 
placental stage, the pushing of the placenta out of the uterus, and is connected to the 
foetus via umbilical cord. This takes ~10-15minutes (Zhang et al., 2002). 
Parturition is characterised by 6 distinct events; cervical ripening, dilation, contractility 
of myometrium, membrane rupture, placental separation and uterine involution. 
Biochemical changes occurring near the end of gestation, leads to cervical ripening, 
membrane rupture and myometrial contractility. The myometrium contractility can be 
divided into 4 distinct phases: 0) quiescence, 1) activation, 2) stimulation and 3) 
involution. In phase 0, quiescence occurs from the time of conception to the initiation of 
parturition where the cervix is soft. Inhibitors such as prostacyclins PGI2 are in action. 
The inhibitors increase the cAMP levels to transducer signals in order to inhibit Ca2+ 
release which is required for Myosine Light Chain Kinase (MLCK) activity, so no uterine 
contraction can occur. Therefore, by diminishing the inhibitors, the timing of birth can 
be controlled and preterm/post term birth prevented. Phase 1 of parturition is the 
activation of uterine contraction by mechanical stretch. Activation is the beginning of 
parturition where the cervix undergoes ripening in preparation for labour. Contraction-
associated proteins (CAPs) include antagonist receptor, prostaglandins (PGs) and 
oxytocins (Lye SJ, 1998.). Phase 2 of parturition is the stimulation of the uterus by 
uterotonins such as prostaglandins, oxytocin and corticotrophin stimulating hormones 
(CRH) (Lye, 1994). Stimulation involves uterine contractility and cervical dilation up to 
foetal and placental expulsion. Finally, phase 3 of parturition is the involution after 
delivery of the foetus and placenta (Gibb and Challis, 2002). Involution is the repair time 
for the cervix and uterine involution. The cervix is made of collagen, smooth muscle and 
elastin embedded in connective tissue. The concentration of elastin decreases during 
pregnancy.  
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Figure 1.8 – Physiological stages of labour divided into three main stages. Labour is 
separated into 3 main stages including dilation (stage 1), expulsion (stage 2) and the placental 
stage where the placenta is removed (stage 3). 
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The collagen is made of fibrils comprising of proteoglycans and glycosaminoglycans and 
the main cellular components are fibroblasts, which synthesise extracellular matrix and 
collagen. Cervical ripening and progression of labour is a result of pro-inflammatory 
response between cells, interleukins and prostaglandins. For instance, SP-D binds to 
decorin containing glycosaminoglycans (Nadesalingam et al., 2003) and induces the 
expression of matrix metalloproteinases (MMPs) 1, 2 and 14 (Kolb et al., 2001) to cleave 
cell receptors and release of apoptotic ligands. This could cause SP-A and SP-D 
migration to bind and clear the removal of apoptotic cells. Binding to 
glycosaminoglycans in decorin introduces reduction in levels of collagen for tissue 
remodelling.  
1.5 Hormones influencing pregnancy and labour 
Reproductive hormones such as progesterone, hCG, oestrogen, oxytocin, CRH and 
prostaglandins are some of the important maternal and foetal hormones involved in the 
labour pathway (Figure.1.9). Progesterone released from the corpus luteum in early 
gestation enables the maintenance of pregnancy by decreasing prostaglandins and 
inhibiting oxytocin and oxytocin receptor expression. Cytokines stimulate the synthesis 
of MMPs, vascular endothelial growth factor (VEGF) and progesterone receptor C 
isoform, which reduce the response of progesterone during labour (Christiaens et al., 
2008). hCG is produced by the syncytiotrophoblasts in the chorion predominantly 
during pregnancy for its maintenance and regulating the levels of progesterone and 
oestrogen. Oestrogen, on the other hand, has opposing effects, causing prostaglandin 
production and promoting expression of oxytocin receptors and stimulating uterine 
contractility (Challis, 2000). Oxytocin released from the posterior pituitary gland at the 
end of gestation stimulates further expression of oxytoxin receptors, inducing uterine 
contractility, and promoting local expression of prostaglandin from foetal membrane 
and the decidua. Another hormone which reaches at its peak levels at the end of 
pregnancy is CRH in the placenta. Highly expressed in the placenta, CRH is detected in 
maternal serum which makes it a great marker for detecting the timing of birth as this 
further increases prostaglandin production by decidua and placental membranes to 
drive the labour process (Challis, 2000). 
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Figure 1.9 – Effects of hormones in the maintenance of pregnancy and in the initiation of 
labour. High levels of progesterone and low levels of oestrogen maintain uterine quiescence and 
cervical rigidity. Low levels of progesterone and high levels of oestrogen and oxytocin stimulate 
prostaglandin synthesis and uterine contraction and cervical ripening (Kota et al., 2013).  
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1.6   Prostaglandin pathway – one of the main hormonal pathways leading upto 
labour 
It is debated whether the signal for inducing labour is similar in term and preterm 
labour. In addition, whether the signal is induced by the foetus or mother or if it’s a 
mutual communication from both remains an area of interest in research. It is largely 
considered the foetus contributes to the timing of birth by secreting components from 
the lungs into the amniotic fluid which can stimulate foetal membranes and 
surrounding tissues to initiate the prostaglandin (PG) pathway for the onset of labour 
(Okita et al., 1983). The importance of PG in promoting parturition was highlighted in a 
study that used PG endoperoxidase H synthase inhibitor that caused a delay in the onset 
of labour (Novy et al., 1974).  
PGs are a sub-class of eicosanoids derived from a 20-carbon fatty acid which are 
responsible for promoting contraction and relaxation of smooth muscle tissues (Nelson 
and Randy, 2005). They are considered as key mediators for the onset of labour (Challis 
and Vaughan, 1987, Novy and Liggins, 1980, Thorburn and Challis, 1979). They can 
induce changes in the extracellular matrix metabolism associated with cervical ripening, 
decidual/membrane activation (Romero et al, 1994) and myometrial contractility 
(Wiqvist et al., 1983, Calder and Greer, 1991). The three main foetal/maternal 
membranes of the placenta include amnion, chorion and decidua (ACD). Each of these 
tissues synthesise different PGs and are expressed in varying levels. The human amnion 
is the thinnest section, made up of epithelial cells and sub-epithelial mesenchymal cells. 
These layers are part of the foetal interface. The amnion is made up of four layers 
including: epithelium, basement membrane, compact layer and fibroblast layer (Figure 
1.10). The chorion being the thickest layer of the two comprises of trophoblast cells 
under the pseudobasement membrane. This is the middle connecting layer between 
foetal amniotic layer and maternal decidual layer (Figure 1.11). The decidua is a thick 
vascularised lining between the chorion and myometrium. The decidua consists of a 
mixture of decidualized stromal cells, bone marrow-derived macrophages, NK cells, 
decidual cells, lymphocytes, endothelial cells and trophoblasts (Saito et al., 1993, Dudley 
et al., 1996a). 
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Figure 1.10 – Layers of amnion and chorion. Different cells distinguish both the amnion and 
chorion layers surrounding the foetus. Both the amnion and chorion are separated by the spongy 
layer with the chorion being the thickest layer of the two containing trophoblast cells under the 
pseudobasement membrane (Bourne, 1960). 
 
 
 
 
 
 
 
 
19 
 
 
 
 
Figure 1.11 - Histological section of decidua tissue of pregnant placenta. The Section shows 
the junction between foetal trophoblast (to form syncytiotrophpoblast and cytotrophoblast) and 
maternal decidua. 
 
 
 
 
 
 
 
 
 
20 
 
PGs are regulated by their precursor, arachidonic acid, which stimulates and drives the 
PG metabolism pathway. The PG pathway is dependent on the amount of arachidonic 
acid available. In response to certain hormones, phospholipase A2 cleaves the 
phospholipid cell-membrane containing arachidonate to be released. In the smooth ER, 
arachidonic acid is converted to prostaglandin H2 (PGH2) by COX/prostaglandin H2 
synthase (PGHS) (Olsen et al, 2003). Two isoforms of PGHS exist: PGHS1/COX-1 and 
PGHS2/COX-2 (we refer this to PTGS2 later), which converts arachidonic acid to PGH2, 
increasing PG levels before parturition (Molnar et al., 1993). Thus, arachidonic acid 
serves as a substrate for PGHS/COX enzymes, resulting in PGH2 production. It has been 
proposed that arachidonic acid from the foetus could serve as a source of PG precursor 
(Lopez Bernal et al., 1988). Although, only 2% of fatty acids in the amniotic fluid are 
arachidonic acid, the amnion layer has a high turnover of fatty acid, serving as a good 
source of arachidonic acid from foetal membranes (Liggins et al., 1977).  The initiation 
of the PG pathway is triggered by paracrine lipid mediators such as arachidonic acid, 
resulting in a sequential oxidation reaction to convert PGH2 to PGD2, PGE2, PGF2 and 
PGI2 (Figure. 1.12) which are controlled by enzymatic reactions of synthases (Table 
1.1). Each PG has its own role for the progression of labour. For example, in human 
myometrium, PGD2 and PGI2 are involved in the relaxation of muscle tone, whereas 
PGE2 and PGF2α are involved in myometrial contractility (Senior et al., 1993). 
PGs are synthesised in the amnion but their enzymes for catabolic activity is sparse and 
mainly located in other areas of membrane. PGHS1/COX-1 and PGHS2/COX-2 mRNA are 
mainly synthesised within the amnion (Hirst et al., 1995) but very little PGDH (15’, 
Hydroxyprostaglandin dehydrogenase). At term, the net basal output of PG produced by 
amnion mesenchymal layer exceeds the level in amnion epithelial cells (Whittle, 2000). 
Similarly, very high concentrations of PGHS/COX enzymes are localised in the chorionic 
layer (Keirse and Turnbull, 1975), suggesting the role of chorion in controlling the 
transfer of PGs and progression of the PG pathway. Over expression of PGHS2/COX-
2and PGE2 levels in the amnion epithelium and mesenchymal fibroblasts has been  
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Figure 1.12 – Enzymes and Hormones of the Prostaglandin pathway in the initiation of 
parturition. Enzymes (orange circles) and the main hormones involved in the cascade of events 
leading to myometrial contraction and expulsion of the baby. This image was generated by me for 
the purpose of this thesis. COX-1/COX-2, prostaglandin G/H synthase 1 / 2; AKR1B1, Aldo-Keto 
Reductase Family 1, Member B1; AKR1C3, Aldo-keto reductase family 1 member C3; CBR1, 
Carbonyl reductase 1, PGH2, prostaglandin H2; PGD2, prostaglandin D2; PGE1/2,prostaglandin 
E1/2; PGF2/2α,prostaglandin F2/2α; PGI2, prostaglandin I2 (Lopez Bernal et al., 1987). 
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Table 1.1 – Prostaglandin pathway and its conversion via different enzymatic 
activity.  
SUBSTRATE ENZYME PRODUCT 
Membrane phospholipid Phospholipase (e.g. PLA2G4A) Arachidonic acid 
Arachidonic acid PGHS1/PTGS1, PGHS2/PTGS2 PGH2 
PGH2 PTGDS, HPGDS PGD2 
PGH2 PTGES, PTGES2, PTGES3 PGE2 
PGH2 AKR1B1, AKRIC3 PGF2α 
PGH2 PTGIS PGI2 
PGD2 AKR1C3 9α-11β- PGF2 
PGE2 CBR1 PGF2α 
Prostaglandins on the left serve as a substrate for the enzymes in the middle to produce 
prostaglandin products described on the right of the table. Prostaglandin H2 (PGH2), 
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2 alpha (PGF2α), 
prostaglandin I2 (PGI2), 9α-11β-prostaglandin F2 (9α-11β- PGF2), prostaglandin H synthase 
(PGHS1/PTGS1, PGHS2/PTGS2), Prostaglandin D2 synthase (PTGDS), hematopoietic prostaglandin 
D2 synthase (HPGDS), prostaglandin E synthase (PTGES, PTGES2, PTGES3), aldo-keto reductase 
family 1, member 1 (AKR1B1), aldo-keto reductase family 1, member C3 (AKRIC3), prostaglandin I 
synthase (PTGIS), carbonyl reductase 1 (CBR1). 
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associated with cases of preterm birth (Skinner and Challis, 1985, Lopez Bernal et al., 
1987, Gibb and Sun, 1996). On the other hand, the decidua has been shown to express 
low levels of PGHS1/COX-1 and PGHS2/COX-2 and PGDH (Liggins et al., 1977, Hirst et 
al., 1995), suggesting this tissue may be involved in the end results of the PG pathway. 
The levels of PGHS2/COX-2 can increase by 80-fold due to several factors including 
cytokines (Romero et al., 1991), growth factors: epidermal growth factor (EGF), platelet 
activating factor (PAF) (Mitchell, 1984), tumour promoters, bacterial endotoxins 
(Bennett et al., 1987, Lamont, 1999, Soloff et al., 2000), which increase levels of 
intracellular cAMP (Anteby et al., 1997, Grammatopoulos and Hillhouse, 1999) and 
glucocorticoids (Potestio et al., 1988, Zakar and Olson, 1989, Gibb and Lavoie, 1990). 
Stimulation of PGHS2/COX-2 increases PG levels, PGE2 and hydroxyprostaglandin 
dehydrogenase (PGDH), regulating the control of the PGs metabolism and transfer 
across the membrane. The high levels of PGs reflect the activity of amnion, which leads 
to cervix dilation (Keirse, 1990). Due to the short half-life of the PGs, they can only 
respond locally for cell-cell signalling. However, an increase in PG level enhances the 
rate of transfer across the decidua and myometrial membrane promoting membrane 
rupture, cervical ripening and parturition. Nakla et al have shown that the amnion and 
chorion are the main sites for PG metabolism and that it protects the free transfer of un-
metabolised PG across the membrane to the decidua or myometrium (Nakla et al., 
1986), which are important in the onset of delivery at term as well as preterm. If this is 
unregulated by factors including infection or down regulation of PGDH expression, PG 
transfer cannot be controlled allowing PGs produced from the different tissues to reach 
the myometrium and induce preterm birth (van Meir et al., 1997).  
PG levels are affected by the rates of synthesis and metabolism (Challis et al., 1999). 
Increased PGDH expression resulted in an increased metabolism in amnion and chorion. 
However, in 15% of idiopathic preterm labour, patients show no PGDH expression even 
if trophoblast cells are undamaged and less PG metabolism takes place (Challis et al., 
1999). However, concentrations of PGs from other tissue increase the rate to parturition 
as these PG can bind to agonist PG receptors more effectively. The levels of PGDH have 
been shown to decrease in the chorion at term and preterm (Van Meir et al., 1996, 
Sangha et al., 1994).  According to Sangha et al, 1994, studies have shown a correlation 
between low expression of PGDH expression activity in chorion trophoblast (the 
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absence of infection) and preterm birth. This suggests an important role of PGDH 
requirement for the biochemical process on the onset of labour. Van Mier et al, (van 
Meir et al., 1997, Van Meir et al., 1996) have also shown a correlation between infection, 
and low levels of PGDH due to loss of trophoblast cells in case of preterm delivery. 
Reduced PGDH expression is not due to trophoblast cell breakdown in chorion, but, due 
to inability of the decidua to produce PGDH. PGDH decreases the levels of PGs to 
inactive metabolites so they cannot get transferred across the foetal membranes to the 
maternal side or vice versa resulting in delayed myometrial contractility (van Meir et al., 
1997). The chorion consists of a trophoblast layer containing high concentration of 
PGDH (15, hydroxyl prostaglandin dehydrogenase), a PG-metabolising enzyme that has 
been identified to control the production of PGs (Keirse and Turnbull, 1975, Keirse et 
al., 1976, Keirse, 1978, Keirse et al., 1985, Okazaki et al., 1981a, Okazaki et al., 1981b, 
van Meir et al., 1997). Several studies have reported that PGDH mRNA concentrations 
are low in spontaneous labour at term (Lopez Bernal et al., 1987, Skinner and Challis, 
1985, Cheung and Challis, 1989, Germain et al., 1994), which would support the 
progression of labour via the PG pathway. This would allow the PGs produced in the 
amnion to be metabolised in the chorion inhibiting premature progression of PG 
synthesis.  
PGHS2/COX-2 mRNA expression within the amnion and chorionic layers results in PGE2 
production (Slater et al., 1995). The majority of the PGs, mainly PGE2, are produced in 
the amniotic layer (Gibb and Sun, 1996). An increase in the levels of PGHS2 and PGE2 at 
term and preterm have been localised within amnion epithelium and mesenchymal 
layer (Skinner and Challis, 1985) during the onset of labour (Slater et al., 1995).  
 
1.7 Innate immunity and pregnancy 
The innate immune system is the first line of defence which modulates the outcome of 
the adaptive immune response. The cellular components of the innate immunity 
comprises of neutrophils, monocytes, macrophages, DCs, natural killer (NK) cells, 
epithelial cells and its secretory materials; cytokines and chemokines, which deal with 
pathogens in addition to collectively influence the adaptive immune response 
(Table1.2). Other molecules in the innate immunity which recognise pathogens include 
specialised pathogen recognition receptors (PRRs) such as toll-like receptors (TLRs), 
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mannose receptor (MR) and soluble factors including collectins encoded within the 
germ line. These collectins include SP-A, and -D, mannan binding lectin (MBL), 
scavenger receptor collectin placenta-1 (CL-P1), collectin liver-1 (CL-L1), collectin 
kidney-1 (CL-K1), conglutinin, collectin of 43 kD (CL-43), and collectin of 46 kD (CL-46) 
(Holmskov et al., 2003). The adaptive immune system can be sub-categorised into 
humoral and cellular immune response. The main players of the adaptive response are 
B-lymphocytes, antibodies, naive T-lymphocytes, T helper cells 1 (Th1) and 2 (Th2), 
cytotoxic T-cells, cytokines and chemokines.  
 
Table 1.2 – Innate and adaptive molecules 
INNATE IMMUNITY ADAPTIVE IMMUNITY 
Neutrophils Dendritic cells  
Monocytes T lymphocytes 
Macrophages  B lymphocytes 
        PRRs (e.g. TLRs) NK cells 
Cytokines Immunoglobulins  
Chemokines   
Complement proteins   
Collectins:  
        Mannose-Bindin Lectin (MBL)  
        Surfactant protein-A (SP-A) and –D (SP-D)  
C-reactive protein  
 
Although the innate immune system is not as specific as compared to adaptive immune 
response to produce an immunological memory, it can distinguish between self and 
non-self as microorganisms contain repeated patterns on their cell surface, called 
pathogen associated molecular patterns (PAMPs), therefore, pathogens can be 
recognised by means of receptor (i.e. PRRs) which bind to these common 
characteristics. There are two types of PRRs, soluble blood plasma proteins such as 
mannose-binding receptor or collectins such as SP-A and SP-D or membrane bound 
PRRs expressed on macrophages and phagocytic cells. Phagocytic receptors can be 
placed in groups including, mannose-receptor, scavenger receptors and toll-like 
receptors (e.g. TLR-2 and TLR-4). Such phagocytic receptors are able to recognise 
common features on pathogens, i.e. PAMPs. For example, scavenger receptors recognise 
low-density lipoproteins and mannose-receptor recognise mannose present on many 
bacterial and viral cell surfaces. Binding of pathogens (i.e. PAMPs) to TLRs with co-
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receptors are capable of activating the adaptive immune response. For example, TLR-4 
binds indirectly to LPS of Gram-negative bacteria, through association with CD14 
initiating the NF-κB pathway, subsequently producing TNF-α from macrophages. TLR-2 
can recognise molecules such as peptidoglycan present on gram-positive bacteria. 
Cytokines, chemokines and co-stimulatory molecules have the essential role in directing 
the adaptive immune response (Figure.1.13) (Janeway CA Jr, 2001).  
Pathogenic microorganisms which have overcome the first line of defence, invading the 
epithelial surface of the body, are recognised by the immune cells to mount an innate 
immune response. Phagocytic neutrophils in the bloodstream recognise these 
microorganisms through their PRRs. The influx of neutrophils is followed by monocyte 
invasion which rapidly differentiate in to active macrophages which recognise and 
ingest the pathogenic microorganisms. Upon phagocytosis, macrophages produce lipid 
mediators of inflammation such as PGs, leukotrienes, platelet activating factors (PAF), 
and cytokines and chemokines.   
1.8 Influence of cytokines in maternal/foetal membranes on the prostaglandin 
pathway  
Inflammation is an integral aspect of labour. Infiltration of leukocytes producing pro-
inflammatory cytokines including TNF-α, IL-6 and IL-1β have been found in increasing 
levels in foetal and maternal compartments including amniotic fluid, myometrium, 
decidua, amnion, chorion and maternal serum as pregnancy progresses (Goldenberg et 
al., 2000). More specifically, pro-inflammatory cytokines, TNF-α, IL-6 and IL-1β, have 
been located in maternal placenta/ trophoblast cells and decidua but only IL-1β and IL-
6 in foetal chorion whereas the amnion expresses TNF-α, IL-1β and IL-6 (Menon et al., 
1995, Fortunato et al., 1994). Both mRNA and protein levels of IL-6, IL-8 and IL-1β 
(Keelan et al., 1999, Dudley, 1997) can be detected in membranes and amniotic fluid 
(Opsjln et al., 1993) perhaps due to granulocyte infiltration in the placentae (Halgunset 
et al., 1994). These Cytokines are up-regulated during spontaneous term labour and 
vaginal delivery (Keelan et al., 2003, Marvin et al., 2002) and are known to influence 
labour (Goldenberg et al., 2000) at term and preterm births even without the presence 
of infection (Elliott et al., 2001) (Figure.1.14). However, cases of preterm labour with 
infection (Romero et al., 2006) irrespective of infection (Elliott et al., 2001) have shown  
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Figure 1.13 – preterm birth stimulated by bacterial infection. Bacterial invasion from 
maternal or foetal tissues are recognised by monocytes by PRRs such as toll-like receptors (TLRs), 
activating NF-κB to transcribe and cytokines. Cytokines such as IL-1, IL-6 and TFN released 
stimulate arachidonic acid release to promote prostaglandin synthesis, which in turn is responsible 
for uterine contractility (Ratajczak and Muglia, 2008).  
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further elevated levels of IL-1β and IL-8 in the amnion, chorion, decidua and 
myometrium. Therefore, early initiation and high levels of these cytokines can lead to 
premature labour.  
IL-10 is an anti-inflammatory cytokine which delays the onset of labour as it 
counterbalances the action of pro-inflammatory cytokines. Fiorentino et al (1991) have 
shown the strong anti-inflammatory effects of IL-10 in rodents which displayed a delay 
in the onset of labour and a decrease in the level of pro-inflammatory cytokines, 
perhaps by desensitising inactivating macrophages (Fiorentino et al., 1991). In contrast, 
in humans, mRNA and protein levels of IL-10 have been detected in low levels in 
amnion and chorion at term (Denison et al., 1998, Dudley, 1997, Simpson et al., 1998) 
but are stable throughout gestation (Roth et al., 1996). The anti-inflammatory 
environment is overridden by TNF-α, which decreases PGDH expression, promoting the 
progression of PG pathway, and hence, initiation of labour (Pomini et al., 1999). The 
release of pro-inflammatory cytokines stimulates uterine activating proteins (UAPs), 
which promotes PGs synthesis, therefore, cytokines including IL-1β and TNF-α are 
essential for indirectly influencing the rate of prostaglandin production towards labour 
(Kniss et al., 1997, Molnar et al., 1993). 
IL-6 levels have been shown to increase with labour in gestational tissues (Keelan et al., 
1999, Laham et al., 1996) and displays strong immunoreactive staining in endothelial 
cells of the placenta (Steinborn et al., 1999). There is a close correlation between 
cytokines present in increased amounts during term labour and the up-regulation of 
mRNA levels of these cytokines in foetal membranes, suggesting that foetal membranes 
are one of the main sources of cytokine production in addition to foetal leukocytes and 
tissues such as the lungs. 
IL-1β is expressed from placental macrophages and trophoblasts (Taniguchi et al., 
1991). Although IL-1β levels decline during gestation, the levels of IL-6 increase with 
the onset of labour (Dudley et al., 1996b). IL-6 gene knockout mice show delay of labour 
when compared to wild type mice, confirming the important role this cytokine plays in 
the progression of labour (Robertson et al., 2006). All of these cytokines are produced 
and secreted by macrophages (decidual macrophages: DMs) which can be located in the 
decidua membranes during late gestation.  
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Figure 1.14 – Pro- and anti-inflammatory molecules in pregnancy and parturition. During 
pregnancy, amniotic fluid levels of IL-10 increases and in the myometrium levels of lipoxin 
synthetic capacity and lipoxin receptor expression increases in the maintenance of pregnancy. 
During labour, the myometrium and cervix expresses high levels of pro-inflammatory cytokines IL-
1, IL-6 and IL-8 which initiate COX-2 expression and MMP expression. MMP expression causes 
collagen breakdown and cervical ripening and COX-2 expression causes myometrial contractions 
leading to labour (Jabbour, et al. 2009). 
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Cytokines have been shown to play a huge role in culminating a successful pregnancy. 
During labour, macrophages level increases (Osman et al., 2006) which would 
ultimately result in higher cytokine and PG production, thus, influencing the timing of 
birth. Different triggers and inhibitors influencing the pro-inflammatory cytokine 
profile modulate the production of PGs, chemokines, cytokines and collagenases in 
order to increase myometrial contractility, effacement and dilation and membrane 
rupture leading to birth (Figure.1.15). 
 
 
Figure 1.15 – Cytokines, chemokines, and Prostaglandins in the inflammatory process of 
parturition. PG, prostaglandin; PR, Progesterone receptor; CAP, contractile associated protein. 
Produced by me for the purpose of this thesis. 
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1.9 Complement system and pregnancy 
Scientist, Jules Bordet, discovered a component of the innate immune system which 
augments the opsonisation and killing of bacteria with and without antibodies named as 
the complement system (Janeway CA Jr, 2001). The complement system is made of 
distinct plasma proteins which react with one another in a cascade of events to opsonise 
pathogens and induce inflammation for the clearance against the infection. The 
complement system protects against infection by three ways; firstly, it uses complement 
proteins which opsonise the pathogen which are recognised by phagocytes through 
their complement binding PRRs. Secondly, complement by-products act as 
chemoattractants which are involved in phagocytic cell recruitment to the site of 
infection and activate these phagocytes. Lastly, complement proteins function in 
forming membrane attack complexes to lyse certain bacteria by creating pores in the 
membrane. There are three distinct pathways of the complement system which 
complement proteins can opsonise the pathogen surface for its clearance: the classical, 
MBL and alternative pathway (Figure1.16). The classical pathway is characterised by 
the binding of first recognition sub component, C1q, to the pathogen surface in three 
ways; binding to the surface directly (e.g. lipoteichoic acid on Gram-positive bacteria), 
or binding to C-reactive protein, as an adapter, that binds to phosphocholine residues 
on the bacterial polysaccharides or binding to antibody-antigen complex, making a key 
link between innate and adaptive immunity. MBL pathway is activated recognition of 
mannose-containing patterns on the bacterial and viral surfaces. The alternative 
pathway is activated by spontaneous binding of C3 on surface of pathogens. Each of the 
three pathways leads to a sequence of reactions to generate a protease called a C3 
convertase (C4b2b – classical and MBL pathway, C3bBb – alternative pathway). This is 
pivotal to all three pathways. The C3 convertase enzyme cleaves C3 to C3a and C3b. C3b 
opsonises the pathogen and binds to complement receptors on phagocytes for 
recognition of attack by promoting phagocytosis. C3b also serves as a paramount for 
forming C5 by binding to C3 convertase to form C5 convertase (C4b2b3b – classical and 
MBL pathway, C3b2Bb – alternative pathway). C5 convertase is responsible for cleaving 
C5 proteins to produce C5b which inserts into the membrane allowing C6, C7, C8 and C9 
proteins to bind to form the membrane attack complex (MAC) for the lysis of cells. 
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Figure 1.16 – Complement system is divided into 3 main pathways; classical, MBL, and 
alternative pathway. Pivotal to all 3 pathways is the C3 convertase. Each pathway leads to 
phagocytic recruitment, opsonisation, membrane attack complex and lysis of pathogens and cells 
for clearance (Janeway CA Jr, 2001).  
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Product of Factor B, Bb, is a marker of the alternative pathway and does not opsonise 
the membrane surface, but forms a complex with C3b as part of the C3 convertase of the 
alternative pathway. Factor H, is a complement-regulatory protein, binding to factor B 
to displace Bb from the convertase in order to inactivate the complement cascade in 
initiating the MAC complex. However, factor P (properdin), has a higher affinity to the 
C3bBb convertase, stabilising the C3 convertase of the alternative pathway by acting as 
a positive regulator (Janeway CA Jr, 2001).  
C1q, MBL and ficolin also contribute to the innate immune response by aiding in 
phagocytic recruitment, binding to receptors on phagocytes and removal of pathogens 
by opsonisation to enhance phagocytosis. Phagocytosis triggered by these innate 
immune cells causes the release of cytokines and chemokines to initiate inflammation. 
C3a, C4a and C5a, also referred to as ‘anaphylatoxins’, due to their ability to increase 
vascular permeability (Schumacher et al., 1991) and stimulate smooth muscle 
contractility (Gorski et al., 1979), and are products in the complement cascade. 
Increasing levels of C3a, C4a and C5a anaphylatoxins have been detected in maternal 
plasma of normal pregnancy, suggesting complement activation of innate immunity 
during pregnancy. It has also been proposed that complement activation could override 
the adaptive immune response in order to maintain pregnancy and to protect the host 
(mother and/or foetus) against pathogens and allergens/autoantigens (Richani et al., 
2005). Other studies have shown increase in the levels of C1q, C4 and C3 in pregnancy, 
but with no complement activation (Adelsberg, 1983).  
It was initially postulated that ‘foetal-allograft’ acceptance is caused by lack of foetal-
antigen presentation or immunosuppression between mother and foetus (Billingham et 
al., 2010), either through lack of foetal antigen presentation to maternal lymphocytes, or 
through suppression of lymphocytes in recognising foetal antigens. It was also proposed 
by Wegmann et al, maternal immune response would be biased to foetal antigen 
presentation by selecting a Th2 antibody mediated response (Wegmann et al., 1993). 
This supported the notion that pregnancy is an immunosuppressive state although 
mothers are not in a completely disadvantaged state, with a higher susceptibility to 
contracting infections. Although the foetal allograft is often compared to tissue 
transplantation, the foetal allograft does not undergo surgical trauma, deliverance of 
acute and large antigens presented by antigen-presenting cells (APCs) which would lead 
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to rejection. Therefore, there is a clear difference in the two models. In addition, the 
placenta is neither inert nor impermeable, and is not generally immunosuppressed. 
Human pregnancy is its own specialised model. Firstly, the foetus is protected by its 
own organ, the uterus, protected by a mucosal barrier; the decidua. Secondly, the 
interaction between foetus and mother is via maternal blood where lipid components, 
hormones, cytokines and foetal and placental cells, displaying the two main points of 
foetal and maternal immune interactions are contained within the decidua and blood. 
The foetus is protected against immune rejection as it lacks MHC class I (HLA-A and 
HLA-B) or MHC class II expression. HLA-G expressed on extravillous trophoblast 
inhibits NK cells (Munz et al., 1997) and does not stimulate a cytotoxic T lymphocyte 
(CTL) (Sargent, 1993) response to placental products such as progesterone (Piccinni et 
al., 1995), and cytokines such as IL-10 (Wegmann et al., 1993). The general 
immunosuppressive state to protect the foetus carries a risk of infections either 
indirectly from the mother or directly to the amniotic fluid through vaginal entry. This is 
one of the major causes of preterm labour, growth defects, miscarriage, and in worse 
cases intrauterine death (still birth). Therefore, understanding the over-suppression of 
the adaptive immune response by innate immunity can help understand the clinical 
presentation of some infection and preeclampsia (Sacks et al., 1999).  
Preeclampsia is strongly associated with foetal growth restriction and is one of the 
leading causes of preterm birth (Steegers et al., 2010). Although some complement 
activity is essential for normal placentation and successful pregnancy, previous studies 
have shown, over activity of complement may contribute to preeclampsia. High levels of 
C3a produced from all three pathways and Bb levels from the alternative pathway have 
been documented as markers for preeclampsia compared to normal pregnancies 
suggesting alternative pathway contributes to the pathogenesis of preeclampsia (Lynch 
et al., 2011, Lynch et al., 2012).  
1.10 Surfactant protein SP-A and SP-D in pregnancy and labour 
The main component that lines the alveoli is the pulmonary surfactant secreted by the 
distal pulmonary epithelia. Pulmonary epithelia is made up of lipids, phospholipids and 
proteins which forms a thin layer at the air-liquid interface to lower the surface tension 
(Perez-Gil, 2002) to make breathing more mechanically sustainable (Rooney et al., 
1994). Pulmonary surfactants consist of 90% lipids and 10% apoproteins. Hydrophillic 
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SP-A and SP-D together with hydrophobic collectins SP-B and SP-C make up the 10% of 
apoproteins. In the alveolar tissue, SP-A comprises 90% of the surfactant proteins 
(compared to SP-B, SP-C and SP-D) and its levels are ~10 fold greater than SP-D. 
Surfactant proteins SP-A and SP-D are hydrophilic apoproteins which are involved in 
the innate immune defence for the pulmonary clearance of infection. In the lungs, SP-A 
and SP-D are synthesised by alveolar type II cells and Clara cells and are secreted into 
the lining of the alveolar epithelium from lamellar bodies. SP-A and SP-D are soluble 
PRRs, and belong to the collectin family which bind with high affinity to infectious 
PAMPs in a calcium dependent manner. Upon recognition of microbe, the proteins, SP-A 
and SP-D activate for the clearance of infectious agent via opsonisation, neutralisation, 
agglutination, and phagocyte activation. The dual binding ability to interact with the 
pathogen and receptors on host immune cells activates the host innate immune 
response. These specific proteins modulate an inflammatory and anti-inflammatory 
response against pathogens and apoptotic cells as well as necrotic cells to promote its 
clearance. 
 
1.11 Location and regulation of SP-A and SP-D gene  
SP-A and SP-D genes are located on chromosome location 10q22.2-23.1 in close 
proximity to MBL. SP-A is a major surfactant apoprotein consisting of two active genes; 
SP-A1 and SP-A2 and a pseudogene (White et al., 1985, Korfhagen et al., 1991). SP-A in 
humans is encoded by two genes unlike rats, rabbits and mice. SP-A1 and SP-A2 are 
94% homologous at a nucleotide level and 96% homology in amino acid sequence 
(Katyal et al., 1992, McCormick et al., 1994), the main difference being, SP-A1 is encoded 
by 5 exons and SP-A2 encoded by 6 exons (Hoover and Floros, 1998). Approximately 
300bp upstream from the DNA sequence for SP-A have been identified for basal 
promoter activity in lung epithelial cells in vitro. Within the 300bp, there is a sequence 
which is necessary for cAMP induction of promoter activity. SP-D promoter contains 
activator protiein-1 (AP-1), hepatocyte nuclear factor-3 (HNF-3), GT box, C/EBP 
elements which are important for SP-D promoter activity (He et al., 2000, He and 
Crouch, 2002) (Figure.1.17).  
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Figure 1.27 – Schematic diagram of promoter regions of surfactant proteins A and D. 
Diagram shows minimal promoter regions of mouse surfactant protein A and D genes. The 
locations (base pairs) are relative to the start of transcription (arrow) (Boggaram, 2003).  
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1.12 Structural organisation of SP-A and SP-D 
The primary structure of SP-A and SP-D are organized into four regions: (i) a cysteine-
containing N-terminus (required for disulphide-dependent oligomerization) that is 
linked to (ii) a triple-helical collagen region composed of repeating Gly-X-Y triplets 
(associated with maintaining the molecules shape, dimension, stability and 
oligomerization), followed by (iii) an α-helical coiled coil neck region (whose main 
function is protein trimerization), and (iv) a globular structure at the C-terminus 
comprising a C-type lectin or CRD that mediates calcium-dependent ligand-binding 
(Kishore et al., 2006) (Figure.1.18). The degree of subunit oligomerization probably 
affects the recognition of and binding strength to the carbohydrate ligands on the 
surface of pathogens (Holmskov et al., 2003). The collagen region consists of repeating 
motifs of Gly-X-Y, where X and Y can be any amino acid (generally proline or 
hydroxyproline). The relatively large collagen region of SP-D probably offers more 
freedom to the distal CRD regions to bind target pathogens and cause agglutination. 
The structure of SP-A in its mature form consists of 6 trimers ~62 kDa each. In this 
hexameric form, a single molecule yields to 630 kDa. The hexameric, structure bears 
close resemblance to C1q with a bouquet-like appearance (Vaandrager and van Golde, 
2000); (Kishore et al., 2006). In the presence of calcium, SP-A can bind in order of 
affinity to: mannose, fucose, glucose, galactose and N-acetylglucosamine (Childs et al., 
1992).  
SP-D is thought to be encoded by only one gene (Lu et al., 1992). SP-D consists of 4 
oligomers and each oligomer comprises of a trimerised polypeptide chains each of 43 
kDa and its oligomeric form (after trimerisation) is 130kDa (Figure.1.18). Once 
oligomerised to its tetrameric cruciform structure (4 of 130 kDa subunits), the protein 
yields a molecule of 520 kDa, each containing an N-linked oligosaccharide structure at 
Asn70. Human SP-D is assembled into a 520 kDa tetrameric structure with four of the 
homotrimeric subunits linked via their N-terminal regions, but trimers, dimers and 
monomers of the 130 kDa subunit can also be present in SP-D preparations. Up to eight 
of the 520 kDa tetrameric structures can undergo further oligomerization to give SP-D 
multimers having a large array, of up to 96 individual chains (12 x 8) (Kishore et al., 
2006); (Holmskov et al., 2003). 
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Figure 1.38 – Sub-components of trimeric SP-A and SP-D and there functions. (a) Trimeric 
form of SP-A (62 kDa) combining to form hexameric structure of SP-A (630 kDa) (b) Trimeric form 
of SP-D (43 kDa) combining to form tetrameric structure of SP-D (520 kDa protein). Contains N-
terminal and carbohydrate recognition domain (CRD) connected to a collagenous region held by a 
supercoiled neck region. The key describes each component of the protein structure and its main 
functions (Nayak et al., 2012). 
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1.13 Functional aspects of SP-A and SP-D  
SP-A and SP-D recognise specific carbohydrate and lipid structures on microorganisms, 
i.e. bacteria, viral particles, fungi and protozoa  (Schelenz et al., 1995, Reid, 1998, 
Reading et al., 1998, Lim and Holmskov, 1996) via its C-type lectin/CRD to initiate an 
effector immune response (table 1.3). The CRD recognises and binds to carbohydrates, 
pathogens, phospholipids and sometimes receptors on phagocytes in a calcium-
dependent manner (Palaniyar et al., 1998) for viral neutralisation, agglutination and 
opsonisation of bacteria, fungi, apoptotic and necrotic cells for clearance by activating 
antigen presenting cells such as DCs and phagocytosis by activated macrophages 
(Kishore et al., 2005). SP-A has a higher affinity to bind to 
dipamitoylphosphatidylcholine (DPPC), a major constituent of surfactant and is 
considered to play a major role in surfactant homeostasis and surfactant turnover 
(Holmskov et al., 2003, Kishore and Reid, 2001). SP-D preferentially binds to 
phosphatidylinositol (PI) and glucosylceramide sugar moieties and constitutes the 
minor part of surfactant (Kishore et al., 1996). SP-A and SP-D can recognise specific 
PAMPs such as rough LPS, mannose and glucose residues on most microbial ligands 
(Holmskov et al., 2003, Kishore and Reid, 2001). SP-A and SP-D can then engage with 
macrophages, neutrophils, lymphocytes and dendritic cells (Wright, 2004).  They inhibit 
the IgE-allergen cross-linking and prevent histamine release from basophils and mast 
cells and modulates the Th cytokine profile and dampen an inflammatory response 
making them anti-inflammatory.  
 
1.14 Biological Functions of SP-A and SP-D in extra-pulmonary tissues 
Human SP-A and SP-D both have pulmonary and extra-pulmonary existence (Nayak et 
al., 2012). Examples of extra-pulmonary sites include: the placenta, foetal amniotic fluid, 
umbilical cord, amnion, chorion, and decidua, detected from 26 weeks of gestation 
(Fisher and Mason, 1995, Madsen et al., 2000b, Madsen et al., 2003, Madsen et al., 
2000a, Herias et al., 2007). SP-A and SP-D are secreted from the foetal lungs to the 
surrounding amniotic fluid and can be detected from the 2nd trimester where the levels 
increase up to term (Bayer et al., 1973). SP-A and SP-D have been localised by 
Immunohistochemistry in the foetal tissues (amniotic epithelium and chorionic 
membrane) and maternal tissues of the uterus (choriodecidual layers) (Miyamura et al., 
1994). 
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Table 1.3 – Recognition of a range of pathogens by SP-A and SP-D 
Viral  
Virus  Role Reference  
Herpes simplex virus 
(HSV) 
SP-A Opsonisation of HSV via 
oligosaccharides for macrophages 
activation  
(van Iwaarden et al., 1992) 
Influenza A virus (IAV) SP-A binding to IAV via sialic acid to 
stimulate respiratory burst of 
neutrophils. SP-D binding to 
hemagglutinin (HA) inhibiting its 
activity. 
(Hartshorn et al., 1996) 
 
 
(Hartshorn et al., 2000) 
Respiratory syncytial 
virus (RSV)  
SP-A binds to the glycoprotein of RSV 
for opsonisation. 
(Hickling et al., 1998) 
Bacteria 
Bacteria  Role Reference  
Staphylococcus  aureus  SP-D binding to peptidoglycan to 
enhance attachment to macrophages 
without phagocytosis 
(van Iwaarden et al., 1992, 
van de Wetering et al., 2001) 
Escherichia coli  Containing LPS, SP-A Enhances 
macrophage phagocytosis  
(van Iwaarden et al., 1992) 
Streptococcus 
pneumonia  
 
Binds, aggregates, and promotes 
macrophages phagocytosis 
(McNeely and Coonrod, 1994) 
Haemophilus  influenza Binds, aggregates, and promotes 
macrophages phagocytosis 
(McNeely and Coonrod, 1994) 
Klebsiella pneumonae 
K21a strain 
Opsonisation and enhances 
phagocytosis by binding to mannose 
receptor on macrophages. 
(Kabha et al., 1997) 
Mycobacterium 
tuberculosis  
SP-A and SP-D bind via CRD to M.tb to 
enhance attachment to alveolar 
macrophages. SP-D however binds to 
lipoarabinnomannan moiety of Mtb 
bacilli to reduce uptake of bacteria by 
macrophages. 
(Downing et al., 1995, 
Ferguson et al., 1999, 
Ferguson et al., 2002) 
Fungal  
Fungal  Role  Reference  
Pneumocystis  carinii SP-A and SP-D binding to 
glycoprotein 120 (gpA) and β-glucans 
(O'Riordan et al., 1995, 
Zimmerman et al., 1992)  
Candida neoforms SP-A and SP-D recognition and 
binding, SP-D opsonisation enhances 
phagocytosis of aggregates 
(Walenkamp et al., 1999) 
Candida albicans SP-D inhibits hyphae and fungal 
growth and inhibits macrophage 
phagocytosis. SP-A prevents pro-
inflammatory cytokine release from 
macrophages 
(Rosseau et al., 1997, Rosseau 
et al., 1999) 
Aspergillus species SP-A and SP-D bind and agglutinate 
Afu conidia to enhance phagocytosis 
by neutrophils and alveolar 
macrophages, killing of germinating 
conidia. 
(Madan et al., 1997) 
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These proteins are considered to play an important role in the development and 
maturation of foetal lungs for respiratory function in the transition between intra-
uterine to extra-uterine environments. SP-A and SP-D may be involved in the 
maintenance of pregnancy, protecting from infections, possibly in the progression to 
parturition. 
 
1.15 Protective roles of SP-A and SP-D against intra-uterine infections 
SP-A and SP-D are innate immune molecules which can potentially recognise, opsonise 
and enhance clearance of infection from foetal membranes and amniotic fluid by 
interacting with the receptors present on amniotic epithelium and decidual 
macrophages. The clearance of infection is important to prevent threatening 
complications related to preterm birth such as lung infections in preterm neonates 
(Awasthi et al., 2001). Infection-associated preterm birth is accompanied by 
inflammation triggered by bacterial products with increased levels of PGs, cytokines 
and other inflammatory mediators. Clinically referred to as chorioamnionitis, it is most 
common at 26-32 weeks gestation when SP-A and SP-D levels are low (Lahra and 
Jeffery, 2004). Near term, SP-A levels rise sharply (Miyamura et al., 1994). The ability of 
SP-A to inhibit TNF-α secretion from DMs may prevent a premature activation of pro-
inflammatory PG pathways delaying labour (Alcorn and Wright, 2004, Hallman, 2013). 
In addition, SP-A and SP-D are involved in the removal of necrotic and apoptotic cells 
therefore, reducing the risk of provoking an inflammatory response.  
 
1.16 A role for surfactant in parturition? 
Pulmonary surfactant is secreted from the foetal lungs into the surrounding amniotic 
fluid, which accumulates in the third trimester. There is a clear association with 
development of foetal surfactant and survival of newborn, suggesting a possibility that 
spontaneous labour may be triggered by foetal lung surfactant as they are responsible 
for lung maturation (Lopez Bernal et al., 1988). Both SP-A and SP-D are synthesised in 
the 26th week of pregnancy and reaches functional levels at 34 weeks. By 40 weeks 
gestation, the levels of SP-A in human amniotic fluid rise dramatically, from 3 to 24 
µg/ml with a steady rise of SP-D, rising from a 1:1 ratio (SP-A/SP-D at 26-34weeks) to 
6:1 (at 38-40 weeks) at the end of gestation of term pregnancies (Miyamura et al., 1994) 
making it an important factor for foetal lung development before parturition. Therefore, 
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surfactant replacement therapy is important for babies born premature suffering from 
respiratory distress syndrome (Gibson, 1997). The presence of SP-A and SP-D in the 
foetal membranes and the levels of SP-D in the amniotic fluid of mice models giving 
birth at different gestational periods may differ. The levels of SP-D detected in amniotic 
fluid ranged from 5ng/ml to 50ng/ml. The levels of SP-A and SP-D could be detected as 
early as 26 weeks of gestation. The ratio between SP-A and SP-D levels in the amniotic 
fluid are roughly identical between 26-34 weeks of gestation, curiously, there is a large 
surge of SP-A between 37-42 weeks of gestation which is the normal time for 
parturition to deliver the baby at term (Miyamura et al., 1994).  
SP-A levels are good indicators of lung maturity which reflects the timing of birth in 
mice (Condon et al., 2004). Mice SP-A secretion near term activates macrophages in 
amniotic fluid which promotes SP-A migration from the foetal membranes to maternal 
side of the uterus, ultimately withdrawing progesterone to initiate the PG pathway to 
parturition (Condon et al., 2004). As progesterone levels decrease, the NF-κB driven 
inflammatory response increases which drives the foetus to labour (Condon et al., 
2004). SP-A and SP-D from human foetal membranes, amnion and choriodecidua, can 
directly regulate the human maternal uterine cell function in the process of initiating 
labour. SP-A can bind to uterine smooth muscle cells and influence its cell signalling 
pathway to cause uterine contractility (Breuiller-Fouche et al., 2010).  
With increased gestational age, SP-D levels in the amniotic fluid and foetal lung tissues 
increase (Leth-Larsen et al., 2004, Miyamura et al., 1994, Dulkerian et al., 1996). 
Therefore, SP-D can be used as a good biomarker for lung maturation (Inoue et al., 
1994) and prediction of gestational age. Dahl et al, investigated the level of SP-D found 
in capillary blood in infants and umbilical cord blood of newborns. They found the 
median level of SP-D detected in umbilical cord blood from 423 infants was 392.1ng/ml. 
In 130 patients, arterial blood was drawn and showed to have 359.0 ng/ml. The venous 
umbilical cords from 263 cases were shown to have 420.8 ng/ml. The median SP-D level 
in the capillary blood of 233 infants determined to be as 779.5 ng/ml of blood, 
considerably greater than umbilical cord blood. It was evident that low levels of SP-D in 
umbilical cord made a difference in the timing of birth but there was no correlation 
between levels of SP-D in capillary blood and timing of birth (Dahl et al., 2005). 
However, the mode of delivery or the timing of birth did not affect the levels of SP-D. In 
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fact, with progression, SP-D levels decreased in the umbilical cord and, as reported 
earlier, levels of SP-D enter into the amniotic fluid from the pulmonary epithelium to the 
infant (Pfister et al., 2001, Callen et al., 1979, Marino and Rooney, 1981, Berger et al., 
1996, Kalache et al., 2002). 
 
1.17 Immunomodulatory properties of SP-A and SP-D in pregnancy and 
parturition 
Garcia-Verdugo et al (2008) have demonstrated the effects of SP-A on human 
myometrial cells (Garcia-Verdugo et al., 2008). Previous studies show that SP-A binds to 
LPS and interacts with components of the LPS receptor complex such as TLR4 or CD14 
(Sano et al., 2000, Yamada et al., 2006) which modulates macrophages to activate NF-κB 
resulting in production of proinflammatory cytokines (Guha and Mackman, 2001) which 
stimulate uterine contractility and parturition (Condon et al., 2004). 
LPS is another stimulatory molecule initiating an inflammatory response, particularly 
activating macrophages through TLR-4, which are present in the cervix, endometrium 
and uterine tubes (Fazeli et al., 2005). At the time of labour, macrophages can 
synthesise TNF-α which is upregulated by infection (Chen et al., 1991). Microorganisms 
such as Ureaplasma urealyticum, cytomegalovirus, Listeria monocytogenes, parovirus 
B19 and Gardnerella and mycoplasma can damage foetus or induce preterm birth 
(Dortbudak et al., 2005), although the link between inflammation and pregnancy loss is 
evident it is still unclear how to develop strategies for preventing or controlling 
undesirable outcomes.  
SP-A not only activates the transcription factor RELA but also MAPK1/3, protein kinase 
C zeta (PRKCZ) and PTGS2 which are all modulators of uterine contractility (Garcia-
Verdugo et al., 2008). Verdugo et al (2008) also found SP-A binds to LPS receptor 
complexes such as CD14, TLR4 and LY96, inhibiting LPS-induced NF-kB activity to 
prevent an inflammatory response (Garcia-Verdugo et al., 2008). SP-A knockout mice 
show a clear correlation between foetal lung development and the timing of birth. 
Following injection of SP-A into amniotic fluid, high levels of NF-kB, IL-1β and amniotic 
fluid macrophages were expressed which induced mice into early labour (Condon et al., 
2004). Condon et al also showed that by inhibiting these pro-inflammatory cytokines 
using inhibitors (e.g. NF-kB peptide inhibitors) the onset of labour can be delayed 
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(Condon et al., 2004, Haagsman, 2002). Consistent with the previous assessment, 
injection of high levels of anti-SP-A antibodies delays the progression to labour (Condon 
et al, 2004), providing strong evidence that SP-A may play a vital role in the parturition 
pathway in mice. 
1.18 SP-A and SP-D as biomarkers of lung maturation 
Surfactant levels of SP-A and SP-D can be potentially good biomarkers for foetal lung 
maturity for its survival in extra-uterine life. Surfactants reduce the surface tension in 
the lungs to allow sufficient oxygen exchange for function and viability of all organs. 
Deprivation of oxygen to the brain (cerebral hypoxia) can lead to severe brain damage 
and intrauterine growth retardation (IUGR). Surfactants play an important role for 
proper lung function and prevention of acute and chronic pulmonary disorders. 
Therefore, sufficient levels of SP-A and SP-D are important for foetal survival.  During 
labour, hormone levels increase to accelerate foetal lung maturation. Hence, caesarean 
sections without labour can lead to lung malfunction such as respiratory distress 
syndrome (RDS). The ability to assess foetal lung maturations in women with high risk 
pregnancy emphasises the requirement for surfactant replacement for the infant after 
birth. Collection of amniotic fluid via trans-abdominal and trans-vaginal amniocentesis 
is good for clinical diagnostics to assess the risk of RDS. Levels of SP-A rise before birth, 
and 24hours after delivery the levels reach 1.7 µg/ml in normal healthy babies. 71% of 
this level suggests RDS and 83% of this level is the minimum value to place in the non-
RDS category (Satoh et al., 1992). Levels of SP-A are lower in diabetic mothers, 
suggesting insufficient lung development in foetus with diabetic mothers. At 30-31 
weeks gestation, levels of SP-A in healthy foetus’ is ~3µg/ml which rises to 24µg/ml at 
40-41 weeks gestation (Snyder et al., 1988). Therefore, the ability to quantify SP-A 
levels before term is a good potential biomarker for foetal lung maturation and early 
diagnosis for development of lung malfunctions. SP-A levels from foetal amniotic fluid 
can have a significant correlation with the maturation of foetal lung. However, other 
sites which express and have localisation of this protein could also serve as prediction 
markers for diseases. For example, in foetal cord blood levels of SP-A in infants born 
preterm, before 32 weeks gestation, have lower levels of SP-A in cases with RDS 
compared to without. Babies with normal weight born preterm express ~5.8ng/ml SP-A 
in cases with RDS and three times this value (15.1 ng/ml) without RDS. However, this 
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comparison could only be made without accounting for heavy weight babies born 
preterm with RDS, in which these cases had higher levels of SP-A (Cho et al., 2000). This 
suggests that other factors such as heavy weight babies should be taken into account for 
diagnostic purposes. In contrast, mice born preterm have similar levels of SP-A and SP-
D in amniotic fluid with or without infection (Chaiworapongsa et al., 2008). This shows 
one of the many difference between mouse and human foetal pregnancy development. 
SP-A is expressed in amniotic epithelium and chorionic trophoblasts, with levels 
appearing higher by 17.4 folds in chorionic membrane in preterm delivery (PTD) with 
chorioamnionitis than without chorioamnionitis, regardless of labour or no labour. 
Furthermore, the levels of SP-A appear higher at term compare to preterm infants (Han 
et al., 2007). SP-A levels have shown to vary with or without labour and in both 
amniotic fluid as well as cord blood. SP-A levels in cord blood are higher at term with 
labour (between 36-38wks) with 4.8-50.2 ng/ml compare to term with no labour with 
2.7-2 1 ng/ml. Labour shows to increase levels of SP-A at least 2-folds compared to no 
labour (Cho et al., 1999). In contrast, another study has shown that the levels of SP-A in 
amniotic fluid are higher at term with no labour, ranging between 2.2-15 µg/ml 
compare to 1.2-10 µg/ml with labour (Chaiworapongsa et al., 2008). However, levels of 
SP-A increase as gestation to term parturition progresses. At 36-39 weeks SP-A levels 
appear 4.8-50.2 ng/ml and this increases by 39-41 weeks to 12.2-44.6 ng/ml. On the 
other hand, maternal serum shows no significant changes in SP-A levels before and after 
labour, varying from 7-74 ng/ml before labour and 9.6-73.6 ng/ml after labour (Cho et 
al., 1999). This suggests that SP-A could potentially signal to parturition by accelerating 
foetal lung maturation for extrauterine survival and this may be a foetal signal to 
parturition. Furthermore, maternal SP-A may not be a favourable marker for timing of 
birth. Another study has shown that overexpression of methionine allele of SP-D gene 
Met31Thr polymorphism is present in preterm infants compared to term infants and 
this genetic predisposition was only found in foetal tissue not maternal tissue 
(Karjalainen et al., 2012). Thus, the timing of birth can be influenced by SP-A and SP-D. 
Therefore, foetal immune molecules may play an important role in promoting labour. 
Levels of SP-A and SP-D have been detected by various methods to predict foetal lung 
maturity such as ELISA from amniotic fluid (Snyder et al., 1988, Shimizu et al., 1989, 
Satoh et al., 1992) and maternal serum (Inoue et al., 1994), immunoblotting (Wiehle et 
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al., 1995), immunohistochemical staining (Khoor et al., 1993, Sati et al., 2010) and stable 
microbubble test (Kumazawa et al., 2003). The ability to detect the levels of SP-A and 
SP-D accurately is going to be useful for reducing neonatal morbidity in infants born 
with RDS. 
SP-A and SP-D genes are independently regulated in foetal lung tissue throughout 
gestation. The mRNA and protein levels can be detected in foetal lungs at the end of the 
2nd trimester of pregnancy (after 75% gestation), whereas, SP-B and SP-C can be 
detected much earlier before differentiation of type II cells. There is some evidence 
which show SP-D to express in bronchial epithelium and alveolar epithelial type II cells 
in human foetal lung as early as 12 weeks of gestation which gradually increases during 
the canalicular and saccular stages, gradually intensifying throughout gestation (Chen et 
al., 2005). During the second trimester, at 19-20 weeks gestation, SP-A mRNA and 
protein can be localised in tracheal epithelium in mucosal folds, bronchial epithelium 
and glands, bronchial cells and pre-type II cells lining the airways of human foetal lungs 
(Khoor et al., 1993). SP-A, SP-B, SP-C and SP-D can be located in extra-pulmonary sites 
such as the placenta, in particular; trophoblastic layers of chorionic villous tree, 
trophoblastic cell columns, stromal cells, hofbauer cells, angiogenic cell cords and 
vascular hematopoietic cells (Sati et al., 2010). SP-D has been localised in all villous and 
extra-villous trophoblast subpopulations and in the endometrium at the secretory 
phase of menstruation. SP-A and SP-D are also present surrounding the placenta such as 
amniotic fluid, foetal membranes and in foetal serum. This indicates these innate 
immune molecules serve important function in protection again uterine infections and 
from the moment of implantation during pregnancy. 
1.19 Hormonal regulation of SP-A and SP-D biosynthesis 
The two genes, SP-A and SP-D are regulated differentially by cAMP and glucocorticoids 
(McCormick and Mendelson, 1994). Cyclic AMP analogs such as PGE2 (Odom et al., 
1987) increase SP-A mRNA (and SP-A protein) levels (Boggaram and Mendelson, 1988). 
Glucocorticoid levels are capable of stimulating and inhibiting the expression of SP-A in 
foetal lung tissues in vitro (Boggaram and Mendelson, 1988, Boggaram et al., 1988, 
Khoor et al., 1994). In vitro studies of human foetal lung from mid-trimester (15-18 
weeks) have shown that 10-9 and 10-10 M glucocorticoid levels stimulate SP-A mRNA 
levels but any higher level have an inhibitory effect (Boggaram et al., 1989). However, 
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glucocorticoid receptor antagonist RU487 can reverse these inhibitory effects 
(Boggaram et al., 1991). Glucocorticoid can also increase SP-D levels in vitro (Dulkerian 
et al., 1996) and rat maternal administration of glucocorticoid stimulates SP-D mRNA 
(Deterding et al., 1994, Mariencheck and Crouch, 1994) and protein levels (Mariencheck 
and Crouch, 1994) in foetal lungs. Hormone dexamethasone has also shown to regulate 
SP-A mRNA levels (McCormick and Mendelson, 1994), which can also be regulated in 
response to TGF-β. In one study, TGF-β family increases SP-A mRNA in human foetal 
lung tissues (Ballard et al., 1990), whereas another study appears to show TGF-β to 
inhibit SP-A mRNA (Beers et al., 1998) and protein (Whitsett et al., 1987) expression in 
human foetal lung. TNF-α, has been shown to inhibit SP-A mRNA expression via p38 
signal transduction pathway (Miakotina and Snyder, 2002). Thus, inhibition via protein 
kinase C could result in lung tissue damage by inflammation. In preterm labour, levels of 
IL-1β and SP-A are high except in the incidence of RDS in preterm labour (Watterberg et 
al., 1996), suggesting IL-1β is also important in regulating surfactant levels and 
promoting lung maturation. 
SP-B and SP-C are independently regulated to SP-A and SP-D, suggesting the levels are 
regulated by different stimulus. Cyclic AMP and glucocorticoids regulate the levels of 
SP-A transcriptionally and both at a gene and protein level respectively. Glucocorticoids 
are clinically used to accelerate foetal lung maturation and can stimulate SP-A and 
inhibit mRNA stability to regulate its levels. Combination of both cAMP and 
glucocorticoids synergistically increase SP-A gene transcription (Mendelson and 
Boggaram, 1990). SP-A is involved in surfactant function and reutilisation by type II 
cells (Mendelson et al., 1991). Cyclic AMP and glucocorticoids affect level of SP-A gene 
expression in mid-trimester of human foetal lung in vitro (Mendelson et al., 1991). PGs 
also play an important role in regulating SP-A levels, as it has been shown, PGE2 and 
PGF2α, the main stimulators for myometrial contractility, when inhibited by 
indomethacin inhibits cAMP formation and, thus, SP-A gene expression. However, 
further stimulation by PGE2 reverses this effect (Mendelson et al., 1991), suggesting 
that PG indirectly regulates SP-A through cAMP. However, the effects of SP-A and SP-D 
on PGs have not yet been investigated. Another corticosteroid drug, dexamethasone, has 
been shown to alter the levels of SP-A by either stimulating or inhibiting its expression 
in human foetal lungs (Boggaram et al., 1991). At high levels the drug inhibits SP-A 
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expression and at lower levels inhibits PG expression. This suggests that SP-A is not 
entirely dependent on cAMP generation by PGs and that other hormones are involved in 
increasing cAMP levels. Therefore, levels of PGs do not necessarily reflect the level of 
SP-A production. However, the production of cAMP is important for the development 
for foetal lung tissue. This has been shown in an earlier study where human foetal lung 
tissue cultured without serum and hormones increased cAMP levels by 140% within 3-
6 days. The addition of isobutylmethylxanthine further doubled cAMP levels and SP-A 
mRNA and protein levels, which was then inhibited by indomethacin. Indocmethacin 
also inhibits SP-B expression, phosphatidylcholine and activity of fatty acid synthase, 
suggesting its possible role to delay labour. However, parallel stimulation of 
indocmethacin with PGE1 and PGE2 further stimulated cAMP levels, reversing the 
inhibitory effects in high PG content. As a result, levels of SP-A increase and showing the 
strong effects of PGs to stimulate the induction to labour (Ballard et al., 1991). This 
suggests indomethacin near term may not be a strong competitive drug to delay labour 
due to the stronger effects of PGs. This also suggests PGs, in particular PGE1 and PGE2, 
are important for accelerating alveolar type II epithelial cell differentiation by 
increasing cAMP production to accelerate foetal lung maturation near term. 
PGs regulate the synthesis of cAMP, PGE stimulates cAMP as a signal for smooth muscle 
cell contraction of the uterus during labour. PGE1 and PGE2 bind to their hormone 
receptors which subsequently stimulates cAMP synthesis because the receptor is paired 
with adenylyl cyclase through its stimulatory G protein (GPC). If an inhibitory G-protein 
(Gi) is coupled to the receptor, the signal will not be sent across the membrane. Another 
transporter molecule responsible for regulating the signal across the cell membrane is 
the human prostaglandin (hPG) transporter (Lu et al., 1996). This transports PGE1, PGE2 
and PGF2α with high affinity (Lu et al., 1996, Itoh et al., 2006) with the adenyl cyclase 
activity. The ability of PGs to bind to transmembrane receptors (G-protein-coupled-
receptors) allows their diffusion through tissues. 
SP-A regulates surfactant uptake and recycling, and thus its deficiencies results in 
diseases such as neonatal RDS. Therefore, regulating the levels of SP-A and SP-D before 
birth is important for proper lung function. Diabetic mothers are hyperinsulinemic and 
have increased rate of neonatal RDS due to surfactant production deficiency by alveolar 
type II cells. Studies have shown that insulin inhibits accumulation of SP-A and SP-B, but 
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not SP-C mRNA levels in human foetal lungs (Sugahara et al., 1994). In this case 
glucocorticoids are used to accelerate foetal lung maturation. Low levels of cortisol 
stimulates SP-A by 20% whereas high levels of cortisol decrease SP-A by 50% but 
increase SP-B and SP-C. Low levels of cortisol, when combined with insulin, also 
decreases SP-A expression. However, surprisingly, high levels of cortisol when 
combined with insulin show a stimulatory effect on SP-A mRNA expression (Dekowski 
and Snyder, 1995). This suggests cortisol in high doses can accelerate foetal lung 
maturation in diabetic mothers undergoing insulin treatment. 
The foetal pituitary gland also regulates hormonal release such as cortisol and PGs. 
Cortisol is known to stimulate foetal lung maturation and stimulate the conversion of 
progesterone to oestrogen to promote uterine contractility and cervical ripening. PGs 
are important for both cervical ripening and myometrial contractility. The foetal 
membrane produces predominantely PGE2 and the decidua produces mainly PGE2α to 
promote cervical ripening and myometrial contractility respectively. Labour is 
associated with increased PG concentrations in both amniotic fluid and maternal 
membrane as well as systemic circulations. If we know how SP-A and SP-D affects the 
PG production and influences the timing of birth we could look at the levels of PGs in 
maternal serum and estimate the risk of mothers to enter preterm birth. Therefore, the 
levels can be regulated by inhibiting the levels of PG to normal levels.  
Cortisol has been shown to stimulate SP-A mRNA expression and SP-A up-regulates 
PGE2 release in chorionic trophoblasts by induction of COX-2 (also known as, PTGS2) 
and microsomal PGE synthase (Sun et al., 2006). Recently, it has been shown that SP-A1, 
SP-A2 and SP-D mRNA expression is predominant in the choriodecidua, and SP-D 
predominantly in the amnion at the end of pregnancy (Breuiller-Fouche et al., 2010). 
This suggests the signal for parturition could be initiated from the foetus and SP-A could 
be a strong contributor to the PG pathway to initiate parturition. The effect of the 
increasing levels of SP-A and SP-D has been shown to induce stress fibre formation in 
cultured myometrial cells via Rho-kinase pathway. Thus, it is important to understand 
the mechanism of myometrial contractility and how the increasing levels of SP-A and 
SP-D can affect it. SP-A has been shown to exert a paracrine effect on F-actin filament in 
the organisation of myometrial cells to induce contraction and parturition (Breuiller-
Fouche et al., 2010). Again, this study also shows that the level of SP-A and SP-D 
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affecting the parturition physiology is from the foetal side. This emphasises the foetus 
plays an important role in parturition and the increasing levels of extra-pulmonary 
surfactant proteins could be huge contributors to stimulating the pathway to labour and 
can potentially help predict the timing of birth. 
 
1.20 Regulation of pro-inflammatory and anti-inflammatory immune responses 
by SP-A and SP-D during pregnancy 
Although SP-A and SP-D are well known as the pulmonary innate immune molecules 
involved in clearing infection, the immunological significance of SP-A and SP-D during 
pregnancy has not been well understood. The placenta is an interesting, yet complex, 
organ which expresses both paternal and maternal antigens which can potentially be 
attacked by the maternal immune system. They escape the maternal immune system by 
releasing immunosuppressive cytokines such as IL-6 activated IL-6-receptor-mediated 
signal transduction pathways to produce hCG. IL-1 and TNF-α augments IL-6 
production to stimulate hCG production. On the other hand, TGF-β has opposite effects, 
suppressing IL-6 production and cytokine mediated hCG production (Matsuzaki, 1994, 
Strayer et al., 1997). In support to this, TGF-β inhibits Ca2+ influxes, which is a negative 
feedback regulator for SP-A (Strayer et al., 1997). This suggests TGF-β regulates and 
modulates intracellular Ca2+ signalling.  IL-6 from cord serum has been shown to 
stimulate SP-A synthesis to promote lung maturation and reduce chances of RDS. IL-6 
derives mainly from chorionic trophoblast cells as well as IL-8 and monocyte 
chemotactic and activating factor (MCAF) which are expressed actively in the 3rd 
trimester for potential defence against chorioamnionitis during pregnancy (Matsuzaki, 
1994). Therefore, these cytokines do not only promote acute-phase protein synthesis 
but also augment the immune defence against infection. IL-1β has stimulatory effects in 
increasing SP-A mRNA levels to promote lung maturation as it has been shown in horn 
foetal lungs (Bry et al., 1997). However, IL-1 activity is high in cases of intraamniotic 
infection associated with preterm labour although it is a lung stimulatory cytokine to 
perhaps prepare foetus for extrauterine life. Murine models have shown SP-A to induce 
the NF-κB pathway, upregulating TNF-α and IL-10 for TLR-4 function in response to 
pathogens and endogenous host mediators (Guillot et al., 2002). In human foetal 
immune system, TNF-α augments IL-6 production and IL-6 stimulates SP-A synthesis to 
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promote lung maturation, whereas, in mice, SP-A shows to regulate TNF-α level to 
protect the host. Another study by Condon et al, 2004, has also shown in mice foetal 
lungs, SP-A stimulates IL-1β to activate NF-κB in cultured amniotic fluid macrophages. 
This leads to the migration of foetal amniotic fluid macrophages to the uterus with 
advancing gestation.  
Parturition has also been associated with prostaglandin release (Keirse, 1978) 
suggesting a possible relation of surfactant and prostaglandins. Studies show 
arachidonate as a precursor for prostaglandin synthesis by phopholipase A2 and 
arachidonate includes 4% of foetal surfactant. However, arachidonic acid is transferred 
from surfactant arachidonylphophatidylcholine to aminocyte 
phosphatidylethanolamine and PI by sequential actions from phopholiase A2 and 
phopholipase C and diacylglycerol lipase (Okita et al., 1982). Moreover, phospholipase C 
and monoacyl- and diacyl-glycerol lipases directly degrade surfactant released from 
foetal lungs to contribute to the pool of free arachidonate in amniotic fluid (Bernal and 
Phizackerley, 2000). Therefore, amniotic epithelium provides a source of arachidonic 
acid for prostaglandin synthesis during labour.  
As previously shown, SP-A up-regulates PGE2 release in chorionic trophoblasts by 
induction of COX-2 (Sun et al., 2006). However, Lee et al, 2010 cultured human amnion 
explants incubated with SP-A to see inhibitory cytokine-cytokine receptor interaction, 
down regulating IL-1β and COX-2, suggesting SP-A maintains pregnancy and promotes 
an anti-inflammatory environment during pregnancy (Lee et al., 2010). Mice models 
have shown that SP-A is critical for the onset of labour (Condon et al., 2004) and further 
investigation supports this view in humans. Labour is characterised by decidual 
activation with the production of pro-inflammatory mediators. A recent study 
investigated the effects of SP-A (100µg/ml) in human decidua. The results reveal that 
SP-A inhibits PGF2α in term decidual stromal cells without affecting other inflammatory 
mediators and SP-A decreases in decidua with labour (Snegovskikh et al., 2011). This 
contradicts the reported increasing levels of SP-A as it has been shown in amniotic fluid, 
amnion and chorionic membrane, therefore the net levels of SP-A in the 3rd trimester 
has been shown to increase. Perhaps the levels of SP-A used in this study was 
unrealistically high, and therefore, shows contradictory results. In sheep, LPS 
instillation in intra-amniotic fluid causes PGE2 expression to increase in foetal lung, 
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which has been established to promote foetal lung maturation and surfactant 
production (Westover et al., 2012). SP-D knockout mice, when challenged with LPS, 
show increased expression of TNF-α, suggesting SP-D promotes an inflammatory 
response in mice (Salminen et al., 2012). It has been postulated that the maintenance of 
pregnancy i.e. quiescence is maintained by increasing progesterone receptor 
transcriptional activity and therefore, spontaneous labour is initiated by biochemical 
events which negatively influence the progesterone receptor (Mendelson and Condon, 
2005). Thus, it could be interesting to see if SP-A could down-regulates the 
progesterone receptor and therefore serve as a hormone to the initiation of labour.  
 
1.21 Lung deficiencies and Preterm birth 
Preterm birth has shown to be the leading cause of infant mortality and morbidity and 
is associated with chronic respiratory illnesses (Berkowitz, 1993, Kramer et al., 1987, 
Hillier et al., 1988, Goldenberg et al., 2000). Lung injury and lung immaturity are the 
major contributors to infant mortality and morbidity (Horbar et al., 2002). The cases of 
preterm birth are continually on the rise and are associated with diseases. 1/10 
preterm born children have been shown to develop a permanent disability such as lung 
disease and cerebral palsy. 80% of extremely preterm babies (before 26 weeks) develop 
some form of disability (Marlow et al., 2005). There is great evidence to suggest preterm 
babies born before 36 weeks in the third trimester have a high incidence of respiratory 
diseases such as acute respiratory distress syndrome (ARDS) (Wang et al., 2004). This is 
supported by Rubaltelli et al, who have documented 30.8% of preterm neonates born 
between 34-36 weeks gestation had respiratory problems (Rubaltelli et al., 1998). The 
three main respiratory diagnoses associated with preterm labour are: respiratory 
distress syndrome (RDS), tachypnea, pneumonia and respiratory failure (Hibbard et al., 
2010). This highlights the importance of full lung development of the neonate for 
defence against respiratory pathogens and the maturation of lungs being vital in the full 
gestational time. There are, however, interventions to aid in lung maturation such as 
antenatal treatments with corticosteroids to induce lung maturation in infants who are 
at risk of preterm delivery before 32-34 weeks gestation (Crowley, 2000). However, due 
to lack of knowledge and understanding of the underlying causes and mechanisms of 
labour, it is difficult to manage the timing of birth effectively.   
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1.22 Hypothesis/objectives 
The main objectives of this thesis were; to investigate how SP-A and SP-D modulate the 
PG pathway and the cytokine profile which influences the pregnancy and labour 
initiating myometrial contractility and membrane rupture. As SP-A and SP-D not only 
influence the hormonal pathway which leads to birth, but are also important in the 
clearance of infection. It has been examined how they maintain a balance in playing a 
protective role during pregnancy and modulate the expression of PGF2α and COX-2, the 
two potent stimulators of the PG pathway and parturition. The rationale is that SP-A 
and SP-D serve as a source of arachidonic acid influencing the rate of PG synthesis. The 
main prostaglandin expression here is PTGS2 which synthesises PGDH – the first 
prostaglandin protein. The receptor expression being focused is PTGFRN, a negative 
regulator receptor for PGF2 – the most potent prostaglandin which accelerates the 
pathway to result in myometrial contractility. IL-1β, which mimics an inflammatory 
response of labour will be used as a positive control for treating amnion, chorion and 
decidua to examine the effects of SP-A and SP-D. To examine the protective roles of SP-A 
and SP-D, the influence of these proteins on the expression of TLRs and cytokines is also 
the focus of this research (Figure.1.20) This will highlight the balance between 
protection against infection and maintenance of pregnancy as well as the induction of 
labour by SP-A and SP-D and any dysfunctions could affect normal pregnancy leading to 
preterm birth, miscarriages, preeclampsia, IUGR and ARDS. 
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Figure 1.19 – Representation of immunomodulation of successful pregnancy and pregnancy 
loss. (Druckmann and Druckmann, 2005). Those highlighted in red were examined in the present 
study (see chapter 4). 
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1.23 Synopsis  
In this PhD thesis, the following objectives have been achieved: 
Chapter 3 – Focuses on the production of full length and homotrimeric lectin domains 
(CRD regions) SP-A and SP-D molecules. In order to purify human native SP-A and SP-D, 
pooled amniotic fluid from term labour was used via affinity chromatography, ion-
exchange and gel filtration. Full length human SP-A1 gene was also cloned and 
expressed in HEK-293T cells as a transient expression system. The gene fragment 
containing neck and CRD region of human SP-A was expressed first under 
bacteriophage T7 promoter system as inclusion bodies, followed by denaturation and 
re-naturation procedure and affinity purification. A similar version of homotrimeric 
CRD region of human SP-A was also expressed using gene fusion technology where an E. 
coli maltose-binding protein (MBP) was used as an affinity partner in order to yield 
soluble form of recombinant protein. The gene fragment containing neck and CRD with 
8 Gly-X-Y amino acids from human SP-D gene was expressed under the bacteriophage 
T7 promoter system as inclusion bodies. This was followed by denaturation and re-
naturatation procedure followed by affinity purification using maltose-agarose column. 
These proteins were characterised for their immunogenicity and primary ligand binding 
abilities prior to their use using placental tissues. The levels of LPS were also measured 
in order to obviate potential pro-inflammatory response due to TLR pathway.    
Chapter 4 – presents the effects of SP-A and SP-D and their truncated versions on the 
hormonal and immunological pathway related to pregnancy and labour. This was 
achieved by making amnion, chorion and decidua (ACD) explants and treating these 
with either IL-1β as inducers of pro-inflammatory immune response. This response was 
also examined in the presence of various versions of SP-A and SP-D molecules in terms 
of production of pro-inflammatory and anti-inflammatory cytokines, prostaglandin 
pathway enzymes and innate immune pattern recognition receptors (PRRs) such as toll-
like receptors (TLRs).  
Chapter 5 – starts with immunohistochemical (IHC) staining in order to localise SP-A 
and SP-D (and its cognate receptor calreticulin) in ACD explants, decidual tissue, 
umbilical cord, placenta and myometrium. Having established the differential existence 
of SP-A and SP-D in these tissues, this study focuses on localisation and fractionation of 
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decidual macrophages (DMs) in the decidual tissues. Since DMs are central to protective 
response against pathogens and inflammations, it was considered imperative to 
examine the immunomodulatory effect SP-A and SP-D can have on resident DMs under 
inflammatory conditions. 
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Chapter 2:  
General Methods and Materials  
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2. General Methods and Materials 
2.1 Collection of pooled amniotic fluid from term labour 
Ethical approval was obtained from Brunel University, Bristol Hospital and Warwick 
University Hospital. All women were consented for obtaining placental, amniotic and 
BALF samples. 
Amniotic fluid is normally collected either following vaginal rupturing of the foetal 
membranes or during spontaneous rupturing. The collected amniotic fluid is usually 
equilibration with 5 mM CaCl2 and stored at -80°C until it is required for purification. 
1 L of pooled amniotic fluid was completely thawed by incubating at 37°C (~ 5-6 hours) 
with occasional mixing. The fat and large aggregates/debris from amniotic fluid were 
sieved through a 3 mm Whatman filter paper three times then through a cell strainer 
twice for a clearer suspension and to avoid future clogging of maltose-sepharose 
column. The SP-A rich pellet was separated from the SP-D rich supernatant by 
centrifugation at 10,000 x g for 40 mins at 4°C. 
2.2  Preparation of Maltose Sepharose 
Prior to Sepharose 4B activation with divinylsulphone (DVS), Sepharose beads were 
washed extensively. Firstly, 100 ml of Sepharose 4B was washed with autoclaved 
deionised water (dH2O) centrifuging at 5,000 rpm for 5 minutes each time. After 
decanting the water, the Sepharose 4B was suspended in 100 ml of 0.5M sodium 
carbonate pH9.5 and stirred at room temperature whilst slowly adding 10 ml DVS drop-
by-drop. The activated Sepharose was left stirring at room temperature for 1 hour 
inside a fume hood, then transferred to a Buchner funnel with filter paper and was 
washed extensively with 3 litres of autoclaved water. The gel was then suspended in 
20% maltose solution made in 0.5% sodium carbonate (Na2CO3) for a further 
incubation overnight on a magnetic stirrer. Under these conditions the Sepharose 
couples to the hydroxyl groups of D-maltose. After 24 hours, the gel was washed with 2 
litres autoclaved dH2O through a Buchner funnel lined with filter paper and then 
washed with 2 litres of 0.5% sodium bicarbonate (NaHCO3). The gel was suspended in 
100 ml 0.5% sodium bicarbonate containing 5% 2-merceptoethanol to block excess 
vinyl groups and mixed for a further 3 hours at room temperature before washing 
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through a funnel with 2 litres of autoclaved dH2O. The maltose-Sepharose was stored in 
affinity column buffer containing 0.02% sodium azide at +4°C. 
2.3  Competent cell and transformation into BL21 (λDE3) and BL21 (λDE3) pLysS 
A single colony of BL21 (λDE3) pLysS was inoculated in 5 ml LB containing 5µl of 
chloramphenicol (50 mg/ml) and incubated overnight in a 37°C shaker at 2000 rpm. 
The next day, 1 ml of primary inoculum was transferred into 25 ml LB containing 50 
mg/ml chloramphenicol. This was incubated for 2-3 hours in the shaking incubator for 
cells to grow to log phase indicated by 0.3-0.4 OD against plain LB medium at 600 nm. 
After correct OD had reached, the sample was centrifuged at 2500 rpm for 10mins to 
collect BL21 (λDE3) pLysS cells to pellet. The supernatant was discarded the pellet was 
resuspended in 12.5 ml of 0.1 M CaCl2. The resuspended pellet was incubated on ice for 
1 hour to make cells competent. The cells were again centrifuged at low speed 
centrifugation of 2500 rpm for 5 mins to pellet the cells. After discarding the 
supernatant, the pellet was resuspended cells in 2 ml 0.1 M CaCl2 that was ready for 
transformation. 
Firstly, 200 µl of competent cells was transferred into a sterile 2 ml eppendorf tube and 
100 ng of plasmid was added. This was mixed by flicking the tube to allow DNA to enter 
the competent cells followed by incubation on ice for 1 hour before applying heat shock 
at 42°C for 90 secs to allow transfer of DNA material. The nuclear pore was closed by 
transferring the tube to ice for 5 minutes. 800 µl of LB was added to the cells and placed 
in a 37°C incubator for 45 mins to allow 1 complete cell cycle replication to take place. 
100 µl of competent cells was spread on an LB agar plate containing ampicillin and 
chloramphenicol 
Note: when using BL21 (λDE3) for transforming pMalC-2 containing MBP fused SP-A 
gene, no antibiotics were used for inoculation of E.coli strain. After transformation, 
transformed cells were streaked on agar containing ampicillin plates and thereafter, 
colonies were inoculated in LB media containing ampicillin. 
2.4  Transformation into OneShot TOP10 competent cells 
Transformation of plasmids into OneShot TOP10 competent cells (Invirtogen, Paisley, 
UK) were carried out according to manufacturer’s recommendation. TOP10 competent 
cells have a transformation efficiency of 1 x 109 cfu/µg supercoiled DNA and allow 
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stable replication of high-copy number plasmids. In brief, 2 vials of TOP10 competent 
cells were thawed on ice and transformation was taken place immediately after 
thawing. 3 µl of overnight incubated ligation mixture was added directly to one vial of 
TOP10 competent cells and mixed by flicking the tube gently. The second vial was used 
as a control so no DNA was added to this. Both vials were incubated on ice for 1 hour 
then heat shocked for the uptake of plasmid at 42°C for 90 seconds in a water bath. The 
vials were then placed on ice for 5 minutes to close cellular pores and prepare for 
replication in S.O.C medium. Aseptically, 250 µl of pre-warmed S.O.C medium was added 
to each vial and placed in an incubator set at 37°C for 1 hour. 50 µl of the culture was 
spread on an ampicillin/agar plate and left overnight at 37°C for colonies to form. 
 
Cloning of recombinant full length SP-A1 in pSecTagC 
2.5 PCR with High Phusion DNA polymerase 
cDNA of full length SP-A cloned into pSecTagC (primer sequences mentioned on p.91) 
was used to amplify neck and CRD region to create trimeric SP-A. High-Phusion DNA 
polymerase (Thermoscientific-F-553 S) has a superior advantage over the tradition Taq 
polymerase as it has an error rate 50-fold lower than Taq. High Phusion DNA 
polymerase has a high thermostability and produces higher yields with lower amount of 
enzyme and in the presence of RNA inhibitors. This makes it more convenient and 
reliable for its use making it great to use for high performance PCR and cloning, which is 
fit for our purpose. 
The necessary reagent provided in the kit contains; Phusion DNA Polymerase 2 U/μl, 5X 
Phusion HF Buffer and dNTP mix (10 mM each). Phusion HF buffer and 1 Unit of DNA 
was added to <250 ng template DNA per 50 µl reaction. Forward and reverse primers 
were used at a final concentration of 10 mM. No template DNA was added to the master 
mix but directly to the tubes and control tube contained water as a substitute to DNA. 
The final volumes of the components in each tube are listed in table (Table 2.1) 
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Table 2.1 – PCR tubes set up to amplify SP-A neck and CRD region using Phusion DNA 
polymerase. 
Component R x n – 50 µl Master mix 4 x n 
5 X Phusion HF buffer 10 40 
10 mM dNTPs 1 4 
10 mM F.Primer 2.5 10 
10 mM R.Primer 2.5 10 
Template DNA 1.5 (6) 
Phusion DNA polymerase 0.5 2 
Nuclease free water 32 128 
TOTAL 50 200 
 
In the 4 labelled tubes, 48.5 µl of master mix was added and 1.5 µg DNA was added 
directly to the tubes except the control tube. 1.5 µl of nuclease free waster was added 
directly to the control tube. The samples were mixed well and loaded into a 
thermocycler at condition mentioned in the table 2.2. Initially, a denaturation of 2 
minutes takes place to separate the double stranded cDNA. This is followed by 30 cycles 
of denaturation (10 secs @ 98°C), annealing of primers (20 secs @ 59°C) and extension 
(1 min @ 72°C) to allow complementary bases bind to make a copy of the template 
strand. At each cycle the amount of DNA doubles. At the end of the reaction there is a 
final extension to complete the cycle. 
Table 2.2 – Thermocycler conditions for PCR with Phusion DNA polymerase 
Thermocycler condition 
Initial denaturation 98°C 2 mins 
30 CYCLES: 
Denaturation  98°C 10 secs 
Annealing 59°C 20 secs 
Extension 72°C 1min 
Final extension 72°C 10 mins 
Store  4°C 
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2.6 Agarose-EtBr gel – 0.7%  
0.7% agarose-EtBr gel was prepared by dissolving 0.35 g agarose powder into 50ml 1 X 
TBE (Tris/Borate/EDTA) buffer and after cooling to hand bearable temperature, 5 µl 
ethidium bromide was mixed before pouring into the casting gel apparatus. After the gel 
had solidified (between 30 mins-1 hour), 1 X TBE buffer was poured over the gel and 
into the tank. The comb was removed and the samples were added. 10 µl of each sample 
were mixed with 6 X DNA loading dye and loaded into the wells with 5 µl DNA marker 
(Hyperladder I – Bioline). The DNA was separated at 70 V for 1.5-2 hours and the bands 
were observed under the transilluminator before capturing an image on the Molecular 
Image Gel Doc XR+ (Bio-Rad, Hemel Hempstead, UK).  
2.7 Gel extraction (QIAquick Gel Extraction kit – QIAGEN) 
After fractionating the DNA PCR product on a 0.7% agarose gel, the PCR product was gel 
extracted using Qiaquick Gel extraction kit (Qiagen, Manchester, UK) according to the 
manufacturer’s protocol. In brief, initially the fragment was excised using a sharp blade 
and added to a 2 ml eppendorf tube. This was weighed and 3 volumes of Buffer QG was 
added (100 mg ~ 100 µl) and incubated in a water bath at 50°C for 12 mins mixing 
occasionally to help dissolve the gel. 1 volume of isopropanol was added directly to the 
dissolved sample and mixed. The suspensions were transferred to a QIAquick spin 
column provided with a 2 ml collection tube. The sample was centrifuged for 1 min at 
the highest centrifugation speed to allow DNA to bind and the flow-through was 
discarded. This was repeated until all content was spun and maximum DNA was 
collected. As the DNA was to be sent for sequencing the column was washed with 0.5 ml 
Buffer QG and centrifuged at 13,000 rpm for 1 min. The DNA was washed with 0.75 ml 
washing buffer, Buffer PE, after incubating for ~5 minutes. Again, the column was spun 
at 13,000 rpm for 1 minute. The flow-through was discarded and the column was spun 
again to remove residual wash buffer. In a clean 1.5 ml microcentrifuge tube, the 
column was added and 50 µl of elution buffer was added and incubated for ~5 minutes 
before centrifuging at 13,000 rpm for 1 min. The quantity and purity of eluted DNA was 
assessed via NanoDrop. The plasmid was transformed into TOP10 E.coli competent cells 
and grown for plasmid isolation and digestion. 
 
63 
 
2.8 Plasmid extraction mini kit 
Plasmid isolation (Qiagen, Manchester, UK) was carried out in order to subject each 
plasmid for restriction digest to check if gene was correctly inserted. Consequently, the 
plasmids containing the gene of interest were sent for sequencing (Beckman Coultier, 
UK). Plasmid isolation was carried out according to manufacturer’s recommendations. 
Briefly, 3 colonies of the transformed cells were selected and individually inoculated in 
6 ml LB + ampicillin (100 µg/ml) and grown overnight in a shaking incubator at 220 
rpm. The next day, 1 ml of the culture was reserved for possible streaking and 5ml of 
the culture was centrifuged in a swing-bucket centrifuge at 5000 rpm for 7 mins. The 
pellet was retained and resuspended in 250 µl Buffer P1 (containing RNase) prior to 
transferring into a clean microcentrifuge tube. 250 µl of Buffer P2 was added and mixed 
thoroughly to lyse the cells until the solution appeared clear. The reaction was 
neutralised with 350 µl of Buffer N3 and mixed immediately by thoroughly inverting the 
tube several times causing the solution to become colourless. This was centrifuged at 
13,000 rpm for 10 minutes in a table-top microcentrifuge. The supernatant was passed 
through a QIAprep spin column by centrifugation at 13,000 rpm for 1 min to allow DNA 
to bind. The column was washed with 0.5 ml Buffer PB to prevent contamination of DNA 
by centrifugation prior to further washing of DNA with 0.75 ml Buffer PE containing 
ethanol and again was centrifuged at 13,000 rpm for 1 minute. The flow-through for 
each sample were discarded after each step and further centrifuged to remove residual 
ethanol contaminants from DNA. Finally, to elute the DNA, 50 µl of Buffer EB was added 
directly to the membrane of the spin column and incubated for ~5mins before 
centrifugation at 13,000 rpm for 1 min. Each plasmid was subjected to digestion to 
check if the gene of interest was inserted.  
2.9 Plasmid digestion 
Colonies were selected to verifying insert of gene of interest. Each colony were 
inoculated in 5 ml LB containing 100 µg/ml ampicillin and grown for 12-17 hours at 
37°C. Cultures were harvested at 5,000 x g for 8 minutes before extracting plasmid with 
mini prep plasmid isolation kit (Qiagen, Manchester, UK) according to manufactures 
recommendation. For digestion, 10 µl of extracted plasmid from each colony were 
incubated in a 50 µl reaction containing 2.5 µl EcoRI and XhoI each, 10 µl 10x BSA and 
5µl NEB buffer 4 incubating at 37°C for 3 hour. The products were verified on an 
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agarose-gel and visualised under a UV Transilluminator (Bio-Rad, Hemel Hempstead, 
UK).  
Colony containing and verified for the gene of interest was subjected to large scale 
plasmid extraction with EZNA FastFilter (VWR, Leicestershire, UK), according to 
manufactures recommendation. Large scale plasmid extraction was used for 
transfection in HEK-293T cells. 
2.10 Plasmid isolation large scale EZNA fastfilter (VWR, Leicestershire, UK) 
Large scale plasmid isolation was carried out to prepare large amounts of plasmid 
pSecTagC and pSecTagC containing full-length human SP-A for expression in 
mammalian HEK cells. EZNA fastfilter was used according to manufactureer’s 
recommendation. Initially, one colony was inoculated in 100 ml of LB containing 
Ampicillin and grown overnight in a shaking 37°C incubator. The next day, the culture 
was pelleted at 3500 rpm for 10 mins. To the pellet, 2.25 ml of Solution A/RNase A was 
added to resuspend the cells. This was then transferred to centrifugation tube capable 
of withstanding 12,000 x g and 2.25 ml of Solution II was added and mixed gently by 
inversion 8-10 times until a flocculent white precipitate was formed. The suspension 
was again centrifuged at 12, 000 x g for 10 mins at room temperature. To a HiBind DNA 
Midi column pre-inserted in a 15 ml collection tube (supplied in kit), 1 ml of 
equilibration buffer was added and incubated for 4-5 mins at room temperature before 
centrifugation at 3000 x g for 3 minutes in a swing-bucket centrifuge. The supernatant 
containing DNA was added to the equilibrated column and centrifuged at 3,000 x g for 5 
mins, flow-through was discarded and repeated to centrifuge the entire content of 
supernatant. To the column, 3 ml of Buffer HB was added to allow further binding of 
DNA to the column and centrifuged at 3,000 x g for 5 mins. The column was washed to 
remove residues using 3 ml of DNA wash buffer diluted with absolute ethanol to the 
Midi column and centrifuged as repeated above. The flow-through was discarded and 
the collection tube was re-used.  Washing step was repeated again and then the column 
was centrifuged to remove excess wash buffer and to remove excess ethanol from the 
column. The column was transferred to a clean 15 ml centrifuge tube and 0.5-1 ml of 
elution buffer (10 mM Tris, pH8.5) was added and incubated for 5 minutes before 
centrifugation at maximum speed for 5 mins to elute DNA.  
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Cell culture and Expression of SP-A in mammalian HEK-293T cells 
2.11 Preparing cell suspension for cell count 
Once cells had grown to 80-90% confluence, the old media was discarded and cells were 
washed with PBS. The cells were dissociated from flask with 3 ml TripLE Select 
(Invitrogen, Paisley, UK) and tripsinised as described before. After inactivating the 
trypsinisation by adding 5 ml supplemented media, cells were used for cell counting.  
2.12 Cell count 
Cell pellet was mixed evenly with gentle agitation and 1 ml of cells was transferred into 
a sterile eppendorf tube using Gilson pipette. Using a 100 µl pipette, 100 µl of cells was 
mixed and transferred into another eppendorf tube containing equal amounts of trypan 
blue dye. 10µl of dyed cells was loaded on a haemocytometer (both sides of the 
chamber) and the lines were focused on the haemocytometer with the 10x objective 
lens. Observing 4 big squares containing 16 small squares, the cells which were not 
taken up by trypan blue (viable cells) were totalled. Each big square containing 16 small 
squares indicated number of cells x 104 per ml. By adding the total number of cells in all 
4 squares and dividing by 4 gives the average number of cells x 104 per ml. This value is 
multiplied by 2 to adjust for the 1:2dilution of cells in trypan blue. The calculated sum 
accounts for the total number of cells x 104 per ml which can be multiplied by the ml the 
cells are resuspended in. For transfection, 1.5 x 106 cells are added to 2 flasks and 2 x 
106 cells were frozen down for future use. 
2.13 Cryopreservation of Cells 
After cell count, 1 ml containing two-four million cells/ml in DMEM was diluted in 500 
µl FBS and 500 µl 10% DMSO and 1 ml was transferred per labelled cryovial. The vials 
were stored at -80°C overnight and in liquid nitrogen the next day. 
 
Cloning and expression of trimeric SP-A in pET101/D TOPO 
2.14 Primer design 
Primers for human SP-A neck and CRD region were designed using the CRD region after 
the 23gly-Xaa-Yaa repeats. The forward primer is designed to contain four bases – CACC 
to complement the overhang in the TOPO vector to allow directional cloning to take 
place by stabilising the PCR product in correct orientation. The forward primer 
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sequence 5’ – CACCATGCATCTAGATGAGGAGCTCCAAGC (amplicon 444 bp) containing 
the leading pET101/D-TOPO sequence (CACC) which hybridizes to the GTGG overhang 
on pET101/D-TOPO vector. The CACC sequence is also necessary for directional cloning 
and a start codon (ATG) to provide optimal spacing for proper translation. The same 
reverse sequence 3’ - GGGCTCGAGTCAGAACTCACAGATGGTCAGTCG containing the XhoI 
site which was used for cloning both trimeric and full length SP-A in HEK-293 cells. The 
gene of interest is controlled by the T7 promoter upstream to the pET101 vector. This 
promoter is regulated by the E.coli strain BL21 (λDE3) pLysS containing expressing the 
T7 RNA polymerase. This is induced by IPTG. 
2.15 PCR with High Phusion DNA Polymerase 
PCR was carried out as described earlier with High Phusion DNA polymerase and the 
products were separated via 0.7% agarose-gel to excise the band containing gene of 
interest. 
2.16 Gel extraction  
After fractionating the DNA on a 0.7% agarose gel, the PCR product was gel extracted 
using Qiaquick Gel extraction kit (Qiagen, Manchester, UK) according to the 
manufacturer’s protocol as previously described. 
2.17 Ligation with pET101/D TOPO vector (Invitrogen)  
The blunt-end PCR purified product was directly cloned into Champion pET101/D-
TOPO vector (Invitrogen, Paisley, UK). The kit has 90% efficiency without requiring 
ligase or restriction enzymes. The pET vector was chosen for its specific features 
including the T7 lac promoter for IPTG inducible expression of the gene of interest 
(Dubendorff and Studier, 1991; Studier et al., 1990). The vector is designed to contain 
the lacI gene encoding the lac repressor to reduce basal level of expression from the T7 
lac promoter in the vector and from the lacUV5 promoter in the E. coli host 
chromosome. The vector contains an ampicillin resistant gene for selection of E. coli 
containing the vector with the gene of interest. 
The ligation was set up according to manufaturer’s guidance. Briefly, two 1.5 ml 
eppendorf tubes were set up containing pET101/D TOPO vector, PCR product, salt 
solution diluted in sterile water. The volumes of each component are listed in table 2.3. 
 
67 
 
Table 2.3 – Ligation set for directional cloning of SP-A N/CRD into vector pET101/D TOPO. 
Reagent Vector only (µl) Vector + PCR insert (µl) 
pET101/D TOPO vector 1 1 
Salt solution 1 1 
PCR product - 3 
Sterile water 4 1 
Final volume 6 6 
Ligation was set-up using pET101/D TOPO. Two reactions were set up, using no PCR 
product as a control expecting no growth of cells on an ampicillin/agar plate as open 
vector cannot be transformed and replicated in E. coli. List of reagents and volume were 
followed as stated in the table. The ligation reaction was carried out at room temperature 
for 30 minutes before incubating at 4°C overnight. 
 
2.18 Transformation of pET101/D TOPO into OneShot TOP10 competent cells 
The ligated sample of SP-A N/CRD in pET101/D TOPO was transformed into ready-
made competent cells (Invitrogen, Paisley, UK) as previously described.  
2.19 Plasmid isolation for pET101/D TOPO containing N/CRD of human SP-A 
Plasmid isolation (Qiagen, Manchester, UK) was carried out for restriction digest to 
check if gene was correctly inserted. Consequently, the plasmids containing the gene of 
interest were sent for sequencing (Beckman Coultier). 6 Plasmid isolations were carried 
out according to manufacturer’s recommendations as previously described.  
2.20 Restriction digestion of pET101/D TOPO containing SP-A (N/CRD) with SacI 
and EcoRI 
The plasmids isolated were set up for digestion using restriction enzymes EcoRI and 
SacI. Six tubes were set up plus one for water control containing no plasmid. A master 
mix was made to contain 7 µl EcoRI, 7 µl SacI, 7 µl Buffer 4, 7 µl 10 X BSA with no 
plasmid. Into 7 individual 1.5 ml microcentrifuge tubes, 8 µl of master mix was added 
and mixed with 2 µl plasmid. For the water control 2 µl nuclease free water was added. 
The samples were incubated at 37°C for 1.5 hours. After digestion had taken place 6 X 
loading dye was added and loaded in a 1% agarose-EtBr gel (0.5 g agarose in 50 ml 1 X 
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TBE buffer). The results were observed under the transilluminator before capturing an 
image on the ImageStream. The plasmids with the correct inserted gene were 
transformed in BL21 (λDE3) pLysS as previsouly described. 
2.21 Expression of the recombinant fragments of homotrimeric CRD regions of 
human SP-A (rfSP-A) and SP-D (rfSP-D) 
Completion of transformation of recombinant fragment SP-A (rfSP-A) colonies of cells 
were formatted on the ampicillin/chloramphenicol (amp/chl) agar plate. 10 colonies 
were selected randomly to examine the expression of the gene of interest. 10 single 
colonies were inoculated individually in 5 ml LB supplement with Amp/chl. before 
growing in a 37°C shaking incubator overnight. The next day, 500 µl of the primary 
culture was transferred into 10 x 10 ml LB with amp/chl. and grown in the a 37°C 
shaking incubator until the cells reach late log phase, indicated by an OD (600 nm) 
between 0.6-0.8. 1 ml of the secondary culture was transferred in a 2 ml eppendorf tube 
to represent the un-induced control to observe expression efficiency. The rest of the 
culture was induced with 0.5 mM IPTG and both un-induced and induced samples were 
further incubated for 3 hours in a 37°C shaking incubator. After induction was complete, 
1 ml of the ‘induced’ sample was transferred into a 2ml eppendorf tube and along with 
the ‘un-induced’ samples, the samples were centrifuged at 13,000 rpm and the pellets 
were reserved. The supernatant was discarded and the pellet was resuspended in 100 
µl of 2 x treatment buffer. The ‘un-induced’ samples along with ‘induced’ samples were 
denatured on a heating block set at 100°C for 10 minutes before briefly centrifuging and 
loading 10 µl (100 µg/ml) of each samples on a 12% SDS-PAGE. Expected size is 
between 18-20 kDa. According to the bands visualised on the gel, the colony with the 
best expression was streaked on an LB amp/chl. plate to grow more colonies. Once the 
best colony for expression has been established the next step was to upscale it to a large 
scale expression. 
2.22 Large scale expression of insoluble proteins rfSP-A and rfSP-D 
A single colony was inoculated individually in 15 ml LB supplement with Amp/chl. 
before growing in a 37°C shaking incubator overnight. The next day,  12.5 ml of the 
primary culture was transferred into 250 ml LB with amp/chl. and grown in the a 37°C 
shaking incubator until the cells reach log phase, indicated by an OD (600 nm) between 
0.6-0.8. 1 ml of the secondary culture was transferred in a 2 ml eppendorf tube to 
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represent the un-induced control to observe expression efficiency. The rest of the 
culture was induced with 0.5 mM IPTG and both un-induced and induced samples were 
further incubated for 3 hours in a 37°C shaking incubator. After induction was complete, 
1 ml of the ‘induced’ sample was transferred into a 2ml eppendorf tube and along with 
the ‘un-induced’ samples, the samples were centrifuged at 13,000 rpm and the pellets 
were reserved. The supernatant was discarded and the pellet was resuspended in 100 
µl of 2 x treatment buffer. The ‘un-induced’ samples along with ‘induced’ samples were 
denatured on a heating block set at 100°C for 10 minutes before briefly centrifuging and 
loading 10 µl (100 µg/ml) of each samples on a 12% SDS-PAGE. Expected size is 
between 18-20 kDa. The 250 ml culture was harvested by centrifugation at 5000 rpm 
for 15 minutes in a swing-bucket centrifuge and stored at -20°C until required for 
further processing. 
2.23 Endotoxin removal from rfSP-A  
The removal of endotoxins from recombinant proteins is important to prevent 
interference in further studies caused by LPS such as in cell culture. 
Lipopolysaccharides (LPS) are found on the outer cell membrane of gram-negative 
bacteria. Thermo Scientific Pierce High capacity endotoxin removal resin in spin 
columns were used for the removal of LPS.  The resins contain porous cellulose beads 
with covalently attached ε-poly-L-lysine which has a high affinity for endotoxins. The 
binding capacity is 2 million endotoxin units (EU) per ml, reducing endotoxin levels by 
99% and should typically result with a final endotoxin concentration below 5 EU/ml 
which is of an acceptable range.  
The use of the columns was followed as instructed by manufacturers’ guidance. Briefly, 
the column was regenerated incubating the spin column in 5-bed volumes (5ml) 0.2N 
NaOH in 95% ethanol for 1-2 hours at room temperature. The column was then washed 
with 5 resin-bed volumes of 2M NaCl followed by a 5 resin-bed volumes of endotoxin 
free, ultrapure water. The column was equilibrated with 5 resin-bed volumes of sodium 
phosphate buffer (Na2HPO4 – 1.42 g in 10ml LPS free water and autoclave, NaH2PO4 – 
1.2 g in 10 ml LPS free water and autoclave  for pH7.4 add 7.74 ml Na2HPO4 with 2.26 
ml NaH2PO4) at room temperature. The sample was added to the column and incubated 
overnight at room temperature and eluted the next day at a flow rate of 10-15 ml/h 
(250 µl/min). The flow-through was collected and the proteins were eluted in 1-2 resin-
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bed volume fraction with endotoxin free equilibration buffer in endotoxin free tubes. 
The flow-through and the fraction were run on a 12% SDS-PAGE. The endotoxin levels 
were determined using the Limulus Amebocyte Lysate (LAL) assay. The endotoxin 
column was cleaned by regenerating the column in 5-bed volumes (5ml) 0.2N NaOH in 
95% ethanol for 1-2 hours at room temperature followed by 5 resin-bed volumes of 2M 
NaCl then 5 resin-bed volumes of endotoxin free, ultrapure water. Finally, the column 
was stored in 20% ethanol at 4°C.  
2.24 Limulus Amebocyte Lysate (LAL) assay (Lonza, Slough, UK) 
The chromogenic Limulus Amebocyte Lysate (LAL test is a quantitative test for gram-
negative bacterial endotoxin. The addition of the LAL reagent causes the protein sample 
to change colour to yellow. The absorbance is determined spectrophotometrically at 
405-410 nm. Since the absorbance is in direct proportion to the endotoxin levels, the 
concentration can be calculated from a standard curve.  
The LAL reagent contains lyophilised lysate from Limulus polyphemus. Endotoxin from 
the protein sample catalyses a pro-enzyme in the Limulus Amebocyte Lysate to an 
active enzyme. The activated enzyme then catalyses to split pNA. The release of this 
substrate is measured spectrophotometrically against a linear gradient of known 
endotoxin standards.  
The standards contain approximate 15-40 EU lyophilised endotoxin. One vial is 
reconstituted with 1 ml of LAL reagent water at room temperature (to yield a 
concentration stated on the Certificate of Analysis e.g. 24 EU/ml) and vortexed for 15 
minutes to detach the endotoxin from the glass. This can be stored at 4°C for up to 4 
weeks. The substrate used is approximated 7 mg of lyophilised substrate which is 
reconstituted in 6.5 ml of LAL reagent water to yield a concentration of ~2 mM. this 
reconstituted substrate solution is stable at 4°C for up to 4 weeks if not contaminated 
with microorganisms. To prepare a set of standards, the reconstituted endotoxin vial 
was vortexted for 1 minute then was diluted to 1 EU/ml. 0.5ml of this was transferred 
to another glass vial to and diluted with 0.5 ml LAL reagent water to halve the 
concentration of EU/ml. 5-10 standards were prepared and vortexted for 1 minute 
before use. The samples were pipetted from tube to tube at the same rate to allow the 
same time for reaction. 50 µl of the standard was mixed with 50 µl of LAL reagent, 
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mixed and incubated for 10 minutes at 37°C. Next, 100 µl of the substrate solution was 
added and mixed vigorously before incubating at 37°C for 6 minutes. Finally, 100 µl of 
the Stop reagent was added and mixed immediately before taking a reading at 405 nm.  
The blank sample contains LAL reagent water instead of the sample and the rest of the 
steps were identical. After the standard graph was recorded, protein endotoxin levels 
were determined using the test tube method.  
Firstly, 50 µl of the sample was dispensed in an endotoxin free glass reaction tube in a 
37°C water bath and at T = 0 minutes, 50 µl of LAL reagent was added and mixed 
thoroughly without vortex. At T = 10 minutes, 50 µl LAL substrate solution (pre-
warmed at 37°C) pipetting same number of times as before when preparing standards. 
At T = 16 minutes, 100 µl of Stop reagent was added and mixed the same number of 
times as before. The absorbance of each sample were taken at 405 nm using distilled 
water to adjust the photometer to zero absorbance. 
 
Native and reduced SDS-PAGE 
2.25 Reduced Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
SDS-PAGE is a technique widely used in biochemistry to separate protein samples 
according to their molecular weight. The size of the protein can be estimated using a 
molecular weight marker. The gel comprises of two parts, a stacking and a resolving gel. 
The stacking gel is standard regardless of the percentage of the gel. This is polymerized 
with a separating comb for samples to be loaded into these wells. The resolving gel is 
made of the same reagents as stacking gel including agarose-bisacrylamide which forms 
a matrix for protein diffusion separated according to size. Smaller fragments of protein 
travel further according to their negative charges towards the positive anode. The 
smaller the protein desired to visualize, the higher the percentage gel is required which 
forms a network of pores small enough to separate a range of low molecular weight 
proteins. After the gel has polymerized it is placed in a tank and 1 X running buffer is 
poured into the tank over the gel and the separating comb is removed. The protein 
samples are mixed with an equal volume of bromophenol blue loading dye and 
denatured by heating at 95°C for 6-8 minutes before being briefly centrifuged prior to 
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loading in the wells. A molecular weight protein marker is also loaded at approximately 
3 µl and the gel is run at 120V for 1.5 hours until the bromophenol blue dye front 
reached near the end of the gel. The negatively charged proteins migrate away from the 
cathode towards the positively charged anode. The size of the protein will determine 
the length it travels through the gel matrix. The gel was then stained with staining 
solution (50% Methanol, 40% acetic acid with 0.1% Coomassie blue). This was left on a 
rotating rocker for 4hours for proteins to incorporate the dye before the de-staining 
process. After destaining the gel, only the proteins stained with Coomassie blue were 
visible as well as the protein marker to estimate the size of the protein. The gel images 
were taken using the Molecular Imager Gel Doc (Peqlab, Sarisbury Green, UK). 
 
A 12% SDS-PAGE was prepared by making a 12% resolving gel followed by a stacking 
gel. The resolving gel was made as mentioned in table 2.4: 
 
Table 2.4 – Composition for preparing 12% resolving SDS-gel 
Component (12% Resolving Gel) Volume (µl) 
De-ionised Water (D.W.) 330 
30% Acrylamide Mix 4000 
1.5M Tris-HCL, pH8.8 2500 
10% sodium dodecyl sulfate (SDS) 100 
freshly made Ammonium persulfate (APS) 100 
TEMED 15 
 
 
 
The resolving gel was left to polymerise at room temperature for 20 minutes. The 
stacking gel was then prepared and loaded on top with a separating comb fixed in place.  
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The stacking gel for all SDS-PAGE is made as mentioned in table 2.5: 
 
Table 2.5 – Composition for preparing 12% resolving SDS-gel 
Component (Stacking Gel) Volume (µl) 
De-ionised Water (D.W.) 3400 
30% Acrylamide Mix 830 
1.5M Tris-HCL, pH8.8 630 
10% sodium dodecyl sulfate (SDS) 50 
freshly made Ammonium persulfate (APS) 50 
TEMED 15 
 
This was left at room temperature to polymerise for 20 minutes before placing it in the 
chamber and pouring 1 X running buffer and loading wells with denatured protein 
samples. The gels were all set at 120V for 90 mins. 
2.26 Native Gels 
There are some exceptions for when preparing and running a native gel. Firstly, no SDS 
is used in the running buffer and gel preparation. Secondly, no 2-merceptoethanol and 
SDS is added to the 2 X treatment buffer. Finally proteins are not denatured on a heating 
block but added directly to the gel.  
2.27 Western blot 
For western blot preparation a 12%SDS-PAGE was first prepared as described earlier. 
Either, semi-wet transfer of proteins were carried out or wet-transfer of proteins to 
membrane. These are described below. 
2.28 Semi-wet transfer of proteins to membrane 
After the proteins had passed through the gel for separation they were ready to be 
transferred to PVDF membrane. Initially, the gel, membrane and 4 stacked pieces of 2.5 
mm thick Blotting Filter paper were equilibrated in 1 X transfer buffer (80% methanol, 
5.8 g Tris-Base, 2.9 g Glycine powder and 0.37 g SDS) for 5 minutes. The membrane is 
then sandwiched with the gel by forming layers of 2 stacked pieces of 2.5 mm thick 
blotting filter paper, followed by placing the PVDF membrane on top, then layering the 
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gel followed by the last 2 stacked pieces of 2.5 mm thick blotting filter papers. This is 
placed in the semi-dry blotter on the anode plate. Note that between each layer of 
sandwich the air bubbles must be removed using a blotting roller to ensure efficient 
transfer of proteins. 100 ml of transfer buffer was poured over the membrane in the 
semi-dry holder and was covered with the cathode lid. The transfer took place at 14V 
for 1 hour.  
2.29 Western blot detection using Chemi-Immunofluorescence (CIF)  
After transfer was complete, the membrane was blocked with PVDF Westernbreeze 
blocking solution (Invitrogen, Paisley, UK) for 1 hour at room temperature on a rocker. 
A 1:1000 dilution of primary antibody (e.g. anti-human SP-A, anti SP-D, anti CRT and 
anti COX-1) was prepared in 0.2% BSA, incubated at room temperature and left on the 
rocker for 2.5 hrs. The membrane with unbound proteins were washed using Tween 20 
detergent (PBS/Tween 20 0.05%) for 5 mins five times. The Luminata Western HRP 
substrate solution poured over the membrane is a premised solution (GE healthcare 
Life sciences, Buckinghamshire, UK). The membrane is soaked in the substrate solution 
for 20 mins. In a dark room the membrane is taken from the substrate solution and 
blotted dry before placing it on top of the film in a dark cassette holder. After 1 minute 
of developing, the film is processed in the processor to visualize results. 
2.30 Wet transfer of proteins  
The gel and western blot material [4 x whatmann paper, 2 x fibropads, nitrocellulose 
membrane] were equilibrated in transfer buffer for 15 mins. The apparatus was set up 
in the following order: black side- fibropad- 3 mm whatmann paper-gel-nitrocellulose 
membrane-3 mm whatmann paper-fibropad-white side in the transfer buffer, removing 
all air bubbles as this would affect the transfer of proteins. Transfer took place at 320A, 
for 1.5 hrs whilst stirring and an ice pack was used to ensure even temperature 
throughout the process.  
2.31 Western blot detection with 3,3′-Diaminobenzidine (DAB) 
The blot was transferred into blocking solution in 5% milk powder-PBS overnight at 
4ºC and the gel was stained as a control to ensure that all proteins had been transferred. 
The next day, the membrane was incubated in primary antibody (rabbit anti human SP-
A & SP-D - (donated by group in Oxford University)) prepared in a 1:1000 dilution in 
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PBS at room temperature for 1hr. The unbound primary antibody was washed with 
stringent - PBS Tween-20, 0.05% thrice for 5mins each. The membrane was then 
transferred in secondary protein A (PA) HRP at 1:1000 dilution in PBS and incubated 
for 1hr at room temperature (RT). The secondary antibody was discarded and 
membrane was washed with PBS Tween 20, 0.05% thrice for 5mins each. DAB tablets 
were dissolved in 15ml dH2O and the membranes was incubated for 10mins to visualise 
the bands. 
2.32 ELISA  
A 96-well microtitre plate was coated with 5µl of cell lysate protein in carbonate buffer 
and double diluted across the wells. This was carried out in duplicates for each of the 
protein. The plate was incubated overnight at 4°C for proteins to bind to the microtitre 
plate. The next day, the buffer and unbound proteins were discarded and unbound sites 
of wells were blocked with 100 µl 2% BSA blocking buffer. The plate was further 
incubated at 37°C for 2 hour before washing 3 times with PBS/Tween 0.05%. Primary 
antibody was diluted by mixing 1 µl rabbit Anti-human SP-A in 5 ml of PBS and 1 µl 
rabbit anti-human SP-D (donated by group in Oxford University) in 5 ml of PBS 
(1:5000) in separate tubes. 100 µl of diluted primary antibody was added to the wells. 
The plate was incubated at room temperature 37°C for 2 hours. Again the wells were 
washed with PBS/Tween 0.05% thrice before adding secondary antibody. Protein A-
HRP was diluted in 1:500 dilution. Again this was mixed in a step-wise manner as 
described above. 100 µl of dilute secondary antibody was added to all the wells. The 
plate was incubated for 1hour at 37°C to allow Protein A-HRP to bind to primary 
antibody. Post incubation, the content was discarded and wells were washed with 
PBS/Tween 0.05% thrice before developing with OPD. To develop the reaction, OPD 
substrate was added to 100µl per well and reacted with the HRP conjugated to Protein-
A and optical density was determined under a plate reader at 450 nm.  
2.33 Immunohistochemistry (IHC) using ABC system 
Immunohistochemistry is a method used which applies the detection of antigens from 
tissue sections. Firstly, the ACD tissue sections were dissected from placenta and 
embedded in formaline fixed paraffin wax to prevent tissue from decaying or 
degenerating. The tissue was cut into fine sections of 3-5 microns thick using a 
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microtome and placed on microscope super frost-free slides. The process of 
Immunohistochemistry involves heat-mediated antigen retrieval for immune-detection.  
The tissue sections were dewaxed using dewax solutions by successive immersions in: 
histoclear x 2, 100% ethanol, 90% ethanol, 70% ethanol, water for 5mins each. The 
endogenous peroxidase activity was blocked by immersion in 1% H2O2 for 15 mins. For 
antigen retrieval, the slides were placed in a dish filled with heated 0.01M Sodium 
citrate buffer pH6.0) 0.05% Tween 20 allowing to stand for 5mins thrice. After washing 
in PBS the buffer was blotted dry and placed at room temperature in a humidifying box 
to carry out the immunodetection process. 200 µl of 2% normal horse serum in PBS 
were added to sections directly over the cells and incubated for 20mins before washing 
in PBS. A 1:1000 dilution of primary antibody (rabbit anti-human SP-A, SP-D and CRT) 
in 2% BSA/PBS was prepared and 100 µl was added and incubated at room 
temperature for 20 mins then left in the humidifying chamber for 1 hour followed by an 
overnight incubation at 4°C. After 24 hour incubation, primary antibody was washed 
and 1:1000 biotinylated secondary antibody (Horse-anti Rabbit) in PBS was added in 
100 µl per slide, followed by further incubation at room temperature for 1 hour. 
Following the incubation, three successive washes were carried out prior to adding 150 
µl of ABC reagent (Vector Lab) for 20 minute incubation at room temperature. After 
successive washing, the slides were incubated with 200µl of DAB (3,3’-
Diaminobenzidine) for 2-10 minutes. 
After immunodetection of SP-A, SP-D and CRT, the slides were ready for counterstaining 
with haematoxylin. The slides were stained in haematoxylin for up to 1 minute and then 
washed before immersing in 1% sodium carbonate followed by 1% HCl in 70% ETOH 
(acid/alcohol) for 5 mins each. The tissue sections were destained with acid/alcohol for 
before running under the tap until slides turn slightly blue. The tissue slides were 
dehydrated in successive washes of – 70%, 90%, 100% alcohol followed by clearing in 
histoclear I and II for 5 mins each. 
For examining the slides, they were blotted dry before adding adhesive and a coverslip 
over the tissue. Images were taken using an Axioskop 2 microscope.  
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2.34 Amnion, Chorion and Decidua (ACD) explants culture and stimulation 
All women gave consent for the collection of tissue according to the requirements of 
Brunel University, School of Health Sciences and Social Care, Research Ethics 
Committee. Each placenta was obtained from not in labour via caesarean section at 39 
weeks. The amnion, chorion and decidua tissues were identified, and a total of 200 mg 
of tissue was added to 8 x 12-well tissue culturing plates. ACD explants were cultured in 
Dulbecco’s modified eagles medium (DMEM) with 1x Penicillin and streptomycin 
(Pen/strep.) (i.e 5 ml in 500 ml DMEM) and 10% foetal calf serum (FCS). The cultures 
were incubated overnight at 37°C for 24 hours in 95% air and 5% CO2 atmosphere. 
After 24 hours, the medium was changed to DMEM + 0.2% lactoalbumin hydrolysate. 
Each well contained 3.3 µg/ml of native SP-A, SP-D, rfSP-D Gly-Xaa-Yaa & rfSP-A, with 
and without IL-1β (200 pMol) in 3ml of media, to examine the direct and indirect effect 
of these proteins on the hormonal and immunological pathway of pregnancy and 
labour. The plates were incubated further, for 12 hours at 37°C in 95% air and 5% v/v 
CO2 atmosphere. 0.1 g of the tissue was subjected to RNA extraction and the rest, 0.1 g 
of tissue per well was subjected to cell lysate extraction.  
2.35 Protein extraction and purification from ACD explants   
Protein extraction is commonly carried out to be used in applications such as western 
blots and Enzyme linked immunoassay (ELISA). RIPA buffer is the main solution used 
for the extraction which extracts cytoplasmic and membrane proteins. Inhibitors such 
as protease and phosphatase inhibitors can be added to prevent proteolysis and to 
prevent phosphorylation of proteins.  
Fresh cultured membranes from the wells were taken and placed in bijou tubes adding 
0.5ml RIPA lysis buffer (50 mM Tris pH7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP40, 
0.25% Triton X-100), with an appropriate inhibitor cocktail  added immediately prior to 
use. Samples were kept on ice before and after homogenization to prevent protein 
degradation and enzyme cleavage. The tissues from each well were individually 
homogenized with a mechanical rotor-stator homogenizer for 20-25 secs. The lysate 
was transferred to 1.5 ml microcentrifuge tubes and centrifuge at 10,000 x g for 25 mins 
at 4oC. The supernatant was transferred to clean tubes. The protein extracted can either 
be stored at -20oC or the protein content can be measured using the BCA assay which is 
read on a spectrophometer at 560 nm using PBS/elution buffer as a control. It is 
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advisable not to keep freeze thawing the protein samples as this will result in low 
quality protein and can denature the protein. 
2.36 RNA extraction and purification 
RNA extraction and purification was carried out using the TRIzol method. TRIzol 
(Invitrogen, Paisley, UK) is a monophasic solution of phenol and guanidine used for 
isolation of high quality yield of RNA during the homogenization of sample. The reagent 
is able to denature proteins and remove RNases which can potentially affect the quality 
of RNA. Hence, the integrity of RNA remains undisrupted whilst the cellular components 
are disrupted and dissolved. The addition of chloroform results in a biphasic mixture. 
Total RNA was recovered by adding 1 ml of TRIzol reagent to each sample of treated 
membranes and mechanically homogenized for 20-25 seconds. The homogenate was 
transferred to RNase free 1.5 ml tubes and centrifuged at 12000 rpm for 10 mins at 4°C. 
The supernatant of each sample were transferred to sterile RNase free tubes and 
incubated at room temperature for 5 minutes. 200 µl of molecular biology grade 
chloroform (Sigma, Dorset, UK) was added to each sample and vortexed vigorously for 
15 seconds and left to incubate at room temperature for 4 minutes. The chloroform 
causes TRIzol to separate into a colourless aqueous phase and an organic lower phase 
containing phenol and chloroform. The tubes were then centrifuged at 12000 rpm for 
15 mins at 4°C to separate the upper aqueous phase containing nucleic acids from the 
phenol, without disrupting the interphase or lower organic phase containing proteins 
and lipids dissolved by the phenol/chloroform. The aqueous phase of each sample was 
transferred to sterile 1.5 ml tubes and 3/5V isopropanol (Fisher) was added to each 
sample and inverted several times. The tubes were then incubated at room temperature 
for 5minutes, followed by centrifugation at 12000 rpm for 10 minutes at 4°C. The 
supernatant was transferred to fresh tubes and 440 µl of isopropanol was added 
inverting several times to precipitate the RNA and incubated at room temperature for 7 
minutes. The samples were then centrifuged to form an RNA pellet at 12000 rpm for 10 
miutes at 4°C.  The supernatant was dispensed without losing RNA pellet and 1 ml ice-
cold 75% ethanol was added to precipitate RNA due to its high salt content. The 
samples were vortexed briefly and centrifuged at 12000 xg for 5 minutes at 4°C. The 
ethanol was fully dispensed and left to air dry before re-dissolving RNA. RNA was 
dissolved in 40-50 µl of nuclease-free water and retropipetted several times to fully 
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dissolve the RNA. Partial dissolving of RNA gives A260/280 nm ratio of <1.6. The RNA 
samples were left on ice for 1hour before being stored at -80°C. 
2.37 Quantifying RNA via NanoDrop 
The absorbance of RNA to determine the quantification of total isolation is read using a 
spectrophotometer (NanoDrop ND-1000). The A260/280 ratio determines the nucleic acid 
purity. A ratio of ~2.0 is generally accepted as “pure” for RNA samples. A value 
appreciably lower than 2.0, may indicate the presence of organic contaminants such as 
phenol. The A260/230 ratio also determines the nucleic acid purity, a value lower than 1.8 
is usually unacceptable, as this indicates the presence of organic contaminants. This 
may interfere with gene expression. This lowers the efficiency for applications such as 
RT-PCR. The absorbance reader was blanked with 1µl of nuclease free water and 1µl of 
each RNA sample was added singly to measure the   A260/280 and A260/230 ratio. 
The RNA after DNase I treatment was quantified using spectrophometer NanoDrop. The 
machine was blanked with 1µl nuclease-free water and each sample was measured by 
adding 1 µl of RNA to the NanoDrop. This measures the   A260/280 and A260/230 ratio to 
estimate RNA quality and presence of any contaminants. The six samples of RNA treated 
with DNase I were converted to cDNA using High capacity RNA-to-cDNA kit (Applied 
Biosystems, Paisley, UK) in a 20 µl reaction 2 µg of RNA is converted to single stranded 
complementary DNA (cDNA).  
The samples were centrifuged briefly to bring components together. The tubes placed in 
a thermo cycler configured to the same settings as described earlier – warmed at 37°C 
for 60 mins and then heated at 95°C for 5 minutes. 
 
2.38 DNase treatment for DNA elimination from RNA samples 
Deoxyribonuclease I (DNase I) is an endonuclease which digests DNA and eliminated 
RNase activity to prepare RNA for sensitive applications such as RT-PCR. DNase I 
(Sigma, Dorset, UK). The entire RNA sample (~50 µl) is treated with 5 µl of the 10  
reaction buffer and 5 µl of Amplification grade DNase I (1 U/µl) and incubated at room 
temperature for 15 minutes. The reaction buffer and Amplification Grade DNase I 
combined, removes contaminating DNA by nucleic digestion at room temperature. The 
DNase is then inactivated by adding 5µl of the stop solution and heating the sample to 
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70°C for 10 minutes. The heating process also denatures secondary RNA structures so 
RNA can be used for reverse transcription. The RNA sample not used for agarose gels or 
cDNA synthesis can be stored at -80°C for future use. 
2.39 Agarose- Ethidium Bromide (EtBr) gel electrophoresis to separate and analyze 
RNA with and without DNase treatment 
The overall RNA quality can be assessed by electrophoresis and also gives a semi-
quantitative indication on RNA yield. Seven samples of RNA, five DNase-treated and two 
not treated have been separated on a 1% agarose-EtBr gel against a DNA sizer III 
(Peqlab, Sarisbury Green, UK). RNA sample was diluted in 6 X Loading dye (Peqlab, 
Sarisbury Green, UK) and the DNA sizer III was also diluted down 6 times in dH2O plus 
the 6 X loading dye. The voltage was set at 70 V until the fast migrating dye 
(bromophenol blue) reached 2/3 the length of the gel. The results should indicate 2 
distinct bands, 28S and 18S rRNA with a 2:1 ratio of intensity, respectively. Bands of a 
very low molecular weight indicate complete degradation of RNA. A smeared 
appearance of rRNA indicates partial degradation, contamination or poly(A) tail near 
the 0.5 kb to 6 kb. The supercoiled RNA remains higher than the nicked RNA. The native 
agarose gel separates nucleic acids according to size and separates through the mesh 
network which decreases in pore size to distinguish large and small sizes of nucleic 
acids. The larger molecules remain higher up the gel whilst the smaller molecules are 
able to migrate lower down the gel. The results were visualized under a UV 
transilluminator and processed under the Alpha Imager.  
2.40 Purification of RNA with QIAGEN RNeasy Plus mini kit  
In attempt to improve the RNA quality by increasing the A260/230 ratio, RNeasy Plus mini 
kit (Qiagen, Manchester, UK) was used. 50 µl samples of RNA with an equal volume of 
70% ethanol was added to 2 V RLT buffer Plusin an RNeasy spin column in a 2 ml 
collection tube. The samples were centrifuged at 8000xg for 15 seconds. The collection 
sample was discarded and 700 µl of Buffer RW1 was added to the RNease spin column 
and centrifuged again at 8000 x g for 15 seconds. The collection tube was fully emptied 
without allowing the column to contact the flow-through. 500 µl of Buffer RPE 
containing ethanol was added to the RNease spin column and centrifuged at 8000 x g 
for 15 seconds. This step was repeated again but centrifuged for a further 2 mins at 
8000 x g. This ensures all ethanol was removed and the spin columns were dry 
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containing the RNA. 30 µl of nuclease free water was added directly over the membrane 
holding the RNA and was centrifuged at 8000 x g for 1 minute to elute the RNA. RNA 
samples were quantified and quality was checked using NanoDrop spectrophometer. 
The spectrophometer was blanked with 1 µl nuclease-free water and an equal volume of 
sample was added to measure as described in 2.47. 
2.41 cDNA synthesis  
cDNA synthesis is a process of converting single stranded RNA to complementary DNA 
using an enzyme, reverse transcriptase. The High capacity RNA-to-cDNA kit (Applies 
Biosystems) contains a 2 X RT buffer and a 20 X Enzyme mix with RNase inhibitor 
giving maximum yield to high quality DNA for real-time PCR.  
Initially the RNA is transcribed to cDNA which is more stable by an enzyme reverse 
transcriptase. This contains RNase inhibitors so prevents RNA degradation in the 
process. In a 20 µl reaction 2 µg of RNA is converted to single stranded complementary 
DNA (cDNA). Using the values from the NanoDrop analyses 2 µg of RNA was used in a 
total 20 µl sample to convert to cDNA. All kit components were thawed on ice including 
RNA samples from -80°C. Table 2.6 indicates the volume of each component used for 
each RNA sample to transcribe to cDNA: 
 
Table 2.6 - Samples preparation for cDNA synthesis for 5 samples 
Component  Component volume/reaction (µl) 
  IL-1β rfSP-A rfSP-D rfSP-A + IL-1β rfSP-D + IL-1β 
2 X RT Buffer 10 10 10 10 10 
20 X Enzyme 
Mix 
1 1 1 1 1 
RNA sample 1.68 2.77 1.79 3.73 1.02 
Nuclease free 
H2O 
7.32 6.23 7.21 5.27 7.98 
Total per 
reaction 
20 20 20 20 20 
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The samples were centrifuged briefly to collect components together. The tubes were 
placed in a thermo cycler. Samples were warmed to 37°C for 60 minutes, then heated to 
95°C for 5 mins before cooling down to 4°C. 
2.40 Real-time PCR  
Real time PCR also known as Q-PCR, amplifies specific gene amplicons over 40 cycles. 
The specificity of product depends on the primers used. The process requires primers 
complementary to the forward (sense -5’-3’) and reverse (antisense- 3’-5’) strands for 
gene specific amplification. The primers anneal to complementary DNA on the sense 
and antisense strand and are extended by DNA polymerase. This makes the reaction 
DNA-specific. The primers are short oligonucleotide sequences and their Tm value 
indicates the optimum temperature of primer annealing. This is usually 5-6degrees 
below the Tm of the primers. The result of different temperatures is due to A-T and C-G 
bonds which have 2 or 3 hydrogen bonds between their complementary bases, 
respectively. The melting temperature is the temperature required to break the 
hydrogen bonds between the bases. As primers differ in length and composition, they 
may have different Tm values.  
During each cycle the number of strands double leading to an exponential amplification.  
This application requires Power SYBR green PCR master mix (A. Biosystems) which is a 
master mix containing AmpliTaq fast DNA polymerase, SYBR green which incorporates 
into the minor groves of DNA, dNTP, uracil-DNA glycosylase (UDG) and an internal 
reference dye. SYBR green is able to amplify specific regions efficiently without 
formation of primer-dimers and non-specific amplification. The amplicons amplified 
have SYBR green incorporated into their DNA. The more the amplicon are amplified this 
results in higher emission of fluorescence. During the dissociation stage the double 
stranded DNA are hydrolysed releasing the reporter molecule which is converted to a 
quantitative value (Ct) which can be used to calculate gene expression from the treated 
tissue. The results are analyzed using the SDS 2.4 (A. Biosystems) and the dissociation 
curve determined using RQ Manager1.2.1 (A. Biosystems) compatible with the 7500HT 
fast system (A. Biosystems). 
Four master mixes were prepared containing 500 nM primer, SYBR green, and nuclease 
free water to a total of 10 µl (table 2.7). The 5 cDNA samples used were; IL-1β, rfSP-A, 
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rfSP-D, rfSP-A + IL-1β & rfSP-D + IL-1β of 100 ng per well. The samples were briefly 
centrifuged prior to adding 9 µl of master mix. The master mix was added to the 
allocated wells of a Fast 96-well plate (A.Biosystems) and 1 µl of cDNA were added to 
the wells directly for a total 10 µl reaction. A negative control was carried out for each 
target. 
Table 2.7 –Master mix using SYBR green for real-time PCR 
 POLR2A PTGS2 PTGFRN IL-8 
Component Volume (µl) 
Power SYBR green master mix 100 100 100 100 
Forward primer 3 3 3 3 
Reverse primer 3 3 3 3 
cDNA template 0 0 0 0 
Water 74 74 74 74 
Total 180 180 180 180 
5µl of sample from the Q-PCR products was mixed with 6 X loading dye and loaded into 
the wells of a 2% agarose-gel. DNA sizer III (Peqlab, Sarisbury Green, UK) was used as a 
molecular weight marker to size the PCR product. The gel was run at 80 V until the 
bromophenol blue line had reached three quaters the length of the gel. The results were 
visualized using the Alpha Imager under UV light. The products should be size of the 
amplicon it amplifies in the PCR reaction. 
2.43 Reverse transcription polymerase chain reaction (RT-PCR) using KAPA-HiFi 
DNA polymerase  
Reverse transcriptase is a polymerase enzyme and in each chain reaction the product 
doubles. Initially the RNA was transcribed to cDNA which is more stable. The double 
stranded molecule is heated to separate the hydrogen bonds and then cooled down 
allowing the enzyme and oligonucleotides to anneal complementary to the bases of the 
template. Finally, the temperature is raised to 72°C for the strands to be extended. This 
cycle is repeated to approximately 40 cycles resulting in 240(2n) strands of DNA 
(i. e. 1.1 x 10-12). 
To optimize cDNA concentration for primer specificity to obtain interpretable results, 
50ng and 100ng of cDNA were used for each primer using KAPA HiFi DNA polymerase 
84 
 
kit (KAPA HiFi) (table 2.8). A negative control was also carried out to ensure product 
specificity and a positive control using 18S rRNA forward and reverse primers. 
Table 2.8 – Master mix using KAPA HiFi DNA Polymerase and 500 nM primer concentration 
Component End concentration 
5 X DNA fidelity buffer  1 X 
dNTP – 0.3mM 0.3mM 
Forward primer 500 nM 
Reverse primer  500 nM 
KAPA HiFi DNA polymerase  (1 U/µl) 
Water quantity sufficient to 25 µl end 
volume 
 
The samples were centrifuged briefly to bring the components together. The tubes were 
placed in a thermo cycler undergoing an initial denaturation followed by 40 cycles of 
denaturation, annealing of primers and extension to replicate amplicon number of 
target gene. Initial denaturation was at 95°C for 45 seconds, followed by denaturation at 
95°C for 20 seconds, annealing at 60°C for 15 seconds and extension at 72°C for 30 
seconds. 
Products from RT-PCR to optimize cDNA concentration were visualized on a 1% 
Agarose-EtBr gel. 10 µl of each sample was mixed with 6 X loading dye and DNA sizer III 
(Peqlab, Sarisbury Green, UK) was used as a molecular weight marker. The gel ran at 80 
V until the bromophenol blue line reached three quarters the length of the gel. For each 
target, 50 ng cDNA product, 100 ng cDNA product and a negative control were loaded 
next to each other.  
2.44 RT-PCR using KAPA-HiFi for primer PTGFRN and cDNA optimization 
PTGFRN required optimization.  As 75 nM primer was insufficient for RT-PCR, 250 nM 
and 500 nM primer concentrations were tested using 3 samples of cDNA from preterm 
placenta: rfSP-D, rfSP-A and rfSP-A + IL-1β at 100 ng and 200 ng. RT-PCR was carried 
out using KAPA HiFI DNA polymerase kit (KAPA HiFi). Samples were made up to 25 µl 
total volume. For each cDNA the tubes contained the following: 
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Table 2.9 – Preparation of  master mix using KAPA HiFi for primer optimisation  
The samples were centrifuged briefly to bring components together. The tubes were 
placed in a thermo cycler and set up the same way as described previously (See 1.2.17). 
The RT-PCR products were separated on a 1% Agarose-EtBr gel. The results were 
visualized using the Alphaimager under UV light.  
2.45 Q-PCR using SYBR green for primer and cDNA optimization  
A Q-PCR was carried out using the optimised conditions of the 12 targets: PTGFRN, 
PTGS2, IL-8, IL-10, TNF-α, TGF-β, TLR2, TLR4, SP-A, SP-D, C1q and factor H with 18S 
rRNA as our endogenous control. Each primer was used at a concentration of 500 µM 
and 100 ng cDNA. The cDNA samples used were from term placenta; rfSP-A, rfSP-D and 
rfSP-A + IL-1β, rfSP-D + IL-1β, IL-1β and RNA from non-treated cells. Master Mix for 
each target containing Power SYBR green (Applied Biosystems, Paisley, UK) was added 
to the fast 96-well plate then cDNA on top.  
cDNA samples rfSP-A + IL-1β and primers IL-8 and 18s rRNA were used to optimize 
cDNA and primer concentrations. The three different cDNA amounts used were: 200 ng, 
100ng and 50 ng cDNA and 500 nM primer concentration (table 2.9). The three primer 
concentrations optimized were 75 nM, 250 nM and 500 nM each with 100 ng cDNA. In 
PTGFRN Volume (µl) 
 250 nM 
primer + 100 
ng cDNA 
250 nM 
primer + 200 
ng cDNA 
500 nM 
primer + 100 
ng cDNA 
500 nM 
primer + 200 
ng cDNA 
5x DNA fidelity 
buffer 
5.00 5.00 5.00 5.00 
Water 17.00 18.00 17.00 18.00 
dNTP 0.75 0.75 0.75 0.75 
Forwards primer 0.38 0.38 0.75 0.75 
Reverse primer 0.38 0.38 0.75 0.75 
DNA template/ 
(water for -ve 
control) 
1.00 2.00 1.00 2.00 
 0.50 0.50 0.50 0.50 
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total, for the three primers and 3 different cDNA concentrations, 9 master mixes were 
made for cDNA optimization.  
Each well of fast 96-well plate for cDNA optimization contained the following 
components: 
Table 2.10 – Components using SYBR green for cDNA optimisation 
Component End concentration 
Power SYBR green master mix  5 µl 
Forward primer  190 nM 
Reverse primer 190 nM 
cDNA template  200 / 100 / 50 ng 
water quantity sufficient for total 10 µl reaction 
 
Each well of fast 96-well plate for primer optimization contained the components 
described in table 2.10: 
Table 2.11 – Components using SYBR green for primer optimisation 
Component End concentration 
Power SYBR green master mix 5 µl 
Forward primer 75 / 250 / 500 nM 
Reverse primer  75 / 250 / 500 nM 
cDNA template  100ng 
Water quantity sufficient for total 10 µl reaction 
 
Water was added to the negative control wells as a substitute to cDNA for every target. 
The plate was briefly centrifuged and the conditions of the template were input into the 
7500HT real-time PCR system (table 2.11). The results were shown using SDS 2.4 and 
the dissociation curve was deduced using the RQ manager 1.2.1. (Applied Biosystems, 
Paisley, UK). 
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Table 2.12 - Settings for thermal cycler 
Times and Temperatures 
Initial Steps PCR (each of 40 cycles) 
Power SYBR green  
DNA polymerase activation 
Melt Anneal/Extend 
HOLD CYCLES 
10 mins @95°C 15 secs @ 95°C 1 min @ 57°C 
 
The final primer and cDNA concentrations used after optimisation were 500nM and 
100ng respectively. 
 
2.46 Temperature optimization for POLR2A - RT-PCR  
RT-PCR was carried out to optimize annealing temperature for primers POLR2A using 
PeqGOLD Taq polymerase. The gradient of temperature ranged between 49.5°C and 
59.2°C using a thermal cycler. The two different primer concentrations used were – 75 
nM and 500 nM (table 2.13) to optimize the annealing temperature (table 2.14). Each 
tube for both primer concentrations contained the following components at their final 
concentrations in a 10 µl end volume are described in table 2.14. 
 
Table 2.14 - Optimisation of primer concentration via RT-PCR  
Component (end conc.)  75 nM primer 
POLR2A 
500 nM primer 
POLR2A 
10x reaction buffer (1x) 1 1 
dNTP mix (800µM) 0.8 0.8 
Forward primer (75 nM/500 nM) 0.15 0.38 
Reverse primer (75 nM/500nM) 0.15 0.38 
Taq DNA polymerase (0.05U/µl) 0.1 0.1 
cDNA template 1 1 
Water  6.8 7.34 
Total  10 10 
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The samples were centrifuged briefly to collect components together. The temperatures 
set on the thermal cycler are described in table 2.15. 
Table 2.15 – Thermocyler conditions for temperature gradient PCR  
Annealing temperature 
(°C) 
75 
nM 
500 
nM 
49.5 1 13 
50.1 2 14 
50.7 3 15 
51.8 4 16 
52.9 5 17 
54 6 18 
55 7 19 
56 8 20 
57.1 9 21 
58.2 10 22 
58.8 11 23 
59.2 12 24 
 
The thermal cycler was configured to a program to denature the double strand DNA at 
95°C and allow annealing of primers with a 54.5°C ± 5°C to optimise the best 
temperature for primer annealing followed by increasing the temperature to 72°C for 
extension of primers to amplify gene products. This cycle was repeated 40 times where 
the product doubles in every cycle. 
2.47 RT-PCR to investigate Taq and dNTP integrity 
As RT-PCR for temperature optimization was unsuccessful, the Taq and dNTPs (Peqlab, 
Sarisbury Green, UK) efficiency were validated using KAPA HiFi DNA polymerase 
dNTPs. This RT-PCR was carried out using 18S primers. Duplicate reactions were 
carried out including negative control which contained water as a substitute of cDNA. 
500 nM primer and 100 ng was used in each reaction tube. 10 X Reaction buffer, dNTP 
mix plus 0.5 U/µl of Taq DNA polymerase were added to each tube of RNA containing 
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primers. After separating results on gel and visualising the amplicon on gel determined 
Taq and dNTP integrity. 
2.48 Statistical analysis for QPCR data  
Results were analysed using the Sequence Detections Software (SDS) V2.4 and RQ 
Manager. Samples were compared to 18S rRNA, the endogenous control, and calibrated 
against non-treated samples. The Ct values were calculated at the point where the PCR 
curve crosses the threshold. For each sample, the geometric mean Ct for each target was 
subtracted from the geometric mean Ct of the endogenous control to give ΔΔCt values. 
The RQ value to give the relative fold change of expression compared to non-treated 
sample and were calculated by 2 to the power of -ΔΔCt (2-ΔΔCt). For all subsequent 
statistical analysis, RQ values were plotted on a logarithmic scale (log10) with the 
standard error of mean to minimise error. All data were calculated by two-way ANOVA 
using GraphPad Prism software. Sequences of primers are listed in the table below: 
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Sequences of primers used in this study are in the table below.  
Table 2.16 – Primer sequences and gene nomenclature  
Gene 
Nomenclature
/Formally 
Primer name Forward primer 
sequence 
Reverse primer 
sequence 
Amplicon 
(bp) 
18s rRNA 18s rRNA GTAACCCGTTGAACCC
CATT 
CCATCCAATCGGTA
GTAGCG 
151 
PTGS2/COX2 Prostaglandin 
H synthase 2 
CTCAGACAGCAAAGCC
TACC 
ATGTGATCTGGATG
TCAACAC 
372 
PTGFRN Prostaglandin 
F2-Alpha 
Receptor 
Regulatory 
Protein 
CTGTCGTTGGCTCTTT
GCCG 
CATCATAGTCACTG
ACGTTGC 
109 
POLR2A  GCACCACGTCCAATGA
CATTG 
GTGCGGCTGCTTCC
ATAAGC 
267 
IL8 Interleukin 8 CTGTGTGAAGGTGCAG
TTTTG 
GTGTTGGCGCAGTG
TGGTC 
137 
IL-10 Interleukin 10 ACATCAAGGCGCATGT
GAAC 
TAGAGTCGCCACCC
TGATGT 
248 
TNF-α Tumour 
necrosis factor 
alpha 
 
CACCACTTCGAAACCT
GGGA 
 
AGGAAGGCCTAAGG
TCCACT 
196 
TGF-β Transforming 
growth factor- 
beta 
CCCAGCATCTGCAAAG
CTC 
GTCAATGTACAGCT
GCCGCA 
190 
TLR2 Toll-like 
receptor 2 
GAGACCTATAGTGACT
CCCAG 
CTGCCCTTGCAGAT
ACCATTG 
150 
TLR4 Toll-like 
receptor 4 
CTTCTCAACCAAGAAC
CTTGG 
GTGGCCTTAGGCTC
TGATATG 
152 
SP-A Surfactant 
protein A 
GTGGGGTGGGATTAGA
TAAATGC 
TACTGAGAGATGTG
TGCTTGGTGAG 
196 
SP-D Surfactant 
protein D 
TGGTTTCTGAGATGGA
GTCGTG 
TGGGGCAGTGGATG
GAGTGTGC 
184 
C1q  ATGGTGACCGAGGACT
TGTG 
GTCCTTGATGTTTC
CTGGGC 
190 
FH Factor H CCCGGGGAAATACAGC
CAAA   
TCTGGGAGTAGGAG
ACCAGC   
182 
SP-A SP-A/pSecTagC GGGGGAATTCGAAGTG
AAGGACGTTTGTGTTG
GAAG 
CGACTGACCATCTG
TGAGTTCTGACTCG
AGCCC 
686 
SP-A SP-A/pMalC-2 GGGGAATTCCATCTAG
ATGAGGAGCTCCAAGC 
GGGGGATCCCTAGA
ACTCACAGATGGTC
AGTCGG 
444 
SP-A SP-A/pET-101 CACCATGCATCTAGAT
GAGGAGCTCCAAGC 
CGACTGACCATCTG
TGAGTTCTGACTCG
AGCCC 
444 
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Chapter 3:  
Cloning, expression and purification of full length and 
truncated forms of human SP-A and SP-D 
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Summary 
The main objective of this thesis was to examine the effects of pulmonary surfactant 
proteins SP-A and SP-D on the explants of amnion, chorion and decidua in terms of their 
ability to modulate immune response under inflammatory conditions and modulation of 
the prostaglandin pathways. Having established the optimal readouts on the ACD 
explants, the plan was to narrow it down to decidual macrophages which are the key 
inflammation modulating immune cells in trimester 2 and 3. Thus, it was imperative to 
prepare various forms of native and recombinant SP-A and SP-D. Full length native SP-A 
and SP-D were purified from pooled amniotic fluid using affinity chromatography. Full 
length cDNA of human SP-A1 was also cloned in a mammalian vector pSecTagC for 
expression in human embryonic kidney cells (HEK-293T). SP-A was purified from the 
culture medium. In order to localise the domains of SP-A and SP-D which have 
immunomodulatory properties, the homotrimeric C-type lectin domains of human SP-A 
and SP-D were expressed in E. coli. The trimeric fragment of human SP-A designated 
rfSP-A was expressed as a fusion protein with maltose binding protein. It was also 
expressed under the T7 promoter as inclusion bodies in E. coli, which were subjected to 
denaturation-renaturation procedures followed by affinity purification.  A similar 
construct and procedure were applied for generating a recombinant fragment of human 
SP-D, designated rfSP-D, that is comprised of homotrimeric neck and carbohydrate 
recognition domain. Each protein preparation were examined for purity and 
immunological identity followed by LPS content. Wherever possible the contaminating 
LPS were removed prior to use in bioassay systems.  
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3.1 Introduction  
SP-A and SP-D belong to the collectin family along with mannose-binding protein. The 
primary structure of SP-A and SP-D are arranged into four subunits: an amino terminal 
involved in the formation of disulphide bonds, collagen region containing Gly-Xaa-Yaa 
repeats, an α-helical neck domain to stabilise the carboxyl-terminal carbohydrate 
recognition domain (CRD) (Holmskov et al., 1994). Three of the polypeptide chains 
intercalate to form a triple helix with 3 CRD heads. These polypeptides form a cruciform 
structure in the case for SP-D and a bouquet-like formation for SP-A. SP-A and SP-D 
recognise pathogens such as house dust mite (Wang et al., 1996) and Aspergillus 
fumigatus (Madan et al., 1997) by its pathogen associated molecular patterns via its CRD 
regions to aid in macrophage uptake for phagocytosis and respiratory burst (van 
Iwaarden et al., 1990, van Iwaarden et al., 1991). Thus showing the importance of SP-A 
in the innate immune system of the lung. SP-A has also shown an importance in 
formation of tubular myelin and for spreading and adsorption of phospholipids at the 
air-liquid interface of alveoli making SP-A fundamental in regulating surfactant 
homeostasis. 
3.1.1 Purification strategies of native SP-A and SP-D from amniotic fluid 
Amniotic fluid is a clear, yellowish fluid surrounding the baby within the amniotic sac 
and circulating the foetal lungs with a pH of 7.0 to 7.5. Initially, the water-like fluid 
enters from the maternal plasma to the amniotic cavity by osmotic and hydrostatic 
pressure. The amniotic fluid at first consists of electrolytes and water then at 
approximately 8 weeks gestation, the kidneys develop allowing the passing of foetal 
urine which enters the amniotic fluid. By around 12-14 weeks gestational age, the liquid 
builds levels of carbohydrates, proteins, lipids, and phospholipids. Analysis of amniotic 
fluid has also shown a large quantity of pluripotent stem cells. These amniotic stem cells 
could be important for therapeutic uses in humans. The volume of amniotic fluid 
increases positively to foetal growth then reaches a plateau of 800 ml at 28 weeks 
gestation then reduces to 400 ml at 42 weeks gestation perhaps reducing because of 
increasing size of foetus (Underwood et al., 2005).  
The origin of some proteins found in the amniotic fluid cannot be determined with 
certainty. There is evidence from studies using electrophorectic techniques (Abbas and 
Tovey, 1960) and labelled proteins that they originate from the maternal circulation 
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which are filtered through the foetal membranes. For examples, human placental 
lactogen (HPL) is found in appreciable amounts in the maternal serum and amniotic 
fluid, however cannot be demonstrated in cord blood (Tallberg et al., 1965). This alarms 
the question of whether the protein originates from the mother or foetal circulation. 
Amongst the proteins found in the amniotic fluid, exists SP-A and SP-D, which are 
synthesised in alveolar type II cells in the foetal lungs and are secreted into the 
surrounding amniotic fluid. Both proteins and lipids are important in the formation and 
function of foetal lungs for uterine and postnatal life. As these proteins are important in 
the defence against infection, it was investigated if there was a difference in the level of 
protein expression in ratio to all proteins in the amniotic fluid in cases with and without 
intra-amniotic infections. The results suggested that there was no change in amniotic 
levels of SP-A and SP-D between 18 and 34 weeks gestation in amniotic infection 
regardless of corticoidsteroid treatment (Chaiworapongsa et al., 2008). Although the 
findings suggest the proteins level do not change with and without IAI, the levels of SP-A 
and SP-D do change with gestational age in the third trimester (Miyamura et al., 1994). 
We decided to purify foetal SP-A and SP-D and investigate if they influence the immune 
pathway during pregnancy, closest to the native context. We show here the purification 
of SP-A and SP-D from amniotic fluid (Strong et al., 1998). The amniotic fluid was 
collected after vaginal rupture at labour and collected by midwives at Bristol University 
Hospital.  The purification protocol involves the separation of SP-A and SP-D from one 
source using their affinity properties. For SP-D, MnCl2 is used for eluting the protein 
which is later removed from the protein by dialysis against calcium buffer. SP-A is 
eluted with EDTA after being bound to maltose on an affinity column. In both situation, 
the proteins were aggregated with the addition of calcium before separating the pellet 
rich SP-A from the supernatant rich SP-D at 10,000 x g for 40 minutes and the proteins 
were recovered by solubilisation with step wise dialysis containing urea starting at 8M 
concentration. The proteins were analysed for functionality via binding with maltosyl-
BSA and determined by ELISA. Each protein were characterised by western blot.  
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3.1.2 Cloning and expression of SP-A and SP-D with mammalian cell system  
 
 3.1.2.1 pSectagC 
In this chapter we have shown cloning of full length human SP-A1 gene into pSecTagC 
for expression in mammalian HEK-293T cells. pSecTagC vector is a 5.2 kb expression 
vector designed for stable and transient expression of genes into mammalian host cells 
(See appendix 8 for map). The proteins are cloned downstream to the Igκ leader 
sequence with the deletion of the host leader sequence to create a fusion allowing 
proteins to be secreted into the supernatant. 
Post-cloning, the plasmid was transfected into mammalian HEK-293T cells. 
Transfection is the process of inserting foreign gene into host i.e. mammalian cells, for 
protein production. This procedure allows the post-translation modification 
(glycosylation) of SP-A which it cannot do in bacterial E.coli cells. Therefore the 
mammalian cell is an important vehicle for the production and folding of functionally 
active human proteins. The DNA is a very negatively charged molecule which requires 
neutralising for transfection to take place. There are many methods of transfection and 
after optimising with cationic polymer polyethylenimine (PEI), lipofectamine and 
calcium phosphate co-precipitation; we found the later to be efficient. There are two 
types of transfection, stable and transient. In stable cell lines, the procedure involves 
careful integration the foreign DNA into the host’s genome to continuously reproduce 
the gene of interest during each passage, whereas, in transient transfection, there is no 
integration of foreign gene into the host and the gene is only expressed in one passage 
of cells. For stable cell lines, a selectable marker is used to select the integrated cells 
which have taken up the gene of interest and for long term production. Full length 
human SP-A has been cloned before into Chinese hamster ovarian (CHO) DXB11 cell line 
(Venkatraman Girija et al., 2010) to create a stable cell line, allowing the efficacy of SP-A 
production to be greater. We chose transient transfection into HEK-293T cell line using 
calcium-phosphate co-precipitation to produce a suitable amount of SP-A desired 
protein for functional and analytical studies. Human embryonic kidney cells often 
referred to as HEK-293T cells was chosen as they grow fast and can readily take up DNA 
for transfection and translation. After optimisation experiments were carried out, 
proteins were produced. HEK-293T cell contains an addition of the SV40 large T-antigen 
to allow episomal replication of transfected plasmids which contain the SV40-derived 
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viral sequence, origin of replication, which contributes to T-antigen recognition. The cell 
line was grown in high-glucose DMEM supplemented with 10% FCS, glutamine, non-
essential amino acids and penicillin/streptomycin. The gene was cloned into pSecTagC 
within EcoRI and XhoI sites after the IgGκ-chain leader sequence. The plasmid was then 
transfected (50µg) into each culture dish and grown up to 120 hours replenishing the 
media each day. The media from each day was collected and harvested for protein 
purification. The protein was dialysed against calcium buffer to aggregate the protein 
and allow efficient binding to maltose on an affinity column. The proteins were eluted 
with EDTA and analysed on a denaturing SDS-PAGE and functionality was confirmed in 
maltosyl-BSA and antibody specific binding.  
 
3.1.3 Cloning and expression of homotrimeric fragment of human SP-A and SP-D 
with without fusion partner 
SP-A and SP-D are important opsonins for interacting with macrophages to initiate an 
innate immune response. These collectins consist of 3 CRDs bound to a neck domain to 
create a binding site. We have constructed plasmids containing gene for neck and CRD 
domains for SP-A and SP-D, SP-D containing the addition of 8 Gly-Xaa,Yaa repeats from 
the collagen region. This will allow us to elucidate the biological function of these 
proteins to understand their importance in modulating an immune response in 
pregnancy and labour. Trimeric SP-A and SP-D were produced in E. coli BL21 (λDE3) 
and BL21 (λDE3) pLysS followed by characterisation via binding ability. Trimeric SP-D 
was produced as previously described (Singh et al., 2003) using the T7 promoter system 
and fusion system with MBP (Eda et al., 1997, Kishore et al., 1996). We have adopted 
both techniques to clone trimeric SP-A.  
The DNA coding for the trimeric region was pulled out from the same cDNA used for 
cloning full length SP-A. The primers used are mentioned in chapter 2. Trimeric 
fragment SP-A to create a fusion protein was inserted into pMalC-2 and that cloned for 
expression under the T7 promoter system was cloned into BL21 (λDE3) pLysS.  
3.1.3.1 pET-101 system 
pET-101 (Invitrogen, Paisley, UK) is a directional cloning vector which contains a 
topoisomerase I which binds to double stranded DNA and cleaves the phosphodiester 
97 
 
backbone at 5’-CCCTT (Shuman, 1991) (figure 3.2-3.3). The reverse reaction can occur if 
phosphor-tyrosyl bond between DNA and enzyme can be attacked by 5’hydroxyl of the 
cleaved strand to release the topoisomerase (Shuman, 1994). In this system, PCR 
products are cloned with by adding the CACC on the forward primer to allow directional 
cloning which anneals to the complimentary GTGG overhang of the open vector to 
stabilise the PCR for annealing (figure 3.3). The Champion pET expression system 
contains the bacteriophage T7 promoter modified to contain a lac operator. The T7 RNA 
polymerase recognises this promoter in BL21 (λDE3) to transcribe the gene of interest. 
This strain contains λDE3 lysogen which contains the lacI gene encoding the lac 
repressor. T7 RNA polymerase gene is under the control of lacUV5 promoter and small 
portion of the lacZ gene. The lacI repressing T7 RNA polymerase is overcome with 
addition of isopropyl β-D-thiogalatosidase (IPTG) allowing the expression of lacUV5 
promoter to express T7 RNA polymerase. The disadvantage of the T7 lac promoter 
system shows that there is always some basal T7 RNA polymerase expression from 
lacUV5 promoter in λDE3 lysogens even without IPTG (Studier and Moffatt, 1986). This 
is not usually a problem, but if the gene of interest is toxic, even small expression of the 
gene of interest may lead to plasmid instability and cell death. The gene of interest 
(trimeric SP-A) was cloned in to pET-101 and transformed into TOP10 competent cells 
(Invitrogen). TOP10 cells do not contain T7 RNA polymerase but provides a host for the 
propagation of recombinant plasmids. The plasmid was transformed into BL21 (λDE3) 
pLysS for expression but could have been transformed for expression in BL21 STAR, 
however this requires fusion-tags at the N-terminus and C-terminus. 
During cloning the forward primer was designed to contain an initiating ATG codon 
following the 5’-CACC overhang. 
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Figure 3.1 Map of pET-101/D-TOPO 
 
 
 
Figure 3.2 – Sequence and cloning sites of pET101/D-TOPO 
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3.1.3.2 pET-3b system 
pET expression vectors derived from pBR322 plasmids which have been engineered to 
contain T7 bactriophage gene10 to promote high level of transcription and translation 
for the gene of interest. This is specific to the bacteriophage RNA polymerase so will not 
be recognised by host RNA polymerase making it very specific. This system is one of the 
most widely used for cloning and in vivo expression system because of its specific 
bacteriophage T7 RNA polymerase promoter sequence. The T7 gene10 leader sequence 
can significantly enhance the gene of interest expression more than 40 folds (Olins et al., 
1988). The sequence of interest is cloned downstream to the T7 RNA polymerase and 
T7 gene10 leader sequence. The high level of T7 RNA polymerase activity out-competes 
transcription by the host RNA polymerase, together with its translation efficiency leads 
to higher level of expression of target protein to constitute majority of the cellular 
proteins within a few hours. Expression is achieved with 0.5mM IPTG which allows 
lacUV5 promoter to express T7 RNA polymerase to transcribe the downstream 
sequence of the gene of interest. SP-A and SP-D were cloned directly into NdeI/HindIII 
site in the pET-3b vector downstream to the gene10 initiation codon (figure 3.4). 
Despite the highly specific activity of T7 RNA polymerase, there are chances of ‘leaky 
expression’ which can be toxic to the cell causing cell death. Alternatively, more 
stringent methods such as the pET-11 vector containing the lac operator can be used for 
toxic genes.  
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Figure 3.3 – Map of pET3b and its restriction cloning sites  
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3.1.3.3 pMal-c2 
The pMal-c2 vector provides a method for cloning a gene for expressing and purifying a 
protein. The gene was cloned downstream to the malE gene of E.coli which codes for 
maltose-binding protein (MBP) to results in a MBP fusion protein (Maina et al., 1988) 
(figure3.5). This method has many advantages, such as the malE initiation sequence and 
“tac” promoter to result in high-level of expression of the gene of interest, a laqI gene for 
lac repressor to keep Ptac low in the absence of IPTG. This system carries a recognition 
site specific for factor Xa protease, 5’ to the polylinker insertion to allow cleaving of 
MBP from the protein of interest. The one-step purification of the fusion protein makes 
it easier to purify the soluble fused protein. To produce the clone in pMal-c2, the gene of 
interest was inserted in frame to the malE gene and has its own stop codon at the 3’ end. 
The pMal-c2 has a deletion of the leader sequence which leads to the cytoplasmic 
expression of the fusion protein and is more stable than other pMal vectors in its series. 
Cloning and production of SP-D using this fusion system has been shown before (Eda et 
al., 1997, Kishore et al., 1996). 
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Figure 3.4 – Map of pMal-c2 and cloning sites  
 
 
 
 
 
 
SP-A 
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3.2 Materials and methods 
3.2.1 Purification of native SP-A from Amniotic fluid 
Amniotic fluid is normally collected either following vaginal rupturing of the foetal 
membranes or during spontaneous rupturing. Method of purification of native SP-A 
from amniotic fluid has been adapted from Strong et al (Strong et al., 1998). Briefly, 1L 
of amniotic fluid was equilibrated with 5 mM CaCl2 and the fat and large 
aggregates/debris were sieved first through a 3 mm Whatman filter paper then through 
a cell strainer for a clearer suspension. The SP-A rich pellet was separated from the SP-
D rich supernatant by centrifugation at 10,000 x g for 40 mins at 4°C. The SP-A rich 
pellet was extracted with 20 ml of 8 M urea Buffer-I (50 mM Tris-HCl, pH7.4, 100 mM 
NaCl, 5mM CaCl2, 0.02%, NaN3, 8 M Urea) and mixed for 1 hour at 4°C. The solubilised 
protein was centrifuged at 10,000 x g for 40 mins at 4°C to collect the supernatant 
containing SP-A. The protein was dialysed against 4 M urea buffer for 2 hours, then 1 M 
urea buffer for 2 hours followed by dialysis against Buffer-I (50 mM Tris-HCl, pH7.4, 
100 mM NaCl, 5 mM CaCl2, 0.02% NaN3) overnight. The next day, the dialysate (~20 ml) 
was centrifuged at 10,000 x g for 20 mins at 4°C and the clear supernatant was used for 
protein purification by affinity chromatography.  
 3.2.2 Affinity chromatography for purification of SP-A from amniotic fluid 
Maltose-sepharose was washed with 10 bed volumes of autoclaved distilled water, 
followed by equilibration with 10 bed volumes of Affinity Buffer-I (50 mM Tris-HCl, 
pH7.4, 100 mM NaCl, 5 mM CaCl2, 0.02% NaN3). The matrix was mixed with the 
supernatant containing SP-A for 30 mins at room temperature to allow binding of native 
SP-A to maltose-sepharose. Consequently, the sample was passed through an affinity 
column thrice to allow the bed to settle and the proteins to be collected on the matrix. 
The column was then washed with 5 bed volumes of Affinity Buffer I containing 1 M 
NaCl (50 mM Tris-HCl, pH7.4, 1 M NaCl, 5 mM CaCl2, 0.02% NaN3). SP-A bound proteins 
were eluted in 20 x 1 ml with Buffer I containing 10 mM EDTA (50 mM Tris-HCl, pH7.4, 
100 mM NaCl, 10 mM EDTA, 0.02% NaN3). Protein purity and integrity were 
determined by SDS-PAGE.  
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3.2.3 Purification of native SP-D from Amniotic fluid 
The supernatant of amniotic fluid rich is SP-D were calcified to 5mM CaCl2 to increase 
volume and decrease viscosity, whilst monitoring the pH to 7.5. After stirring for 1hour 
at 4°C to allow aggregation of the calcium dependent proteins, SP-D, the sample was 
passed thrice through maltose-agarose equilibrated with 10 bed volumes of Affinity 
Buffer I (50 mM Tris-HCl, pH7.4, 100 mM NaCl, 5 mM CaCl2, 0.02% NaN3). Non-specific 
bound proteins were washed with 5 bed volumes of 1 M NaCl buffer (50 mM Tris-HCl, 
pH7.4, 1 M NaCl, 5 mM CaCl2, 0.02% NaN3). 10 x 1ml fractions of SP-D were eluted with 
elution buffer containing manganese chloride (50 mM Tris-HCl, pH7.4, 100 mM NaCl, 10 
mM MnCl2, 0.02% NaN3) over ice. Optical density of each fraction is read at 280 nm 
using Elution Buffer without MnCl2 as a reference.  
3.2.4 Removal of BSA and manganese chloride and concentration of SP-D protein 
To remove manganese chloride (MnCl2), the fractions with the highest concentrations 
were pooled and dialysed against 1L elution buffer containing 5mM EDTA overnight at 
4°C.  To concentrate the protein, the dialysis bag was placed in a beaker containing 
Polyethylene Glycol MW 6000-10,000 (Sigma, Dorset, UK) for 2 hours until the 
concentration reached ~500 µg/ml. The proteins were stored in 1ml fractions at -20°C.  
3.2.5 SDS-PAGE and Western blotting 
SDS-PAGE was performed in a 4% stacking and 12% separating/resolving gel with an 
unstained protein molecular marker (Peqlab, Sarisbury Green, UK). Protein bands were 
visualised by Coomassie brilliant blue R-250 (Bio-Rad, Hemel Hempstead, UK). In SDS-
PAGE for Western blotting, full-range rainbow molecular weight marker were used (GE 
healthcare Life sciences, Buckinghamshire, UK). 
Immunoblotting was carried out essentially as described previously (Towbin et al., 
1979) in a blotting chamber from Bio-Rad (Mini Trans blot) (Bio-Rad, Hemel 
Hempstead, UK) using nitrocellulose membrane (Millipore, Watford, UK). After transfer 
(340A for 90 mins), the membrane was blocked overnight at 4°C in 5% v/v non-fat 
milk-powder in PBS (blocking buffer). After washing in PBS with 0.05% Tween -20 
(washing buffer) the membrane was incubated for 1.5 hours at room temperature in 1 
µg/ml rabbit anti-human SP-A in blocking buffer. After washing, the membrane was 
incubated in 1/1000 dilution Protein A-HRP (Invitrogen, Paisley, UK) for 1 hour at room 
temperature. Subsequently, the blot was developed in DAB (Sigma, Dorset, UK) 
according to manufactures recommendation.  
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3.2.6 Cloning of full length SP-A in pSecTagC for expression in mammalian HEK-
293T cells 
PCR amplification, DNA digestion, separation of fragments by agarose-gel 
electrophoresis, ligation of DNA fragments and transformation of E.coli with plasmid 
DNA was performed as described by Maniatis et al. (Malke, 1990). cDNA containing 
genetic code for full length SP-A was used as a template and provided by Umakanth, 
Leicester University. On the basis of the map for pSecTagC, two PCR primers were 
designed selecting two restriction sites after the Igκ chain leader sequence which did 
not cut within the full length sequence of SP-A. SP-A primers were designed excluding 
its own leader sequence as it will be initiated by the vector leader sequence itself. SP-A 
gene was amplified with forward oligonucleotide primer (5’-3’) – 
GGGGGAATTCGAAGTGAAGGACGTTTGTGTTGGAAG and reverse primer (5’-3’) – 
CGACTGACCATCTGTGAGTTCTGACTCGAGCCC. These were designed using the CDS 
region of the cDNA coding for SP-A excluding the leader sequence. Sequence data were 
from GeneBank/EMBL. Synthetic oligonucleotide primers were prepared by Sigma 
(Sigma, Dorset, UK).  
Template DNA (250 ng) and primers (500 µM each) were incubated in a 50 µl reaction 
mixture containing 5 x Phusion HF buffer, 10mM deoxytrinucleoside triphosphate 
(dNTPs), and 2 units/µl High-Phusion DNA polymerase (Thermoscientific, 
Loughborough, UK), set in a thermocycler at 98°C (10 secs), 59°C (20 secs) and 72°C (1 
mins) for 30 cycles. Vector, pSecTagC, was digested with EcoRI/HF and XhoI (NEB, 
Hitchins, Herts, UK) for 3hrs at 37oC. The products were gel purified with QIAquick gel 
extraction kit (Qiagen, Manchester, UK) according to manufactures recommendation.  
3.2.7 Ligation and transformation in TOP10 competent cells 
Prior to transformation of plasmid in TOP10 competent cells (Invitrogen, Paisley, UK), 
digested vector and insert were ligated with T4 DNA ligase (NEB, Hitchins, Herts, UK). 
For ligation, 1:3 vector to insert were incubated in a 20 µl reaction containing 1 µl 
enzyme and 2 µl T4 ligase buffer. This was incubated at room temperature for 20 
minutes and overnight at 4°C. The ligated product was transformed in TOP10 
competent cells with SOC media, incubating on ice for 1 hour, applying heat chock at 
42°C for 2 minutes, ice for 5 minutes and after adding SOC media the culture was 
incubated at 37°C for 1 hour before plating 50 µl on LB agar/ampicillin plates.  
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3.2.8 Plasmid isolation and digestion 
Colonies were selected for verifying successful cloning of gene of interest. Each colony 
were inoculated in 5 ml LB containing 100 µg/ml ampicillin and grown for 12-17 hours 
at 37°C. Cultures were harvested at 5,000 x g for 8 minutes before extracting plasmid 
with mini prep plasmid isolation kit (Qiagen, Manchester, UK) according to 
manufactures recommendation. 10 µl of extracted plasmid from each colony were 
incubated in a 50 µl reaction with 2.5 µl EcoRI and XhoI each, 10 µl 10x BSA and 5 µl 
NEB buffer 4. After 3 hour digest at 37°C the products were gel fractionated on an 
agarose gel and visualised under a UV Transilluminator (Bio-Rad, Hemel Hempstead, 
UK). Colony containing gene of interest was subjected to large scale plasmid extraction 
with EZNA FastFilter (VWR, Leicestershire, UK) according to manufactures 
recommendation. Large scale plasmid extraction was used for transfection in HEK-293T 
cells. 
3.2.9 HEK 293T transfection with pSecTagC/SP-A 
HEK293T (human embryonic kidney 293T) cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 5% heat-inactivated FBS (foetal bovine 
serum), 100 units/ml penicillin and 100 µg/ml streptomycin at 37 °C under humidified 
air containing 5% CO2. After HEK-293T cells were seeded 5 x 106 cells and grown for 12 
hours for cells to adhere. Next day, fresh media was added and transfection with 
calcium phosphate was prepared. 50 µg of DNA was incubated with 2M CaPO4 to make a 
final volume of 500 µl to form DNA-calcium phosphate complex. This was added to 500 
µl 2 x HBS (280 mM NaCl / 1.5 mM Na2HPO4 / 50 mM HEPES, pH 7.05) drop wise and 
incubated at room temperature for 30 minutes. The complex was added to the cells in 
fresh media and incubated for 4-5 days. Each day the media was replenished and 
harvested to purify protein secreted in the supernatant.  
3.2.10 Protein purification 
Media collected at 24, 48, 72, 96 and 120 hours and was harvested at 5000 x g for 10 
minutes and pooled before dialysing against Buffer-I containing 5 mM CaCl2 (50 mM 
Tris-HCl, 100 mM NaCl, 5 mM CaCl2, 0.02% NaN3, pH7.4) for 3 hours before purification 
by high affinity chromatography through a maltose-agarose matrix. The column was 
washed with 3 bed volumes of buffer-I followed by 3 bed volumes of buffer-I containing 
1 M NaCl to remove non-specific bound proteins. The maltose binding SP-A was eluted 
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at 1 ml/min with elution buffer containing 5 mM EDTA (50 mM Tris-HCl, 100 mM NaCl, 
5 mM EDTA, 0.02% NaN3) and collected in 1 ml fractions over ice. These fractions were 
separated on a 12% SDS-PAGE to observe protein yield, quality and purity. 
3.2.11 Cloning of recombinant fragment human trimeric-SP-A (rfSP-A) comprising 
of neck and CRD regions in pMal-c2 for expression in E.coli BL21 (λDE3) 
Cloning of trimeric fragment SP-A (rfSP-A) was adapted from (Eda et al., 1997, Kishore 
et al., 1996).  PCR amplification, DNA digestion, separation of fragments by agarose-gel 
electrophoresis, ligation of DNA fragments and transformation of E.coli with plasmid 
DNA was performed as described by Maniatis et al. (Malke, 1990). cDNA containing 
genetic code for full length SP-A was used as a template and provided by Umakanth, 
Leicester University. On the basis of the map for pMal-c2, two PCR primers were 
designed to amplify the CRD region after the 23gly-Xaa-Yaa repeats to clone the neck 
and CRD of SP-A. Two restriction sites were selected which were within the pMal-c2 
vector but not within the N/CRD region of SP-A. This was verified with digest finder 
from NEB using the sequence data from GeneBank/EMBL. Primers were designed to 
contain EcoRI site on forward primer and BamHI on the reverse primer. Recombinant 
fragment of human SP-A gene was amplified with forward oligonucleotde primer (5’-3’) 
– GGGGAATTCCATCTAGATGAGGAGCTCCAAGC and reverse primer (5’-3’) – 
GGGGGATCCCTAGAACTCACAGATGGTCAGTCGG. Synthetic oligonucleotide primers 
were prepared by Sigma (Sigma, Dorset, UK). The gene of interest was cloned 
downstream to the MalE gene of E.coli which encodes the maltose binding protein 
(MBP) gene to result in a fusion protein for cytoplasmic expression. SP-A neck and CRD 
cloned into pET-101 was carried out the same way as described for cloning in pMal-c2 
except the plasmid used was pET-101 and the forward primer was substituted with – 
CACCATGCATCTAGATGAGGAGCTCCAAGC. The expression and purification for SP-A 
cloned into pET-101 was carried out the same way as described for proteins in inclusion 
bodies. 
High-Phusion DNA polymerase (Thermoscientific, Loughborough, UK) was used to 
amplify the gene of interest. Template DNA (250 ng) and primers (500 µM each) were 
incubated in a 50 µl reaction mixture containing 5 x Phusion HF buffer, 10mM 
deoxytrinucleoside triphosphate (dNTPs), and 2 units/µl High-Phusion DNA 
polymerase (Thermoscientific, Loughborough, UK), set in a thermocycler at 98°C (10 
108 
 
secs), 59°C (20 secs) and 72°C (1 mins) for 30 cycles. Vector, pMal-c2, was digested with 
EcoRI/HF and BamHI (NEB, Hitchins, Herts, UK) for 3 hours at 37oC. The products were 
gel purified with QIAquick gel extraction kit (Qiagen, Manchester, UK) according to 
manufactures recommendation.  
3.2.12 Ligation and transformation in TOP10 competent cells 
Prior to transformation of plasmid in TOP10 competent cells (Invitrogen, Paisley, UK), 
digested vector and insert were ligated with T4 DNA ligase (NEB, Hitchins, Herts, UK). 
For ligation, 1:3 vector to insert were incubated in a 20 µl reaction containing 1 µl 
enzyme and 2 µl T4 ligase buffer. This was incubated at room temperature for 20 
minutes and overnight at 4°C. The ligated product was transformed in TOP10 
competent cells with SOC media, incubating on ice for 1 hour, applying heat chock at 
42°C for 2 minutes, ice for 5 minutes and after adding SOC media the culture was 
incubated at 37°C for 1 hour before plating 50 µl on LB agar/ampicillin plates.  
3.2.13 Isolation of the recombinant construct and characterisation by restriction 
digestion and DNA sequencing 
Colonies were selected for verifying gene of interest insertion. Each colony was in 
inoculated in 5 ml LB containing 100 µg/ml Ampicillin and grown for 12-17 hours at 
37°C. Cultures were harvested at 5000 x g for 8 minutes before extracting plasmid with 
mini prep plasmid isolation kit (Qiagen, Manchester, UK) according to manufactures 
recommendation. 10 µl of extracted plasmid from each colony were incubated in a 50 µl 
reaction with 2.5 µl EcoRI and BamHI each, 10 µl 10x BSA and 5 µl NEB buffer 4. After 3 
hours digest at 37°C the products were gel fractionated on an agarose gel and visualised 
under a UV Transilluminator (Bio-Rad, Hemel Hempstead, UK). Plasmids were 
sequenced by BD genomics and varied by BLAST on NCBI. Colony containing gene of 
interest in pMal-c2 vector was transformed in BL21 (λDE3) and colonies containing 
gene of interest in pET-3b or pET101 was transformed in BL21 (λDE3) pLysS 
(Invitrogen, Paisley, UK) for protein production.  
3.2.14 Expression and purification of soluble proteins – MBP fused SP-A 
Single colony of BL21 (λDE3) with the right construct was subjected to large scale 
expression in 250 ml for protein production. This was purified by affinity 
chromatography through a amylose-resin column. Initially, the colony was inoculated in 
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LB supplemented with 100 µg/ml ampicillin and grown at 37°C shaking for 12-17 
hours. 12.5 ml of the primary culture was transferred into 250 ml LB with 100 µg/ml 
ampicillin and grown at 37°C shaking until the cells reach log phase, indicated by an OD 
(600 nm) between 0.6-0.8. The culture was induced with 0.5 mM IPTG and further 
incubated for 3 hours in a 37°C shaking for production of protein. The culture was 
harvested 13,000 x rpm. The pellet was further processed to extract soluble proteins.  
The cell pellet containing protein was separated by breaking aggregates with lysis 
buffer and sonication. Initially, the pellet was dissolved in 30 ml ice-cold lysis buffer (20 
mM Tris-HCl, 500 mM NaCl, 1 mM EDTA, 0.25% Tween-20, pH8.0) and stirred for 1h 45 
mins at 4°C. PMSF and lysozyme was added to a final concentration of 10 mM and 50 
µg/ml respectively to prevent protein degradation and aid the lysis of cells. The 
suspension was sonicated for 15 cycles at 40 kHz for 30 seconds with 2 minute 
intervals. All stages of sonication were carried out on ice to prevent proteins 
denaturing. The sonicated sample was harvested at 13000 rpm for 15 mins to collect 
protein rich supernatant. The supernatant was diluted 5-fold with column buffer 
containing tween-20 with an end concentration 100 mM NaCl and applied to the 
equilibrated amylose resin (GE healthcare Life sciences, Buckinghamshire, UK) column 
for purification. 
3.2.15 Affinity chromatography purification of MBP-SP-A 
The amylose column was washed with 3 bed volumes of column buffer containing 
tween-20 (20 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 0.25% Tween-20, 5% glycerol, 
pH8.0). This was followed by passing the diluted supernatant once and washing with 3 
bed volumes of column buffer without tween-20. The column wash then washed with 
25 ml factor Xa buffer (20 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl2, 5% glycerol, pH8.0) 
to remove non-specific bound proteins and proteins were eluted with 20 ml elution 
buffer (20 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl2, 10 mM Maltose, 5% glycerol, pH8.0) 
in 1 ml fractions over ice. The OD was checked at 280 nm to obtain protein yield before 
cleavage of protein with FactorXa protease. 
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3.2.16 Cleavage of MBP with FactorXa protease 
Proteins were dialysed against column buffer with glycerol but without tween for 3-4 
hours. The samples were concentrated to 1 mg/ml with polyethylene glycol. Factor Xa 
protease (1 U/100 µg of fusion protein) was added to 100 µl same and incubated for 24 
hours at R/T until cleavage is complete.  
3.2.17 Purification of MBP-SP-A with maltose-agarose after cleavage 
Proteins were dialysed against affinity buffer (50 mM Tris-HCl, pH7.4, 100 mM NaCl, 5 
mM CaCl2, 0.02% NaN3) for 2-3 hours and passed through maltose-sepharose column 
thrice. The column was washed with 10 ml affinity buffer containing 1 M NaCl2 (50 mM 
Tris-HCl, pH7.4, 1 M NaCl, 5 mM CaCl2, 0.02% NaN3) to remove any impurities and non-
specific bound proteins. Proteins were eluted in 0.5 ml fractions with elution buffer 
containing 5 mM EDTA buffer (50 mM Tris-HCl, pH7.4, 100 mM NaCl, 5 mM EDTA, 
0.02% NaN3). 
3.2.18 Expression and purification of rfSP-A and rfSP-D in T7 system E.coli BL21 
(λDE3) pLysS  
Plasmid containing rfSP-A and rfSP-D was provided by Dr Uday Kishore, Brunel 
University. These plasmids and rfSP-A in pET-101 were transformed in BL21 (λDE3) 
pLysS. A single colony was selected for large scale expression, inoculated individually in 
15 ml LB supplemented with Amp/chl. 100 µg/ml and 50 µg/ml respectively. The 
inoculum was grown overnight at 37°C shaking. 12.5 ml of the primary culture was 
transferred into 250 ml LB supplemented with amp/chl. and grown for approximately 3 
hours at 37°C until the cells reached log phase, indicated by an OD (600 nm) between 
0.6-0.8. 1 ml. The culture was induced with 0.5 mM IPTG and further incubated for 3 
hours in a 37°C shaking incubator. Post induction, the culture was harvested at 13000 
rpm for 10 min and pellets were stored at -20°C.  
3.2.19 Lysis and sonication of insoluble proteins in inclusion bodies 
The cell pellet containing protein in inclusion bodies were separated by breaking 
aggregates with lysis buffer and sonication. Initially, the pellet is dissolved in 25 ml ice-
cold lysis buffer (50 mM Tris-HCl, 200 mM NaCl, 5 mM EDTA, pH7.4) with PMSF and 
lysozyme at an end concentration of 10mM and 50 µg/ml respectively. After lysis for 1 
hour at 4°C the suspension of lysed cells was sonicated for 15 cycles at 40 kHz for 30 
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seconds with 2 minute intervals. All stages of sonication were carried out on ice to 
prevent proteins denaturing. The sonicated sample was harvested at 13,000 rpm for 15 
mins to collect protein rich pellet.  
3.2.20 Refolding of proteins from inclusion bodies by step-wise dialysis 
The proteins recovered in the pellet were solubilised with 25 ml 8 M urea buffer (50 
mM Tris-HCl, 100 mM NaCl, 5 mM EDTA, pH7.5, 8 M Urea) containing 10 mM 2-
merceptoethanol whilst stirring on a magnetic stirrer for 1 hour at 4°C. The solubilised 
protein was centrifuged at 13,000 rpm for 15 minutes and transferred into a dialysis 
bag. The proteins were dialysed against dialysis buffer containing 4 M urea and 2-
merceptoethanol for 2 hours at 4°C, transferred to dialysis buffer containing 2 M urea 
with 2-merceptoethanol followed by dialysis buffer containing 1 M urea and fresh 2-
merceptoethanol, stirring for 2 hours at 4°C at each step. Finally, the buffer was changed 
to dialysis buffer with no urea stirring at 4°C overnight. The following day, the proteins 
were purified by affinity chromatography on a maltose-agarose column.  
3.2.21 Purification of proteins from inclusion bodies expressed in E.coli via Affinity 
chromatography 
The next day, the buffer was changed to affinity buffer containing 5 mM CaCl2 to remove 
EDTA and to calcify the protein in preparation of affinity chromatography. The refolded 
rfSP-A and rfSP-D-gly-x-y proteins were purified by high affinity chromatography 
containing a maltose-agarose matrix to allow the proteins to specifically bind. Initially 
the column was prepared by equilibrating with 5 bed volumes of affinity buffer (50 mM 
Tris-HCl, 100 mM NaCl, 5 mM CaCl2, pH7.5). Next, the protein was passed through the 
column thrice before non-specific and weakly bound proteins were washed off the 
column with affinity buffer containing 1 M NaCl (50 mM Tris-HCl, 1 M NaCl, 5 mM CaCl2, 
pH7.5). Proteins were eluted with elution buffer containing 5 mM EDTA (50 mM Tris-
HCl, 100 mM NaCl, 5 mM EDTA, pH7.5) in 20 x 1ml fractions over ice. The absorbance 
readings of each fraction were observed at A280 and the presence and purity of the 
protein was determined by 12% SDS-PAGE. Endotoxin removal was carried out and LPS 
levels were determined by LAL assay (Lonza, Slough, UK). 
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3.2.22 Endotoxi removal from rfSP-A with endotoxin removal spin columns (Thermo 
Scientific) 
The use of the columns was followed as instructed by manufacturers’ guidance and as 
described in chapter 2.  
3.2.23 Limulus Amebocyte Lysate (LAL) assay (Lonza, Slough, UK) 
The LPS levels in finally purified proteins were measured using the chromogenic 
Limulus Amebocyte Lysate (LAL) assay as described under chapter 2. 
 
Characterisation of SP-A and SP-D  
3.2.24 Bis-(sulfosuccinimidyl)-suberate (BS3) cross-linking 
A 25mM solution of BS3 was prepared by dissolving 2 mg BS3 in 140 μL of DMSO. Using 
a 20-fold excess approach (20:1 Crosslinker: Protein), BS3 crosslinker solution was 
mixed with the protein sample so that the final crosslinker concentrations are at 3 
different concentrations -  1 mM, 0.1 mM and 0.01mM BS3. This was incubated at room 
temperature for 45 minutes to 1 hour. As a control, quench and unreacted BS3 mixed in 
25 mM to 60 mM Tris-HCl (pH-7.5) was incubated for 10-15 minutes at room 
temperature. The samples were separated on an SDS-PAGE. 
3.2.25 Maltosyl-BSA binding with native and recombinant proteins 
96-well ELISA plate was coated with 5µg maltosyl-BSA double diluted 5 times and 
incubated overnight at 4°C. The next day, the sample was discarded and blocked in 2% 
BSA-PBS for 2hours at 37°C. Protein at 5µg per well were added in duplicates per 
dilution of maltosyl-BSA and incubated for 1.5 hours at 37°C. The unbound proteins 
were discarded and wells were washed thrice with PBS + 0.05% Tween-20. Primary 
antibody (1:1000 dilution – anti-human SP-A and anti-human SP-D) was added and 
incubated for 1.5 hours, followed by thrice washes with PBS-Tween 20, 0.05%. Finally 
secondary antibody, PA-HRP, was added to 1:5000 dilution and incubated for 1.5 hours 
at 37°C. After the final washing off wells, the binding was detected cholometrically by 
addition of OPD (Sigma, Dorset, UK) until colour developed. This was detected under an 
ELISA plate reader (Bio-Rad, Hemel Hempstead, UK) at 450nm. 
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3.3 Results 
3.3.1 Purification of native and recombinant proteins and binding to maltosyl-BSA 
Native SP-A and SP-D were purified from amniotic fluid and observed under reducing 
conditions.  Both monomeric and dimeric forms of SP-A and SP-D were visible 
(Figure.3.6, 3.7 & 3.8). These were confirmed by western blot (Figure. 3.7 & 3.10). For 
characterisation these proteins were coated on an ELISA plate and to ensure specificity 
of these proteins antibodies against the proteins were used and binding was detected. 
Results displayed a positive trend of protein dilution binding to antibody. Native SP-A 
and full length rSP-A bound best to the antibody shown by a stronger signal on the 
spectrophometer. rfSP-A and rfSP-D showed weaker binding to the antibodies 
(Figure.3.12). Another method was via Westernblot, which confirmed specificity of the 
native proteins. Finally, binding of proteins (2.5µg) to maltosyl-BSA (ranging from 5-
0.625µg) detected with antibodies specific to the protein, displayed best binding from 
native SP-A, rSP-A, rfSP-A in order of affinity, however rfSP-D showed stronger binding 
to maltosyl-BSA at 1.25µg (Figure.3.11).  
Purification of native SP-A from Amniotic fluid 
 
Figure 3.5 – Purified native SP-A from amniotic fluid. Lane 1 – protein marker, lane 3 – nSP-A 
F10 batch 2, lane 4 – nSP-A F1 Batch1, lane 5 – nSP-A F5 Batch1, lane 6 – nSP-A F6 Batch 3, lane 6 
– nSP-A F.11 Batch 3, lane 8 – nSP-A F.2 Batch 4. Results show bands for dimmers (66 kDa) and 
monomers (~33 kDa) in Batch 1 (L5 & 6). 
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Westernblot characterisation of native SP-A from amniotic fluid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 – Western blot to detect native SP-A from amniotic fluid. Initially 1µg and 2 µg 
proteins were separate on a SDS-PAGE and transferred at 320amps for 90mins.  The membrane 
was blocked with 5% milk-powder/PBS buffer and probed with anti-human SP-A in a 1:5000 
dilution. The primary antibody was detected with a HRP conjugated Protein A in a 1:5000 dilution. 
The bands were visible after DAB reacting with HRP to display protein bands; monomers and 
dimers of SP-A at 33kDa and 64kDa respectively. 
 
Purification of native SP-D from Amniotic fluid 
 
Figure 3.7 – SDS-PAGE – Purified SP-D from amniotic fluid. Purified SP-D from amniotic fluid 
purified via affinity chromatography with maltose-agarose separated under reducing conditions 
on an SDS-PAGE. Protein appears at 46kDa. Lane 1 – protein marker, lane 2 – SP-D fraction 1, lane 
3 – SP-D fraction 2. 
 
1                              2                   
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Purification of native SP-D from Amniotic fluid 
 
Figure 3.8 – SDS-PAGE – Purified SP-D from amniotic fluid. Purified SP-D from amniotic fluid 
purified via affinity chromatography with maltose-agarose separated under reducing conditions 
on an SDS-PAGE. Protein appears at 46kDa. Lane 1 – protein marker (14.4, 18.4, 25, 35, 45, 66.2, 
116kDa), lane 2-10 – fractions 1-9. Protein appears in trimeric form at ~65kDa.separated under 
reducing conditions, stained with coomassie blue.  
 
Westernblot characterisation of native SP-D from amniotic fluid 
 
Figure 3.9 – Western blot detection of nSP-D under reducing conditions. SP-D is 
composed of a 43 kDa polypeptide chain, with faint bands corresponding to dimers and 
trimers of the 43kDa chain can also been seen.  
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Characterisation of native and recombinant SP-A and SP-D 
 
Figure 3.10 – binding of native and recombinant SP-A and SP-D to maltosyl-BSA. Dilutions 
from 5 µg of maltosyl-BSA were diluted 4-folds to observe best concentration for binding of protein 
(2.5 µg). Maltosyl-BSA was coated in a 96-well multititre plate incubated overnight. The next day, 
the bound proteins were blocked with 5% v/v non-fat milk powder in PBS for 2hours at 37°C. After 
3 consecutive washed the proteins were added at a constant concentration of 2.5 µg and incubated 
for 1.5 hours at 37°C. Following 3 consecutive washed, the secondary antibody at 1 µg/ml was 
added and incubated for a further 1 hour. The binding of protein-protein interaction was observed 
with the addition of DAB reacting with the HRP on the secondary antibody protein A and 
quantified via spectrophometer at 450 nm. 
 
 
Figure 3.11 – binding of antibodies against native and recombinant proteins. Proteins were 
double diluted 4 times and detected with antibodies at 1 µg/ml (1:1000 dilution). Secondary 
antibody protein-A conjugated with HRP bound to primary antibody which was detected with DAB 
and results were quantified spectrophotometrically at 450 nm. 
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3.3.2 Transient expression of recombinant SP-A (rSP-A) in HEK-293T cells with 
calcium phosphatase 
Full length SP-A (686 bp) was successfully cloned into pSecTagC and expressed in 
mammalian HEK-293T cells by transient expression. The two restriction sites selected 
were XhoI and EcoRI which were not present in the human SP-A mRNA. After successful 
cloning, the insertion of fragment was verified by restriction digests of isolated 
plasmids, out of all three plasmids, the fragment has dropped out (figure 3.14). The 
plasmids were sent for sequencing to Beckman Coulter Genomics and there was a 100% 
match in the sequence (see appendix). The plasmids were transfected by two methods, 
lipofectamine 2000 (Invitrogen) and calcium phosphate method (figure 3.15-3.16). Both 
showed efficient uptake therefore, it was chosen to opt for the inexpensive reproducible 
method using calcium phosphate. This yields 2-3mg per 50µg plasmid in 3 x 80 cm3 
culture flask (figure 3.17-3.18).  
Cloning and expression of recombinant full length SP-A in HEK-293T cells  
 
Figure 3.12 – DNA fractionation of recombinant human full length SP-A on a 0.7% agarose-
EtBr gel. 0.7% Agarose gel was prepared and 10 µl of each sample including digested and gel 
purified SP-A1 and pSecTagC were loaded. Lane 1 – DNA hyperladder I, lane 2 – pSecTagC uncut 
(1:10 dilution), lane 3 – pSecTagC cut with XhoI and EcoRI, lane 4 SP-A1 cut with XhoI and EcoRI, 
lane 5 – SP-A1 after PCR uncut, lane 6 – DNA hyperladder I. 
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Double digest with EcoRI and XhoI to check for insert 
Figure 3.13 – Restriction digestion of pSecTagC with SP-A gene of interest. Figure 2. 1% 
Agarose gel - Digested sample were loaded in each well. Three colonies of SP-A1 ligated into 
pSecTagC were selected for double digestion and each showed a fragment of 686 bp to drop out. 
Lane 1 – hyperladder I, lane 2 - pSecTagC + SP-A1 E/X col.1, lane 3 - pSecTagC + SP-A1 EcoRI col.1, 
lane 4 - pSecTagC + SP-A1 XhoI col.1, lane 5 - pSecTagC + SP-A1 E/X col.2, lane 6 - pSecTagC + SP-
A1 EcoRI col.2, lane 7 - pSecTagC + SP-A1 XhoI col.2, lane 8 - pSecTagC + SP-A1 E/X col.3, lane 9 - 
pSecTagC + SP-A1 EcoRI col.3, lane 10 - pSecTagC + SP-A1 XhoI col.3, lane 12 - pSecTagC + SP-A1 
uncut, lane 13 - pSecTagC uncut, lane 14 – hyperladder I 
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Purified SP-A expressed in HEK-293T cells 
 
Figure 3.14 – SDS-PAGE 1/2 – purified SP-A expressed in HEK-293T cells. 12% SDS-PAGE – 
Purified fractions of recombinant full length SP-A after affinity chromatography with maltose-
agarose – lane 1 – protein marker, L.2 – flow through, L.3 – 1M NaCl wash, L.4-10 – fractions 1-7 
 
Figure 3.15 – SDS-PAGE 2/2 – Purified SP-A expressed in HEK-293T cells. 12% SDS-
PAGE – Purified fractions of recombinant full length SP-A after affinity chromatography 
with maltose-agarose - lane 1 – protein marker, L.2-4 – Fraction 8-10 
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3.3.3 Expression of recombinant fragment SP-A (rfSP-A)– neck and CRD region in 
pET-101 
Neck and CRD fragment of SP-A was cloned into pET-101 at restriction sites EcoRI and 
SacI. After digestion, fragment of interest had dropped out successfully (figure 3.20); 
although the fragment drop was very faint the sequence was verified by Beckman 
Coultiers, showing a 100% match to SP-A gene. The plasmids were transformed into 
BL21 (λDE3) and pLysS strains of E.coli. Cultures transformed into pLysS were unable 
to grow and those transformed into BL21 (λDE3), OD to reach 0.6-0.8 typically took 4-8 
hours which gave slight expression (Figure.3.21-3.23, 3.26). To verify if the protein was 
present in the induced samples, a western blot was carried out and protein was 
detected at ~66kDa rather than the expected 18kDa after IPTG induction (Figure.3.24-
3.25). The sample was lysed and sonicated to see if protein can be purified, after 
another western blot analysis; the protein was detected again at ~66kDa and in the 
supernatant rather than the expected pellet (Figure.3.26-3.27). The proteins are usually 
found in the inclusion bodies which are collected in the pellet that are later extracted. 
The protein was detected in the supernatant which was dialysed against affinity buffer 
and purified via affinity chromatography using a maltose-sepharose column. The 
purified samples were analysed by immunoblot and no protein was detected in the 
fractions however was in the flow through (Figure.3.28). This suggests the protein was 
denatured or was not refolded correctly to be functionally/biologically active, and did 
not bind to the column. To confirm this was not a one off situation, many pilot and large 
scale expressions were carried out, each giving the same results. 
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DNA fractionation of recombinant human SP-A (N/CRD) on a 0.7% agarose-EtBr gel 
 
Figure 3.16 – agarose gel – PCR amplification of human gene, neck and CRD region of SP-A. 
DNA separation of SP-A (N/CRD) after PCR reaction. PCR products were separated through a 
0.7% agarose-EtBr gel using the cDNA of full length SP-A cloned in pSecTagC as a control. This 
shows a 444bp product against the DNA marker to suggest amplification of the gene of interest. 
Lane 1: DNA marker (Hyperladder I – Bioline 14 bands from 200 bp - 10,037 bp), Lane 2-3: PCR 
reaction 1, 2, Lane 4: cDNA template containing full length SP-A (686 bp) in pSecTagC (5.2 kbp).  
 
Trimeric fragments of SP-A were amplified and separated on an agarose gel (figure. 
3.19). The fragment and digested plasmid were purified and ligated before transfection 
in Top10 competent cells. Six colonies were selected for plasmid extraction and 
digested with EcoRI and SacI. Five out of six plasmids of rfSP-A cloned in pET-101 
appeared to have the gene of interest drop out after restriction digestion. Subsequently, 
4 plasmids were selected for sequencing at Beckman Coultier. Sequencing required a 
single reverse primer, T7 rev., as the fragment is very small (444 bp). This checks each 
base for any errors or mismatches which is compared to the human genome to identify 
a close match. Plasmids 2 and 5 gave the best match for cloning SP-A successfully. This 
was used for transformation in BL21 (λDE3) pLysS. 
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Restriction digestion of pET101/D TOPO containing SP-A (N/CRD) with SacI and 
ECORI 
 
Figure 3.17 – Restriction digestion of pET101-D/TOPO with EcoRI/SaCI. 1% Agarose gel – 6 
plasmid restriction digestion with EcoRI and SacI. Recombinant trimeric SP-A (444 bp) in pET101 
after restriction digestion with EcoRI and SacI 
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Pilot scale expression of recombinant fragment SP-A (N/CRD) 
 
Figure 3.18 – SDS-PAGE – Pilot scale expression of recombinant fragment SP-A in pET-101. 
12% SDS-PAGE – Pilot scale expression of 4 colonies from 2 different plasmids. Lane 1 PM, lane 2 – 
Un-induced (UI), lane 3-6 colonies 1-4 from plasmid 2, lane 7-10 colonies 1-4 from plasmid 5. 
 
Figure 3.19 – SDS-PAGE – Pilot scale expression of recombinant fragment SP-A in pET-101. 
12% SDS-PAGE – Pilot scale expression of recombinant human SP-A trimeric.  3 colonies from 2 
different plasmids subjected to pilot scale expression. Lane 1 PM, lane 2 – Un-induced (UI) at 0hrs, 
lane 3 – UI at 3hrs, lane 4-6 colonies 1-3 from plasmid 2, lane 7-9 colonies 1-3 from plasmid 5. 
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Figure 3.20 – SDS-PAGE – Pilot scale expression of recombinant fragment SP-A in pET-101. 
12% SDS-PAGE – pilot scale expression of recombinant trimeric SP-A (pET101/D TOPO). Lane 1 – 
Protein marker, lane 2 – Un-induced at 0 hrs, lane 3 – Un-induced at 3 hrs, lane 4-8 induced col.1-5. 
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Figure 3.21 – SDS-PAGE – for western blot to detect recombinant fragment SP-A in pET-101 
after pilot scale expression. 12% SDS-PAGE of 2 colonies selected from pilot scale expression to 
detect protein expression via western blot. Lane 1 – PM, lane 2 – Induced col. 1, lane 3 – induced 
col.2, lane 4 – UI col.1, lane 5 – UI col.2  
 
Figure 3.22 – Western blot to detect recombinant fragment SP-A in pET-101 after pilot scale 
expression. Western blot of 2 colonies selected from pilot scale expression to detect protein 
expression via western blot – lane 1 – Induced col. 1, lane 2 – induced col.2, lane 3 – UI col.1, lane 4 
– UI col.2 
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Large scale expression of rfSP-A (pET101), lysis and sonication 
 
Figure 3.23 – SDS-PAGE – large scale expression of recombinant fragment SP-A in pET-101 
and after lysis and sonication of proteins from inclusion bodies. 12% SDS-PAGE – Large scale 
expression of rfSP-A and lysis/sonication of protein from inclusion bodies. Lane 1 –PM, lane 2 – UI 
bacth 1, lane 3 – Induced batch 1, lane 4 – UI batch 2, lane 5 – Induced batch 2, lane 6 – 
supernatant after lysis and sonication, lane 7 pellet after lysis and sonication.  
 
Figure 3.24 – Western blot – detection of recombinant fragment SP-A in pET-101 after lysis 
and sonication of proteins from inclusion bodies. Westernblot after lysis and sonication of rfSP-
A (pET101). After transfer, membrane was blocked in 5% non-fat milk powder/PBS overnight at 
+4°C. the next day the membrane was incubated in primary antibody; rabbit anti human SP-A 
(1:1000) for 1.5hrs at room temperature, after washing 3times in PBS tween 20, 0.05%,  secondary 
antibody; Protein A (1:1000) was added and incubated for 1hour. After washing, DAB tablets 
dissolved in water were used to detect for SP-A. Protein was detected in supernatant.   
SP-A 
~60kD
a 
Supernatant Pellet 
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Figure 3.25 – dot blot – detection of purified recombinant fragment SP-A in pET-101. Dot 
blot of pure rfSP-A protein. No protein was detected in the fraction except the flow through, 
suggesting protein was degraded and was unable to bind to the column or there is non-specific 
binding by protein A to other contaminants in the flow through. 
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3.3.4 Cloning and Expression of human trimeric SP-A in pMal-c2 - Expression of 
soluble recombinant fragment SP-A (rfSP-A) in pMal-c2 – MBP fusion system 
Neck and CRD of SP-A was cloned into pMal-c2 to create a fusion protein with MBP as 
this system provided a higher yield and makes the proteins soluble for the ease of 
purification. After amplifying the gene of interest (Figure. 3.29) and cloning into pMal-
c2 at site EcoRI and BamHI, the transformed cloned plasmids were subjected to 
restriction digest to verify presence of gene of interest. The fragment dropped at 444 bp 
(Figure.3.30) and expressed the fused MBP-SP-A protein at 60 kDa (Figure.3.31-3.33). 
Proteins were purified with amylose resin and eluted with 5mM EDTA. Fused proteins 
expressed at 60 kDa and MBP alone expressed at ~43 kDa (Figure.3.35) as seen in the 
eluted samples. To separate the fused proteins, factor Xa protease was added at 1µg per 
µg of protein in a 50 µl reaction at room temperature for at least 6 hours to separate 
MBP from SP-A (Figure.3.36). The cleaved protein was washed through amylose resin 
allowing MBP to bind and SP-A to be collected in the flow through (Figure.3.37). 
 
Digestion of pMal-c2 and PCR gel extracted product 
 
Figure 3.26 – cut and uncut vector pMal-c2 and digested and undigested SP-A gene 
fragment. 0.7% agarose gel –Lane 1 hyperladder I, Lane 2 – pMal-c2 uncut (10ul), lane 3 – pMal-
c2 cut E/B – 30ul, lane 4 –SP-A tri after PCR – 10ul, lane 5 – SP-A tri after PCR and gel extracted 
and digested E/B – 30ul 
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Agarose gel after digestion of 3 plasmids 
 
Figure 3.27 – Digested MBP-SP-A from pMal-c2 with EcoRI and SaCI to check for gene of 
interest. 1% agarose gel – SP-A is 444bp which can be seen against the DNA marker (Peq DNA 
ladder 100 - 10,000 bp) has been digested with EcoRI and SacI. 
 
Pilot scale expression of MBP-SP-A after transforming in TOP10 competent cells 
 
Figure 3.28 – SDS-PAGE – Pilot scale expression of MBP fused SP-A after transformation in 
TOP10 E.coli. 12% SDS-PAGE – pilot scale expression of MBP-SP-A in TOP10. Lane 1 – PM, lane 2 
UI, Lane 3-4 – col.1-2 induced with 0.5mM IPTG. Estimated size at 60kDa. 
 
130 
 
Pilot scale expression of recombinant fragment SP-A (pMal-c2) 
 
Figure 3.29 – SDS-PAGE – Pilot scale expression of MBP fused SP-A after transformation in 
BL21 (λDE3). 12% SDS-PAGE – pilot scale expression of MBP fused SP-A. lane 1 – protein marker, 
lane 2 – PSE Un-Induced col.1 – plasmid 1, lane 3 – PSE Induced col.1 – plasmid 1 , lane 4 – P SE 
Induced col.2 – plasmid 1, lane 5 – PSE Induced col.1 – plasmid 2, lane 6 – PSE Induced col.2 – 
plasmid 2. 
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Large scale expression and purification of fusion proteins – SP-A-tri-MBP 
 
Figure 3.30 – SDS-PAGE – large scale expression of MBP fused SP-A. 12% SDS-PAGE – large 
scale expression of MBP-SP-A. lane 1 – PM, lane 2 –un-induced MBP-SP-A, lane 3-4 – induced batch 
1 and 2 large scale expression. 
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Affinity chromatography purification of MBP-SP-A 
 
 
Figure 3.31 – SDS-PAGE – Lysis, sonication and purification of MBP fused SP-A. 12% SDS-
PAGE. Lane 1 PM, Lane 2 – diluted supernatant with column buffer, lane 3 – pellet after lysis and 
sonication, lane 4 – flow through, lane 5 – 1M NaCl wash, lane 6-10 fractions 1-5. 
 
 
 
Figure 3.32 – SDS-PAGE – Purified fractions of MBP fused SP-A through maltose-agarose 
column. 12% SDS-PAGE of purified fractions of MBP-SP-A. Lane 1 PM, Lane 2-5 – fractions 6-9. 
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Cleavage of MBP with FactorXa 
 
Figure 3.33 – SDS-PAGE – MBP fused SP-A cut with Factor Xa protease, before and after 
cleavage. 12% SDS-PAGE – MBP-SP-A after cleavage with Factor Xa protease. MBP is seen at 
42.5kDa and SP-A is approximately 16-17kDa. Lane 1 – PM, lane 2 – Uncut MBP-SP-A tri, lane 3 – 
Cut MBP-SP-A tri.  
 
Figure 3.34 – Purified rfSP-A through maltose-agarose after cleavage from MBP with Factor 
Xa. 12% SDS-PAGE of SP-A separated from MBP after cleavage with Faxtor Xa and purification via 
maltose-agarose. 
134 
 
3.3.5 Expression of insoluble recombinant fragment SP-D (rfSP-D) in BL21 (λDE3) 
pLysS 
Neck and CRD region with 8 Gly-Xaa-Yaa repeats from the collagen region were 
expressed in pET-3b at NdeI/HindIII restriction sites under the T7 promoter system. 
The ampicillin resistant plasmid was transformed into BL21 (λDE3) pLysS and induced 
at log phase for expression of gene of interest (Figure.3.38). The protein expressed well 
in 2 out the 3 colonies which was subjected to extraction from inclusion bodies. The 
insoluble proteins in inclusion bodies were lysed and sonicated to extract the over-
expressed proteins from inclusion bodies and were collected in the pellet after another 
round of centrifugation (Figure.3.39). The pellet of proteins was solubilised with urea at 
8M concentration and via step-wise dialysis the proteins were re-folded and purified via 
affinity chromatography using maltose-agarose matrix (Figure.3.40-3.41). 
Approximately 5 mg per 1L of culture was retrieved.  
 
Expression of rfSP-D (pUK-D1) 
 
Figure 3.35 – large scale expression of rfSP-D. 12% SDS-PAGE – 3 colonies selected of rfSP-
D expressed in 1L batches. Protein expressed at ~20kDa. Lane 1 – protein marker, lane 2 – un-
induced, lane 3 – Induced, lane 4 – un-induced, lane 5 – Induced, lane 6 – un-induced, lane 7 – 
Induced. 
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Lysis and sonication of rfSP-D 
 
Figure 3.36 – Lysis and sonication of rfSP-D (pUK-D1). 12% SDS-PAGE – proteins in 
inclusion bodies were lysed and sonication. After centrifugation, insoluble proteins were visible 
in the pellet at ~20kDa. Lane 1 – protein marker, lane 2 – pellet after lysis and sonication, lane 
3 – supernatant after lysis and sonication.  
 
Purification of rfSP-D 
 
Figure 3.37 – purification of rfSP-D (pUK-D1) via affinity chromatography. 12% SDS-
PAGE – rfSP-D (pUK-D1) was purified through maltose-agarose matrix by affinity 
chromatography eluted with 5mM EDTA. Purified proteins are seen at 20kDA. Peak fraction is 
fraction 5. Lane 1 – supernatant before purification, lane 2 – pellet before purification and 
after dialysis, lane 3- flow through, lane 4 – flow through after 1M NaCl wash, lane 5  – protein 
marker, lane 6-10 – fraction 1-5. 
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Purified rfSP-D 
 
Figure 3.38 – purification of rfSP-D (pUK-D1) via affinity chromatography. 12% SDS-
PAGE – rfSP-D (pUK-D1) was purified through maltose-agarose matrix by affinity 
chromatography eluted with 5mM EDTA. Purified proteins are seen at 20kDA. Peak fractions 
include fraction 6-8. Lane 1 – protein marker, lane 2-10 – fractions 6-13 
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3.3.6 Expression of insoluble recombinant fragment SP- A (rfSP-A) in BL21 (λDE3) 
pLysS 
Neck and CRD region of human SP-A was expressed in pET-3b at NdeI/HindIII 
restriction sites influenced under the T7 promoter system. The ampicillin resistant 
plasmid was transformed into BL21 (λDE3) pLysS and induced at log phase for 
expression of gene of interest (Figure.3.42). The protein expressed well in both colonies, 
expressed at ~17 kDa which were subjected to extraction from inclusion bodies 
(Figure.3.42). The insoluble proteins in inclusion bodies were lysed and sonicated to 
extract the over-expressed proteins from inclusion bodies and were collected in the 
pellet after another round of centrifugation (Figure.3.43). The pellet of proteins was 
solubilised with urea at 8M concentration and via step-wise dialysis the proteins were 
re-folded and purified via affinity chromatography using maltose-agarose matrix 
(Figure.3.44). Approximately 1 mg per 1L of culture was retrieved. The proteins were 
characterised by trimerization assays which displayed monomers, dimers and trimers 
of recombinant fragment proteins SP-A and SP-D (figure 3.45-3.46). 
 
Expression and purification of rfSP-A (pET-3b) 
 
Figure 3.39 – large scale expression of rfSP-A (pUK-A1 in pET-3b). 12% SDS-PAGE – 2 
colonies selected of rfSP-D expressed in 1L batches. Protein expressed at ~17kDa. Lane 1 – 
protein marker, lane 2 – un-induced, lane 3 – Induced, lane 4 – induced. 
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Figure 3.40 – lysis and sonication of rfSP-A (pUK-A1). 12% SDS-PAGE – Protein expressed at 
~17kDa. Lane 1 – protein marker, lane 2 – supernatant after lysis and sonication, lane 3 – pellet 
after lysis and sonication.  
 
 
Figure 3.41 – purification of rfSP-A (pUK-A1) via affinity chromatography. 12% SDS-PAGE – 
rfSP-A (pUK-A1) was purified through maltose-agarose matrix by affinity chromatography eluted 
with 5mM EDTA purified proteins are seen at ~17kDA. Peak fractions are at 3-5. Lane 1 – flow 
through, lane 2 – flow through after 1M NaCl wash, lane 3 – protein marker, lane 4-8 – fractions 1-
5. 
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Figure 3.42 – Trimerization of rfSP-A using chemical cross-linker BS3 and SDS –PAGE 
analysis – SDS-PAGE 15 % (w/v) gel under reducing conditions after BS3 cross linking and 
stained with coomassie blue. 5µl of 0.01mM, 0.1mM and 1.0mM concentration of BS3 was 
incubated with 45 µl of the dialysate for 1 min, 2 mins and 4 mins at room temperature. The cross-
linking reaction was separated by electrophoresis on a 15 % (w/v) SDS-PAGE gel under reducing 
conditions after adding equal volume of treatment buffer at each time point and stored at room 
temperature. After all reactions were complete and treatment buffer was added, the samples were 
boiled together at 95⁰C for 10 minutes. Upon reaction with cross liking agent at various incubation 
time higher oligomers such as monomer (18 KDa), dimer (~40 KDa), and trimer (~60KDa) were 
seen. Lane 1 – protein marker, Lane 2 - No BS3 + protein, Lane 4 - 0.01mM + protein, Lane 6 – 
0.1mM + protein, Lane 8 – 1.0mM BS3 + protein incubated for 4mins.  
 
 
Figure 3.43 – SDS–PAGE (12% w/v) bis (sulfosuccinimidyl) suberate (BS3) cross-linking of 
recombinant fragment of human SP-D containing trimeric neck + CRD region (rfSP-D). 
Treatment of rfSP-D with two different concentrations of BS3: 0.1mM (lane 2), 0.01mM (lane 3) 
and 1mM (lane3) analysed against protein containing no BS3. 
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3.4 Discussion 
SP-A and SP-D are synthesised within the alveolar type II cells in the foetal lungs and 
are secreted into the surrounding amniotic fluid making it a good source for purification 
of SP-A and SP-D. SP-A and SP-D are also found in large amounts in the bronchoalveolar 
lavage (BALF) of alveolar proteinosis patients (APP). APP patients have shown to have 
either GM-CSF deficiencies or anti-GM-CSF neutralising antibodies. In this disease there 
is a dysregulated secretion of a number of pulmonary proteins including SP-A and SP-D. 
Although the occurrence of this disease and availability in the clinic are quite rare, lung 
washings from APP patients provide an extra-ordinary good source of extracting SP-A 
and SP-D as compared to amniotic fluid. Most of the SP-A remains bound to the 
phospholipid pool and thus goes to the pellet following centrifugation, thus the 
supernatant becomes a good source for purifying SP-D while the pellet requires butane 
extraction or denaturation/renaturation procedures using chaotropic agents such as 
urea and guanidine hydrochloride. While SP-D can be recovered from the supernatant 
using affinity column chromatography, the refolded material in solution out of 
phospholipid pellet offers a generous amount of SP-A.  
Because of the low levels of SP-A and SP-D in amniotic fluid and rarity of APP patients 
visiting the anaesthesia award it was considered empirical to express full length SP-A in 
mammalian cells. Thus the use of HEK cells was designed to maximise the post-
translational features of SP-A. After cloning the entire open reading frame of human SP-
A1 in pSecTagC, the transfection and transient expression system was established. This 
protein present in the supernatant and after purification appeared to retain the 
biological properties of SP-A. Although the yield of the protein was on the lower scale 
for HEK expression system this offers opportunities to examine mutational analysis of 
the collagen, neck and CRD regions of human SP-A.  
We decided to opt for mammalian expression system to express and purify human SP-
A1. Mammalian system was chosen for expressing the full length protein because good 
quality and biologically active SP-A would require post-translational modification of 
collagen regions for refolding of the triple helical structure which cannot be achieved in 
baculovirus or E. coli. We chose to opt for mammalian HEK cells against CHO cells as 
HEK cells are the closest to human environment for protein production.  
141 
 
In order to localise the domains of human SP-A and SP-D which are most likely to 
interact with the cells of amnion, chorion and decidua, we considered it important to 
express homotrimeric fragments of neck and CRD regions of human SP-A and SP-D in E. 
coli. To this effect bacteriophage T7 promoter system was used to express both proteins 
in BL21 (λDE3) pLysS. Although this expression system yielded into inclusion bodies 
cytoplasmically, denaturation and renaturation procedure using a gradient of urea 
helped to recover a good amount of the trimers of SP-A and SP-D C-type lectins. When 
the construct containing neck and CRD regions of SP-A and SP-D were transformed in to 
DE3 no expression was observed (data not shown), it is likely, that the 2 human protein 
fragments were being toxic to E. coli cells, thus, we used pLysS strain which offers a 
tight regulation on T7 promoter by virtue of producing T7 lysozyme cloned on a pACYC 
plasmids (low copy number plasmid). T7 lysozyme thus acts as an inhibitor of T7 RNA 
polymerase. Both proteins went to insoluble inclusion bodies following cell lysis, 
sonication and high speed centrifugation. Proteins expressed using pLysS system did 
not require any lysozyme to lyse the bacterial cells. After following a dialysis gradient 
starting from 6M urea, 4M, 2M, 1M and no urea, the soluble proteins were recovered in 
the supernatant. Only 10% of soluble fraction bound to the maltose-affinity column 
suggesting that although refolding protein produced soluble trimmers only a small 
proportion was intact in terms of three-dimensional structures, thus it bound to affinity 
column. The final yield of 2-5mg/L was considered sufficient for further biochemical 
characterisations and biological assays. Since these proteins were meant to be 
examined on ACD explants and decidual macrophages it was important that most LPS 
content was removed. This was achieved as validated by measurement of endotoxin 
level by amoebocyte lysate method. As the literature suggests, a small amount of LPS 
contamination can skew the balance of macrophage response towards an excess of TNF-
α production.  
Since the α-helical coiled-coiled neck region is considered to be the nucleation centre 
for the trimerization of C-type lectin domains of SP-A and SP-D, we also confirmed that 
trimerising properties of affinity purified homotrimeric rfSP-A and rfSP-D. It was 
possible to see a gradient of monomer, dimer and trimer in a dose and time dependent 
manner when BS3 was used as a chemical cross-linker. This also established the 
homogeneity of the finally purified recombinant fragments. The investigation also 
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passed through a phase when neck and CRD region of human SP-A were cloned using 
pET-3b and pET-101, however for a some strange reason the one cloned in pET-101 
didn’t express very well and the rfSP-A in pET-3b expressed very poorly. To expedite 
the process of further experimentation, an interim construct expressing neck and CRD 
region of neck and CRD region of SP-A was cloned downstream to E. coli maltose-
binding protein (MBP). The fusion protein expressed under the Ptac promoter 
comprised of MBP, factor Xa cleavage site and the SP-A. The fusion protein was soluble 
intracellularly and non-toxic to the host cell. It was possible to separate the rfSP-A away 
from MBP through factor Xa cleavage. This construct may be quite useful as an affinity 
matrix where a possible receptor on the cell surface can be passed through this column. 
The fusion protein can also be used to target CRD ligands of SP-A using anti-MBP 
antibodies in situations where anti-SP-A antibodies interfere with SP-A ligand 
interactions.  
Thus, this chapter describes the procedures involved in purifying human SP-A and SP-D 
and expressing full length and truncated recombinant proteins. These products were 
used in subsequent studies.  
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Chapter 4: 
Immunomodulatory effects of SP-A and SP-D on amnion, chorion and 
decidua explants derived from normal term placentae 
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Summary 
The placenta hosts an allogeneic fetus allowing a genetically different individual to 
coexist in the mother. The ambiguous nature of how the mother can sustain an allograft 
is not clearly understood yet it is tolerated for approximately 9 months. As the initiation 
of labour is not clearly understood, the mechanism to control the timing of birth is not 
well established. During fetal maturation, the lungs, secrete fetal surfactant proteins SP-
A and SP-D into the amniotic fluid and may signal for fetal maturation. Near term, the 
levels of SP-A and SP-D have been shown to increase, with SP-A levels surging just 
before labour. During labour, the levels decrease dramatically, suggesting the levels of 
SP-A and SP-D could travel to maternal tissues influencing the inflammatory pathway to 
labour. We propose that SP-A and SP-D could modulate the immune pathway in 
controlling the inflammatory response through interaction with decidual macrophages 
and suppressing the cytokine profile and prostaglandin production.  
In this chapter, cultured amnion, chorion and decidua (ACD) explants from term 
placentae were exposed to IL-1β with and without SP-A and SP-D. Targets chosen for 
QPCR are PTGS2, PTGFRN, TLR2, TLR4, IL-8, IL-10, TNF-α, TGF-β, C1q, Factor H (FH), 
SP-A and SP-D which are linked in the immune pathway to analyse if SP-A and SP-D 
modulate a pro inflammatory or anti-inflammatory response. For protein analysis, 
ELISAs were carried out to examine the changes in C1q, FH, SP-A, SP-D and PTGF2a 
levels to see if SP-A or SP-D treated explants affect the pro- and anti-inflammatory 
pathways.  
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4.1 Introduction 
4.1.1 Immunomodulations of pregnancy and labour 
Each year, there are approximately 15 million babies worldwide born preterm which is 
the leading cause of neonatal mortality and morbidity in developing countries 
(Blencowe et al., 2012). Preterm birth, defined as birth before 37 weeks gestation is 
caused by infection in 20-30% of cases, premature rupture of membranes (PROM) in 
25-30% of cases and 40-45% of cases are idiopathic (Romero et al., 1988, Green et al., 
2005, Goldenberg et al., 2008).  Mice models have been used to identify a cellular and 
molecular pattern in preterm and term labour (Hirsch and Wang, 2005, Condon et al., 
2004). Although infection and spontaneous birth lead to the same end result of 
contraction and birth, the initiating initial events are distinct. The initiation of labour 
from an immunological and endocrinological perspective is multifactorial. However, 
both term and preterm births are associated with inflammatory markers such as IL-1β, 
TNF-α, IL-8 and IL-6. We have used IL-1β as a stimulant of the inflammatory pathway 
and examined the levels of TNF-α at a transcriptional levels and both TNF-α and IL-8 at 
a protein level in maternal and fetal tissues (Cox et al., 1997). This occurs during 
macrophage and neutrophil infiltration (Thomson et al., 1999, Osman et al., 2003) 
within fetal membranes, cervix, decidua and myometrium (Osman et al., 2003). The 
inflammatory onset triggers activation of pro-inflammatory transcription factors such 
as NF-κB which increases expression of contraction associated proteins (CAP) genes. 
Examples of CAP genes include cyclooxygenase 2 (COX2), which is critical for 
contraction (Mendelson, 2009). This study examines whether SP-A and SP-D affect the 
expression of this gene and expression of the potent prostaglandin protein, PGF2α, a 
contractile protein. 
 
4.1.2 SP-A and SP-D in pregnancy and labour 
The fetus appears to provide a critical signal for parturition through sequential 
inductions of SP-A from the fetal lung and amniotic fluid (Montalbano et al., 2013). Mice 
studies have recently shown that SP-A and SP-D induce a pro-inflammatory effect on 
activating amniotic fluid macrophages through interaction of TLR2. This increases CAP 
genes expression and accelerated timing of labour. On the other hand, mice deficient in 
SP-A and SP-D have delayed parturition, especially in their second and third 
pregnancies. Mice deficient in TLR2 expression had significantly lower levels of SP-A 
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and SP-D expression. This suggests that SP-A and SP-D interaction with their receptors 
promote expression of pro-inflammatory cytokines to contribute to the pathway of 
labour (Montalbano et al., 2013). Although a huge proportion of preterm births are due 
to infection, studies have shown, that in cases of intrauterine infection in women 
amniotic fluid did not affect the levels of SP-A and SP-D expression (Chaiworapongsa et 
al., 2008). A recent study has shown the expression of SP-A and SP-D in amnion and 
choriodecidua at a protein level and transcriptional level, where higher levels of SP-A 
were localised in choriodecidua and SP-D was predominant in the amnion. SP-A was 
only expressed in the supernatant of human fetal membranes; amnion and 
choriodecidua (Breuiller-Fouche et al., 2010). SP-A has been shown to induce F-actin 
filament organisation in myometrial cells to induce stress fiber formation in the motion 
of contractility. This would indicate that SP-A from fetal amniotic fluid and tissues 
regulate the formation of myometrial stress fibers to induce contractility (Breuiller-
Fouche et al., 2010). SP-A and SP-D have also been localised in the first trimester of 
pregnancy, and thus, are likely to be important in the protection of the fetus against 
infection at the early stages of pregnancy. SP-A and SP-D were localised in the  
trophoblastic layers of the chorionic tree, particularly in trophoblastic cell columns, 
stromal cells, Hofbauyer cells, angiogenic cell cords, and vascular endothelium (Sati et 
al., 2010). SP-A appears more apparent in syncytiotrophoblasts and trophoblasts, and 
moderate levels in hofbauyer cells, vascular cords and angiogenic cell cords. SP-D was 
apparent in low levels in angiogenic cell cords, moderate in Hofbauyer cells but was 
more apparent in the vascular endothelium (Sati et al., 2010). The importance of SP-A 
and SP-D in the protection against environmental pathogens after birth has shown of 
great significance in mice models. SP-A deficiency was related to high mortality 
compared to wild-type and SP-D deficient mice and the mortality was more associated 
to gastrointestinal pathologies rather than lung pathologies, and oral administration of 
SP-A to pups improved their survival in their bacterial-laden environment (George et al., 
2008). This suggests that SP-A is more important than SP-D in the protection of the 
new-born against infection and levels of SP-A are important for reducing mortality. 
C/EBPα (transcription factor protein) has been shown to be significant for fetal lung 
maturation especially in the third trimester. Deficiency in the gene has shown to affect 
normal synthesis of SP-A and SP-D and is related to causing RDS, a common cause of 
morbidity and mortality in preterm infants (Martis et al., 2006). This suggests that the 
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gene is essential for perinatal lung maturation and surfactant homeostasis in order to 
allow mechanical breathing possible. Preterm infants with IUGR have revealed an 
increase in developing acute and chronic pulmonary disorders. Mice models have 
revealed that hypoxic conditions lead to preterm birth and IUGR, which is significantly 
altered in the development of the surfactant system (Gortner et al., 2005). SP-A and SP-
D has been shown to be regulated by glucocorticoids and hydrocortisone in fetal rat 
experiments (Deterding et al., 1994). Human and rabbit lung cultures also show that 
cAMP and glucocorticoids are important for SP-A synthesis. cAMP regulates 
transcription of SP-A, whereas, glucocorticoids stimulate SP-A transcription and 
enhances mRNA stability (Mendelson and Boggaram, 1990). Levels of SP-A and SP-D 
appear to express mostly in the third trimester. Levels of SP-A in amniotic fluid have 
been shown to increase sharply from 32 weeks towards term and decrease sharply 
during labour whereas SP-D levels increase moderately from 32 weeks and decrease 
during labour (Miyamura et al., 1994). This could be due to the amniotic rupture of 
membrane that would release the amniotic fluid containing SP-A and SP-D. 
 
4.1.3 Complement activation in pregnancy and labour 
The complement system is crucial in the innate and adaptive immune defence but, 
excessive activity can lead to disorders (Oksjoki et al., 2007). Animal studies suggest 
activation of the complement system and deposit of C3b and release of anaphylatoxins 
(C3a, C5a), promotes leukocyte infiltration, generating the lytic membrane attack 
complex (MAC). Over complement deposits leads to destruction of fetal-placental tissue 
ultimately resulting in fetal loss (Munn et al., 1998, Mellor et al., 2001, Xu et al., 2000, 
Holers et al., 2002, Caucheteux et al., 2003). However, regulatory proteins for the 
complement system limit complement activation (Sjoberg et al., 2009). There are 
evidence of recent reports of early activation of the complement system is associated 
with the pathogenesis to preeclampsia. Factor Bb were significantly higher in maternal 
serum from 20 weeks gestation in preeclamptic pregnancies (Lynch et al., 2008). This 
suggests the activation of the alternative pathway. However, factor H levels have been 
reported in high levels (Derzsy et al., 2010), suggesting alternative pathway regulation 
even in the presence of apoptotic cells, suggesting, Factor H:C3 ratios would be 
significant in the regulation of the alternative path in pregnancies to prevent the 
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activation of the complement cascade and cell lysis which ultimately would lead to 
inflammation and early onset of labour. Factor H is a complement regulator protein of 
the alternative pathway by promoting proteolytic degradation of C3b to prevent lysis of 
cells (Kemper and Hourcade, 2008). The alternative pathway takes place on cell 
surfaces of pathogenic microorganisms including yeast, bacteria and bacteria and can 
also be triggered through IgG and IgA antibody-antigen complexes (Carroll and Sim, 
2011). This pathway is triggered through a conformational change of C3 though 
cleavage of a single site by serine protease C3 convertase (Carroll and Sim, 2011). 
Cleavage of C3 leads to generation of to C3a and C3b. Factor B anchors the C3b on cell 
surfaces in the presence of Mg2+ cleaving to form C3bB. This allows the recognition and 
binding of Factor D, a serine protease to bind and cleave factor B into Ba and Bb 
fragments. The Bb fragment bound to C3b forming C3bBb, generates C3 convertase of 
the alternative pathway. Under physiological conditions C3bBb is not very stable but is 
stabilized by binding of another complement protein, properdin, to form, C3bBbP, this 
allows this C3 convertase to generate many C3 molecules. The C3 convertase, C3bBb 
binding to adjacent C3b molecules leads to the formation of C5 convertase which 
cleaves C5 molecules into C5a and C5b. Generation of C5b initiates the formation of the 
MAC complex to causes cell lysis. Factor H, a regulator protein of the alternative 
pathway, inhibits C3 convertase through binding with C3b and accelerating the half-life 
of the C3 convertase to inactivate the alternative pathway (Sim et al., 1993), therefore, 
functions as a downregulator of the alternative pathway.  Although there are evidence 
of recent reports of early activation of the compliment system is associated with the 
pathogenesis to preeclampsia, the complement system has not yet completely been 
elucidated. 
It has recently been reviewed that SP-A and SP-D do not initiate the pathway to labour, 
however may contribute to the maintenance of pregnancy (Yadav et al., 2011). Our 
study investigates the possible roles of SP-A and SP-D in modulating the immune and 
prostaglandin pathway to delay labour and perhaps help us understand the 
immunoregulatory roles of SP-A and SP-D in pregnancy and labour to help prevent 
preterm birth in human pregnancies. 
We propose SP-A and SP-D could modulate the cytokine profile and prostaglandin 
production using ACD explants of term placentae and via QPCR, PTGS2 and PTGFRN 
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were examined. PTGS2, otherwise known as COX2, is an initiator of the PG pathway that 
converts arachidonic acid to PGH2. PGFRN, is a negative regulator of the PG pathway. 
Additional targets including TLR2 and TLR4, C1q and FH are also examined. These are 
associated with directing immune milieu to an inflammatory response through 
modulation of macrophages or complement system, How SP-A and SP-D can affect the 
levels of cytokine expression was examined by examining IL-8, IL-10, TNF-α and TGF-β.  
4.3 Methods and materials 
4.3.1 Amnion, Chorion and Decidua (ACD) explants culture and stimulation 
4.3.1.1 Collection of tissue 
This study was approved by the Research Ethics Committee, School of Health Sciences 
and Social Care, Brunel University, London. Placentae were collected by midwives from 
St. Michael’s Hospital, Bristol and Warwick University Hospital and John Radcliffe 
Hospital, Oxford University. Each placenta was obtained from women at elective 
caesarean term-not-in-labour (TNIL) at 39 weeks (N=4). The women were of mixed 
parity and delivered live births with no sign of infection. Tissues were dissected 
immediately after delivery, washed in sterile saline for preparation of cell culture.  
 
4.3.1.2 Amnion, Chorion and Decidua (ACD) cell culture 
The amnion, chorion and decidua tissues from TNIL were washed in saline solution and 
a total of 200 mg of tissue was added to a 12-well tissue culturing plate per patient 
(Table 4.1). ACD explants were cultured in Dulbecco’s modified eagles medium (DMEM) 
supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin and 10% fetal calf 
serum (FCS). The cultures were incubated overnight at 37°C for 24 hours in 95% air and 
5% CO2 atmosphere. The media was then removed and replaced with DMEM containing 
0.2% lactoalbumin hydrolysate. Each well of 200 mg tissue was treated with 10 µg of 
native SP-A, SP-D, rfSP-D-Gly-Xaa-Yaa & rfSP-A, with and without IL-1β (200 pMol) and 
incubated for 12 hours at 37°C in 95% air and 5% v/v CO2 atmosphere. 0.1 g of the 
tissue was subjected to RNA extraction and 0.1 g of tissue per well was subjected to cell 
lysate extraction procedures.  
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Figure 4.1 – Image of placenta and ACD section from placenta. 
 
 
Table 4.1 – Plate layout for experimental design  
10 µg rfSP-A 10 µg rfSP-A + IL-1β 200 pMol IL-1β  No Treatment (NT) 
10 µg rfSP-D + IL-1β 10 µg rfSP-D + IL-1β   
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4.3.2 RNA extraction  
RNA was extracted as described in chapter 2 and the concentration of RNA was 
determined by a spectrophometer (NanoDrop ND-1000).  
4.3.3 DNase treatment and cDNA synthesis 
Prior to cDNA synthesis, deoxyribonuclease I (DNase I) treatment to digest DNA and 
eliminate RNase activity was carried out to prepare RNA for RT-PCR. DNase I (Sigma, 
Dorset, UK) treatment was carried out according to the manufacturer’s 
recommendation. Briefly, the RNA sample (~50 µl) was treated with 5 µl of the 10 x 
reaction buffer and 5 µl of Amplification grade DNase I (1 U/µl) and incubated at room 
temperature for 15 minutes. The reaction buffer and Amplification Grade DNase I 
combined, removes contaminating DNA by nucleic digestion at room temperature. The 
DNase was then inactivated by adding 5 µl of the stop solution and heating the sample 
to 70°C for 10 minutes. The overall RNA quality was assessed by electrophoresis and 
also gave a semi-quantitative indication on RNA yield. Samples of RNA were separated 
on a 1% agarose-EtBr gel against a DNA sizer III (Peqlab, Sarisbury Green, UK) at 70V 
until the fast migrating dye (bromophenol blue) reached 2/3 the length of the gel. The 
integrity of RNA was indicated by 2 distinct bands, 28S and 18S rRNA with a 2:1 ratio of 
intensity, respectively. The results were visualized under a UV transilluminator (Bio-
Rad, Hemel Hempstead, UK).  
 
RNA samples were quantified and quality was checked using NanoDrop 
spectrophometer. 2µg of total RNA were used as a template for cDNA synthesis primed 
by random primers using the High-Capacity RNA-to-cDNA kit (Applied Biosystems, 
Paisley, UK). Briefly, in a 20 µl reaction, 2 µg of RNA was incubated with 2 X RT Buffer, 
and 20 X enzyme mix. This was placed in a thermocycler at 37°C (60 minutes) and 95°C 
(5 mins) and stored at 4°C. 
4.3.4 Real-time PCR and statistical analysis   
In a 10 µl reaction, 100 ng of cDNA and 500 µM forward and reverse primers were 
mixed with powerSYBR Green PCR Master Mix (Applied Biosystems, Paisley, UK). These 
were set in a qPCR thermocycler for 40 cycles of 95°C (15 mins) 57°C (1 min) followed 
by a dissociation curve using a 7900HT Real-Time PCR system. Results were analysed 
using the Sequence Detections Software (SDS) V2.4 and RQ Manager. Samples were 
compared to 18S rRNA, the endogenous control, and calibrated against non-treated 
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samples. The Ct values were calculated at the point where the PCR curve crosses the 
threshold. For each sample, the geometric mean Ct for each target was subtracted from 
the geometric mean Ct of the endogenous control to give ΔΔCt values. The RQ value to 
give the relative fold change of expression, were calculated by 2 to the power of -ΔΔCt 
(2-ΔΔCt). For all subsequent statistical analysis, RQ values were plotted on a logarithmic 
scale (log10) with the standard error of mean to minimise error. Sequences of primers 
used in this study are in the table below.  
 
Table 4.2 – Primer sequences for RT-PCR 
Gene 
Nomenclatur
e/Formally 
Primer name Forward primer 
sequence 
Reverse primer 
sequence 
18s rRNA 18s rRNA GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGC
G 
PTGS2/COX2 Prostaglandin H 
synthase 2 
CTCAGACAGCAAAGCCTACC ATGTGATCTGGATGTCAAC
AC 
PTGFRN Prostaglandin F2-
Alpha Receptor 
Regulatory Protein 
CTGTCGTTGGCTCTTTGCCG CATCATAGTCACTGACGTT
GC 
POLR2A  GCACCACGTCCAATGACATT
G 
GTGCGGCTGCTTCCATAAG
C 
IL8 Interleukin 8 CTGTGTGAAGGTGCAGTTT
TG 
GTGTTGGCGCAGTGTGGTC 
IL-10 Interleukin 10 ACATCAAGGCGCATGTGAA
C 
TAGAGTCGCCACCCTGATG
T 
TNF-α Tumour necrosis 
factor alpha 
 
CACCACTTCGAAACCTGGGA 
 
AGGAAGGCCTAAGGTCCAC
T 
TGF-β Transforming growth 
factor- beta 
CCCAGCATCTGCAAAGCTC GTCAATGTACAGCTGCCGC
A 
TLR2 Toll-like receptor 2 GAGACCTATAGTGACTCCC
AG 
CTGCCCTTGCAGATACCAT
TG 
TLR4 Toll-like receptor 4 CTTCTCAACCAAGAACCTTG
G 
GTGGCCTTAGGCTCTGATA
TG 
SP-A Surfactant protein A GTGGGGTGGGATTAGATAA
ATGC 
TACTGAGAGATGTGTGCTT
GGTGAG 
SP-D Surfactant protein D TGGTTTCTGAGATGGAGTC
GTG 
TGGGGCAGTGGATGGAGTG
TGC 
C1q  ATGGTGACCGAGGACTTGT
G 
GTCCTTGATGTTTCCTGGG
C 
FH Factor H CCCGGGGAAATACAGCCAA
A   
TCTGGGAGTAGGAGACCAG
C   
All primers were stored at a stock concentration of 5µM in 10mM Tris pH7.5 at -20°C. The final 
concentration of 500nM was used in the qPCR reactions.  
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4.3.5 Protein Extraction  
Proteins were extracted as described in chapter 2 for further protein analysis 
4.3.6 Immunoblotting and ELISA 
ELISA plates were coated in duplicates with 5, 2.5, 1.25, 0.625, 0.3125 µl proteins per 
microtitre well and incubated overnight at 4°C. The next day, the unbound proteins 
were discarded and un-coated wells were blocked with 5% non-fat w/v milk 
powder/PBS for 2 hour at 37°C. Following 3 consecutive washes with PBS containing 
0.05% Tween-20, the wells were incubated with primary antibody of 1/500 dilution 
(rabbit α-human SP-A, rabbit α-human SP-D, rabbit α-human C1q, PTGF2-α) and 
1/5000 (rabbit α-human Factor h) for 2 hours at 37°C and washed prior to adding 
secondary antibody, 1/1000 Protein-A conjugated to horse radish peroxidase (HRP) 
and incubated at 37°C for 1 hour. After three consecutive washes, the wells were 
developed with OPD (Sigma, Dorset, UK) according to manufactures recommendation 
and optical density was checked at 450nm. The treated cell lysates were compared to 
non-treated cell lysate results to understand the effects of SP-A and SP-D with and 
without IL-1β on the expression of innate immune and prostaglandin proteins.  
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4.4 Results  
4.4.1 RNA extraction, characterisation and validation  
As seen from figure 4.2, samples treated with DNase Amplification grade (Sigma, Dorset, 
UK) displays 2 clear bands depicting RNA integrity. Samples not treated with DNase 
contain DNA which has remained in the wells. The two bands seen are 18S and 28S 
which are the small and large subunits of RNA (rRNA) in eukaryotes.  The DNase 
treatment of RNA was successful as it is visible in samples not DNase treated due to the 
large size of DNA and small pore sizes of the agarose gel.  
A high yield of RNA was achieved using the TRIzol method. The RNA extracted was from 
200 ng of tissue with end results of 50 µl concentrated RNA. The 260/280 reading 
represents the purity of the RNA, in the case of these samples, they are pure and free 
from amino acids. 
Similarly, RNA from term placenta treated in the same way as preterm were also 
extracted and purified using the TriZol (Invitrogen, Paisley, UK) method. The samples 
were; non-treated (control sample), IL-1β, SP-A, SP-D, SP-A + IL-1β, SP-D + IL-1β and 
each were DNase treated before quantifying RNA concentration, see table below. 
Each of the term samples of RNA were converted to cDNA using High capacity RNA-to-
cDNA kit (Applied Biosystems, Paisley, UK). The values of the 260/230 ratio were below 
2.0, however, after converting 2µg of RNA to cDNA, the samples 260/230 ratio values 
were between the optimum 2.0-2.2. This shows contamination level to be diluted giving 
suitable 260/230 ratios. 
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Figure 4.2 – RNA samples after DNase treatment on agarose gel. 1% Agarose gel of RNA 
samples. 5 samples are DNAase treated and two are not. DNA remains in wells. The DNA marker 
used is DNA Sizer III containing 13 fragments with molecular weight (largest first): 21226, 5148, 
4973, 4268, 3530, 2027, 1904, 1584, 1375, 947, 831, 564 and 125 base pairs. Lane 1 – DNA sizer III 
(Peqlab), lane 2 – IL-1β (DNase treated), lane 3 – IL-1β (not DNase treated), lane 5 – 10µg SP-A 
(DNase treated), lane 6 – 10 µg SP-D (DNase treated), lane 7 – 10 µg SP-A + IL-1β (not DNase 
treated), lane 9 – 10 µg SP-D + IL-1β (DNase treated), lane 10 – non-treated sample (DNase 
treated). 
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An RT-PCR experiment was carried out to optimise cDNA concentration for each primer 
set. The two amounts of cDNA used were 25 ng and 100 ng. We had chosen to use 25 ng 
to follow a published protocol, however, due to unsuccessful results an RT-PCR was 
carried out. The results displayed higher amplification of amplicon with a higher 
concentration of cDNA. Unfortunately 18S product and PTGFRN product was mixed 
hence the bands in lanes 15 and 18 are identical (figure 4.3). The product for PTGS2 was 
very faint when 25 ng or 100 ng of cDNA suggesting primer optimisation may be 
required. Alternatively, PTGS2 primer may be necessary for redesigning as the amplicon 
size is very large and would be difficult to break the G-C rich bonds for QPCR analysis. 
A Q-PCR experiment was carried out after optimising the best primer concentration and 
the targets were identified from each treated sample as a qualitative method. In figure 
4.4, the endogenous control 18S rRNA showed equal amount of expression in ACD 
explants regardless of treatment or no-treatment.  
 
 
Figure 4.3 – 2% Agarose-EtBr Gel to separate 18S rRNA products from 6 cDNA samples 
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The results show expression of the endogenous control 18S rRNA, in treated and non-
treated samples (figure 4.4). Negative controls (NTC) were also separated on the gel to 
show experimental quality that no expression took place without cDNA therefore 
validating minimal contamination error. The same validation process for PTGS2, 
PTGFRN, IL-8, TLR-2 and TLR-4 were carried out to collate qualitative results for target 
gene expression. In figure 4.5, PTGS2 shows a clear 372bp amplicon size and 109bp for 
PTGFRN amplicon size (figure 4.5-4.6). 
 
 
Figure 4.4 – 2% Agarose-EtBr gel was carried out to visualise QPCR products for PTGS2 and 
PTGFRN. For PTGS2 there was no amplification of the amplicon as seen in the gel. PTGFRN and 
POLR2A gave positive results. 18S was an additional endogenous control used as it is consistent in 
placental tissue and is expressed in high amounts. Lane 1 – Hyperladder I (Peqlab), lane 3 – non-
treated sample, lane 4 – IL-1β, lane 5 – rfSP-A, lane 6 – rfSP-D, lane 7 – rfSP-A + IL-1β, lane 8 – SP-
D + IL-1β, lane 9 – NTC, lane 12 – non-treated sample, lane 13 – IL-1β, lane 14 – rfSP-A, lane 15 – 
rfSP-D, lane 16 – rfSP-A + IL-1β, lane 17 – SP-D + IL-1β, lane 18 – NTC 
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Figure 4.5 – 1% Agarose-EtBr gel to separate QPCR products of TLR2 and TLR4 expressed in 
all treated and non-treated samples separated. 
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4.4.2 Effect of rfSP-A and rfSP-D on mRNA levels in ACD explants 
As seen in figure 4.6, rfSP-A increases PTGS2 levels by 10-fold without IL-1β and more 
than 100-fold with IL-1β compared to ‘no treatment’. IL-8, PTGFRN levels are slightly 
suppressed in the presence of IL-1β although their expressions do not vary as much 
compared to non-treated samples. IL-10 levels are relatively the same with and without 
IL-1β although there is an up-regulation of IL-10 compared to non-treated samples. 
rfSP-A causes a large increase in TNF-α expression by almost 10-folds. This is supressed 
in the presence of IL-1β. There is a slight up-regulation of TGF-β by rfSP-A, but this is 
downregulated in the presence of IL-1β. rfSP-A down regulates TLR-2, which is further 
enhanced when combined with stimulation of IL-1β. There is an up-regulation of TLR-4 
in ACD explants, which is very slightly dampened by IL-1β. However, the change is not 
considerable. rfSP-A shows to suppress its own gene expression, which is reversed 
when stimulated with rfSP-A + IL-1β. There is a slight up-regulation of SP-D in ACD 
when stimulated with rfSP-A, which does not show to be effected by IL-1β. There is a 
slight suppression of C1q in ACD when stimulated with rfSP-A with and without IL-1β 
however the level of expression doesn’t vary so much compared to non-treated 
samples. There is a huge up-regulation of Factor H in ACD explants compared to non-
treated samples, varying by at least 5-fold (log-10) regardless of IL-1β treatment. As 
expected, IL-1β, has a more stimulatory effect on the genes in the absence of SP-A and 
SP-D. Each experiment was carried out in triplicates three times. 
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Qualitative gene expression of prostaglandins, cytokines and innate immune proteins after 
surfactant protein stimulation 
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Figure 4.6 – Qualitative gene expression of prostaglandins, cytokines and innate immune 
proteins after surfactant protein stimulation. Fold change in mRNA levels relative to non-
treated control sample (mean ± SEM). ACD explants were treated with 10µg of either SP-A or 
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SP-D with or without 200pMol IL-1β n=4. RNA was extracted using standard Trizol method and 
mRNA levels were quantified by quantitative-PCR using SYBR green. Each experiment was 
carried out in triplicates and measured by two-way ANOVA as shown from a-x. a) Change in 
PTGS2 mRNA levels after SP-A treatment of ACD explants, b) Change in PTGS2 mRNA levels 
after SP-D treatment of ACD explants, c) Change in PTGFRN mRNA levels after SP-A treatment of 
ACD explants, d) Change in PTGFRN mRNA levels after SP-D treatment of ACD explants, e) 
Change in IL-8 mRNA levels after SP-A treatment of ACD explants, f) Change in IL-8 mRNA levels 
after SP-D treatment of ACD explants, g) Change in IL-10 mRNA levels after SP-A treatment of 
ACD explants, h) Change in IL-10 mRNA levels after SP-D treatment of ACD explants, i) Change 
in TNF-α mRNA levels after SP-A treatment of ACD explants, j) Change in TNF-α mRNA levels 
after SP-D treatment of ACD explants, k) Change in TGF-β mRNA levels after SP-A treatment of 
ACD explants, l) Change in TGF-β mRNA levels after SP-D treatment of ACD explants, m) Change 
in TLR-2 mRNA levels after SP-A treatment of ACD explants, n) Change in TLR-2 mRNA levels 
after SP-D treatment of ACD explants, o) Change in TLR-4 mRNA levels after SP-A treatment of 
ACD explants, p) Change in TLR-4 mRNA levels after SP-D treatment of ACD explants, q) Change 
in SP-A mRNA levels after SP-A treatment of ACD explants, r) Change in SP-A mRNA levels after 
SP-D treatment of ACD explants, s) Change in SP-D mRNA levels after SP-A treatment of ACD 
explants, t) Change in SP-D mRNA levels after SP-D treatment of ACD explants, u) Change in C1q 
mRNA levels after SP-A treatment of ACD explants, v) Change in C1q mRNA levels after SP-D 
treatment of ACD explants, w) Change in Facto H mRNA levels after SP-A treatment of ACD 
explants,  x) Change in Factor H mRNA levels after SP-D treatment of ACD explants. Data shows 
no significance between tests. 
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4.4.3 Effect of SP-A and SP-D on SP-A, SP-D, PGF2α, C1q and Factor H protein levels in 
ACD treated placentae 
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Figure 4.7 – Qualitative change in protein levels relative to non-treated control sample 
(mean ± SEM). ACD explants were treated with 10µg of either SP-A or SP-D with or without 
200pMol IL-1β n=4. Cell lysates were extracted by standard Trizol method and analysed by 
ELISA using polyclonal antibodies either specific to SP-A or SP-D. Each experiment was carried 
out in triplicates and measured by two-way ANOVA as shown from a-x. a) Qualitative changes in 
SP-A protein levels after SP-A treatment of ACD explants with and without inflammatory IL-1β 
stimulation, b) Qualitative changes in SP-A protein levels after SP-D treatment of ACD explants 
with and without inflammatory IL-1β stimulation, c) Qualitative changes in SP-D protein levels 
after SP-A treatment of ACD explants with and without inflammatory IL-1β stimulation, d) 
Qualitative changes in SP-D protein levels after SP-D treatment of ACD explants with and 
without inflammatory IL-1β stimulation, e) Qualitative changes in C1q protein levels after SP-A 
treatment of ACD explants with and without inflammatory IL-1β stimulation, f) Qualitative 
changes in C1q protein levels after SP-D treatment of ACD explants with and without 
inflammatory IL-1β stimulation, g) Qualitative changes in Factor H protein levels after SP-A 
treatment of ACD explants with and without inflammatory IL-1β stimulation, h) Qualitative 
changes in Factor H protein levels after SP-D treatment of ACD explants with and without 
inflammatory IL-1β stimulation, i) Qualitative changes in PGF2α protein levels after SP-A 
treatment of ACD explants with and without inflammatory IL-1β stimulation, j) Qualitative 
changes in PGF2α protein levels after SP-D treatment of ACD explants with and without 
inflammatory IL-1β stimulation. Data shows no significance between tests. 
 
Statistics 
Results are the average of four placentae from term caesarean at 39 weeks. QPCR and 
ELISA experiments were carried out thrice in triplicates and error bars are ± SEM 
determined by two-way ANOVA. Significance was accepted for P < 0.05. Results show 
statistical significance of P >0.05, therefore treated as not-significant. 
 
169 
 
4.5 Discussion 
SP-A and SP-D are pulmonary surfactant proteins also known as collectins due to their 
collagen and lectin domains. They reside in pulmonary tissues such as alveolar type II 
tissues and Clara cells and extra-pulmonary tissues such as placentae. These 
hydrophilic, pathogen recognition receptors can recognise glycoproteins on pathogens 
binding in a calcium dependent manner to promote phagocytic clearance, thus, 
providing a good link between innate and adaptive immune response. This makes SP-A 
and SP-D important molecules for the clearance of infection, one of the contributing 
factors of preterm birth (i.e. chorioamnionitis). Preterm birth accounts for the highest 
cause of infant mortality and be a cause of many complications including cerebral palsy, 
preeclampsia, intrauterine growth retardation (IUGR), hypoxia, vision/learning 
impairment and lung infection.  
Parturition is characterised as an inflammatory response, characterised by vascular 
dilation, cell recruitment and muscle contraction. During the second stage of pregnancy, 
levels of decidual macrophages are the most dominant immune cells in the maternal 
tissue. Thus, we have investigated the roles of SP-A and SP-D in modulating the innate 
immune response and the main hormonal pathway of labour (the prostaglandin 
pathway) and in chapter 5 we have examined further how SP-A and SP-D modulate 
decidual macrophages in an inflammatory situation.  
Studies have shown levels of SP-A and SP-D to increase at a 6:1 ratio in human amniotic 
fluid between 34-42 weeks (Miyamura et al., 1994). Complimenting this investigation, 
another study has shown, administration of SP-A to mice activates macrophage NF-κB 
to stimulate prostaglandin production resulting in induction of birth within 6-12 hours 
(Condon et al., 2004). This lead to explore if there is a link between SP-A and SP-D and 
the biochemical pathway, and how they could contribute to modulating the 
inflammatory pathway to initiation of labour in humans using term placentae.  
As the initiation of labour is not well understood and the mechanisms to control the 
timing of birth are not well established, it is well documented SP-A and SP-D are a signal 
for lung maturation and levels increase just before labour. As lung maturation is 
important for foetal survival after birth, we propose they play a key purpose in 
modulating the inflammatory pathway to labour. Hence we have looked at how 
stimulation of SP-A and SP-D under inflammatory condition affect the prostaglandin 
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(PG) and cytokine profile on fetal/maternal tissues. Although the QPCR revealed no 
level of significance, the results suggest very interesting trends worth mentioning. 
rfSP-D had a positive up-regulatory effect on PTGS2, increasing the gene expression by 
5-fold – this is doubled in the presence of IL-1β. Thus, under inflammatory conditions 
the level of PTGS2 increases, however, under no inflammatory stimuli the levels PTGS2 
expressions are low. Comparing this to protein level of study, native SP-A appears to 
suppress PGF2α levels suggesting, SP-A in its full form suppresses the progression of 
the prostaglandin pathway hence dampening the inflammatory response. rfSP-D has 
shown to down-regulate PTGFRN gene regardless of IL-1β. 
Interestingly, in their trimeric form, SP-A and SP-D suppress the levels of IL-8 again 
supporting the notion that they increases the pro-inflammatory threshold by 
suppressing an inflammatory response via IL-8. IL-8 is a neutrophil recruitment factor, 
thus suppressing neutrophil activation and MMP-8 secretion preventing cervical 
ripening. 
In support of the suppression of inflammatory profile, SP-A shows to increase levels of 
IL-10 regardless of inflammatory environment and both SP-A and SP-D show to 
increase levels of IL-10 under non-inflammatory situation. Thus suggests SP-A and SP-D 
modulates macrophages towards an anti-inflammatory response and under 
inflammatory conditions, SP-A further stimulates IL-10 levels by 5-fold. Similarly, SP-A 
protects the foetus from an inflammatory attack by suppressing TNF-α levels by 5-fold 
under inflammatory conditions. This suggests SP-A to play a vital role in the 
suppression of inflammation, increase in the anti-inflammatory threshold and provide 
protection in its trimeric form. SP-A protects the foetus by increasing levels of TGF-β 
under non-inflammatory conditions i.e during pregnancy, to promote vascular growth 
as low levels of TGF-β have shown to be associated with preeclampsia. An increase in 
TGF-β may suppress TNF-α expression by macrophages and indirectly suppressing PG 
production as TNF-α promotes PGF2α expression, again SP-A suggests to protect human 
foetus from attack. 
Our studies to date have shown SP-A to modulate macrophages via TLR-2 ligand 
suppression, especially by SP-A under inflammatory conditions by 5-fold. SP-A suppress 
TLR-2 expression (confirmed by previous studies in mice -Agarwal et al, 2013) 
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suggesting SP-A down regulates TLR-2 pathway induced inflammatory response. TLR-4 
on the other hand, appears to be less affected by SP-A and SP-D suggesting they protect 
the foetus against infection from gram negative bacteria. Furthermore, IL-10 increases 
TLR-4 levels, therefore SP-A and SP-D could increase TLR-4 indirectly.  
Factor H expression increased by 8 fold, compared to normal, although there was a low 
level of factor H gene present, compared to normal, the little increase shows a big 
difference, hence a higher fold change compared to negligible amounts of factor H in 
non-treated samples. Factor H appeared to increase slightly when stimulated with nSP-
A + IL-1β, nSP-D, nSP-D + IL-1β, rfSP-A + IL-1β and rfSP-D. 
SP-D levels were mostly suppressed with SP-A treatments (full length and recombinant 
fragments) with and without IL-1β. However, the suppression is less with SP-D 
treatment (with and without IL-1β), but sharply increases with rfSP-D with IL-1β 
treatment. On the other hand, SP-A levels were consistently low regardless of treatment, 
especially with SP-A and SP-D treatment, suggesting a negative feedback mechanism to 
regulate surfactant levels.  
Treatment of fetal maternal tissue with nSP-A + IL-1β, protein levels of C1q were 
detected the highest, followed by factor H, then SP-D and lastly SP-A. C1q levels 
increases most with rfSP-A + IL-1β and increased slightly with nSP-A + IL-1β suggesting 
there is a strong pro-inflammatory effect controlled by C1q.  
Progress in the prevention and management of preterm labour continues to be 
frustrated by our lack of understanding of the mechanism of parturition in women. 
Surfactant proteins SP-A and SP-D are biologically active proteins secreted by the fetal 
lung into the amniotic fluid, which appear to have important roles in the onset of labour 
by controlling the activation of the prostaglandin cascade in the fetal membranes and 
decidua. Thus, we used natural and recombinant forms of human SP-A and SP-D and 
measure their effect on prostaglandin and cytokine release by ACD explants. These 
experiments provided insight into paracrine events in the maternal/fetal interface that 
may be involved in the onset of labour at term, and highlight possible 
pathophysiological alterations in preterm labour. Although to identify possible 
alterations in spontaneous preterm labour was not the main thrust of the current study, 
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the specific aims of the study was designed to establish the role of SP-A and SP-D in the 
regulations of cytokine and prostaglandin release by ACD in relation to parturition. 
Birth defects and preterm birth contribute significantly to perinatal health and are the 
leading causes of infant mortality. The association between birth defects, preterm birth 
and low birth weight has been well documented, but the explanation for this association 
remains unknown (Dolan et al., 2007). Effective measures to reduce birth defects and 
preterm birth are desperately needed, but this requires continued research to 
understand the pathophysiological mechanisms and the shared risks factors of these 
adverse neonatal conditions. Moreover, the relative risks of cerebral palsy, mental 
retardation and psychiatric disorders in preterm survivors increase exponentially with 
decreasing gestational age at birth (Moster et al., 2008). Alterations in the timing of 
birth per se are the leading, but potentially preventable, cause of neonatal mortality and 
morbidity. Thus, there is an urgent need to investigate the mechanism of spontaneous 
preterm labour, which may or may not result from the same endocrine and intracellular 
pathways as the physiological onset of labour at term.  
The onset of labour is the result of cascade of intrauterine biochemical events that 
culminates in cervical softening and dilatation and increased uterine contractility. 
Lopez Bernal et al, have proposed that fetal surfactant (a mixture of lipids and 
apoproteins) is a signal for parturition because it provides a link between fetal lung 
maturation which is essential for extrauterine life, and the onset of labour through 
stimulation of prostaglandin production. It has been shown that amniotic fluid 
surfactant, which reflects fetal lung maturation, is an important intrauterine source of 
arachidonic acid, and increases the rate of prostaglandin synthesis in the fetal 
membranes (Bernal and Phizackerley, 2000). This effect is due to the release of fatty 
acids, including arachidonate, from the lipids of fetal surfactant by the sequential action 
of phospholipase C and diglyceride lipase activities in amniotic fluid and by the transfer 
of arachidonate from surfactant phosphatidylcholine to phosphatidylethanolamine and 
phosphatidylinositol in amnion cells (Bernal and Phizackerley, 2000). These lipid 
pathways provide a link between the process of maturation of the fetus in preparation 
for birth and the labour-initiating prostaglandin activation.  
Moreover, in addition to the effect of its lipid components, fetal surfactant is likely to be 
involved in the process of parturition through the effects of the surfactant associated 
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proteins SP-A and SP-D (Kishore et al., 2005). SP-A and SP-D concentrations in amniotic 
fluid rise sharply from about 26 weeks gestation to term and the proteins are found in 
the fetal membranes and decidua (Miyamura et al., 1994). The evidence in support of a 
likely role of SP-A and SP-D in pregnancy and parturition are as follows: (i) SP-A and SP-
D perform immunomodulatory functions in the lungs via macrophage activation, control 
of inflammation, recognition and clearance of microbes, apoptotic and necrotic cells. (ii) 
SP-A interacts with toll-like receptors TLR-2 and TLR-4 on macrophages and increases 
the expression of interleukin IL-1β and NF-κB  (Crouch and Wright, 2001). (iii) In mice, 
intra-amniotic injection of SP-A provokes premature delivery by a process which 
involves NF-B activation with pro-inflammatory outcomes (Condon et al., 2004). (iv) 
SP-A has direct stimulatory effects on human myometrial cells through activation of NF-
κB and mitogen-activated protein (MAP) kinase pathways (Garcia-Verdugo et al., 2008). 
(v) SP-D has been shown to modulate expression of matrix metalloproteases for tissue 
remodelling and macrophage homeostasis. (vi) SP-D binds DNA from bacteria and on 
the surface of dying cells, enhancing the clearance of nucleic acids and limiting 
inflammatory reactions at sites of infection or apoptosis. (viii) SP-D is localised in the 
endometrium of the secretory phase and in placental villi and may have a role in the 
prevention of intrauterine infections at the time of implantation and during pregnancy 
(Leth-Larsen et al., 2004). This is important because infection-associated preterm 
labour is associated with the worst perinatal outcomes. 
A possible role of surfactant proteins SP-A and SP-D in modulating the induction of 
proteins involved in the prostaglandin pathway being reported here is a novel and very 
important aspect of the study. Prostaglandin synthesis in fetal membranes and decidua 
is a key event in parturition and is driven by the availability of arachidonic acid which is 
converted to PGH2 by the cyclooxygenases (COX-1 and COX-2) (Olson, 2003). The 
production of PGs of the D, E and F series depends on specific terminal PG synthases. 
Moreover, detailed temporal in vivo studies in animal models and women suggest that a 
critical step for the onset of labour is a relative increase in intrauterine PGF release, 
with lower or unchanged production of PGE2, PGD2 and prostacyclin. This suggests that 
changes in the availability of PGF synthase may be a key step for parturition. The human 
prostaglandin transporter (hPGT) regulates the transfer of PGs across the cell 
membrane and has an important role in promoting the decidualization of human 
endometrium (Kang et al., 2006). Prostaglandin dehydrogenase (PGDH) is the major PG 
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catabolic enzyme in choriodecidua and may be a target for regulatory control of PG 
availability at parturition. We used real-time PCR probes for these key genes and 
suitable antibodies to measure their expression at the protein level. The purpose of this 
study was to determine the direct effect of highly purified natural and recombinant 
forms of surfactant proteins SP-A and SP-D on the activation of the prostaglandin 
cascade by pro-inflammatory stimuli IL-1β that is a good representation of response 
induced by bacterial products (LPS) and pro-inflammatory mediators at the interface of 
the decidua-fetal membranes. There is a strong association between infection 
(chorioamnionitis) and preterm labour, and it is likely that inflammatory mediators are 
involved in the preparation for parturition by promoting cervical ripening and 
increased myometrial contractility.  
 
In summary, IL-1β dampens the effect of IL-8, TNF-α, TGF-β, TLR-2, TLR-4, SP-A1 and 
SP-D expression when stimulated by rfSP-D. However, SP-A appears to upregulate COX-
2/PTGS2 levels of expression suggesting its involvement in setting up PG pathway. This 
is coupled with up-regulation of IL-10 by SP-A which may raise the threshold of antigen 
sensitisation and promote a regulatory, anti-inflammatory environment. Thus, in 
addition to participating in labour, SP-A is likely to create an immunologically safe 
environment for the foetus. SP-D appears to have a homeostatic role during pregnancy. 
This is explained by a massive surge in SP-A levels prior to labour and birth while the 
level of SP-D does not get affected.  
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Chapter 5: 
Localisation, identification and immunological characterisation of 
decidual macrophage in term placenta 
 
 
 
 
 
 
 
 
 
 
176 
 
Summary  
As evident from the previous chapter, SP-A and SP-D being resident within placentae 
can have remarkable and distinct effects on the pro- and anti- inflammatory response 
which may have directly or indirectly influenced the PG pathway. Thus, here we sought 
to examine the localisation of SP-A and SP-D in various constituents of placentae 
including, amnion, chorion and decidua membranes, placenta, umbilical cord and 
myometrium. Since calreticulin (CRT)-CD91 complex is considered to be a bonafide 
candidate receptor for the collagen region of SP-A and SP-D, we also examined the 
concomitant localisation of human calreticulin. Having established the presence of these 
proteins and receptors in placental tissues/membranes, we wanted to localise the 
cellular component responsible for immune activity and prostaglandin production. The 
obvious target cell was DM which is one of the most abundant cells in 2nd trimester of 
pregnancy. Thus, DMs were sequestered from decidual tissue in cell suspension and 
analysed for CD14 positivity. Their response to LPS challenge via pattern recognition 
receptors like TLR were also examined using production TNF-α as a read-out, here we 
show, that a recombinant fragment of SP-D composed of homotrimeric neck and lectin 
domain, can suppress TNF-α production by LPS induced DM in a dose and time-
dependent manner. These read-outs are consistent with our observations when IL-1β 
activated ACD explants over expressed TNF- α, which in turn, were suppressed by 
recombinant proteins. Thus, modulation of DMs by SP-A and SP-D is likely to play an 
important role in suppressing or keeping homeostasis under conditions of 
inflammation. 
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5.1 Introduction 
5.1.1 Decidual macrophages in pregnancy and labour 
Decidual macrophages (DMs) constitute an important component of the innate immune 
system in the third trimester. Responsible for intrauterine defence mechanism, DMs 
protect the fetus against infection which could lead to preterm labour. The decidua is 
part of the maternal endometrial tissue during pregnancy which is shed during 
parturition. The decidua hosts a number of immune molecules such as macrophages, 
natural killer cells (NK), granulocytes and B and T lymphocytes (Bulmer et al., 1988, 
Vince et al., 1990). At term, 47% of cells are of bone-marrow origin, 18% of which 
constitute of macrophages (Vince et al., 1990), 20-30% are local leukocyte population 
located at the implantation site during the third trimester (Vince et al., 1990, Heikkinen 
et al., 2003) and NK cells which are constant throughout pregnancy (Mor and 
Abrahams, 2003). However, full understanding of the roles played by each of these cells 
is very important. DMs play a big role in the recognition and clearance of infection 
(table 5.1), where infection is the cause of more than a third of preterm births between 
23 and 36 weeks gestation (Lettieri et al., 1993). Bacterial products such as LPS 
entering the amniotic fluid stimulates phospholipase A2 production from DMs, which 
leads to the production of prostaglandin E2 and F2α (potent stimulants of labour) 
(Casey et al., 1989). In response to an infection, DMs can produce inflammatory 
cytokines such as IL-1β, TNF-α and IL-6 (figure 5.1). The early onset activity of DMs can 
therefore lead to preterm birth (McGregor et al., 1988). Studies of the role of DMs in 
intrauterine immunity have been examined through their interaction with yeast 
zymosan and pathogenic bacteria resulting in phagocytosis, release of superoxide in 
respiratory burst and production of pro-inflammatory cytokines such as TNF-α (Singh 
et al., 2005). This suggests that the major immune cell constituent of decidua, DMs, are 
responsible for the clearance of infection and production of TNF-α which selectively 
stimulates production of prostaglandin F2α by human DMs (Norwitz et al., 1991). Thus, 
failure of DMs in the clearance of infection could lead to preterm birth. Previous studies 
have also shown, isolated macrophages from amniotic fluid from pregnant mice secrete 
IL-1β and activated the NF-κB pathway in response to SP-A which could activate uterine 
activation and labour (Condon et al., 2004) and as it is known the levels of SP-A rise 
sharply towards term (Miyamura et al., 1994), therefore, we sought to examine the 
effects of SP-A on human DMs. 
178 
 
 
 
 
Table 5.1 – Ligands and receptors on macrophages and its immunomodulatory functions to 
emphasise the importance in pregnancy and labour 
Ligand/receptor 
on DMs 
Function  Reference 
B7-H1 Co-stimulatory molecule binds to corresponding 
receptor PD-1 to negatively regulate T-cell function by 
suppressing IFN-γ production. Present in early 
pregnancy not at term. Stimulated by IFN-γ 
Possible role in regulating local IFN-γ during 
pregnancy. 
(Sayama et al., 
2013) 
Secretion of 
TGF-β 
Prevents lytic activity after decidual NK cell killing 
extravillous cytotrophoblast (CTB) and macrophage 
phagocytose to clear the cellular debris for successful 
pregnancy. 
(Co et al., 2013) 
FasL ligand Increases with corticotrophin-releasing hormone (CRH) 
in vitro. Expressed on decidual macrophages. CRH 
levels higher in preeclamptic patients to induce 
apoptosis of extravillous trophoblasts (EVT) disturbing 
placentation 
(Petsas et al., 
2012) 
Class A 
scavenger 
receptor 
Recognition receptor for Clostridium sordelli for 
phagocytosis  
(Thelen et al., 
2010) 
PGF2-α Secreted by DMs stimulated by TNF-α in human term 
decidua. 
(Norwitz et al., 
1992a) 
Prostaglandin 
D2 (PGD2) 
Major source of PGD2 production by bone-marrow 
defined macrophages in decidua. HLA-DR had the 
highest PGD2 production rate and not influenced by 
labour. 
(Norwitz et al., 
1992b) 
TNF-α Secreted by decidual macrophages (and chorionic and 
decidual villous tissues) at term. 
(Vince et al., 
1992) 
HLA-DR Expressed in DMs and are of maternal origin, those 
expressed on macrophages in amnion and chorionic 
villi are of fetal origin 
(Sutton et al., 
1983) 
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Figure 5.1 – function of receptor CD14 expressed on DMs for LPS recognition to promote 
TLR-4 induced endocytosis and interferon expression. Inflammatory mediators such as LPS 
stimulates up-regulation of CD14 receptors on macrophages to secrete inflammatory cytokines to 
induce an inflammatory response (Zanoni et al., 2011). 
 
 
 
 
180 
 
5.1.2 Immune modulations of decidual macrophages during pregnancy and labour 
There is a fine balance which needs to be met for pregnancy progression and preventing 
pregnancy complications and miscarriages. The semi-allogenic fetus carries half its 
genes from the father; therefore, the uterine environment is in an immunocompetitive 
state to achieve fetal tolerance at the maternal/fetal interface. The maternal fetal 
interface is the maternal tissue interacting with fetal trophoblasts in the decidua (Lewis 
et al., 1993). The decidua, mainly the decidua basalis is infiltrated with large number of 
leukocytes, including macrophages, dendritic cells and natural killer cells (Loke and 
King, 2000). The cells interact with fetal trophoblast cells throughout pregnancy. These 
molecules play pivotal roles in pregnancy and the inflammatory pathway of labour. 
Macrophages make up 20-30% of decidual cells from the time of implantation and 
throughout pregnancy (Vince et al., 1990). Macrophages are responsible for vascular 
growth and placental development. Amongst these functions consists of effector 
functions, including removal of infection causing pathogens and tumour cells, thus, 
producing an inflammatory or anti-inflammatory milieu depending on its stimulus. 
Macrophages are present in one of two states, represented as M1 or M2. Activation of 
macrophages to a pro-inflammatory, M1 phenotype occurs through Th1 cytokines such 
as IFN-γ, TNF-α or bacterial LPS (Gustafsson et al., 2008). Inflammatory suppression can 
be achieved through anti-inflammatory cytokines including IL-4, IL-10 and IL-13 
stimulating monocyte/macrophages to skew to an alternative activated, M2 phenotype 
(Gordon and Taylor, 2005). Macrophages have also shown to be altered by its ligand 
binding, HLA-G antigens. Trophoblast cells express non-classical MHC class I, HLA-G 
antigens, which are ligands for leukocyte immunoglobulin-like receptors (LILR), present 
on all leukocytes as a membrane bound receptor, although soluble isoforms of HLA-G do 
exist. Although other HLA-I molecules can also bind to these receptors, HLA-G is the 
only HLA-I antigen which has a higher affinity for these receptors for antigen 
presentation to macrophages, DCs and NK cells for fetal tolerance (Apps et al., 2007). 
The HLA-G gene family was first identified by Geraghty et al in 1987 (Geraghty et al., 
1987). Each molecule is composed of a heavy chain composed of 3 main domains; the 
α1, α2, α3, a transmembrane region and a cytoplasmic tail. The α3 chain is non-
covalently bound to a β2-microglobulin which is a non-classical MHC encoded light 
chain (Hviid, 2006). Soluble HLA-G have been located in peripheral maternal blood, on 
placental trophoblasts, including villous cytotrophoblasts and syncytiotrophoblast, cord 
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blood and amniotic fluid (Le Bouteiller and Blaschitz, 1999). HLA-G is not highly 
polymorphic suggesting it has not gone under evolution pressure. Therefore, maternal 
and paternal HLA-G genes must be similar or identical. the HLA-G genes present 
antigens to leukocytes with higher affinity to other HLA molecules, to suppress the 
other ligands in presenting non-self-antigens, allowing the fetus to escape attack from 
maternal immune system (Hunt and Langat, 2009). HLA-G protects the fetus by 
inhibiting IFN-γ production by NK cells (Carosella et al., 2008), presenting antigens 
through APC to Treg cells in order to differentiate naïve T cells into CD4+ and CD8+ 
suppressor T cells (Carosella et al., 2008) and inducing apoptosis of activated CD8+ T 
cells. HLA-G is involved in direct suppression of maternal immune cells such as CD4+ T 
cells from stimulating B cells production of allo-antibodies (inhibiting complement 
activation) against fetal antigens by inhibiting proliferation and inducing T cell anergy 
(LeMaoult et al., 2004), thus, contributing to fetal tolerance. As mentioned earlier, 
macrophages are responsible for producing pro- and anti-inflammatory cytokines to 
protect the fetus. HLA-G molecules has shown to directly influence these levels by 
suppressing pro-inflammatory Th1 cytokines including IL-2, TNF-α and IFN-γ and 
stimulates pro-inflammatory Th2 cytokines including IL-4, IL-10 and IL-13 (Le 
Bouteiller et al., 2003). The influences of hormones, cytokines, chemokines and pattern 
recognition receptors (PRRs) regulates the phenotype and response of macrophages in 
the decidua (Stout and Suttles, 2004) to a M2 phenotype for protection in the host and 
for tissue repair (Varin and Gordon, 2009). 
 
5.1.3 NK cells at the decidua during pregnancy 
The decidua is also infiltrated with a high number of NK cells amongst other active 
leukocytes. Maternal decidual NK cells (dNK cells) express polymorphic killer Ig-like 
receptor (KIR) genes which recognise HLA-C expressed on trophoblast cells (figure 5.3), 
stimulating GM-CSF which aids in trophoblast migration for the development of 
placentation (Xiong et al., 2013). HLA-G can also down regulate decidual NK cell activity 
through direct interaction with inhibitory receptors on decidual NK cells (Hviid, 2006) 
(figure 5.3). Co-culture experiments of cells with HLA-G positive cells resulted in 
increased production of IL-10 from DCs (Apps et al., 2007) and macrophages (McIntire 
et al., 2004). HLA-G can also bind to macrophage cells through inhibitory receptors 
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Human inhibitory receptors Ig-like transcript 2 (ILT2) and 4 (ILT4) down-regulating 
the migration of dendritic cells to prevent antigen presentation to naïve T cells (Liang et 
al., 2008) preventing T cell mediated cell lysis (Hviid, 2006, Rouas-Freiss et al., 1997). 
Activation of NK cells results in the release of pro-inflammatory  cytokine IFN-γ, which 
activates macrophages causing them to come into close contact with trophoblast cells 
expressing HLA-G, and these can interact with ILT2 and ILT4 receptors on macrophages 
providing inhibitory signals for apoptosis and cell lysis and modulate the production of 
cytokines for Th2 cytokine bias, which would result in inflammatory suppression, 
macrophage recruitment and T and B lymphocyte tolerance, suggesting the importance 
of HLA-G to be important in protection of fetal tissues against maternal immune attack.  
 
Placentation is important for fetal survival and inadequate invasion is associated with 
IUGR, preeclampsia and miscarriages (Brosens et al., 1977, Khong et al., 1986, Norwitz, 
2006) (figure 5.2). Decidual NK cells have been shown to play an important role in 
human trophoblast invasion for successful pregnancies (Ashkar et al., 2003, Ashkar and 
Croy, 2001, Croy et al., 2003, Croy et al., 2002, Parham, 2004). 
 
 
Figure 5.2 – trophoblast invasion of normal and pre-eclamptic situations. The spiral arteries 
are remodelled by trophoblasts and NK cells. The left image is of a non-pregnant endometrium in 
the secretory phase of the menstrual cycle just before menstruation. The right panel shows a 
normal pregnant endometrium with spiral arteries penetrating up to the endometrium. The 
middle panel shows a preeclamptic situation of the spiral arteries do no remodel to the depths of 
the myometrium and the large vessels become invaded with endovascular trophoblast cells 
(ENVT). Image taken from (Moffett-King, 2002). 
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Figure 5.3 – NK cells inhibiting HLA-C2 molecules recognised by EVT cells. extravillous 
trophoblasts cells (EVT) expressing HLA-C2 (MHC-Class I receptor)  interacting with HLA-C2 which 
is recognised by its inhibitor on NK cells, the KIR2DL1 receptor. This inhibition favours 
preeclampsia. Image taken from (Moffett-King, 2002). 
 
 
Decidual NK cells are key molecules expressing receptors and interacting with fetal cells 
and secreting cytokines, chemokines and growth factors. Decidual NK cells secrete IL-8 
to regulate trophoblast invasion and interferon-inducing protein (IP)-10 have direct 
contact with fetal trophoblast cells to allow cell invasion for vascular growth (Lockwood 
et al., 2013). They also play an important role during pregnancy for angiogenesis for 
fetal development and survival (Li et al., 2001). 
 
5.1.4 Leukocyte activation in pregnancy complications  
Leukocyte activity and regulation are fundamental for vascularisation to provide blood 
to the fetus, trophoblast invasion and maintenance of immunosuppression, as a defect 
would lead to pregnancy complications such as preeclampsia, IUGR and miscarriages. It 
has been reported in preeclamptic women and IUGR cases have a low level of 
macrophages secreting more pro-inflammatory cytokines including IL-1β, TNF-α and 
IFN-γ which can induce apoptosis in extravillous trophoblasts, restricting trophoblast 
invasion (Reister et al., 2001, Abrahams et al., 2004). Therefore in pregnancy loss, there 
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may be a higher populations of inflammatory cytokine-producing macrophages (Varin 
and Gordon, 2009). 
 
5.1.5 DCs in decidua during pregnancy  
In humans, DCs have shown to migrate to the decidua basalis from as early as 9 weeks 
gestation (Schuster et al., 2009) (figure 5.5). As the antigens presented on trophoblasts 
are of fetal origin, antigen presenting cells mediating presentation of alloantigens is 
exclusively to maternal origin. hDC are found in low levels in decidua and unmarked 
high levels infiltrated in decidua basalis associated with preeclampsia in humans 
(Huang et al., 2008) and decidual T-cells clusters surround decidual DC regardless of 
placental pathologies (Kammerer et al., 2000) (figure 5.6). This suggests that constant 
antigen presentation to T-cell is common and with higher level of antigen presentation 
leads to increased chances of fetal rejection. Although the decidua is proposed to have a 
immunosuppressive nature, they do show to possess many immunocompetent markers 
such as CD45+, CD40+, HLA-DR++ and CD83 on decidual DC during early pregnancy 
(Kammerer et al., 2000). This has shown to be of particular importance for fetal skin 
development and skin immune maturation to exhibit a protective role against infections 
after birth (Schuster et al., 2009). 
 
5.1.6 SP-A and SP-D as a modulator of macrophage functions 
SP-A and SP-D have shown to bind to receptors SIRPα, a signal-inhibitory regulatory 
protein α, controlling alveolar macrophage activity, suppressing macrophage 
phagocytosis and inflammation (Janssen et al., 2008, Gardai et al., 2003).  During LPS 
stimulation, SIRPα can be post-transcriptionally modulated which results in reduction 
of SIRPα and increases macrophage inflammatory response (Zhu et al., 2013) (figure 
5.4). Further studies have shown the ability of MMP-9 to cleave SP-D to inactivate its 
innate immune functions. As MMP-9 is over-expressed in several diseases such as 
asthma and cystic fibrosis, these patients can be more susceptible to pulmonary 
infection possibly due to MMP-9 contribution. However, cleaved SP-D and un-cleaved 
SP-D have shown to still bind to LPS (Bratcher et al., 2012) suggesting the CRD region 
was still intact, therefore, SP-D can communicate to macrophages through CRD region, 
but its effect will be much less. SP-D has also shown more efficient clearance of late 
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apoptotic cells in lungs through opsonisation by SP-D and clearance through alveolar 
macrophages without eliciting an inflammatory response. This suggests SP-D can clear 
late apoptotic cells whilst dampening the inflammatory effects of LPS (Litvack et al., 
2010). It has recently been shown that despite increase in inflammatory cells, SP-D 
dampens LPS inflammatory effects through GM-CSF-dependent pathway during indirect 
lung injury in mice (King and Kingma, 2011). A bacterial respiratory pathogen, 
Legionella pneumophilia (L. pneumophilia) can replicate within macrophages to cause 
opportunistic infections. However it has been recently shown in mice models that SP-A 
and SP-D can bind to LPS on L. pneumophilia and blocks the growth of the pathogen 
providing protective measures (Sawada et al., 2010). SP-D functions in suppressing 
macrophage activity after LPS stimulation from bacteria is not located only in the lungs 
but also has been shown to suppress nitric oxide (NO) formation in the whole organism 
depending on the phenotype of macrophages (Atochina-Vasserman et al., 2009). It is 
important for SP-D to be in its correct oligomeric form, to fulfil its activity as previous 
studies have shown, coiled-neck and lectin domain of SP-D binding to LPS to dampen an 
inflammatory response to macrophages through TLR4/MD-2 complex. However, it is 
not as strong as native SP-D in inhibiting macrophage activation through LPS (Yamazoe 
et al., 2008). A study opposing the protective effects of SP-A in mice levels suggests LPS 
decreases TLR2 and 4, SP-A and SP-D expression leading to preterm birth. Moreover, 
there is evidence of SP-A expression in maternal uterus to suggest that this could have 
pro-inflammatory effects whereas the fetal surfactants from lung provide protective 
anti-inflammatory effects yet clearing infection (Salminen et al., 2008). SP-D has been 
shown to downregulate LPS through inhibition of CD14/TLR4 receptors (Liu et al., 
2005, Senft et al., 2005). SP-D has been shown to regulate CD14 through MMP-12 and 
MMP-9, in SP-D deficient mice, MMP-9 and MMP-12 cleave CD14 into a soluble form and 
showed that with LPS stimulation, there was less TNF-α production  (Senft et al., 2005). 
In this chapter, preparation and fractionation of DMs are being reported. Their response 
to LPS challenge in the presence or absence of SP-A and SP-D is also being reported. 
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Figure 5.4 – schematic diagram of anchoring villous with invading macrophages, T cells 
and dendritic cells. Majority of the dendritic cells are located at the basal layer of the decidual 
basalis interacting with some T cells and decidual macrophages are scattered throughout the 
decidual layer. Image taken from (Tagliani and Erlebacher, 2011). 
 
 
Figure 5.5 – a schematic representation of the pregnant mouse uterus and the decidual 
cells, NK cells and T cells interaction at the maternal-fetal interface. There are NK cells and 
DC cells interaction with T cells for trophoblast remodelling in the decidua. There is less DC in 
decidua for less exposure of alloantigens to T cells. The decidual cells share the same features as 
the human uterus. Taken from (Tagliani and Erlebacher, 2011).  
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5.2 Methods and Materials 
5.2.1 Preparation of histological slides for antigen retrieval  
The histology slides containing fresh ACD membranes, placenta, umbilical cord and 
myometrium were embedded in wax and sliced with a microtome to place on 
microscope slides for antigen detection by the histology team in Bristol University. 
Antigen detection was carried out using ABC system (Vector Labs, Peterborough, UK). 
The decidual cells and tissue slides were prepared as described by Singh et al (2005). 
The process of Immunohistochemistry involves heat-mediated antigen retrieval for 
immune-detection. Initially, the tissue sections were de-waxed by successive 
immersions in: histoclear twice, 100% ethanol, 90% ethanol, 70% ethanol followed by 
water for 5mins each. The endogenous peroxidase activity was blocked by immersion in 
1% H2O2 for 15mins. For antigen retrieval, the slides were placed warm 0.01M Sodium 
citrate buffer (pH6.0) containing 0.05% Tween-20. After 15 minute incubation, slides 
were washed in PBS then blotted dry and placed at room temperature in a humidifying 
box to carry out the immunodetection process.  
 
5.2.2 Immunohistochemistry (IHC) using ABC system (Vector Labs, Peterborough, 
UK)  
ACD membranes, placenta, umbilical cord and myometrium were stained for SP-A, SP-D 
and calreticulin (CRT), a bonafide receptor in complex with CD91 for SP-A and SP-D. 
This was carried out with the ABC system (VectorLabs, Peterborough, UK). Initially, 
200µl of 2% normal horse serum in PBS was added to sections directly over the cells 
and incubated for 20mins, followed by washing in PBS. 100µl  1:1000 dilution of 
primary antibody (rabbit anti-human SP-A, SP-D and CRT) in 2% BSA/PBS was added to 
the cells and incubated at room temperature for 20 minutes, 1 hour in a humidifying 
chamber and overnight at 4°C. After 24 hour incubation, primary antibody was washed 
and slides were incubated in 100µl 1:1000 biotinylated secondary antibody (Horse-anti 
Rabbit) in PBS at room temperature for 1hour. Finally after 3 successive washes, slides 
were incubated in 150µl of ABC reagent (Vector Labs, Peterborough, UK) for 20minute 
at room temperature followed by another round of washing and developed by 
Incubating cell sections with 200µl of DAB (3,3’-Diaminobenzidine) for 2-10minutes. 
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After immunodetection of targets e.g. SP-A, SP-D and CRT, the slides were 
counterstained with haematoxylin. Briefly, the slides were immersed in haematoxylin 
for 1minute, washed, immersed in 1% sodium carbonate followed by immersion in 1% 
HCl in 70% ETOH (acid/alcohol) for 5mins at each step. The tissue sections were 
destained with acid/alcohol before running under the tap water until slides turn slightly 
blue. The tissue slides were dehydrated in successive washes of – 70%, 90%, 100% 
alcohol followed by clearing in histoclear I and II for 5mins each. For examining the 
slides, they were blotted dry before adding adhesive and a coverslip over the tissue. 
Images were taken using an Axioskop 2 microscope.  
5.2.3 Human Decidual Tissue collection 
Term placentae were collected after spontaneous or caesarean delivery with informed 
consent and processed within 45 min of delivery. All women delivered healthy singleton 
infants.  
5.2.4 Alkaline phosphatase–anti-alkaline phosphatase (APAAP) staining of decidual 
sections 
Rolls were made from amnion choriodecidua, as previously described (Sutton et al., 
1986). Frozen sections were cut at 7 mm thick and fixed in acetone and blocked in 40 µl 
rabbit serum for 5 minutes. After washing thrice in PBS, slides were incubated with 50 
µl monoclonal mouse anti-humanCD14 monoclonal antibody (Serotech, Oxford, UK) for 
30 minutes. Slides were washed in washing buffer (50 mM Tris-HCl, 0.15M NaCl, pH7.6) 
for 2 minutes followed by incubation in rabbit anti-mouse serum (DAKO, Cambridge, 
UK) for 30 minutes and incubation in anti-mouse APAAP complex (DAKO, Cambridge, 
UK) for 30 minutes. Slides were stained in a solution containing 160 mM Napthol 
(Sigma, Dorset, UK) diluted in 200 µl Dimethylformamide (Sigma, Dorset, UK), 9.8 ml 
0.1M Tris-buffer (pH 8.2), 1 mM Levamisole (Sigma, Dorset, UK), 1 mM Phe-Gly-Gly and 
10 mg Fast Red (Sigma, Dorset, UK), for 15 minutes at room temperature. Slides were 
then counterstained with haematoxylin/eosin for 15 seconds. The same procedure was 
carried out with other targets of macrophage receptors. Please refer to table 5.2. 
5.2.5 Decidual cell suspension from term placenta 
The decidual cell suspension was prepared as described by Vince et al (Vince et al., 
1990). For each placenta, 2 to 9 g of decidual tissue was obtained, decidual cells was 
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scraped from fetal membranes and washed in Dulbecco’s PBS to remove red blood cells. 
Decidual tissue was suspended in RPMI-1640 medium (10ml/g of tissue) supplemented 
with L-Glutamine (Life technologies LTD, Paisley, UK), 100 U/ml benzylpenicillin and 
100 µg/ml streptomycin and incubated with Dispase II (5 mg/ml; from Bacillus 
polymyza; Boehringer Ingelheim Limited, Bracknell, UK) for 30 minutes at 37 °C. The 
digested tissue was washed in PBS, centrifuged at 600 x g, 5 minutes, and the pellet was 
resuspended in RPMI-1640 containing 0.5 mg/ml collagenase type IV (Sigma, Dorset, 
UK), 2 mg/ml hyaluronidase type I-S (Sigma, Dorset, UK), 50 µg/ml DNAse type IV and 
10% v/v heat-inactivated fetal calf serum (FCS; Sigma, Dorset, UK) incubating at 37 °C 
for 1 hour. This was followed by centrifugation at 650 x g for 10 minutes and cells were 
syringed through a 40 µM filter and allowed to recover overnight at 4 °C in RPMI-1640 
containing 10% v/v heat-inactivated FCS. To obtain live cells, the cell pellet was re-
suspended in 25% Percoll, underlayered by 50% Percoll and centrifuged at 650 x g for 
30 min. The live cells were in the interface and were washed in PBS and examined using 
trypan blue to count in a haemocytometer. The cells were washed and re-suspended in 
PBS containing 0.1% w/v bovine serum albumin (BSA) to adjust the concentration to 1 
x 106 cells per 50 µl. 
 
5.2.6 CD14 staining with cytospin 
The slides and filters were inserted into the appropriate slots in the cytospin to allow 
cells to reach the slides. The cells were diluted in Tris buffered saline containing 0.1% 
w/v BSA to adjust 0.025 x 104 cells per 100 µl and added to the slides quickly. The 
samples were cytospun at 150 x g for 6 minutes. After examining the slides to ensure 
the cells have annealed properly the slides were left to dry in a desiccation chamber 
overnight. The cells were stained for CD14 as described for FACS. 
5.2.7 CD14-Antibody labelling for flow cytometry 
50 µl of Decidual cells were suspended in PBS containing 20 mM glucose and 5% v/v 
normal human serum (PGN) and were incubated with mouse anti-human CD14-
phcoerythrin (RPME) conjugate (Serotec, Kidlington, UK) for 30 minutes at 4 °C. Cells 
were washed in PBS containing 20 mM glucose and 5% BSA (PGB) and resuspended in 
300 µl PBS containing FCS and analysed by flow cytometry. To identify non-viable cells, 
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50 µg/ml propidium iodide was added to one tube. Mouse IgG isotype-RPE (Beckman 
Coulter, High Wycombe, UK) was used as a non-specific control. 
5.2.8 Intracellular cytokine staining for CD14 and TNF-α 
Decidual cells were suspended in 1 ml RPMI-1640 supplemented with 10% v/v FCS and 
100 µM monensin (Sigma, Dorset, UK) stimulated with 0.5 µg/ml LPS and were 
incubated in a non-adherent 24-well tissue culture plate at 37 °C in a 5% v/v CO2 
incubating chamber. The cells were then washed and incubated in anti-CD14-RPE for 30 
minutes over ice then fixed using PBS containing 0.25% v/v paraformaldehyde and 2% 
w/v glucose for 10 minutes at 4°C. The cells were then permeabilised using PBS 
containing 0.1% saponin (Sigma, Dorset, UK) and 0.1% w/v BSA, incubating for 20 
minutes at 4°C followed by incubation inn mouse anti-human TNF-α-FITC (Serotec) for 
30 minutes over ice. Cells were washed again and then analysed by two-colour FACS. 
Decidual cells stimulated with 0.5 µg/ml LPS without monensin were used as a control.  
Each experiment was carried out 3 times and 2-3 placenta were required for one 
experiments to collect sufficient decidual cells. 
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5.3 Results  
5.3.1 Localisation of SP-A and SP-D in fetal/maternal tissues from normal term 
patients 
IHC results of the same amnion, chorion and decidua (ACD) sections were stained with 
haematoxylin and location of SP-A and SP-D were detected with antibodies conjugated 
with biotin. The brownish detection is due to the biotin-avidin interaction. Figure 5.7 
and 5.8 show ACD and placental sections respectively stained for SP-A, SP-D and CRT 
(Vandivier et al, 2002). The amnion sections show SP-A and SP-D to be present at equal 
levels. The chorion displays less SP-A and SP-D, however, the decidua again shows the 
greatest staining but more for SP-D than SP-A.  
In addition, to localise SP-A, SP-D and CRT in ACD membranes, we looked at SP-D and 
CRT location in myometrium (figure.5.10), which is the maternal membrane. Results 
display a strong indication of SP-D localisation, however, the CRT expression appears 
fairly faint, suggesting that the maternal membrane may control the effects of SP-D on 
local tissue only in the suppression of inflammatory molecules to support the 
maintenance of pregnancy and avoid premature myometrial contractility. The umbilical 
cord displays similar results (figure.5.9). There is a strong indication of SP-A and SP-D 
staining with lower level of CRT expression, suggesting the proteins provoke an anti-
inflammatory mileu protecting the fetus against blood borne pathogens entering via 
arterial canal.  
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5.3.2 Immunological properties of human decidual macrophages 
Decidual tissues and identification of decidual macrophages using the APAAP methods 
revealed CD14 macrophages within the decidual layer identification of decidual 
macrophages in decidual layer and amniotic membrane. 
 
 
 
Figure 5.6 – Unlabelled, negative control of placenta sections (x10 mag.) and decidual 
macrophages (x100.). 
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Figure 5.7 – Mouse IgG labelled, positive control of placenta sections (x10.) and decidual 
macrophages (x100.). A significant number of macrophages (stained red using an anti-CD14-
conjugate), can be seen in the decidua (De), and to a lesser extent, amniotic (Am) and trophoblast 
(Tr) layers of the fetal membranes.  
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Figure 5.8 – CD14 labelled placental sections (x10.) and decidual macrophages (x100.). 
CD14 – surface antigen present on monocytes/macrophages and neutrophils, binds to bacterial 
lipopolysaccharides and delivers it to MD-2/TLR-4 complex to initiate an innate immune response 
for the removal of infection. CD14 lacks a cytoplasmic signaling domain and requires coupling to 
elicit a biological response. Binding to LPS and interactin with TLR4 to result in the production of 
cytokines and chemokines (da Silva Correia and Ulevitch, 2002) allowing phaocytosis of bacteria 
(Schiff et al., 1997), lipid transportation (Yu et al., 1997) and clearance of apoptotic cells (Gregory, 
2000). Binding of soluble CD14, results in the down-regulation of monocyte/macrophage 
activation (Schutt, 1999, Bazil and Strominger, 1991).  
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5.3.3 Effects of SP-A and SP-D on decidual macrophage TNF-α expression in the 
presence of LPS reduces TNF-a production compared to SP-A alone  
A number of antibody markers were used to show resident and perhaps infiltrated 
immune cells, in the ACD, and most predominating in the decidua (figure 5.7-5.22). 
There was a lack of SP-A staining in the decidua samples whereas SP-D was found to be 
in good amounts at the transcript level (figure 5.23). A number of resident DMs were 
found in the decidual tissue. These DMs were fractionated using CD14 positive cell and 
sorted suspension (figure 5.25a) following stimulation with LPS, DMs produced TNF-α, 
as expected, that peaked at 6 and 48 hours post-challenge. The double positive DMs 
(CD14 and TNF-α using anti-human CD14 and anti-human TNF-α antibodies) were 
visualised under microscopy. 
We have shown local SP-A and SP-D production in term placentae (figure.5.23). After 
treating DMs with LPS there was clear up-regulation of TNF-α production from CD14+ 
cells (figure.5.24).  As seen in figure.5.25, SP-A and SP-D appears to suppress TNF-α 
levels with LPS, but SP-A up regulates TNF-α at lower amounts 5ug and SP-D down 
regulates TNF-α with higher amounts. Thus, SP-A could induce inflammation at higher 
levels but in the presence of infection, they suppress the activation of macrophages. 
Comparing lower and higher levels of SP-A with LPS shows that lower levels of SP-A 
provides dampening effects of TNF-α and at higher levels of SP-A, there is higher 
macrophage interaction that stimulates the levels of TNF-α production inducing 
inflammation. This is on the contrary to SP-D, which show no difference regardless of its 
level whereas in another situation, SP-D at a lower level has suppressive response to 
TNF-α and hardly any suppressive effects at higher levels of SP-D. 
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Figure 5.9 - Real time RT-PCR amplified products separated by agarose gel electrophoresis. 
Gene expression of SP-A & SP-D in the decidua at term in two placentae (1) and (2). One μg total 
RNA in decidua was used for RT-PCR. Lane 1: Ladder (100bp); Lane 2: 18s; Lane 3: 18s NTC; Lane 
4: SP-A positive control (lung); Lane 5: SP-A decidua; Lane 6: SP-A NTC; Lane 7: SP-D  positive 
control (lung); Lane 8: SP-D decidua; Lane 9: SP-D NTC. 
 
 
Figure 5.10 – Confocal images on a Zeiss 510 meta microscope performed by 
counterstaining the decidual cells with DAPI. a) CD14 positive cells (red); b) TNF-α 
expression (green) c)  DAPI staining  (blue). 
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Figure 5.11 – Effects of SP-A & SP-D on the production of TNF-α, pro-inflammatory cytokine 
by intracellular cytokine assay. Decidual cell were isolated, and then stimulated with rfSP-A or 
rfSP-D (5 and 10μg) or LPS (100ng, derived E. coli strain 011:B4) for 1 hour. Percentage of CD14 
positive cells and TNF-α cytokine was measured by two color flow cytometry. TNF-α was highly up 
regulated (2 fold) in the presence of LPS. Low dose of rfSP-A (5μg) &high dose of rfSP-D (10μg) 
more significantly down regulates (more than 3 fold) TNF-α production by macrophages. Similar 
down regulatory effect was also seen when decidual cells were pretreated with LPS followed by 
low-dose rfSP-A /rfSP-D (5μg) blue – TNF-α levels and green – CD14+ cells. 
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5.4 Discussion 
We have fractionated CD14+ DMs in decidual cell suspension and examined the effects 
of LPS with and without SP-A and SP-D. The intracellular staining allows us to compare 
secretion of TNF-α in CD14 positive decidual cells. The stimulation with recombinant 
trimeric SP-D (rfSP-D) shows suppression of this inflammatory response to link to our 
previous data that shows that SP-D is an anti-inflammatory molecule important in the 
maintenance of pregnancy. This is consistent with our QPCR data showing that SP-A and 
SP-D (more SP-D) suppresses TNF-α to prevent an inflammatory response by 
modulating DMs. After showing the impact DMs have on stimulating PGF2α levels with 
and without SP-D suggests that DMs play an important role in modulating the 
inflammatory pathway in the third trimester. Therefore, DMs which play an important 
role in pregnancy and labour can be influenced by SP-A and SP-D. LPS can bind to TLR-
4/CD14 complex to stimulate more CD14 expression thus increasing TNF-α levels to 
induce inflammation.  
The mechanism of labour in women remains elusive and as a consequence the 
prevention and management of preterm labour is poor, resulting in potentially severe 
and lasting complications in the new born.  Premature activation and disruption of 
decidual cells due to infection, haemorrhage or other stimuli may provoke preterm 
labour. The decidua provides a place of immune tolerance and also a line of defence to 
protect the fetus and the placenta from infections. Thus, we characterised resident 
macrophage populations in human decidua referred to as decidual macrophages (DMs) 
and their response to LPS, a non-self PAMP, and how that can be modulated in the 
presence of SP-A and SP-D, especially the production of pro-inflammatory cytokines 
such as TNF-α. We wished to investigate whether at parturition, DMs change to a 
classical phenotype characterised by the production pro-inflammatory cytokines (IL-1; 
TNF-), which can impact upon the release of prostaglandin F which provokes uterine 
contractility through stimulatory FP receptors. We aimed at increasing our 
understanding of the local biochemical equilibrium that allows the maintenance of 
pregnancy, and will highlight pathways that increase the release of prostaglandin F by 
DMs leading to preterm birth.  
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According to literature, DMs are of immunosuppressive nature, perhaps SP-A and SP-D 
contribute to this suppression, as we have shown in our findings. In addition, during an 
infection which causes preterm birth or miscarriages (post-stimulation with LPS), SP-A 
and SP-D appear to suppress macrophages, however, they appear to secrete more pro-
inflammatory cytokines without them, suggesting  that DMs during normal pregnancy 
are of M1 phenotype and during an infection, macrophages switch to M2 phenotype 
causing a pro-inflammatory response as seen before (Guenther et al., 2012). As 
mentioned in earlier studies, the response from macrophages after SP-D stimulation 
depends on macrophage phenotype (Atochina-Vasserman et al., 2009). 
 
It has recently been reported that SP-A suppresses inflammation via TLR-2 interaction. 
SP-A, an endogenous ligand for TLR-2 suppresses IL-1β and TNF-α in pregnant mice, 
preventing preterm birth and inflammation (Agrawal et al., 2013). We have also shown 
that SP-A down regulates TLR-2 in human ACD explants, which is further suppressed 
when treated with IL-1β, whereas, SP-D does not have a prominent effect. However, we 
have also shown that SP-A and SP-D up regulate TLR-4, as SP-A and SP-D can bind to 
TLR-4, inhibiting LPS-induced phosphorylation of p65 producing IL-1β, preventing 
inflammation (Rakhesh et al., 2012). This thus inhibits an LPS-induced inflammatory 
response. This mechanism may be relevant in IUGR, preeclampsia and miscarriages. 
 
DMs make a large contribution to prostaglandin and cytokine release during labour due 
to their high expression of LPS and chemokine receptors (Norwitz et al., 1991, Bulmer 
and Johnson, 1984, Gordon and Taylor, 2005). Given the proximity of decidual tissue to 
myometrial smooth muscle cells, it is likely that release of prostaglandins and other 
inflammatory mediators in this area will have a direct effect on myometrial function.   
DMs secrete TNF- and are particularly sensitive in an autocrine fashion to TNF- as a 
stimulus for PGF production (Norwitz et al., 1992a, Singh et al., 2005). Thus, modulation 
of LPS-induced TNF-a production by SP-A and SP-D can also alter the output of 
prostaglandin F2α (PGF2α) by DMs in response to TNF- in the presence and in the 
absence of surfactant proteins, something that needs to be examined.   
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DMs exhibits ‘classically activated’ (pro-inflammatory) or ‘alternatively activated’ (anti-
inflammatory) phenotypes as a balance in immune reactions (Gordon and Taylor, 2005, 
Goerdt et al., 1999, Gordon, 2003). A population of alternatively activated DMs provides 
important immunosuppressive functions in early human pregnancy through the 
secretion of IL-10 and TGF- (Lidstrom et al., 2003). It is thought that progesterone 
provides the stimulus for the alternatively activated status and for the inhibition of the 
pro-inflammatory phenotype of DMs (Kudo et al., 2004), either directly or through 
cross-stimulation of glucocorticoid receptors (Cupurdija et al., 2004).  By contrast, 
classical macrophages, characterised by the production of pro-inflammatory cytokines 
(IL-1, TNF-), in response to interferon (IFN-) or bacterial LPS, appear to be less 
prominent in normal first trimester decidua. Uterine natural killer (NK) cells are a 
dominant source of IFN- and DMs express IFN- receptors. The induction of classically 
activated macrophages at term may be associated with the onset of labour (Cupurdija et 
al., 2004, Heikkinen et al., 2003). In term decidua, nearly 50% of cells are of bone 
marrow origin, comprising up to 20% macrophages (Vince et al., 1990). Here, we have 
shown that DMs prepared from women delivered at term produce TNF- when 
challenged with LPS. Moreover TNF- and IL-1β have strong autocrine and paracrine 
effects on DMs, stimulating the release of PGF2 (Norwitz et al., 1992a).  
 
In summary, we have localised DMs in term placenta and developed a method to 
generate decidual cell suspension that can be subjected to confocal microscopic and 
FACS analysis. Through intracellular cytokine analysis, LPS was shown to trigger TNF-α 
production by CD14+ DMs. The cytokine expression was considerably reduced by co-
incubation with recombinant SP-A and SP-D, suggesting that CRDs are capable of 
modulating interaction of LPS (PAMPs) with DMs surface PRRs that in turn can down 
regulate pro-inflammatory response, most likely involving NF-κB transcription factor. 
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Chapter 6: 
General conclusions and future perspectives 
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6. General conclusion and future perspective 
The immunological basis of foetus-mother interaction is still being investigated in terms 
of maintenance of pregnancy and parturition. Although a number of studies have 
examined a range of immune cells presented in various parts of the placenta, the 
importance of soluble factors which are capable of molecular pattern recognition and 
innate immune effector functions are beginning to be investigated. The interaction and 
importance of SP-A and SP-D in pregnancy and parturition become pertinent since there 
is a maternal as well as fetal component involved in terms of origin and biosynthesis of 
these two innate immune molecules. The presence of SP-A and SP-D in amniotic fluid, 
predominantly originating from fetal lungs and local production of SP-A and SP-D in 
maternal placental tissues appear to suggest that their functions may have dichotomous 
relevance during pregnancy. The constitutive level of SP-A and SP-D during pregnancy 
and massive up-regulation of SP-A biosynthesis prior to parturition appeared to suggest 
a link between these proteins and prostaglandin pathways involved during birth. There 
is plenty of evidence from murine work which have been extrapolated on human 
placental tissues in the current study.  
Having established the above mentioned, experiments and evidence, it will be 
interesting to pursue a range of ideas in future that will validate the hypothesis arising 
from this thesis.  
1. As highlighted in the Introduction, a number of miscarriages and preterm births 
are induced by intrauterine infections that itself can generate a robust pro-
inflammatory response. Almost 30% of preterm births accounts for 
amniochorionitis. The current study has used IL-1β as a pro-inflammatory 
stimulus. Thus, the effect of a range of LPS from bacteria that have been shown to 
cause intrauterine infections during pregnancy need to be examined using ACD 
explants model system. We have attempted to mimic this context in the case of 
fractionated decidual macrophages; however, the interplay of various cells intact 
within the layers of amnion, chorion and decidua when exposed to bacteria or 
LPS will be very interesting.  
2. The effect of the first recognition sub-component of the classical complement 
pathway, C1q, on ACD explants with and without pro-inflammatory stimuli will 
again be quite important to understand. The classical pathway activation and its 
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possible regulation by Factor H and factor H like molecules is likely to play an 
important role in the maintenance of pregnancy under inflammatory conditions 
due to infection, injury or stress.  
3. Having established the ACD explant model to understand the relationship 
between surfactant protein SP-A and SP-D and immune cells, it will be 
worthwhile to examine how ACD explants compare between normal and IUGR, 
preeclampsia and miscarriages. These studies should also be extended to 
fractionated decidual macrophages.   
4. Stimuli for the parturition could come from fetus and may affect the maternal 
tissue. We have looked at the levels of SP-A and SP-D expression in ACD gene and 
protein levels. Examining their as well as PG levels in the myometrium will be 
worthwhile. Whether PG levels is a rich source for PGF2α synthesis as it houses 
high level of DMs to stimulate myometrial contractility and timing of birth are 
obvious questions to answer. Clearly, differences between normal placentae and 
those coming from abnormal cases such as preterm, IUGR and miscarriages will 
help understand the importance of the roles of DMs and how influential they are 
in the presence and SP-A and SP-D.  
5. IL-6, a pro- and anti- inflammatory cytokine, stimulates prostaglandin synthesis, 
PGE2 – a potent stimulator for myometrial contractility. IL-6 is responsible for 
lung maturation and SP-A synthesis. Thus, in chorioamnionitis cases, levels of IL-
6 are high, and low in cases of RDS as lung have matured. This suggests SP-A 
could have an indirect effect on PG synthesis. 
6. This study used IL-1β to stimulate PG synthesis and mimic inflammatory 
pathway to labour. It is known that IL-1β releases arachidonic acid. If IL-1β 
affects SP-A and SP-D biosynthesis, one can correlate if the levels of arachidonic 
acid released by IL-1β are proportional to SP-A synthesis. 
7. Understanding the events in early parturition may lead to more effective 
therapeutic strategies. Leukocyte infiltration event occurs early in parturition 
and is 4-fold higher in term labour than non-infection induced preterm birth 
which is 2.5-folds higher, however neutrophils which were unchanged in term 
labour, increased from 5- to 53-folds higher in preterm with infection (Hamilton 
et al., 2012). Macrophages make up 20-30% of leukocytes and therefore could 
play a fundamental role in regulating parturition. 
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8. TNF-α has previously been shown to enhance both prostaglandin E2 (PGE2) and 
F2α (PGF2α) (Rauk and Chiao, 2000). Therefore, if SP-A and SP-D can suppress 
TNF-α secretion levels in DMs, this could have an indirect effect on PGE and PGF 
synthesis - most potent PGs for inducing labour. 
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8. Appendix  
 
8.1 Sequencing of full length recombinant SP-A in pSecTagC 
Plasmids of cloned full length SP-A in pSecTagC were sent to Beckman Coultier for 
sequencing. Results revealed an exact match for all three colonies and were all in frame 
of pSecTagC. 
SP-A1 in pSecTagC colony 1 
>NKA22021_03_T7P_G23 
NNNNGNNNNCNNGANNNGANCACTCCTGCNATNGGTACTGCTGCTCTNGGTTCAGGTTCCACTGGTGACGCGG
CCCAGCCGGCCAGGCGCGCGCGCCGTACGTACGAAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGG
AATTCGAAGTGAAGGACGTTTGTGTTGGAAGCCCTGGTATCCCCGGCACTCCTGGATCCCACGGCCTGCCAGGCA
GGGACGGGAGAGATGGTCTCAAAGGAGACCCTGGCCCTCCAGGCCCCATGGGTCCACCTGGAGAAATGCCATGTC
CTCCTGGAAATGATGGGCTGCCTGGAGCCCCTGGTATCCCTGGAGAGTGTGGAGAGAAGGGGGAGCCTGGCGAGA
GGGGCCCTCCAGGGCTTCCAGCTCATCTAGATGAGGAGCTCCAAGCCACACTCCACGACTTTAGACATCAAATCCT
GCAGACAAGGGGAGCCCTCAGTCTGCAGGGCTCCATAATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCA
GTCCATCACTTTTGATGCCATTCAGGAGGCATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAATCCAGA
GGAAAATGAGGCCATTGCAAGCTTCGTGAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAG
CCCTGGAGACTTCCGCTACTCAGACGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCCGCAGGTCG
GGGAAAAGAGCAGTGTGTGGAGATGTACACAGATGGGCAGTGGAATGACAGGAACTGCCTGTACTCCCGACTGA
CCATCTGTGAGTTCTGACTCGAGTCTAGAGGGCCCGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCCG
TCGACCATCATCATCATCATCATTGAGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATC
TGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAG
GAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGNNTNGGGTGGGGCAGGACAGCAAGGGGG
AGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTNGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGC
TGGGGCTCTAGGGGGTATCCCCNNNNGNCCTGGNACGGCGCATTAANNNNGNNGGGGNNGGTGGTTACCGCCA
CCNTGNCCNNNNNNNTTGC 
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SP-A1 in pSecTagC colony 2 
Sequence from Beckman 
>NKA22021_02_T7P_E23 
NNGGTGCNNNNGANNNGANNACTCCTGCTATGGGTACTGCTGCTCTNGGTTCAGGTTCCACTGGTGACGCGGCC
CAGCCGGCCAGGCGCGCGCGCCGTACGTACGAAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGGAA
TTCGAAGTGAAGGACGTTTGTGTTGGAAGCCCTGGTATCCCCGGCACTCCTGGATCCCACGGCCTGCCAGGCAGG
GACGGGAGAGATGGTCTCAAAGGAGACCCTGGCCCTCCAGGCCCCATGGGTCCACCTGGAGAAATGCCATGTCCT
CCTGGAAATGATGGGCTGCCTGGAGCCCCTGGTATCCCTGGAGAGTGTGGAGAGAAGGGGGAGCCTGGCGAGAGG
GGCCCTCCAGGGCTTCCAGCTCATCTAGATGAGGAGCTCCAAGCCACACTCCACGACTTTAGACATCAAATCCTGC
AGACAAGGGGAGCCCTCAGTCTGCAGGGCTCCATAATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCAGT
CCATCACTTTTGATGCCATTCAGGAGGCATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAATCCAGAGG
AAAATGAGGCCATTGCAAGCTTCGTGAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAGCC
CTGGAGACTTCCGCTACTCAGACGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCCGCAGGTCGGG
GAAAAGAGCAGTGTGTGGAGATGTACACAGATGGGCAGTGGAATGACAGGAACTGCCTGTACTCCCGACTGACC
ATCTGTGAGTTCTGACTCGAGTCTAGAGGGCCCGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCCGTC
GACCATCATCATCATCATCATTGAGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTG
TTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGA
AATTGCATCGCATTGTCTGAGTAGGTGCATTCTATTCTGGGGGNNNNGGGTGGGGCAGGACAGCAAGGGGGAGG
ATTGGGAAGACAATANCAGGCATGCTGGGGATGCGGTNGGCTCTATGGCTTCTGAGNCGNNAAGAANCAGCTNG
GGNNCTAGGGGNATCCCNNNNNNCCTGGNACNGCCATTAACCNNGGCGGGNTGGGGGNTTANCNNNNNNTGA
CCNTTACTTNNNNNGGNCCTAAGNNNCNNNCNTTTCGNTTTTCCCNNCCT 
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SP-A1 in pSecTagC colony 3 
Sequence from Beckman 
>NKA22021_03_T7P_G23 
NNNNGNNNNCNNGANNNGANCACTCCTGCNATNGGTACTGCTGCTCTNGGTTCAGGTTCCACTGGT
GACGCGGCCCAGCCGGCCAGGCGCGCGCGCCGTACGTACGAAGCTTGGTACCGAGCTCGGATCCACTAG
TCCAGTGTGGTGGAATTCGAAGTGAAGGACGTTTGTGTTGGAAGCCCTGGTATCCCCGGCACTCCTGG
ATCCCACGGCCTGCCAGGCAGGGACGGGAGAGATGGTCTCAAAGGAGACCCTGGCCCTCCAGGCCCCAT
GGGTCCACCTGGAGAAATGCCATGTCCTCCTGGAAATGATGGGCTGCCTGGAGCCCCTGGTATCCCTG
GAGAGTGTGGAGAGAAGGGGGAGCCTGGCGAGAGGGGCCCTCCAGGGCTTCCAGCTCATCTAGATGAG
GAGCTCCAAGCCACACTCCACGACTTTAGACATCAAATCCTGCAGACAAGGGGAGCCCTCAGTCTGCA
GGGCTCCATAATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCCA
TTCAGGAGGCATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAATCCAGAGGAAAATGAGGCC
ATTGCAAGCTTCGTGAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAGCCCTGG
AGACTTCCGCTACTCAGACGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCCGCAGGTC
GGGGAAAAGAGCAGTGTGTGGAGATGTACACAGATGGGCAGTGGAATGACAGGAACTGCCTGTACTC
CCGACTGACCATCTGTGAGTTCTGACTCGAGTCTAGAGGGCCCGAACAAAAACTCATCTCAGAAGAGG
ATCTGAATAGCGCCGTCGACCATCATCATCATCATCATTGAGTTTAAACCCGCTGATCAGCCTCGACT
GTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCC
ACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTAT
TCTGGGGGNNTNGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGG
GGATGCGGTNGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCNNN
NGNCCTGGNACGGCGCATTAANNNNGNNGGGGNNGGTGGTTACCGCCACCNTGNCCNNNNNNNTTG
C 
EcoRI – GAATTC 
XhoI - CTCGAG 
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8.2 Cloning and expression of trimeric SP-A in pET101/D TOPO 
Primer-BLAST 
The primers were checked to ensure they are correct and specific for this gene. To check 
if primers are specific for the desired gene, the primer sequence was checked using 
primer-basic local alignment search tool (Primer-BLAST) software provided by NCBI 
was used. This suggested a 100% match for the human SP-A gene (see fig below) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer pair 1 
 
Sequence (5'->3') Length Tm GC% 
Self 
complementarity 
Self 3' 
complementarity 
Forward 
primer 
CATCTAGATGAGGAGCTCCAAGC 23 60.31 52.17 10.00 4.00 
Reverse 
primer 
TCAGAACTCACAGATGGTCAGTCG 24 62.11 50.00 4.00 2.00 
Products on intended target 
 
Products on allowed transcript variants 
 
Products on potentially unintended templates 
 
Products on target templates 
 
>NM_001098668.2 Homo sapiens surfactant protein A2 (SFTPA2), mRNA 
 
product length = 444 
Forward primer  1    CATCTAGATGAGGAGCTCCAAGC  23 
Template        401  .......................  423 
 
Reverse primer  1    TCAGAACTCACAGATGGTCAGTCG  24 
Template        844  ........................  821 
 
232 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 – Primer-BLAST using tool from NCBI.  Forward and reverse sequences 
for SP-A trimeric region checked for specificity to clone this region specifically. All 
parameters are in acceptable range and the no base mismatches were identified.   
 
 
>NM_001164647.1 Homo sapiens surfactant protein A1 (SFTPA1), transcript variant 4, mRNA 
 
product length = 444 
Forward primer  1    CATCTAGATGAGGAGCTCCAAGC  23 
Template        371  .......................  393 
 
Reverse primer  1    TCAGAACTCACAGATGGTCAGTCG  24 
Template        814  ........................  791 
 
>NM_005411.4 Homo sapiens surfactant protein A1 (SFTPA1), transcript variant 1, mRNA 
 
product length = 444 
Forward primer  1    CATCTAGATGAGGAGCTCCAAGC  23 
Template        442  .......................  464 
 
Reverse primer  1    TCAGAACTCACAGATGGTCAGTCG  24 
Template        885  ........................  862 
 
>NM_001164646.1 Homo sapiens surfactant protein A1 (SFTPA1), transcript variant 6, mRNA 
 
product length = 444 
Forward primer  1    CATCTAGATGAGGAGCTCCAAGC  23 
Template        295  .......................  317 
 
Reverse primer  1    TCAGAACTCACAGATGGTCAGTCG  24 
Template        738  ........................  715 
 
>NM_001164645.1 Homo sapiens surfactant protein A1 (SFTPA1), transcript variant 5, mRNA 
 
product length = 444 
Forward primer  1    CATCTAGATGAGGAGCTCCAAGC  23 
Template        287  .......................  309 
 
Reverse primer  1    TCAGAACTCACAGATGGTCAGTCG  24 
Template        730  ........................  707 
 
>NM_001164644.1 Homo sapiens surfactant protein A1 (SFTPA1), transcript variant 3, mRNA 
 
product length = 444 
Forward primer  1    CATCTAGATGAGGAGCTCCAAGC  23 
Template        401  .......................  423 
 
Reverse primer  1    TCAGAACTCACAGATGGTCAGTCG  24 
Template        844  ........................  821 
 
>NM_001093770.2 Homo sapiens surfactant protein A1 (SFTPA1), transcript variant 2, mRNA 
 
product length = 444 
Forward primer  1    CATCTAGATGAGGAGCTCCAAGC  23 
Template        431  .......................  453 
 
Reverse primer  1    TCAGAACTCACAGATGGTCAGTCG  24 
Template        874  ........................  851 
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8.3 –  Sequencing of SP-A (N/CRD)cloned in pET101/D TOPO 
Homo sapiens surfactant protein A2 (SFTPA2), mRNA 
NCBI Reference Sequence: NM_001098668.2 
>gi|257743448|ref|NM_001098668.2| Homo sapiens surfactant protein A2 (SFTPA2), 
mRNA 
AACTTGGAGGCAGAGACCCAAGCAGCTGGAGGCTCTGTGTGTGGGTCGCTGATTTCTTGGAGCCTGAAAA 
GAAGGAGCAGCGACTGGACCCAGAGCCATGTGGCTGTGCCCTCTGGCCCTCACCCTCATCTTGATGGCAG 
CCTCTGGTGCTGCGTGCGAAGTGAAGGACGTTTGTGTTGGAAGCCCTGGTATCCCCGGCACTCCTGGATC 
CCACGGCCTGCCAGGCAGGGACGGGAGAGATGGTGTCAAAGGAGACCCTGGCCCTCCAGGCCCCATGGGT 
CCGCCTGGAGAAACACCATGTCCTCCTGGGAATAATGGGCTGCCTGGAGCCCCTGGTGTCCCTGGAGAGC 
GTGGAGAGAAGGGGGAGGCTGGCGAGAGAGGCCCTCCAGGGCTTCCAGCTCATCTAGATGAGGAGCTCCA 
AGCCACACTCCACGACTTCAGACATCAAATCCTGCAGACAAGGGGAGCCCTCAGTCTGCAGGGCTCCATA 
ATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCCATTCAGGAGGCAT 
GTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAATCCAGAGGAAAATGAGGCCATTGCAAGCTTCGT 
GAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAGCCCTGGAGACTTCCGCTACTCA 
GATGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCTGCAGGTCGGGGAAAAGAGCAGTGTG 
TGGAGATGTACACAGATGGGCAGTGGAATGACAGGAACTGCCTGTACTCCCGACTGACCATCTGTGAGTT 
CTGAGAGGCATTTAGGCCATGGGACAGGGAGGATCCTGTCTGGCCTTCAGTTTCCATCCCCAGGATCCAC 
TTGGTCTGTGAGATGCTAGAACTCCCTTTCAACAGAATTCACTTGTGGCTATTAGAGCTGGAGGCACCCT 
TAGCCACTTCATTCCCCTGATGGGCCCTGACTCTTCCCCATAATCACTGACCAGCCTTGACACTCCCCTT 
GCAAACCATCCCAGCACTGCACCCCAGGCAGCCACTCCTAGCCTTGGCCTTTGGCATGAGATGGAGGCCT 
CCTTATTCCCCATCTGGTCCAGTTCCTTCACTTACAGATGGCAGCAGTGAGGCCTTGGGGTAGAAGGATC 
CTCCAAAGTCACACAGAGTGCCTGCCTCCTGGTCCCCTCAGCTCTGCCTCTGCAGCCCACTGCCTGCCCA 
GTGCCATCAGGATGAGCAGTACCGGCCAAGCATAATGACAGAGAGAGGCAGATTTCAGGGAAGCCCTGAC 
TGTGTGGAGCTAAGGACACAGTGGAGATTCTCTGGCACTCTGAGGTCTCTGTGGCAGGCCTGGTCAGGCT 
CTCCAGGTGGTCAGAGGGCCCAGTGGTGCCCCAGCACGGTGGTGCCCAAGCCAACCCTGTGACTGACATG 
TACGATTCACTCCTTTGAGTCTTTGGATGCCAACTCAGCCCCCTGACCTGGAGGCAGCCGGCCAAGGCCT 
CTAGGGAAGAGCCCCCCACTGCAGACATGACCCGAGTAACTTTCTGCTGATGAACAAATCTGCACCCCAC 
TTCAGACCTCGGTGGGCATTCACACCACCCCCCATGCCACCGGCTCCACTTTCCCCTTTTATTAATACAT 
TCACCCAGATAATCATTAAAATTAACATGTGCCAGGTCTTAGGATGTGTCTTGGGGTGGGCACAGTACCC 
GGTGACTCTTGGGGATATTTATTTATTTTCCCTGAGCCTATATCTTCATCTGTGAAATGGGGATAAAAAT 
ACTTGTTGCTGTCACAATTATTACCATCTCTCCAGCTAGCAAAATTACTACCAGAGCCGTTACTACACAC 
AAAGGCTATTGACCGAGCACATACCATGTGCCACACACCTTGACAAAATCTTTTAATACAGTTTATTATG 
TACTATTCAATCTTTACACAATGTCACGGGACCAGTATTGTTTACCCAATTTTTTATAAGGACACTGAAG 
CTTAGAGGAGTGAAATGTTTTGAGTGTTATTTCAGAGAGCAAATGGCAAAGACTGGATCCAAACCCATCT 
TCCTGGACCTGAAGTTCATGCTCCCAGCCACCCCACCCCTGAGCTGAATAAAGATGATTTAAGCATAATA 
234 
 
AATCGTTAGTGTGTTCACATGAGTTTCCATA 
8.4 – CDS sequence for SP-A  
atg tggctgtgcc ctctggccct 
      121 caccctcatc ttgatggcag cctctggtgc tgcgtgcgaa gtgaaggacg tttgtgttgg 
      181 aagccctggt atccccggca ctcctggatc ccacggcctg ccaggcaggg acgggagaga 
      241 tggtgtcaaa ggagaccctg gccctccagg ccccatgggt ccgcctggag aaacaccatg 
      301 tcctcctggg aataatgggc tgcctggagc ccctggtgtc cctggagagc gtggagagaa 
      361 gggggaggct ggcgagagag gccctccagg gcttccagct catctagatg aggagctcca 
      421 agccacactc cacgacttca gacatcaaat cctgcagaca aggggagccc tcagtctgca 
      481 gggctccata atgacagtag gagagaaggt cttctccagc aatgggcagt ccatcacttt 
      541 tgatgccatt caggaggcat gtgccagagc aggcggccgc attgctgtcc caaggaatcc 
      601 agaggaaaat gaggccattg caagcttcgt gaagaagtac aacacatatg cctatgtagg 
      661 cctgactgag ggtcccagcc ctggagactt ccgctactca gatgggaccc ctgtaaacta 
      721 caccaactgg taccgagggg agcctgcagg tcggggaaaa gagcagtgtg tggagatgta 
      781 cacagatggg cagtggaatg acaggaactg cctgtactcc cgactgacca tctgtgagtt 
      841 ctga 
8.5 – Original N/CRD sequence for human SP-A gene  
CATCTAGATGAGGAGCTCCA 
AGCCACACTCCACGACTTCAGACATCAAATCCTGCAGACAAGGGGAGCCCTCAGTCTGCAGGGCTCCATA 
ATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCCATTCAGGAGGCAT 
GTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAATCCAGAGGAAAATGAGGCCATTGCAAGCTTCGT 
GAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAGCCCTGGAGACTTCCGCTACTCA 
GATGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCTGCAGGTCGGGGAAAAGAGCAGTGTG 
TGGAGATGTACACAGATGGGCAGTGGAATGACAGGAACTGCCTGTACTCCCGACTGACCATCTGTGAGTT 
CTGA 
 
8.6 – Sequence 1 – SP-A N/CRD col. 1  
GNNNNNTCCTNTAGAATATTTTGTTTACTTTAAGAAGGAATTCAGGAGCCCTTGGGCTCGAGTCAGAACT
CACAGATGGTCAGTCGGGAGTACAGGCAGTTCCTGTCATTCCACTGCCCATCTGTGTACATCTCCACACACT
GCTCTTTTCCCCGACCTGCGGGCTCCCCTCGGTACCAGTTGGTGTAGTTTACAGGGGTCCCGTCTGAGTAGC
GGAAGTCTCCAGGGCTGGGACCCTCAGTCAGGCCTACATAGGCATATGTGTTGTACTTCTTCACGAAGCTTG
CAATGGCCTCATTTTCCTCTGGATTCCTTGGGACAGCAATGCGGCCGCCTGCTCTGGCACATGCCTCCTGAA
TGGCATCAAAAGTGATGGACTGCCCATTGCTGGAGAAGACCTTCTCTCCTACTGTCATTATGGAGCCCTGCA
GACTGAGGGCTCCCCTTGTCTGCAGGATTTGATGTCTAAAGTCGTGGAGTGTGGCTTGGAGCTCCTCATCTA
GATGCATGGTGAAGGGCGAGCTCAATTCGAAGCTTGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCG
235 
 
ATTCTACGCGTACCGGTCATCATCACCATCACCATTGAGTTTGATCCGGCTGCTAACAAAGCCCGAAAGGAA
GCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGG
GGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCCCGCAAGAGGCCCGGCAGTACCGGCATAACCAAG
CCTATGCCTACAGCATCCAGGGTGACGGTGCCGAGGATGACGATGAGCGCATTGTTAGATTTCATACACGG
TGCCTGACTGCGTTAGCAATTTAACTGTGATAAACTACCGCATTAAAGCTTATCGATGATAAGCTGTCAAA
CATGAGAATTAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAA
TAATGGGTTTCTTAGACGTCAGGGNGGCACTTTTTCGGGGGAAATGNNGCGCGGNAACCCCCTANTTGGTT
TANTTTTCCTAAATACATTNCNAATATGGTATCCNNNTCATGNAAACAATAANCCNTGGANNAATGGCTT
CCAATNAANATTGGAANAAANGGANNAANNNTGANNNATTCCAACANTTTTCCGNNGGTCNNCCNNTT
NNNTCCCCNTTTTTTTGGGGGNATTTTTNGCCTTNCCNNGGNTTTTTGGCNNNNCCCCAAAAANNCCCTT
NG 
 
 
 
The sequence was used in NCBI database BLAST to evaluate accuracy of gene cloned. 
The results show the sequence matches up with SP-A 
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Sequence 2 – N/CRD for SP-A col.2 
GNTTCCNTCNNAATATTTTGTTTACTTTAAGAAGGAATTCAGGAGCCCTTCACCATGCATCTAGATGAGGA
GCTCCAAGCCACACTCCACGACTTTAGACATCAAATCCTGCAGACAAGGGGAGCCCTCAGTCTGCAGGGCTC
CATAATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCCATTCAGGAGG
CATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAATCCAGAGGAAAATGAGGCCATTGCAAGCTTC
GTGAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAGCCCTGGAGACTTCCGCTACTCA
GACGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCCGCAGGTCGGGGAAAAGAGCAGTGTGT
GGAGATGTACACAGATGGGCAGTGGAATGACAGGAACTGCCTGTACTCCCGACTGACCATCTGTGAGTTCT
GACTCGAGCCCAAGGGCGAGCTCAATTCGAAGCTTGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCG
ATTCTACGCGTACCGGTCATCATCACCATCACCATTGAGTTTGATCCGGCTGCTAACAAAGCCCGAAAGGAA
GCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGG
GGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCCCGCAAGAGGCCCGGCAGTACCGGCATAACCAAG
CCTATGCCTACAGCATCCAGGGTGACGGTGCCGAGGATGACGATGAGCGCATTGTTAGATTTCATACACGG
TGCCTGACTGCGTTAGCAATTTAACTGTGATAAACTACCGCATTAAAGCTTATCGATGATAAGCTGTCAAA
CATGAGAATTAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAA
TAATGNTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTC
TAAATACATTCCAANTATGTATCCNGCTCATGAAANCAATAACCCCTGANTNAATGCTTCAATNAATATT
238 
 
NGAAAAANNGAANGAGTATNNAGTATTCAACANTTTCCNNGGCCGCCNNTAANTCCNNTTTTTTGCGGN
ANTTTTNNCCTTCCTGGTTTTTGNNNNNNCCNNAANNCNNNGGNNGAAANGTAAAANNNNNNNTNNA
AANNNNNNTTTGGGGNGNN 
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Sequence for colony 3 – N/CRD of SP-A 
AANTNCCTCNNAATATTTTGTTTACTTTAAGAAGGAATTCAGGAGCCCTTCACCATGCTTCTAGATGAGGA
GCTCCAAGCCACACTCCACGACTTTAGACATCAAATCCTGCAGACAAGGGGAGCCCTCAGTCTGCAGGGCTC
CATAATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCCATTCAGGAGG
CATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAATCCAGAGGAAAATGAGGCCATTGCAAGCTTC
GTGAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAGCCCTGGAGACTTCCGCTACTCA
GACGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCCGCAGGTCGGGGAAAAGAGCAGTGTGT
GGAGATGTACACAGATGGGCAGTGGAATGACAGGAACTGCCTGTACTCCCGACTGACCATCTGTGAGTTCT
GACTCGAGCCCAAGGGCGAGCTCAATTCGAAGCTTGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCG
ATTCTACGCGTACCGGTCATCATCACCATCACCATTGAGTTTGATCCGGCTGCTAACAAAGCCCGAAAGGAA
GCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGG
GGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCCCGCAAGAGGCCCGGCAGTACCGGCATAACCAAG
CCTATGCCTACAGCATCCAGGGTGACGGTGCCGAGGATGACGATGAGCGCATTGTTAGATTTCATACACGG
TGCCTGACTGCGTTAGCAATTTAACTGTGATAAACTACCGCATTAAAGCTTATCGATGATAAGCTGTCAAA
CATGAGAATTAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAA
TAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTC
TNAATACATTCAAATATGTATCCGCTCATGAANCAATAACCNTGATNAATGCTTCCATAATATTNNAAAA
240 
 
GGAAGANNANGAGTATTCAACATTTCCGGGNCGNCCTTATTCCCTTTTTTGCGGNATTTTNCCTTCCTGN
NTTTGCTCANCCNNNAACNCTTNGGGAAAGNNAAAGNNNCTGAAAANNNNNTTGGGGGNNNNNNNNN
GGGTTAATNNNAACTGGNNNNNCNAAGCGGNAAAANCTCTTNNAANNNTTNCNCCCNNNAAAANGNTT
TCCAANANNNNAANCNTTTAANNNNNNNNTNNNNGNNNGGNNNNNNNCCC 
 
 
 
 
 
241 
 
 
 
Sequence for colony 5 for N/CRD SP-A 
NNGNNTTCCTNNNAATATTTTGTTTACTTTAAGAAGGAATTCAGGAGCCCTTCACCATGCATCTAGATGA
GGAGCTCCAAGCCACACTCCACGACTTTAGACATCAAATCCTGCAGACAAGGGGAGCCCTCAGTCTGCAGGG
CTCCATAATGACAGTAGGAGAGAAGGTCTTCTCCAGCAATGGGCAGTCCATCACTTTTGATGCCATTCAGG
AGGCATGTGCCAGAGCAGGCGGCCGCATTGCTGTCCCAAGGAATCCAGAGGAAAATGAGGCCATTGCAAGC
TTCGTGAAGAAGTACAACACATATGCCTATGTAGGCCTGACTGAGGGTCCCAGCCCTGGAGACTTCCGCTAC
TCAGACGGGACCCCTGTAAACTACACCAACTGGTACCGAGGGGAGCCCGCAGGTCGGGGAAAAGAGCAGTG
TGTGGAGATGTACACAGATGGGCAGTGGAATGACAGGAACTGCCTGTACTCCCGACTGACCATCTGTGAGT
TCTGACTCGAGCCCAAGGGCGAGCTCAATTCGAAGCTTGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTC
TCGATTCTACGCGTACCGGTCATCATCACCATCACCATTGAGTTTGATCCGGCTGCTAACAAAGCCCGAAAG
GAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTG
AGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCCCGCAAGAGGCCCGGCAGTACCGGCATAACC
AAGCCTATGCCTACAGCATCCAGGGTGACGGTGCCGAGGATGACGATGAGCGCATTGTTAGATTTCATACA
CGGTGCCTGACTGCGTTAGCAATTTAACTGTGATAAACTACCGCATTAAAGCTTATCGATGATAAGCTGTC
AAACATGAGAATTAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGA
TAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGNTTATTT
242 
 
TTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAANCCTGATAAATGCTTCAATAATATTGNAA
AAGGGANNNGTATGAGTATTCAACATTTCCGTNTNNCCCTTATTCCCTTTTTTGNNGNNNTTTTGCCTTC
CTNNNTTTTNCTNNNCCANAAACGCTGGNNNNANNNAAANNTNNTGAAAANNANTTGGGTGNNCNNA
NNNGGTTAATTNNAANNGG 
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Once the sequences had been received, they were examined by ChromasLite. For colony 
2 the ChromasLite sequencing image is shown below 
 
For colony 5 the ChromasLite sequencing image is shown below 
244 
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8.7 – Primer design for trimeric SP-A to clone in pMalC-2 
Forward strand 5’ – SP-A1 
CAT CTA GAT GAG GAG CTC CAA (tm 57oC) 
 
Enzyme – forward – EcoRI – GAATTC 
GGGGAATTC CAT CTA GAT GAG GAG CTC CAA 
 
Reverse Primer 
Enzyme – REVERSE – BamHI – GGATC 
CCGACTGACCATCTGTGAGTTC (tm 57oC) 
Reverse strand 3’ (reverse and complement) – SP-A1 
GAACTCACAGATGGTCAGTC 
246 
 
 
 
 
 
 
 
 
 
 
 
 
 
247 
 
8.8 – enzymes that don’t cut within trimeric region of SP-A 
 
Enzymes that don't cut 
  
SP-A tri  
Help 
 
  Comments 
 
Number of cuts 0     
  
# Enzyme Specificity 
 1   AatII  G ACGT C  
 2   AccI  GT MK AC  
 3   AclI  AA CG TT  
 4   AcuI  CTGAAG(N)14 NN  
 5   AfeI  AGC GCT  
 6   AflII  C TTAA G  
 7   AflIII  A CRYG T  
 8   AgeI  A CCGG T  
 9   AleI  CACNN NNGTG  
 10   AlwI  GGATCNNNN N  
 11   ApaI  G GGCC C  
 12   ApaLI  G TGCA C  
 13   ApeKI  G CWG C  
 14   ApoI  R AATT Y  
 15   AscI  GG CGCG CC  
 16   AseI  AT TA AT  
 17   AsiSI  GCG AT CGC  
 18   AvaI  C YCGR G  
 19   AvrII  C CTAG G  
 20   BaeGI  G KGCM C  
 21   BaeI  (N)5 (N)10ACNNNNGTAYC(N)7 (N)5  
 22   BamHI  G GATC C  
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 23   BbvCI  CC TCA GC  
 24   BbvI  GCAGC(N)8 NNNN  
 25   BceAI  ACGGC(N)12 NN  
 26   BcgI  NN (N)10CGA(N)6TGC(N)10 NN  
 27   BciVI  GTATCC(N)5 N  
 28   BclI  T GATC A  
 29   BfuCI  GATC  
 30   BglI  GCCN NNN NGGC  
 31   BglII  A GATC T  
 32   BlpI  GC TNA GC  
 33   BmgBI  CAC GTC  
 34   BmrI  ACTGGGNNNN N  
 35   BmtI  G CTAG C  
 36   Bpu10I  CC TNA GC  
 37   BpuEI  CTTGAG(N)14 NN  
 38   BsaAI  YAC GTR  
 39   BsaBI  GATNN NNATC  
 40   BsaHI  GR CG YC  
 41   BsaI  GGTCTCN NNNN  
 42   BsaWI  W CCGG W  
 43   BsgI  GTGCAG(N)14 NN  
 44   BsiWI  C GTAC G  
 45   BsmBI  CGTCTCN NNNN  
 46   BsmI  GAATG CN  
 47   BsoBI  C YCGR G  
 48   BspDI  AT CG AT  
 49   BspEI  T CCGG A  
 50   BspHI  T CATG A  
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 51   BspQI  GCTCTTCN NNN  
 52   BsrBI  CCG CTC  
 53   BsrFI  R CCGG Y  
 54   BssHII  G CGCG C  
 55   BssSI  C ACGA G  
 56   BstAPI  GCAN NNN NTGC  
 57   BstBI  TT CG AA  
 58   BstEII  G GTNAC C  
 59   BstUI  CG CG  
 60   BstXI  CCAN NNNN NTGG  
 61   BstYI  R GATC Y  
 62   BstZ17I  GTA TAC  
 63   Bsu36I  CC TNA GG  
 64   BtgI  C CRYG G  
 65   BtgZI  GCGATG(N)10 NNNN  
 66   BtsCI  GGATG NN  
 67   ClaI  AT CG AT  
 68   CspCI  NN (N)11CAA(N)5GTGG(N)10 NN  
 69   DpnI  GA TC  
 70   DpnII  GATC  
 71   DraI  TTT AAA  
 72   DraIII  CAC NNN GTG  
 73   DrdI  GACNN NN NNGTC  
 74   EarI  CTCTTCN NNN  
 75   EciI  GGCGGA(N)9 NN  
 76   EcoP15I  CAGCAG(N)25 NN  
 77   EcoRI  G AATT C  
 78   EcoRV  GAT ATC  
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 79   FokI  GGATG(N)9 NNNN  
 80   FseI  GG CCGG CC  
 81   FspI  TGC GCA  
 82   HaeII  R GCGC Y  
 83   HgaI  GACGC(N)5 (N)5  
 84   HhaI  G CG C  
 85   HinP1I  G CG C  
 86   HincII  GTY RAC  
 87   HpaI  GTT AAC  
 88   HpaII  C CG G  
 89   HphI  GGTGA(N)7 N  
 90   Hpy99I  CGWCG  
 91   HpyCH4IV  A CG T  
 92   KasI  G GCGC C  
 93   MboI  GATC  
 94   MfeI  C AATT G  
 95   MluCI  AATT  
 96   MluI  A CGCG T  
 97   MlyI  GAGTC(N)5  
 98   MmeI  TCCRAC(N)18 NN  
 99   MscI  TGG CCA  
 100   MseI  T TA A  
 101   MspA1I  CMG CKG  
 102   MspI  C CG G  
 103   MwoI  GCNN NNN NNGC  
 104   NaeI  GCC GGC  
 105   NarI  GG CG CC  
 106   NciI  CC S GG  
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 107   NcoI  C CATG G  
 108   NgoMIV  G CCGG C  
 109   NheI  G CTAG C  
 110   NmeAIII  GCCGAG(N)19 NN  
 111   NruI  TCG CGA  
 112   NsiI  A TGCA T  
 113   PacI  TTA AT TAA  
 114   PaeR7I  C TCGA G  
 115   PciI  A CATG T  
 116   PflFI  GACN N NGTC  
 117   PflMI  CCAN NNN NTGG  
 118   PleI  GAGTCNNNN N  
 119   PluTI  G GCGC C  
 120   PmeI  GTTT AAAC  
 121   PmlI  CAC GTG  
 122   PshAI  GACNN NNGTC  
 123   PsiI  TTA TAA  
 124   PspOMI  G GGCC C  
 125   PspXI  VC TCGA GB  
 126   PvuI  CG AT CG  
 127   PvuII  CAG CTG  
 128   RsrII  CG GWC CG  
 129   SacII  CC GC GG  
 130   SalI  G TCGA C  
 131   SapI  GCTCTTCN NNN  
 132   Sau3AI  GATC  
 133   SbfI  CC TGCA GG  
 134   ScaI  AGT ACT  
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 135   SexAI  A CCWGG T  
 136   SfiI  GGCCN NNN NGGCC  
 137   SfoI  GGC GCC  
 138   SgrAI  CR CCGG YG  
 139   SmaI  CCC GGG  
 140   SmlI  C TYRA G  
 141   SnaBI  TAC GTA  
 142   SpeI  A CTAG T  
 143   SphI  G CATG C  
 144   SspI  AAT ATT  
 145   SwaI  ATTT AAAT  
 146   TaqI  T CG A  
 147   TseI  G CWG C  
 148   Tsp45I  GTSAC  
 149   TspMI  C CCGG G  
 150   Tth111I  GACN N NGTC  
 151   XcmI  CCANNNN N NNNNTGG  
 152   XhoI  C TCGA G  
 153   XmaI  C CCGG G  
 154   ZraI  GAC GTC  
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 Chapter 21 
 Purifi cation of Native Surfactant Protein SP-A from Pooled 
Amniotic Fluid and Bronchoalveolar Lavage 
 Najmunisa  Karbani ,  Eswari  Dodagatta-Marri ,  Asif  S.  Qaseem , 
 Priyaa  Madhukaran ,  Patrick  Waters ,  Anthony  G.  Tsolaki , 
 Taruna  Madan , and  Uday  Kishore 
 Abstract 
 Surfactant protein SP-A is a hydrophilic glycoprotein, similar to SP-D, which plays an important role in 
pulmonary surfactant homeostasis and innate immunity. SP-A is actively expressed in the alveolar type II 
cells and Clara cells. Their basic structure consists of triple-helical collagen region and a C-terminal carbo-
hydrate recognition domain (CRD). By binding to the infectious microbes, SP-A (like SP-D) are involved 
in pathogen opsonization and agglutination and subsequent clearance of the microorganism, via recruit-
ment of phagocytic cells via receptors for the collagen region. SP-A has also been localized at extra- 
pulmonary sites such as salivary epithelium, amniotic fl uid, prostate glands, and semen. The presence of 
SP-A in fetal and maternal tissue and amniotic fl uid suggests it is involved in pregnancy and labor. Native 
SP-A can be purifi ed from amniotic fl uid and bronchiolar lavage fl uid (BALF) via affi nity chromatography. 
In addition, we also report here a procedure to express and purify a recombinant form of trimeric CRD in 
 Escherichia coli . The availability of highly pure native SP-A and CRD region can be central to studies that 
examine the diverse roles that SP-A play in surfactant homeostasis, pulmonary infection and infl ammation 
and pregnancy. 
 Key words  Surfactant protein-A ,  SP-A ,  Purifi cation ,  Amniotic fl uid ,  BALF ,  Recombinant , 
 Infl ammation ,  Affi nity chromatography 
1  Introduction 
 The respiratory system gets exposed to inhaled toxins, infectious 
microbes, and allergens. Surfactant proteins are important for 
 lowering surface tension to allow inhalation and expiration with-
out diffi culty and to mediate the innate immune response against 
pathogen causing diseases for the clearance of inhaled microorgan-
isms to maintain lung sterility [ 1 ]. There are four surfactant pro-
teins characterized so far including; SP-A, SP-B, SP-C, and SP-D. 
Surfactant protein A (SP-A) are phospholipid-binding proteins 
Mihaela Gadjeva (ed.), The Complement System: Methods and Protocols, Methods in Molecular Biology, vol. 1100, 
DOI 10.1007/978-1-62703-724-2_21, © Springer Science+Business Media New York 2014
258
synthesized by alveolar type II epithelial cells and stored as 
 intracellular inclusion organelles called “lamellar bodies”. During 
deep inhalation, the surfactants are secreted covering the alveolar 
space minimizing surface tension at the air-liquid interface to pre-
vent lungs from collapsing. They are collagen-containing, calcium 
dependent C-type lectins belonging to the collectin family [ 2 ,  3 ]. 
SP-A is the most abundant protein amongst the other surfactant 
proteins, making up 90 % of the proteins out of SP-A, SP-B, SP-C, 
and SP-D. SP-A is expressed by two alleles; SP-A1 and SP-A2 
which are localized on the long arm of chromosome 10 at position 
10q21-24 forming a cluster with SP-D and MBL [ 4 ]. In compari-
son to SP-D, SP-A is tenfolds higher in level of expression and 
plays a major role in surfactant turnover and homeostasis [ 5 ,  6 ]. 
The primary structure of SP-A consists of an amino-terminus, 
triple- helical collagen-like domain of tripepetide Gly-X-Y repeats, a 
lectin connector neck region which stabilizes the trimers and 
a C-terminus C-type lectin carbohydrate recognition domain 
(CRD). SP-A forms a hexameric shape consisting of 18 polypep-
tide (6 trimerized) chains with seven amino acids at the N-terminal, 
23 Gly-x-y repeats at the collagen region and 148 amino acids at 
the globular C-terminal [ 7 ,  8 ]. The overall structure of SP-A 
resembles that of C1q with bouquet-like conformation. The hexa-
meric, hydrophobic protein of 630 KDa is made up of 6 × 105 kDa 
subunits. These subunits are made up of three polypeptide chains 
of 35 KDa each [ 9 ]. The three polypeptides are bound together by 
the disulfi de bonds at the N-terminal region. 
 SP-A plays a major role in the pulmonary innate immunity. 
In the trimeric form, the CRD can recognize and bind to carbohy-
drates moieties and pattern associated molecular patterns (PAMPs) 
on the surfaces of viruses, bacteria, yeast, and fungi in a Ca 2+ -
dependent manner [ 10 ,  11 ]. They can also recognize and opsonize 
pathogenic microorganisms via CRD region for chemotaxis by 
interacting to receptors on immune molecules such as macrophages 
and neutrophils [ 12 ]. SP-A is known to exert both infl ammatory 
as well as anti-infl ammatory effects depending on the receptor it 
binds to. The interaction of SP-A via calcium- dependent CRD to 
signal inhibitory regulatory protein α (SIRPα) results in an anti-
infl ammatory effect and the binding of SP-A collagen domain to 
CD91/calreticulin activates the pro-infl ammatory pathway [ 13 ]. 
 SP-A proteins are lipid and carbohydrate recognition molecules 
which in most cases bind to glucose and mannose residues part of 
most microbial ligands. SP-A can recognize both gram- positive 
bacteria such as  Staphylococcus aureus [ 12 ] and  Mycobacterium 
tuberculosis [ 14 ] and gram-negative bacteria. In the case of 
 M. tuberculosis, SP-A enhances the interaction of  M. tuberculosis to 
alveolar macrophages [ 14 ,  15 ] suggesting its antimicrobial activity 
for its clearance. SP-A is relevant for yeast and fungi agglutination 
and phagocytosis. In cases of  Candida albicans SP-A suppresses 
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pro-infl ammatory cytokine and chemokine production, i.e.,  TNF-α, 
IL-1β, MIP-α, and MCP-1 by alveolar macrophages and mono-
cytes [ 16 ,  17 ]. 
 By interacting with phagocytes, SP-A not only modulates the 
release of several cytokines, but also primes innate immune response 
against pathogens. In the situation of a viral infection caused by 
infl uenza A virus (IAV), the virus can enter the host lungs via its 
trimeric hemagglutinin (HA) molecule binding to sialic acid resi-
dues on the surface of epithelial cells of the lungs. SP-A benefi ts the 
host in two main ways: Firstly, the sialic acid present on the CRD of 
SP-A allows IAV to bind to promote agglutination inhibiting the 
infectivity [ 18 ]. Secondly, the binding of SP-A to IAV enhances 
virus to stimulate the respiratory burst of neutrophils [ 19 ]. 
 SP-A is considered one of the primordial agents of innate 
immune defense. It can protect against allergenic challenges via 
allergen scavenging, inhibition of allergen-IgE cross-linking and 
histamine release, suppression of mast cells, basophils, B and T-cell 
proliferation, modulation of dendritic cells and macrophages, and 
Th cell polarization [ 20 ]. Subsequently, SP-A has been shown to 
bind to house dust mite extract  Dermatophagoides pteronyssinus; 
Derp and 3-week culture fi ltrate (3wcf) as well as glycoprotein 
allergens; gp55 and gp45 of  Aspergillus fumigatus in a carbohy-
drate specifi c and calcium dependent manner, blocking histamine 
release [ 21 ,  22 ]. This shows the signifi cance of SP-A protection 
against in pulmonary hypersensitivity by resisting allergenic chal-
lenges and dampening hypersensitivity reactions in the lungs. 
 Using RT-PCR, SP-A is shown not to only synthesize in type 
II alveolar cells and Clara cells in the lungs, but extra-pulmonary 
sites of expression have also been shown. These include serum, 
amniotic fl uid [ 23 ], sputum [ 24 ], thymus, prostate and mesentery 
[ 25 ], and also synoviocytes, lacrimal and salivary epithelia [ 26 ] as 
well as the human colon [ 27 ]. In pregnancy, the expression of 
SP-A is induced as early as 20 weeks gestation during fetal lung 
development. In the third trimester, there is a sudden surge of 
SP-A at 26 weeks rising six times more than SP-D between 26 and 
40 weeks gestation [ 28 ], this could be linked to a possible signal to 
labor by preparing fetal lung maturation for survival in extra- 
uterine environment and pathogen clearance to prevent intra- 
amniotic infection. 
 In this chapter we describe protocols illustrating the purifi ca-
tion of native SP-A from amniotic fl uid and bronchoalveolar lavage 
fl uid (BALF) adapted from Strong et al. [ 29 ], via Affi nity 
Chromatography. We also describe the expression of a recombi-
nant fragment of human SP-A (rhSP-A) in  Escherichia coli and its 
purifi cation via affi nity chromatography. The rhSP-A contains the 
homotrimeric neck and CRD region inserted into the pET-101 
vector. The bacterial cloning vector, pET-101 contains a T7 
 promoter site and an ampicillin resistant gene. pET-101 is then 
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transfected into the competent plasmid, BL21 (λDE3) pLysS. 
This plasmid has a T7 lysozyme inserted to suppress the basal levels 
of T7 promoter by naturally inhibiting T7 RNA polymerase. The 
recombinant protein is localized in inclusion bodies due to over- 
expression. Following denaturation–renaturation cycles with urea 
gradient, the rhSP-A is fi nally purifi ed using a maltose–sepharose 
matrix in affi nity chromatography. 
2  Materials 
  1.  8 M Urea buffer I: 50 mM Tris–HCl, pH 7.4, 100 mM NaCl, 
5 mM CaCl 2 , 0.02 % NaN 3 , 8 M urea. 
  2.  Buffer I: 50 mM Tris–HCl, pH 7.4, 100 mM NaCl, 5 mM 
CaCl 2 , 0.02 % NaN 3 . 
  1.  Affi nity buffer I: 50 mM Tris–HCl, pH 7.4, 100 mM NaCl, 
5 mM CaCl 2 , 0.02 % NaN 3 . 
  2.  Affi nity buffer I with 1 M NaCl: 50 mM Tris–HCl, pH 7.4, 
1 M NaCl, 5 mM CaCl 2 , 0.02 % NaN 3 . 
  3.  SP-A elution buffer with EDTA: 50 mM Tris–HCl, pH 7.4, 
100 mM NaCl, 10 mM EDTA, 0.02 % NaN 3 . 
  1.  Affi nity buffer: 10 mM CaCl 2 , 20 mM Tris–HCl, pH 7.5. 
  2.  SP-A elution buffer: 10 mM EDTA, 20 mM Tris–HCl, pH 7.5. 
  1.  1 L LB media: 10 g Tryptone, 10 g yeast, 5 g NaCl. 
  2.  100 mg/ml Ampicillin: 1 g Ampicillin in 10 ml of autoclaved 
dH 2 O—fi lter-sterilized by passing through 0.2 μm fi lter. 
  3.  50 mg/ml Chloramphenicol: 0.5 g Chloramphenicol in 10 ml 
ethanol (100 %). 
  4.  1 M IPTG—2.83 g in 10 ml of autoclaved dH 2 O—fi lter- sterilized 
by passing through 0.2 μm fi lter. 
  1.  50 mg/ml Lysozyme: 0.5 g in 10 ml of autoclaved dH 2 O use. 
  2.  100 mM Phenylmethylsulfonyl fl uoride (PMSF) stock: 0.174 g 
PMSF dissolved in 10 ml isopropanol. 
  3.  50 ml/L Pellet Lysis buffer: 50 mM Tris–HCl, 200 mM NaCl, 
5 mM EDTA, 0.1 %Triton-X, 1 mM PMSF, 0.50 mg/ml 
 lysozyme (add PMSF and lysozyme (1:100 dilution of stock) 
fresh into lysis buffer just before use). 
2.1  Purifi cation 
of Native SP-A from 
Amniotic Fluid
2.2  Affi nity 
Chromatography 
for Native SP-A 
Purifi cation
2.3  Purifi cation 
of SP-A from BALF
2.4  BL21 ( λDE3) 
pLysS: Competent Cell 
of Transformation and 
Expression
2.5  Cell Lysis 
and Inclusion Bodies 
Preparation in 
Order to Extract 
Recombinant SP-A 
Fragment Protein 
Containing 
Homotrimeric Neck 
and CRD Domain 
(rhSP-A)
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  1.  50 ml Resolubilization buffer with 6 M urea: 50 mM 
Tris–HCl, pH 7.5, 100 mM NaCl, 5 mM EDTA, 70 μl 
2- mercaptoethanol (β-ME), 0.02 % NaN 3 , 6 M urea. 
  2.  1 L 4 M-Urea buffer: 50 mM Tris–HCl, pH 7.5, 100 mM 
NaCl, 5 mM EDTA, 0.02 % NaN 3 , 4 M urea. 
  3.  1 L 2 M-Urea buffer: 50 mM Tris–HCl, pH 7.5, 100 mM 
NaCl, 5 mM EDTA, 0.02 % NaN 3 , 2 M urea 
  4.  1 L 1 M-Urea buffer: 50 mM Tris–HCl, pH 7.5, 100 mM 
NaCl, 5 mM EDTA, 0.02 % NaN 3 , 1 M urea. 
  5.  1 L Final dialysis buffer: 50 mM Tris–HCl, pH 7.5, 100 mM 
NaCl, 5 mM EDTA, 0.02 % NaN 3 . 
  6.  1 L Calcium buffer/Affi nity buffer: 20 mM Tris–HCl pH 7.5, 
100 mM NaCl, 5 mM CaCl 2 , 0.02 % NaN 3 . 
  1.  1 L Affi nity buffer: 50 mM Tris–HCl, pH 7.5, 100 mM NaCl, 
5 mM CaCl 2 , 0.02 % NaN 3 . 
  2.  500 ml High salt buffer: 1 M NaCl, 50 mM Tris–HCl, pH 7.4, 
5 mM CaCl 2 , 0.02 % NaN 3 . 
  3.  SP-A elution buffer containing 5 mM EDTA: 50 mM Tris–
HCl, pH 7.4, 100 mM NaCl, 5 mM EDTA, 0.02 % NaN 3 . 
  1.  SDS-gel: 30 % Bis-acrylamide, 1.5 M Tris–HCl, pH 8.8 
(resolving gel), 1.0 M Tris–HCl, pH 6.8 (stacking gel), 10 % 
dodecylsulfate (SDS), 10 % ammonium persulfate (APS), 
TEMED. 
  2.  1× Running buffer (1 L): 3 g Tris base, 14.4 g glycine, 10 ml 
SDS (10 %), 990 ml dH 2 O. 
  3.  2× SDS sample buffer (10 ml): 1.25 ml 0.5 M Tris–HCl, 
pH 6.8, 2 ml 50 % glycerol, 2 ml 10 % SDS, 0.5 ml β-ME, 
0.5 % Bromophenol blue, 4 ml dH 2 O. 
  4.  Coomassie blue stain (1 L): 100 ml Glacial acetic acid, 400 ml 
methanol, 1 g Coomassie Blue R250, and 500 ml dH 2 O. 
  5.  De-stain solution (1 L): 100 ml Glacial acetic acid, 400 ml 
methanol, and 500 ml dH 2 O. 
 1× Transfer buffer (1 L): 2.9 g Glycine, 5.8 g Tris base, 0.37 g 
SDS, 200 ml methanol, 800 ml dH 2 O. 
3  Methods 
 Amniotic fl uid is normally collected following vaginal rupturing of 
the fetal membranes or during spontaneous rupturing. The col-
lected amniotic fl uid is usually stored at −80 °C after equilibration 
with 5 mM CaCl 2 until it is required for purifi cation.
2.6  Denaturation 
of Inclusion Bodies 
and Renaturation 
of rhSP-A
2.7  Purifi cation of 
rhSP-A via Affi nity 
Chromatography Using 
Maltose–Sepharose 
Purifi cation Column
2.8  Sodium Dodecyl 
Sulfate Polyacrylamide 
Gel Electrophoresis
2.9  Western 
Blot Buffers
3.1  Purifi cation 
of SP-A from Human 
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  1.  Thaw 1 L of pooled amniotic fl uid completely by incubating at 
37 °C (usually it takes 5–6 h) with occasional mixing.  See  Note 1 . 
  2.  Pass amniotic fl uid through 3 mm Whatman fi lter paper three 
times for a clearer suspension and to avoid future clogging of 
maltose-sepharose column. 
  3.  Pass amniotic fl uid through a cell strainer to remove fat and 
other large aggregates/debris. 
  4.  Centrifuge at 13,800 ×  g for 40 min at 4 °C to separate SP-A 
rich pellet from the supernatant that is rich in SP-D. 
  5.  Add 20 ml of 8 M urea buffer I to the pellet for further SP-A 
extraction. The urea helps to extract and unfold the protein 
which is then folded back to correct conformation by urea 
 gradient dialysis. 
  6.  Stir for 1 h at 4 °C using a magnetic stirrer to allow solubiliza-
tion of SP-A. 
  7.  Centrifuge the suspension at 13,800 ×  g in a microcentrifuge 
for 20 min at 4 °C and collect the supernatant. 
  8.  Transfer the supernatant into a dialysis membrane and dialyze 
against 1 L of Buffer I containing no urea inside a measuring 
cylinder to remove urea from SP-A. Leave cylinder on a mag-
netic stirrer overnight at 4 °C. 
  9.  Next day, collect dialysate (~20 ml) in a centrifugation tube 
and spin at 10,000 ×  g for 20 min at 4 °C and discard the pellet. 
Solubilized and correctly folded SP-A should be in the 
supernatant. 
  10.  Proceed to affi nity chromatography. 
  1.  Wash 5 ml bed volume maltose-sepharose with 50 ml auto-
claved distilled water (the preparation of maltose-sepharose is 
described in Chapter  22 ), followed by equilibration with four 
bed volumes of Affi nity Buffer I. 
  2.  Add the equilibrated maltose-sepharose into the supernatant 
containing SP-A and allow it to mix on a magnetic stirrer for 
30 min at room temperature. This allows binding of soluble 
SP-A to maltose-sepharose. 
  3.  Pass this supernatant containing maltose-sepharose bound to 
SP-A through the column three times in order to allow the bed 
to settle. 
  4.  Wash the column after collecting all the fl ow through with fi ve 
bed volumes of Affi nity Buffer I containing 1 M NaCl 
  5.  Elute 20 × 1 ml fractions of SP-A with Buffer I containing 
10 mM EDTA. Collect all 1 ml fractions over ice ( see  Note 2 ). 
  6.  25 μl of each fraction is separated on a 12 % SDS-PAGE 
( see Table  1 ) to assess protein and its purity (Fig.  1 ).
3.2  Affi nity 
Chromatography
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 Table 1 
 Components and volume for preparing 12 and 15 % SDS-PAGE 
 Resolving gel  12 %  15 %  Stacking gel 
 Components  Volume (ml)  Components  Volume (ml) 
 dH 2 O  3.3  2.3  dH 2 O  3.4 
 30 % Bis-acrylamide mix  4  5  30 % Bis-acrylamide mix  0.83 
 1.5 M Tris–HCl, pH 8.8  2.5  2.5  1.0 M Tris–HCl, pH 6.8  0.63 
 10 % SDS  0.1  0.1  10 % SDS  0.05 
 10 % APS  0.1  0.1  10 % APS  0.05 
 TEMED  0.015  0.015  TEMED  0.014 
 Prepare the stacking and resolving gel separately and add resolving gel fi rst to the casting plates. After this has polymer-
ized, add TEMED to the stacking gel and mix. Add this on top of the resolving gel inserting a comb to create wells after 
polymerization. The gel is then ready to be placed in a holder and into the tank containing 1× running buffer for wells 
to be fi lled with samples and protein marker. Set voltage to 100 V for 90 min for proteins to be separated according to 
size and charge 
 Fig. 1  SDS-PAGE (10 % w/v) analysis of purifi ed native SP-A under reducing conditions purifi ed from BAL fl uid. 
Majority of SP-A is the monomeric polypeptide chain of SP-A (33 kDa) and the lighter band corresponds to the 
non-reducible dimer proportion of SP-A. There are slight traces of the SP-A in its oligomeric form. This is con-
fi rmed by western blotting 
116.0 
66.2
45.0
35.0
25.0
18.4
14.4
64 kDa Native SP-A 
(non-reducible dimers)
33 kDa monomeric native 
SP-A 
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 To prepare a 12 % or 15 % SDS-PAGE, follow the instructions below:
  1.  In two separate 50 ml beakers label one “resolving gel” and 
the other “stacking gel”. 
 For a standard size gel, 10 ml of resolving gel and 5 ml of 
stacking gel is suffi cient. 
  2.  Assemble the clean glass plates onto the glass holder and stand 
and check for no leakages. 
  3.  Prepare resolving gel for either 12 % or 15 % (Table  1 ).  See  Note 3 . 
  4.  Once the TEMED has been added to the resolving gel the 
polymerization reaction will have begun, mix well then add the 
resolving gel to the plates ( see  Note 4 ). 
  5.  After 20 min the gel will have polymerized. Add 10 % APS and 
TEMED to the stacking gel and pipette directly on top of the 
resolving gel, inserting the comb to form wells as the gel 
polymerizes. 
  6.  Mix the protein samples with equal amounts of 2 × SDS sample 
buffer and heat to 95 °C for 10 min for protein denaturation. 
  7.  The sample is then cooled to room temperature and centrifuged 
at 13,800 ×  g for 1 min before loading one sample per well. 
  8.  Protein standard marker is added to the fi rst well to determine 
the size of protein. 
  9.  Add 1× running buffer to the tank as instructed by manufacturer. 
  10.  Set the power pack connected to the gel apparatus to 100 V for 
90 min to allow the proteins to be separated according to size, 
with the smaller molecules separating through the gel matrix 
faster with the larger molecules trailing behind. 
  11.  The gel is then placed in staining solution overnight to be 
taken up by the proteins and destained to remove background 
staining for the protein bands to become visible. 
  1.  Equilibrate maltose-sepharose column with 100 ml Affi nity 
buffer. Discard fl ow through. 
  2.  Pass the BALF through the column four times to ensure effi -
cient binding. 
  3.  Wash the sepharose column with 10 ml of Affi nity buffer I with 
1 M NaCl. Discard fl ow through. This removes unbound non-
specifi c proteins. 
  4.  Elute the proteins with 20 ml SP-A eluting buffer containing 
EDTA in 1 ml fractions over ice (Fig.  2 ).
  1.  Inoculate a single colony of BL21 (λDE3) pLysS in 5 ml LB 
containing 5 μl of chloramphenicol (50 mg/ml). 
  2.  Incubate overnight (~16 h) in a 37 °C shaker at 700 ×  g . 
Primary inoculum is now ready. 
3.3  SDS-PAGE: 
12 % and 15 %
3.4  Purifi cation 
of SP-A from BALF
3.5  Competent Cell 
Preparation of BL21 
( λDE3) pLysS for 
Recombinant SP-A 
Production
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  3.  Next day, transfer 1 ml of primary inoculum into 25 ml LB 
containing chloramphenicol. 
  4.  Incubate for 2–3 h in the shaking incubator for cells to grow 
to log phase indicated by 0.3 against plain LB medium at 
OD 600 nm . 
  5.  Centrifuge the sample at 1,800 ×  g for 10 min to collect BL21 
(λDE3) pLysS cells to pellet. 
  6.  Discard supernatant in disinfectant and resuspend pellet in 
12.5 ml 0.1 M CaCl 2 . 
  7.  Incubate pellet on ice for 1 h to make cells competent. 
  8.  Centrifuge cells again at low speed centrifugation 1,800 ×  g for 
5 min to pellet the cells. 
  9.  Discard supernatant and resuspend cells in 2 ml 0.1 M CaCl 2 . 
  10.  The cells are now ready for transformation. 
  1.  Take 200 μl of competent cells and add to a 15 ml Falcon tube. 
  2.  Add 2 μl of plasmid directly to the competent cells and incu-
bate on ice for 1 h. 
  3.  Heat shock the cells to take up the plasmid at 42 °C for 90 s. 
  4.  Transfer the culture to ice for 5 min. 
3.6  Transformation 
of Recombinant 
SP-A-Trimeric 
(pUK-A1) in BL21 
( λDE3) pLysS
 Fig. 2  Western blot to detect native SP-A from amniotic fl uid. Initially 1 and 2 μg 
proteins were separate on a SDS-PAGE and transferred at 320 amp for 90 min. 
The membrane was blocked with 5 % milk-powder/PBS buffer and probed with 
anti-human SP-A in a 1:5,000 dilution. The primary antibody was detected with 
a HRP conjugated Protein A in a 1:5,000 dilution. The bands were visible after 
DAB reacting with HRP to display protein bands; monomers and dimers of SP-A 
at 33 kDa and 64 kDa, respectively 
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  5.  Add 800 μl of LB to the sample to make 1 ml total volume, 
and incubate at 37 °C for approximately 45 min to allow one 
full cell cycle to take place to increase transformed cells. 
  6.  Add 100 μl of transformed cultured to an LB agar + ampicil-
lin/chloramphenicol plate and incubate overnight at 37 °C 
( see  Note 5 ). 
  1.  Inoculate four separate colonies in 5 ml LB containing 5 μl of 
ampicillin and chloramphenicol to grow overnight in shaking 
incubator at 37 °C. 
  2.  Next day, transfer 500 μl of primary culture into 10 ml LB with 
10 μl ampicillin and chloramphenicol and incubate in the 
37 °C shaking incubator to grow to log phase, indicated by a 
reading of 0.6–0.8 at 600 nm against plain LB medium. 
  3.  When optimum OD has been reached, take 1 ml of un-induced 
sample and add 5 μl of 1 M IPTG to make a fi nal concentration 
of 0.5 μM to the 10 ml culture. 
  4.  Incubate both induced and un-induced in a 37 °C shaking 
incubator for a further 3 h to allow induction to take place and 
to over-express protein of interest. 
  5.  After 3 h, take 1 ml of un-induced and induced samples and 
centrifuge at 13,800 ×  g for 15 min to pellet cells. 
  6.  Discard supernatant. 
  7.  Add 100 μl of 2× treatment buffer and denature proteins 
to separate 10 μl of each sample on a 15 % SDS-PAGE 
( see Table  1 ) ( see  Note 6 ). 
  8.  After observing gel, the colony giving best expression can be 
streaked on a LB agar plate containing ampicillin and chloram-
phenicol using the primary inoculum. 
  9.  This plate of colonies can be used to make multiple large-scale 
batches before reseeding the plate of colonies the following 
month. 
  10.  Proceed to large-scale expression. 
  1.  Inoculate one colony from SP-A-trimeric culture plate into 
25 ml LB medium with 25 μl ampicillin and chloramphenicol. 
  2.  Incubate in a 37 °C shaking incubator for 16 h. 
  3.  Transfer 25 ml of the primary culture into 1 L LB medium 
with 1,000 μl ampicillin and chloramphenicol. 
  4.  Incubate this secondary culture at 37 °C shaker for approxi-
mately 3 h until the OD reaches between 0.6 and 0.8. 
  5.  Pipette 1 ml sample from culture for negative control (“un- 
induced sample”). 
3.7  Pilot-Scale 
Expression
3.8  Large-Scale 
Expression
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  6.  To the rest of the sample, “induce” add 500 μl 0.5 mM IPTG 
from 1 M stock and re-incubated in the 37 °C shaker for 3 h 
with “un-induced” sample. 
  7.  After 3 h, take 1 ml from “induced” sample and centrifuge 
along with 1 ml “un-induced” sample at high speed 13,800 ×  g 
for 15 min. 
  8.  Discard supernatant and add 100 μl of 2× treatment buffer to 
the pellet. Denature at 95 °C and separate on a 15 % SDS- 
PAGE (Table  1 ) to determine protein expression (Fig.  3 ).
  9.  Centrifuge the entire 1 L “induced” culture at 13,800 ×  g at 
4°C, for 15 min to collect pellet containing proteins in  inclusion 
bodies. 
  10.  The pellet can be stored at −20 °C or used straight away for 
lysing and sonication. 
  1.  If pellet was stored at −20 °C, it should be thawed on ice. 
  2.  Resuspend the pellet in 50 ml lysis buffer and stir at 4 °C. 
  3.  Whilst stirring, add PMSF to 1 mM and 0.5 mg/ml lysozyme 
to the lysis buffer. Allow to stir for ~2 h (until there are no 
 visible lumps). 
  4.  Keep suspension on ice and sonicate at 4 kHz for 30 s with 
2 min interval between each cycle to allow sonicator to cool 
down, repeating for 15 cycles. 
3.9  Lysing Inclusion 
Bodies to Extract 
Protein
 Fig. 3  SDS-PAGE after large-scale expression of SP-A-trimeric. Expression of 
recombinant SP-A showing un-induced ( lane 2 ) and induced ( lane 3–5 ) of 3 × 1 L 
batches.  Lane 1 : Protein marker contains molecular weight ranging from lowest 
to highest: 14.4, 18.4, 25.0, 35.0, 45.0, 66.2, 116.0,  Lane 2 : un-induced,  Lane 
3–5 : induced batches 1–3. 10 μl of sample including 2× treatment buffer was 
loaded to each well 
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  5.  Centrifuge sample to collect the protein rich pellet out of 
 inclusion bodies at 13,800 ×  g for 15 min at 4 °C. 
  6.  Collect 50 μl sample of supernatant and pellet to separate on a 
12 % SDS-PAGE (Table  1 ) to confi rm protein is visible in 
 pellet (Fig.  4 ) ( see  Note 7 ).
  1.  To the pellet, add 50 ml resolubilization buffer containing 6 M 
urea. 
  2.  Incubated pellet at 4 °C whilst on a magnetic fl ea containing 
resolubilization buffer for exactly 1 h. 
  3.  Centrifuge sample at 13,800 ×  g , at 4 °C, for 15 min to sepa-
rate the debris rich pellet and supernatant containing protein. 
Take a sample of the supernatant to separate on an SDS-PAGE 
to ensure protein is in the supernatant and has been extracted 
out of pellet. 
  1.  Transfer the supernatant into a dialysis bag and add to a 1 L 
measuring cylinder containing 1 L 4 M-urea buffer and fresh 
β-ME. 
  2.  Dialyze the sample for 2 h on a magnetic stirrer at 4 °C. 
3.10  Denaturing 
and Refolding 
Recombinant Proteins
3.11  Stepwise 
Dialysis to Refold 
Protein and Remove 
Urea Traces
 Fig. 4  15 % SDS-PAGE after lysis, sonication. Pellets containing SP-A in inclusion 
bodies are lysed and sonicated. After centrifugation of sample, protein is present 
in pellet before solubilsation.  Lane 1 : Protein marker contains molecular weight 
ranging from lowest to highest: 14.4, 18.4, 25.0, 35.0, 45.0, 66.2, 116.0,  Lane 2 : 
supernatant after centrifugation of lysed and sonicated sample,  Lane 3 : pellet 
after centrifugation of lysed and sonicated sample. 10 μl of sample including 
2× treatment buffer was loaded to each well 
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  3.  Transfer the dialysis bag to another 1 L cylinder containing 
2 M-urea buffer with fresh β-ME. 
  4.  Repeat  step 2 . 
  5.  Transfer the dialysis bag to another 1 L cylinder containing 
1 M-urea buffer with fresh β-ME and repeat  step 2 . 
  6.  Transfer the dialysis bag to another 1 L cylinder containing 
0 M-urea fi nal dialysis buffer. 
  7.  Dialyze sample overnight at 4 °C whilst stirring. 
  8.  The next day, clarify dialysate by centrifugation at 13,800 ×  g , 
at 4 °C, for 15 min. 
  9.  Transfer the supernatant into a new dialysis bag and dialyze 
against 1 L of calcium buffer for 3 h to completely remove 
traces of urea. 
  10.  Clarify dialysate by centrifugation at 13,800 ×  g , at 4 °C, for 
15 min. 
  11.  The sample is now ready for affi nity chromatography. 
  1.  Wash maltose-sepharose column thoroughly with 100 ml 
autoclaved dH 2 O. 
  2.  Equilibrate the maltose-sepharose column with 75 ml affi nity 
buffer (with 5 mM CaCl 2 ). 
  3.  Pass the supernatant through the maltose-sepharose column 
four times. 
  4.  Wash column with 20 ml high-salt buffer (1 M NaCl) to 
remove any debris and unbound proteins. 
  5.  Elute proteins with 20 ml elution buffer in 1 ml fractions over 
ice. 
  6.  Estimate protein concentration at OD280, using elution buffer 
as a reference. 
  7.  Separate proteins on a 12 % SDS-PAGE (Table  1 ) to determine 
protein estimation and purity (Fig.  5 ).
  1.  Initially, prepare a 12 % SDS-PAGE (Table  1 ) and separate 
desired protein of interest to be probed. 
  2.  After the dye front has reached the end of the gel, remove gel 
and equilibrate in 1× transfer buffer along with fi bro pads, 
nitrocellulose membrane and fi lter paper for 10 min. 
  3.  Assemble the sandwich in the following order: fi bro pads, 
2× fi lter paper, gel, membrane, 2× fi lter paper and fi bro pads 
( see  Note 8 ). 
  4.  After closing the cassette, place inside the holder and into the 
tank containing 1× transfer buffer with the black side of cas-
sette facing the black side of holder. 
3.12  Recombinant 
SP-A Purifi cation 
by Affi nity 
Chromatography
3.13  Western Blot
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  5.  For transfer to take place, set power pack to 340 amp for 
90 min for proteins to be transferred to the nitrocellulose 
membrane. 
  6.  Block the membrane with 5 % nonfat milk powder/PBS buffer 
overnight at room temperature to prevent nonspecifi c binding. 
  7.  The next day, decant the blocking buffer and wash membrane 
with 20 ml 1× PBS for 10 min. 
  8.  Add 10 ml of 1:500 dilution of primary antibody (rabbit anti- 
human SP-A) (1 mg/ml) to the membrane and incubate for 
2 h at room temperature on a rocker. 
  9.  Decant the antibody and wash the membrane thrice with PBS 
containing 0.05 % Tween-20, for 10 min each removing old 
wash buffer each time. 
  10.  Add 10 ml of 1:1,000 dilution of secondary antibody (protein 
A-HRP) (1 mg/ml) over the membrane and leave for a 1 h 
incubating at room temperature on a rocker. 
 Fig. 5  12 % SDS-PAGE of purifi ed SP-A samples after affi nity chromatography. The eluted samples were sepa-
rated on a protein gel to determine size and purity. As controls the fl ow through after passing sample and fl ow 
through after  washing column with affi nity buffer was loaded to check for protein loss and contaminant 
removal.  Lane 1 : fl ow through from sample containing recombinant trimeric SP-A,  Lane 2 : fl ow through after 
washing column with affi nity buffer containing 1 M NaCl,  Lane 3 : Protein marker contains molecular weight 
ranging from lowest to highest: 14.4 kDa, 18.4 kDa, 25.0 kDa, 35.0 kDa, 45.0 kDa, 66.2 kDa, 116.0 kDa,  Lane 
4–8 : eluted samples 1–5 containing pure protein. 20 μl of  sample including 2× treatment buffer was loaded 
to each well 
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  11.  Again, decant the antibody and wash the membrane with PBS 
Tween 20, 0.05 % thrice for 10 min each. 
  12.  Whilst the fi nal wash is taking place, prepare two tablets 
of DAB (sigma) dissolved in dH 2 O as recommended by 
manufacturer. 
  13.  After removing wash buffer, pour DAB over the membrane 
and incubate for 2–10 min until suffi cient color develops for 
bands to be visible. 
4  Notes 
  1.  Proteins can be cleaved by proteases if left for too long at room 
temperature. 
  2.  If the concentration is low then the samples can be pooled and 
concentrated using polyethylene glycol. 
  3.  Keep at least 1 cm distance from the wells to the resolving gel 
to allow proteins to stack evenly before being separated 
through the resolving gel. 
  4.  Do not add TEMED until just before adding to the glass plates 
as this will start the polymerization reaction. 
  5.  Add the rest of the culture (i.e., 900 μl) to 5 ml LB and grow 
overnight to streak next day. This is done as a backup, in case 
the number of transformed colonies is very low. 
  6.  Un-induced sample is used as a control to detect SP-A. SP-A 
should be expressed in induced sample only, which is indicated 
as a thick band most highly expressed at ~18 kDa. 
  7.  Supernatant can be stored at −20 °C in case there was still 
some protein that needed further extraction. 
  8.  Ensure that there are no air bubbles in between the gel and 
membrane as this will affect the transfer of proteins. 
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 Chapter 22 
 Purifi cation of Surfactant Protein D (SP-D) from Pooled 
Amniotic Fluid and Bronchoalveolar Lavage 
 Eswari  Dodagatta-Marri ,  Asif  S. Qaseem ,  Najmunisa  Karbani , 
 Anthony  G.  Tsolaki ,  Patrick  Waters ,  Taruna  Madan , 
and  Uday  Kishore 
 Abstract 
 Surfactant protein SP-D is a multimeric collagenous lectin, called  collectin . SP-D is a multifunctional, 
pattern recognition innate immune molecule, which binds in a calcium dependent manner to an array of 
carbohydrates and lipids, thus offering resistance to invading pathogens, allergen challenge, and pulmo-
nary infl ammation. SP-D is predominantly found in the endoplasmic reticulum of type 2 pneumocytes and 
in the secretory granules of Clara or non-ciliated bronchiolar cells. The highest expression of SP-D is 
observed in the distal airways and alveoli. There is also an extra pulmonary existence of SP-D. The com-
mon sources of native full-length human SP-D are bronchoalveolar lavage (BAL) washings from normal 
or preferably patients suffering from alveolar proteinosis who overproduce SP-D in the lungs. Amniotic 
fl uid collected at the term during parturition is another reasonable source. Here, we describe a simple and 
rapid method of purifying native SP-D away from SP-A which is also present in the same source. We also 
describe procedures of expressing and purifying a recombinant fragment of human SP-D (rhSP-D) com-
prising trimeric neck and carbohydrate recognition domains that has been shown to have therapeutic 
effects in murine models of allergy and infection. 
 Key words  Surfactant protein-D ,  SP-D ,  Purifi cation ,  Amniotic fl uid ,  Recombinant SP-D ,  Infl ammation , 
 Affi nity chromatography 
1  Introduction 
 The respiratory surface in the lungs inevitably interacts with a vari-
ety of inhaled toxins, microbes and other particulate matter. Host 
defense mechanisms within the lungs must facilitate clearance of 
inhaled pathogens and particles, while minimizing an infl amma-
tory response that could damage the thin delicate gaseous-exchange 
lining of the alveoli and distal airways. Pulmonary surfactant is a 
complex of lipids and proteins that are physiologically essential. 
There are of four types of surfactant proteins; SP-A [ 1 ], SP-B [ 2 ], 
SP-C [ 3 ], and SP-D, which constitute 5.3, 0.7, 0.4, and 0.6 % of 
Mihaela Gadjeva (ed.), The Complement System: Methods and Protocols, Methods in Molecular Biology, vol. 1100, 
DOI 10.1007/978-1-62703-724-2_22, © Springer Science+Business Media New York 2014
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total surfactant, respectively [ 4 – 7 ]. The gene encoding the SP-D 
protein is localized at the genomic region of 10q22.2–23.1 near 
the MBL gene [ 8 ] of chromosome 10 in humans. The SP-D poly-
peptide chain is 355 residues long, with N-terminal 25 non- 
collagen residues, 177 collagenous residues and 153 residues of 
the C-terminal lectin domain [ 9 ] (Fig.  1 ). The lectin domain is the 
globular head region of the protein which binds to pathogen- 
associated molecular patterns (PAMPs), whilst the collagenous 
region initiates phagocytosis [ 10 ].
 Both SP-A and SP-D bind to carbohydrate structures on the 
surfaces of pathogens, such as viruses [ 11 ], bacteria [ 12 ], yeast 
[ 13 ], fungi [ 14 ], pollen, apoptotic and necrotic cells [ 15 – 18 ]. 
SP-D also directly binds to type II cell apical membranes [ 19 ] and 
alveolar macrophages [ 20 ]. Most of SP-D is found in the aqueous 
bronchoalveolar lavage fl uid (BALF), which binds to phosphoti-
dylinositol (PI) and glucosylceramide, which are sugar moieties 
present in surfactants [ 21 ]. As a potent opsonin, SP-D interacts 
with a range of pathogens and engineers clearance mechanism 
including aggregation/agglutination, growth inhibition, enhance-
ment of phagocytosis by phagocytic cells, and production of super-
oxidative burst and nitric oxide [ 22 ]. 
 SP-D has also been implicated in protecting lungs against 
allergenic challenge [ 23 ]. SP-D can bind allergens derived from 
house dust mite [ 24 ] and  Aspergillus fumigatus [ 25 ] inhibit spe-
cifi c IgE binding to allergens and dampen histamine release by 
sensitized basophils [ 14 ]. The interaction with allergens is medi-
ated via CRD region. Thus, the rhSP-D composed of trimeric 
 Fig. 1  SDS–PAGE (10 % w/v) analysis of purified SP-D under reducing con-
ditions. SP-D is composed of a 43 kDa polypeptide chain, with  faint bands 
corresponding to dimers and trimers of the 43 kDa chain can also been seen 
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neck and CRD region only, produced in  Escherichia coli , has been 
shown to be protective in murine models of lung allergy 
[ 26 – 28 ]. 
 A signifi cant level of SP-D has been detected immunohisto-
chemically in human trachea, brain, testis, salivary gland, heart, 
prostate, kidneys, small intestine, pancreas, and placenta. Lower 
levels of expression have also been detected in spleen, adrenal 
gland, uterus, and mammary glands [ 29 – 31 ]. SP-A, on the other 
hand, is found to be at low levels in the human and rat small and 
large intestines [ 32 ], mesentery, and colon [ 33 – 35 ]. SP-A is found 
in human prostate, thymus, amniotic fl uid and epithelium, and 
salivary glands in very low quantities [ 34 ]. SP-A has also been 
detected in the entire human lacrimal apparatus including lacrimal 
gland, nasolacrimal ducts, conjunctiva, cornea, and human tear 
fl uid [ 35 ]. 
 Here, we describe a step-by-step method to purify human 
SP-D from pooled amniotic fl uid and BAL fl uid. The BAL wash-
ings from pulmonary alveolar proteinosis patients are excellent 
source of native SP-D [ 36 ]. The fact that SP-D binds to maltose 
reasonably well, via its CRD region, has been exploited for purifi -
cation that involves use of maltose agarose or sepharose as an affi n-
ity matrix. 
2  Materials 
  1.  Low salt affi nity buffer: 50 mM Tris–HCl, pH 7.4, 100 mM 
NaCl, 5 mM CaCl 2 . 
  2.  High salt affi nity buffer: 50 mM Tris–HCl, pH 7.4, 1 M NaCl, 
10 mM CaCl 2 . 
  3.  Elution buffer: 50 mM Tris–HCl, pH 7.4, 50 mM MnCl 2 and 
0.02 % NaN 3 . 
  4.  EDTA buffer: for MnCl 2 removal 50 mM Tris–HCl, pH 7.4, 
100 mM NaCl, 5 mM EDTA and 0.02 % NaN 3 . 
  5.  Buffer I + 8 M urea: 50 mM Tris–HCl, pH 7.4, 100 mM NaCl, 
5 mM CaCl 2 , 0.02 % NaN 3 and 8 M urea. 
  6.  Buffer I: 50 mM Tris–HCl, pH 7.4, 100 mM NaCl, 5 mM 
CaCl 2 0.02 % NaN 3 . 
  1.  High salt affi nity buffer: 50 mM Tris–HCl, pH 7.4, 1 M NaCl, 
5 mM CaCl 2 ,0.02 % NaN 3 . 
  2.  Low salt affi nity buffer: 50 mM Tris–HCl, pH 7.4, 100 mM 
NaCl, 5 mM CaCl 2 0.02 % NaN 3 . 
  3.  SP-D eluting buffer with maltose: 50 mM Tris–HCl, pH 7.4, 
100 mM NaCl, 25 mM maltose, 0.02 % NaN 3 . 
2.1  Protein 
Purifi cation Buffers
2.2  Ion Exchange 
Chromatography
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  1.  SDS-gel: 30 % Bis-acrylamide, 1.5 M Tris–HCl, pH 8.8 
(resolving gel), 1.0 M Tris–HCl, pH 6.8 (stacking gel), 10 % 
SDS, 10 % APS, TEMED. 
  2.  1× Running buffer (1 l): 3 g Tris base, 14.4 g glycine, 10 ml 
SDS (10 %), 990 ml dH 2 O. 
  3.  2× SDS sample buffer (10 ml): 1.25 ml 0.5 M Tris–HCl, 
pH 6.8, 2 ml 50 % glycerol, 2 ml 10 % SDS, 0.5 ml 
β-mercaptoethanol, 0.5 % Bromophenol blue, 4 ml dH 2 O. 
  4.  Coomassie blue stain (1 L): 100 ml Glacial acetic acid, 400 ml 
methanol, 1 g Coomassie blue R250, and 500 ml dH 2 O. 
  5.  De-stain solution (1 L): 100 ml Glacial acetic acid, 400 ml 
methanol, and 500 ml dH 2 O. 
  1.  1× Transfer buffer: 2.9 g Glycine, 5.8 g Tris base, 0.37 g SDS, 
200 ml methanol, 800 ml dH 2 O. 
  1.  Divinylsulfone (DVS). 
  2.  Sepharose 4B. 
  3.  0.5 M Sodium carbonate. 
  4.  0.5 M Sodium bicarbonate. 
  5.  20 %  D -maltose in 0.5 M sodium carbonate. 
  1.  HEPES buffer [10 mM HEPES (pH 7.5), 100 mM NaCl, 
1 mM EDTA]. 
  2.  DMSO (Dimethyl sulfoxide). 
3  Methods 
  1.  Amniotic fl uid can be collected following vaginal rupturing of 
the fetal membranes which is carried out to induce or facilitate 
the progress of labor or during spontaneous rupturing from 
pregnant women at term following appropriate ethical approval. 
This is usually stored at −80 °C until required for purifi cation. 
  2.  Thaw amniotic fl uid from −80 °C at 37 °C for 5–6 h or overnight 
at 4 °C. Make sure (whilst at 37 °C) that it is regularly mixed to 
keep temperature consistent to avoid overheating of proteins. 
  3.  Pool all amniotic fl uid to allow purifi cation of protein in large 
amounts. 
  4.  Centrifuge the pooled amniotic fl uid in a table top bench cen-
trifuge at 10,000 ×  g for 40 min at 4 °C to separate SP-A, 
mainly in the pellet, from the supernatant containing SP-D. 
  5.  The amniotic fl uid is then passed through a cell strainer to 
remove fat and other large aggregates. This will remove phos-
pholipids and large unwanted material. 
2.3  SDS-PAGE
2.4  Western Blot 
Buffers
2.5  Maltose–
Sepharose
2.6  Bis(Sulfosuccin-
imidyl)Suberate 
Cross-linking
3.1  Purifi cation of 
Surfactant protein D  
3.1.1  Separation of SP-D 
from Amniotic Fluid
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  6.  To further separate other cellular material, the amniotic 
fluid is passed through muslin cloth three times for a clearer 
suspension and to avoid future clogging of maltose–sepharose 
column during affi nity chromatography. 
  7.  The amniotic fl uid is calcifi ed to 5 mM CaCl 2 to increase the 
volume and decrease viscosity (CaCl 2 is added drop-by-drop 
whilst monitoring pH to 7.5). 
  8.  Stir at 4 °C for 1 h. This allows aggregation of the calcium 
dependent proteins SP-A and SP-D. 
  9.  Proceed to affi nity chromatography. 
  1.  Maltose–sepharose (see the preparation of affi nity matrix 
below) is washed with 100 ml autoclaved distilled water and 
then equilibrated with four bed volumes of low salt affi nity 
buffer I ( see Subheading  2.1 ,  item 1 ). 
  2.  The maltose–sepharose bed is then transferred to the amniotic 
fl uid supernatant obtained from the previous step to allow 
SP-D to bind to the maltose–sepharose for effi cient purifi ca-
tion. This is left to stir at 4 °C for a further 1 h. 
  3.  Pass the amniotic fl uid containing the maltose–sepharose 
through the column and allow the maltose–sepharose to set-
tle, collect the fl ow through and pass through the column 
thrice in total. 
  4.  Remove nonspecifi cally bound proteins with four bed volumes of 
affi nity buffer containing 1 M NaCl ( see Subheading  2.1 ,  item 2 ). 
  5.  10 × 1 ml fractions of SP-D are eluted with elution buffer I 
over ice ( see  Note 1 ). 
  6.  Optical density of each fraction is read at 280 nm using elution 
buffer without MnCl 2 as a reference ( see  Notes 2 and  3 ) 
(Fig.  2 ).
  7.  100 μl of each fraction is used for TCA precipitation and this 
is separated on a 15 % SDS–PAGE to visualize protein concen-
tration and purity. 
  8.  The fractions with the highest concentrations are pooled and 
dialysis bag is immersed in 1 L EDTA buffer to remove MnCl 2 
(see Subheading  2.1 , item 4). 
  9.  The dialysis bag is left in a cylinder on a magnetic stirrer over-
night at 4 °C ( see  Note 4 ). 
 10.  The dialysis bag is then placed in a beaker containing polyeth-
ylene glycol MW 6,000–10,000 (Sigma) for 2 h until the vol-
ume of the dialysate is reduced by half. 
 11.  The content from the dialysis bag can then be aliquoted into 
1 ml fractions for storage at −20 °C. 2× 100 μl fractions will be 
required for protein estimation using BCA assay (see below). 
3.1.2  Affi nity 
Chromatography
3.1.3  Removal 
of BSA and Manganese 
Chloride and Concentration 
of SP-D Protein
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 To further clean the purifi ed SP-D away from minor contaminants 
SP-A and DNA etc., gel fi ltration chromatography can be performed.
 12.  Prepare Superose 6 preparative column; add concentrated 
SP-D preparation onto the column. 
 13.  Equilibrate with name of the buffer (20 mM Tris–HCl, 
100 mM NaCl, 1 mM EDTA). 
 14.  SP-D elutes as a single peak with molecular weight of 
>1,000 kDa and SP-A elutes as broad peak with molecular 
weight of 670 kDa.
 15.  Other contaminants that co-purify with the proteins on the affi nity 
column elute late, close to the inclusion volume of the column. 
 16.  The fractions with good protein concentrations can be pooled 
and concentrated adopting the method described above with 
polyethylene glycol. 
  1.  Inoculate a single colony of  E. coli BL21 (λDE3) pLysS 
(Invitrogen) in 10 ml of Luria broth (LB) media with 10 μl of 
chloramphenicol (stock: 50 mg/ml dissolved in ethanol) over-
night at 37 °C shaker. 
  2.  Following morning, remove 500 μl from BL21 (λDE3) pLysS 
culture and inoculate into a 50 ml Falcon tube containing 
25 ml of LB medium with 25 μl of chloramphenicol. 
3.1.4  Gel Filtration 
Chromatography
3.2  Preparation 
of Competent Cells
 Fig. 2  NaCl wash and elution of SP-D with MnCl2 from the maltosyl–agarose column. Several proteins, includ-
ing HSA and histone degradation products bind nonspecifi cally to maltosyl–agarose and are readily eluted with 
high salt wash in the presence of calcium while SP-D remains bound. SP-D is specifi cally eluted by replacing 
CaCl 2 with MnCl 2 when changing to elution buffer containing 50 mM MnCl 2 after 25 ml of the sodium chloride 
high salt wash, as outlined in Subheading  2 
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  3.  Incubate at 37 °C on a shaker (200 rpm) and measure optical 
density (A 600 ) every hour until it reaches a value between 0.3 
and 0.4 (early log Phase). 
  4.  Centrifuge the culture at 2,000 ×  g for 5 min. 
  5.  After centrifugation, discard the supernatant, and add 12.5 ml 
of sterile 0.1 M CaCl 2 to the cell pellet. 
  6.  Resuspend the cells and place them in the temporary state of 
competence at ice for 1 h. 
  7.  After 1 h, centrifuge the cells for 5 min at 2,000 ×  g . 
  8.  Discard the supernatant, and resuspend the pellet in 2 ml of 
0.1 M CaCl 2 and store in ice, the cells are now ready to be 
transformed. 
  1.  Remove 200 μl of cells from the competent cells prepared 
earlier, and place inside a 10 ml Falcon tube containing 1–2 μl 
of (pUK-D1) construct. 
  2.  Place the mixture on ice for 1 h. 
  3.  Give a heat shock to the mixture at 42 °C for 90 s. 
  4.  Following heat shock, place the cells on ice for a further 5 min, 
and then resuspend in 800 µl of LB. 
  5.  Place the mixture inside a 37 °C incubator for approximately 
45 min. 
  6.  After incubation, streak the cells on an LB agar plate contain-
ing (Amp/Chl) and leave inside a 37 °C incubator to grow 
overnight. 
  1.  Grow a single colony of transformed (pUK-D1) cells in 25 ml 
LB along with 100 μg/ml ampicillin + 50 μg/ml chloram-
phenicol overnight in a shaker at 37 °C. 
  2.  On the following morning, inoculate the overnight primary 
culture of 25 ml bacterial culture into 1 L LB along with 
100 μg/ml ampicillin + 50 μg/ml chloramphenicol and grow 
inside a 37 °C shaker, until the absorbance A 600 reaches 
0.6–0.8. 
  3.  After the cells reach log phase (A 600 at 0.6–0.8) induce with 
0.4 mM IPTG for 3 h and harvest the cells by centrifugation 
at 9,000 ×  g for 15 min. 
  4.  Following centrifugation, discard the supernatant and store 
the pellet at −20 °C for further processing (Fig.  3 ).
  1.  Resuspend the cell pellet obtained after IPTG induction in ice 
cold lysis buffer containing (50 mM Tris–HCl, 200 mM NaCl, 
5 mM EDTA, 0.1 % v/v Triton X-100, 0.1 mM PMSF, 
pH 7.5, 50 μg/ml lysozyme) and vortex for 1 h in cold room 
at 4 °C and then sonicate the sample (ten cycles at 30 s each). 
3.3  Transformation 
of Cells
3.3.1  Protein Expression
3.3.2  Cell Lysis
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  1.  Harvest the sonicate by centrifugation at 9,000 ×  g for 15 min 
and solubilize the recovered rh SP-D in the inclusion bodies in 
100 ml buffer I (50 mM Tris–HCl pH 7.5, 100 mM NaCl) 
containing 10 mM 2-mercaptoethanol and 8 M Urea. 
  2.  Carry out a step wise dialysis of the resolubilized material 
against buffer I containing 4 M urea, 2 M urea, 1 M urea and 
no urea, each for 2 h. 
  3.  Centrifuge the dialysate at 9,000 ×  g for 15 min to clarify, and 
then dialyze with calcium buffer (20 mM Tris–HCl pH 7.5, 
100 mM NaCl, 10 mM CaCl 2, 0.05 % sodium azide) for 3 h 
to completely remove urea from the dialysate (Fig.  4 , lane 1). 
  1.  The rhSP-D is purifi ed by affi nity chromatography using malt-
ose–sepharose column. 
  2.  Rinse the maltose–sepharose column with distilled water prior 
to use. After thorough rinsing of the column with dH 2 O, pass 
50 ml of affi nity column buffer containing (50 mM Tris–HCl 
pH 7.5, 100 mM NaCl, 5 mM CaCl 2 , sodium azide-0.05 %) 
through the column. 
  3.  After rinsing the column pass the protein sample through the 
column once. 
  4.  Wash the column with affi nity column buffer. 
3.3.3  Dialysis
3.3.4  Protein Purifi cation 
by Affi ninty 
Chromotography
 Fig. 3  SDS–PAGE (12 % w/v) analyses of rhSP-D at various stages of expression and purifi cation. A recombinant 
fragment of human SP-D containing homotrimeric neck and CRD regions (rhSP-D) was expressed as inclusion 
bodies using Escherichia coli BL21 (λDE3) pLysS as hosts under T7 promoter. 3 h after induction with 0.4 mM 
IPTG, the rhSP-D accumulated as an over-expressed protein of 20 kDa (lane 4 ) compared with uninduced cells 
(lane 2 ) and induced cells at zero hr (lane 3 ). Bacterial cells were sonicated and the inclusion bodies (lane 6 ) 
containing insoluble rhSP-D were recovered in the pellet. The supernatant of the sonicate (lane 5 ) did not 
contain rhSP-D 
Eswari Dodagatta-Marri et al.
281
  5.  Elute the bound protein by using elution buffer containing 
5 mM EDTA (25 ml) (50 mM Tris–HCl pH 7.5, 100 mM 
NaCl, 5 mM EDTA, 0.05 % sodium azide) (Fig.  4 ). The affi n-
ity eluted protein ran as a trimer on a Superose-12 gel fi ltera-
tion column (Fig.  5 ).
  1.  5 ml of Polymyxin B agarose gel (Sigma) is packed in a 20 ml 
column. 
  2.  Wash with 50 ml of 1 % sodium deoxycholate and then further 
rinse with 50 ml of autoclaved distilled water to completely 
remove 1 % sodium deoxycholate. 
  3.  After rinsing the column, the protein is loaded onto the col-
umn, and left to incubate at room temperature for half an 
hour for the protein to bind completely. 
  4.  After the incubation period the protein is eluted and collected 
in 1.0-ml fractions. 
  5.  The LPS free rhSP-D protein is then checked for purity by 
running it on 15 % SDS gel to ensure the removal of LPS. 
  6.  The endotoxin level was examined by QCL-1000 Limulus 
amebocyte lysate system (BioWhittaker, Walkersville, MD, 
USA) and was found to be ~4 pg µg-1 of rhSP-D. 
  7.  The protein is further quantifi ed by measuring the absorbance 
at 280 nm of the eluted and the concentration of the sample 
was determined via Spectrophotometry. 
3.4  Endotoxin 
Removal from 
Recombinant SP-D
 Fig. 4  SDS–PAGE (12 % w/v) analyses of rhSP-D of purifi cation. Insoluble rh 
SP-D were refolded via a denaturation and renaturation procedure and the solu-
ble fraction was further purifi ed using Q-sepharose ion-exchange chromatogra-
phy. The refolded protein (lane 1) was passed through maltose-agarose. 
A signifi cant proportion of the refolded rh SP-D did not bind to the column (lane 
2). Lane 3 is standard protein marker. The peak fractions containing rhSP-D were 
subsequently affi nity purifi ed on a maltose–agarose column (lanes 4–10) 
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 Fig. 5  (a) Elution profi le of rhSP-D from an FPLC Superose 12 column (HR 10/30). The column was eluted with 
Tris-buffered saline–EDTA buffer at a fl ow rate of 0.3 ml/min. (b) Calibration of the column was carried out 
using the following marker proteins: blue dextran (2,000 kDa), β-amylase (200 kDa), alcohol dehydrogenase 
(150 kDa), carbonic anhydrase (29 kDa), and cytochrome C (12.4 kDa) 
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 Preparation of  D -maltose-sepharose 4B by divinylsulfone activation 
method: (immobilizing hydroxyl-containing compounds) 
Sepharose is fi rst activated with the bifunctional reagent divinyl 
sulfone (DVS) (Sigma) and then coupled under basic conditions to 
the hydroxyls of  D -mannose. Reductive amination, epoxy and DVS 
activation provide three excellent alternatives for the obtaining an 
optimal affi nity support. 
 Immobilization: (DVS to activate sepharose) ( see  Note 5 ).
  1.  Activate sepharose 4B (100 ml settled gel with DVS); DVS is 
a bifunctional cross-linking reagent, used to activate agarose 
and other hydroxyl matrices ( see  Note 6 ). 
  2.  DVS introduces reactive vinyl groups into the matrix that will 
couple to amines, alcohols, sulfhydryls, and phenols ( see  Note 7 ). 
  3.  DVS activated gels are more reactive than epoxy-activated 
gels, and therefore coupling proceeds rapidly and completely 
( see  Note 8 ). 
  1.  Wash sepharose 4B (100 ml) settled gel with 1 L water in a 
sintered glass funnel, suction dry to a wet cake and transfer to 
a 500 ml beaker. 
  2.  Suspend the gel in 100 ml 0.5 M sodium carbonate and stir 
the suspension. 
  3.  Slowly add, drop wise, DVS (10 ml) with constant stirring 
over a 15 min period. After addition is completed, stir gel sus-
pension for 1 h at room temperature. 
  4.  Extensively wash the activated gel with water until the fi ltrate 
is no longer acidic ( see  Note 9 ). 
  1.  Wash the DVS-activated sepharose 4B with 1 L water, suction 
dry to a moist cake and add to a  D -maltose solution (20 % 
 D -maltose in 0.5 M sodium carbonate). 
  2.  Stir the reaction mixture at room temperature for 24 h. 
  3.  Filter and wash the gel successively with 2 L each of water 
and 0.5 M sodium bicarbonate containing 5 ml 
β-mercaptoethanol. 
  4.  Mix at room temperature for 2 h to block the excess vinyl groups. 
  5.  Finally wash the gel with 2 L of water. 
  6.  D -maltose-sepharose 4B can be stored in 0.02 % sodium azide 
at 4 °C. 
  1.  Prepare a 25 mM solution of BS3, by dissolving 2 mg BS3 in 
140 μl of DMSO. 
  2.  Using a 20-fold excess approach (20:1 cross-linker–protein), 
add BS 3 cross-linker solution to the protein sample so that the 
fi nal cross-linker concentration is between 0.5 and 5 mM. 
3.5  Preparation 
of Maltose–Sepharose 
Column
3.5.1  Activation
3.5.2  Immobilization
3.6  Bis(Sulfosuccin-
imidyl)Suberate (BS 3 ) 
Cross-linking
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  3.  Incubated rhSP-D with different concentrations (1 mM, 
0.1 mM, and 0.01 mM BS 3 ). 
  4.  Allow the sample to react at room temperature for 45 min to 
1 h. Allow slightly longer if reaction must be done on ice (this 
reaction rate is only slightly slower at low temperatures). 
  5.  Quench and unreacted BS 3 with 25 to 60 mM Tris–HCl (pH 7.5) 
and allow reacting for 10–15 min at room temperature. 
  6.  Run the SDS-PAGE for the detection of cross-linking 
(Figs.  6 and  7 ).
 Fig. 6  ( a ) SDS–PAGE (12 % w/v) bis (sulfosuccinimidyl) suberate (BS3) cross-linking of recombinant fragment 
of human SP-D containing trimeric neck containing CRD region (rhSP-D). Treatment of rhSP-D with 0.01 mM 
BS3 at different time intervals of 0, 1, 2, 4, 6, 8, 16, 32 min, respectively ( lanes 3 – 9 ) and the  lane 10 showing 
1 mM BS3. ( b ) SDS–PAGE (12 % w/v) bis (sulfosuccinimidyl) suberate (BS3) cross-linking of recombinant frag-
ment of human SP-D containing trimeric neck containing CRD region (rhSP-D). Treatment of rhSP-D with three 
different concentrations of BS3: 0.1 mM ( lane 1 ), 0.01 mM ( lane 2 ), and 1 mM ( lane 3 ) 
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  1.  Take 200 μl of protein and mix with equal volumes of 20 % 
TCA (trichloroacetic acid) in a 2 ml Eppendorf tube, keep on 
ice for 20 min. if concentrations are low then keep 5 min on 
ice and 15 min at −20 °C. 
  2.  Centrifuge for 15 min at 20,000 ×  g at 4 °C, decant the super-
natant and add 200 µl of 70 % ethanol, fl ick and mix content, 
centrifuge for 15 min at 20,000 ×  g at 4 °C and decant 
supernatant. 
  3.  Allow excess ethanol to air dry for 5–10 min. Do not allow 
excessive drying as this makes the pellet diffi cult to dissolve. 
  4.  Add 30 µl of 2× protein treatment buffer and pipette up and 
down for equal mixing. 
  5.  Denature protein on heating block for 10 min at 95 °C. 
  6.  Add each sample to a well of SDS-PAGE. 
 BCA assay is carried out according to manufacturer’s instructions. 
See below for protocol using BCA (Thermo Scientifi c).
  1.  To carry out protein estimation, it is important to perform a 
standard curve by preparing protein standards using the BSA 
of 2 mg/ml provided in the kit. 
  2.  Nine vials are labeled A-I and BSA is diluted to range from 
20 µg to 2 mg/ml according to Tables  1 and  2 using PBS as a 
diluent.
  3.  Prepare working reagent by mixing reagent A and reagent B at a 
1:50 dilution. 2 ml of working reagent is required per sample 
including for the protein standards which is repeated twice. 
3.7  TCA Assay
3.8  Bicinchoninic 
Acid Protein Assay
 Fig. 7  SDS–PAGE (12 % w/v) bis (sulfosuccinimidyl) suberate (BS3) cross- 
linking of recombinant fragment of human SP-D containing trimeric neck con-
taining CRD region (rhSP-D). Treatment of rhSP-D with three different 
concentrations of BS3: 0.01 mM ( lane 3 ), 0.1 mM ( lane 4 ), and 1 mM ( lane 5 ), 
and untreated rhSP-D ( lane 2 ) 
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The following formula can be used to calculate the total working 
reagent required (no. of standards + no. of unknown samples) × (2 
replicates) × (2 ml volume of working reagent per sample). 
  4.  Label 2× test tubes for each sample containing 100 µl of sam-
ple + 2 ml working reagent. 
  5.  This is incubated at 37 °C for 30 min. The reagent will turn 
from purple to green, depending on the protein concentra-
tion. The higher the concentration the greener the solution. 
 Table 1 
 Dilution of protein standards to perform standard curve for protein estimation 
 Dilution scheme for standard test tube protocol and microplate procedure (working 
range = 20–2,000 μg/ml) 
 Vial  Volume of diluent (μl)  Volume and source of BSA (μl)  Final BSA concentration (μg/ml) 
 A  0  300 of stock  2,000 
 B  125  375 of stock  1,500 
 C  325  325 of stock  1,000 
 D  175  175 of vial B dilution  750 
 E  325  325 of vial C dilution  500 
 F  325  325 of vial E dilution  250 
 G  325  325 of vial F dilution  125 
 H  400  100 of vial G dilution  25 
 I  400  0  0 = Blank 
 Table 2 
 Components and volumes for preparing 12 and 15 % SDS-PAGE 
 Resolving gel  12 %  15 %  Stacking gel 
 Components  Volume (ml)  Components  Volume (ml) 
 dH 2 O  3.3  2.3  dH 2 O  3.4 
 30 % Bis-acrylamide mix  4  5  30 % Bis-acrylamide mix  0.83 
 1.5 M Tris–HCl, pH 8.8  2.5  2.5  1.0 M Tris–HCl, pH 6.8  0.63 
 10 % SDS  0.1  0.1  10 % SDS  0.05 
 10 % APS  0.1  0.1  10 % APS  0.05 
 TEMED  0.015  0.015  TEMED  0.014 
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  6.  The test tubes are then cooled down to room temperature, 
however measuring the absorbance within the fi rst 10 min. 
  7.  Using a spectrophotometer at 562 nm, each sample optical 
density is detected and the average of the duplicate sample is 
taken for a more accurate measurement of protein. The working 
reagent is used as a reference. 
  8.  A standard curve can be made using the standard protein sam-
ples and the optical density detected for the unknown samples 
can be used to detect the approximate protein content in the 
sample. 
 Protocol : 
 To prepare a 12 % or 15 % SDS-PAGE, follow the instructions 
below:
  1.  In two separate 50 ml beakers label one “resolving gel” and 
the other “stacking gel”. 
  2.  For a standard size gel, 10 ml of resolving gel and 5 ml of 
stacking gel is suffi cient. 
  3.  Assemble the clean glass plates onto the glass holder and stand 
and check for no leakages. 
  4.  Prepare the following for either 12 % or 15 % resolving gel 
then the standard stacking gel. Do not add TEMED until 
required just before adding to the glass plates. 
  5.  Once the TEMED has been added the polymerization reaction 
will have begun, therefore add the resolving gel immediately. 
  6.  After 20 min the gel will have polymerized and then 10 % APS 
and TEMED can be added to the stacking gel and loaded on 
top of the resolving gel with the comb inserted for the gel to 
polymerize and form wells. 
  7.  The gel with the glass plates can be assembled into the gel 
holder with the anode and cathode conductors and a buffer 
dam can be added to the opposite side to allow current to 
fl ow. 
  8.  The protein samples for separation are mixed with equal 
amounts of 2× SDS sample buffer and heated to 95 °C for 
10 min for denaturation. 
  9.  The sample is then cooled to room temperature and microfuged 
at 12,000 ×  g for 1 min before loading one sample per well. 
 10.  Protein standard marker is added to the fi rst well to determine 
unknown protein sample size. 
 11.  1× Running buffer is added to the tank as instructed by 
manufacturer. 
 12.  Set the power pack connected to the gel apparatus to 100 V 
for 90 min to allow the proteins to be separated according to 
3.9  SDS-PAGE: 12 % 
and 15 %
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size, with the smaller molecules passing through the gel matrix 
quickly with the larger molecules trailing behind. 
 13.  The gel is then placed in staining solution overnight and 
destained the next day for the protein bands to be visible. 
4  Notes 
  1.  Add MnCl 2 fresh on the day you need to use it as MnCl 2 
oxidizes. 
  2.  Due to color changes over time of MnCl 2 giving improper 
protein estimations. 
  3.  Both supernatant and fl ow through and buffers should always 
be on ice. 
  4.  Note if the color is still dark; allow dialysis to continue for up 
to 48 h. 
  5.  Since DVS is highly toxic, all operations involved in activation 
and coupling should be done in the fume hood. 
  6.  DVS activated gels are very useful for immobilizing sugars 
through hydroxyl groups. 
  7.  Immobilized ligands prepared by the DVS method are unsta-
ble at alkaline pH (not stable above pH-8.0-amine linked gels 
and above pH-9.0- or 10.0-hydroxyl-linked gels). 
  8.  Primary stability of this procedure is caused by the liability of 
the ether bond formed between DVS and the matrix at the 
time of activation. 
  9.  Gel can be used to couple to ligands or stored for further use. 
For storage, extensively wash the activated gel with acetone 
and keep as suspension in acetone at 4 °C . 
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